CA2820541A1 - Caspase inhibitors and uses thereof - Google Patents
Caspase inhibitors and uses thereof Download PDFInfo
- Publication number
- CA2820541A1 CA2820541A1 CA2820541A CA2820541A CA2820541A1 CA 2820541 A1 CA2820541 A1 CA 2820541A1 CA 2820541 A CA2820541 A CA 2820541A CA 2820541 A CA2820541 A CA 2820541A CA 2820541 A1 CA2820541 A1 CA 2820541A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- compound
- formula
- compound according
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010076667 Caspases Proteins 0.000 title claims description 37
- 102000011727 Caspases Human genes 0.000 title claims description 37
- 239000003112 inhibitor Substances 0.000 title description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 336
- 239000000203 mixture Substances 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 66
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- -1 -OR9 Chemical group 0.000 claims description 148
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 55
- 201000010099 disease Diseases 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 125000004429 atom Chemical group 0.000 claims description 34
- 150000001412 amines Chemical class 0.000 claims description 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 claims description 23
- 230000001404 mediated effect Effects 0.000 claims description 21
- 230000008878 coupling Effects 0.000 claims description 20
- 238000010168 coupling process Methods 0.000 claims description 20
- 238000005859 coupling reaction Methods 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 230000006907 apoptotic process Effects 0.000 claims description 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 210000000056 organ Anatomy 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 201000003274 CINCA syndrome Diseases 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 208000020084 Bone disease Diseases 0.000 claims description 10
- 208000034578 Multiple myelomas Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 238000009169 immunotherapy Methods 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010002352 Interleukin-1 Proteins 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 125000006244 carboxylic acid protecting group Chemical group 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 6
- 208000035690 Familial cold urticaria Diseases 0.000 claims description 6
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 210000004351 coronary vessel Anatomy 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000004384 Alopecia Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 5
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 208000001490 Dengue Diseases 0.000 claims description 5
- 206010012310 Dengue fever Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 208000003807 Graves Disease Diseases 0.000 claims description 5
- 208000015023 Graves' disease Diseases 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 208000037357 HIV infectious disease Diseases 0.000 claims description 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 5
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 5
- 208000005176 Hepatitis C Diseases 0.000 claims description 5
- 206010019773 Hepatitis G Diseases 0.000 claims description 5
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 5
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 102100039898 Interleukin-18 Human genes 0.000 claims description 5
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 5
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 5
- 208000027747 Kennedy disease Diseases 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 206010033645 Pancreatitis Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 241000721454 Pemphigus Species 0.000 claims description 5
- 208000024777 Prion disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 208000017442 Retinal disease Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 206010040550 Shigella infections Diseases 0.000 claims description 5
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 5
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 5
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 5
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims description 5
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 5
- 208000003152 Yellow Fever Diseases 0.000 claims description 5
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 231100000360 alopecia Toxicity 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 5
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000030833 cell death Effects 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 208000025729 dengue disease Diseases 0.000 claims description 5
- 230000001066 destructive effect Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 208000000718 duodenal ulcer Diseases 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 201000005917 gastric ulcer Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 208000021039 metastatic melanoma Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 206010028417 myasthenia gravis Diseases 0.000 claims description 5
- 208000031225 myocardial ischemia Diseases 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 230000000737 periodic effect Effects 0.000 claims description 5
- 208000025487 periodic fever syndrome Diseases 0.000 claims description 5
- 206010034674 peritonitis Diseases 0.000 claims description 5
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 230000037390 scarring Effects 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 201000005113 shigellosis Diseases 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 206010043554 thrombocytopenia Diseases 0.000 claims description 5
- 201000008827 tuberculosis Diseases 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000010836 blood and blood product Substances 0.000 claims description 3
- 229940125691 blood product Drugs 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 claims description 2
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 claims 1
- 238000003287 bathing Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 13
- 239000000543 intermediate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 description 289
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 198
- 125000003118 aryl group Chemical group 0.000 description 59
- 101150041968 CDC13 gene Proteins 0.000 description 55
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 22
- 238000003556 assay Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 18
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 16
- 230000003647 oxidation Effects 0.000 description 16
- 238000007254 oxidation reaction Methods 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- 239000012895 dilution Substances 0.000 description 14
- 238000010790 dilution Methods 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 12
- 150000001241 acetals Chemical class 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 11
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 11
- 125000001931 aliphatic group Chemical group 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000002841 Lewis acid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 150000007517 lewis acids Chemical class 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 102100035904 Caspase-1 Human genes 0.000 description 6
- 108090000426 Caspase-1 Proteins 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229930192474 thiophene Chemical group 0.000 description 5
- 238000013389 whole blood assay Methods 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 4
- 229940123169 Caspase inhibitor Drugs 0.000 description 4
- 102000004091 Caspase-8 Human genes 0.000 description 4
- 108090000538 Caspase-8 Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000006859 Swern oxidation reaction Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000003147 proline derivatives Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 2
- JPCISVSOTKMFPG-UHFFFAOYSA-N 3-methoxy-2-methylbenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1C JPCISVSOTKMFPG-UHFFFAOYSA-N 0.000 description 2
- 241000408939 Atalopedes campestris Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- QYTDEUPAUMOIOP-UHFFFAOYSA-N TEMPO Chemical group CC1(C)CCCC(C)(C)N1[O] QYTDEUPAUMOIOP-UHFFFAOYSA-N 0.000 description 2
- 229910010066 TiC14 Inorganic materials 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125890 compound Ia Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 102220024375 rs201069984 Human genes 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229950009390 symclosene Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OXCFTOLNDJJUCF-LURJTMIESA-N tert-butyl (3s)-3-amino-4-hydroxybutanoate Chemical compound CC(C)(C)OC(=O)C[C@H](N)CO OXCFTOLNDJJUCF-LURJTMIESA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- YRUCPAPUFQOPDX-JKUQZMGJSA-N (1s,2s,4r)-3-azabicyclo[2.2.1]heptane-2,3-dicarboxylic acid Chemical compound C1C[C@H]2N(C(O)=O)[C@H](C(=O)O)[C@@H]1C2 YRUCPAPUFQOPDX-JKUQZMGJSA-N 0.000 description 1
- JXGVXCZADZNAMJ-NSHDSACASA-N (2s)-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1=CC=CC=C1 JXGVXCZADZNAMJ-NSHDSACASA-N 0.000 description 1
- NSVNKQLSGGKNKB-LLVKDONJSA-N (2s)-3,3-dimethyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 NSVNKQLSGGKNKB-LLVKDONJSA-N 0.000 description 1
- UBXPAGGJJMSWLC-JTQLQIEISA-N (2s)-4-hydroxy-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound OCC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 UBXPAGGJJMSWLC-JTQLQIEISA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- GGXRLUDNGFFUKI-ORGXJRBJSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GGXRLUDNGFFUKI-ORGXJRBJSA-N 0.000 description 1
- RGFKJRWDZOGFEG-ZCFIWIBFSA-N (5r)-5-ethoxyoxolan-2-one Chemical compound CCO[C@H]1CCC(=O)O1 RGFKJRWDZOGFEG-ZCFIWIBFSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 1
- SGJBIFUEFLWXJY-UHFFFAOYSA-N 1-(dibutoxymethoxy)butane Chemical compound CCCCOC(OCCCC)OCCCC SGJBIFUEFLWXJY-UHFFFAOYSA-N 0.000 description 1
- RWNXXQFJBALKAX-UHFFFAOYSA-N 1-(dipropoxymethoxy)propane Chemical compound CCCOC(OCCC)OCCC RWNXXQFJBALKAX-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JHSPCUHPSIUQRB-UHFFFAOYSA-N 2,6-dichlorobenzamide Chemical compound NC(=O)C1=C(Cl)C=CC=C1Cl JHSPCUHPSIUQRB-UHFFFAOYSA-N 0.000 description 1
- JFARSZKBZGPJGR-UHFFFAOYSA-N 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4-fluoro-4-methylpiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide Chemical compound FC1(CCN(CC1)C1=NC(=CC(=N1)NC(C1=C(C=C(C=C1)NS(=O)(=O)CCO)N1CCC2(CC2)CC1)=O)C)C JFARSZKBZGPJGR-UHFFFAOYSA-N 0.000 description 1
- QBAYIBZITZBSFO-UHFFFAOYSA-N 2-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C(F)(F)F QBAYIBZITZBSFO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- FPIVAWNGRDHRSQ-UHFFFAOYSA-N 2-[di(propan-2-yloxy)methoxy]propane Chemical compound CC(C)OC(OC(C)C)OC(C)C FPIVAWNGRDHRSQ-UHFFFAOYSA-N 0.000 description 1
- BQPQFVVEWXYRMH-UHFFFAOYSA-N 2-amino-3-(trifluoromethoxy)benzoic acid Chemical compound NC1=C(OC(F)(F)F)C=CC=C1C(O)=O BQPQFVVEWXYRMH-UHFFFAOYSA-N 0.000 description 1
- WOMXORLJLQSCTD-UHFFFAOYSA-N 2-chloro-3-(trifluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=CC(OC(F)(F)F)=C1Cl WOMXORLJLQSCTD-UHFFFAOYSA-N 0.000 description 1
- RBGDLYUEXLWQBZ-UHFFFAOYSA-N 2-chlorobenzamide Chemical compound NC(=O)C1=CC=CC=C1Cl RBGDLYUEXLWQBZ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- YMQRRCHODQGLDI-UHFFFAOYSA-N 2-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=CC2=NN(O)N=C21 YMQRRCHODQGLDI-UHFFFAOYSA-N 0.000 description 1
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- BMVVXSIHLQYXJJ-UHFFFAOYSA-N 3-azoniabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1CC2C(C(=O)O)NC1C2 BMVVXSIHLQYXJJ-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102100039068 Interleukin-10 Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102100022223 Neuronal growth regulator 1 Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 108010038407 acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BWJYPABMMFBINC-UHFFFAOYSA-N n-[2-(4-azido-3-iodophenyl)ethyl]-4-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]pentanamide Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNC(C)CCC(=O)NCCC1=CC=C(N=[N+]=[N-])C(I)=C1 BWJYPABMMFBINC-UHFFFAOYSA-N 0.000 description 1
- SIMWTRCFFSTNMG-AWEZNQCLSA-N n-[[(5s)-3-[3-fluoro-4-[4-(2-hydroxyacetyl)piperazin-1-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCN(C(=O)CO)CC1 SIMWTRCFFSTNMG-AWEZNQCLSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000012026 peptide coupling reagents Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- YNBQAYKYNYRCCA-UHFFFAOYSA-N venadaparib Chemical compound C1(CC1)NCC1CN(C1)C(=O)C=1C=C(CC2=NNC(C3=CC=CC=C23)=O)C=CC1F YNBQAYKYNYRCCA-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a compound of formula (I):
wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula (I), and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions.
(see formula I)
wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula (I), and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions.
(see formula I)
Description
CASPASE INHIBITORS AND USES THEREOF
This application is a divisional of Canadian Patent Application No. 2,557,645, filed February 28, 2005.
It will be understood that any reference to "the present invention" or the like may refer to the subject matter of this .
divisional application and/or its parent.
Field of the Invention [0001] This invention relates to compounds, and compositions thereof, that are useful as caspase inhibitors.
This application is a divisional of Canadian Patent Application No. 2,557,645, filed February 28, 2005.
It will be understood that any reference to "the present invention" or the like may refer to the subject matter of this .
divisional application and/or its parent.
Field of the Invention [0001] This invention relates to compounds, and compositions thereof, that are useful as caspase inhibitors.
[0002] This invention also relates to processes for preparing these compounds.
[0003] This invention further relates to pharmaceutical compositions comprising said compounds and to the use of the compounds and compositions thereof for the treatment of diseases and disorders related to caspase-mediated conditions.
Background of the Invention [0004] Caspases are a family of cysteine protease enzymes that are key mediators in inflammation. Caapase-1 (ICE) processes pre-IL-113 to produce the active form of IL-113 [WO
99/47545]. ICE has also been linked to the conversion of pro-TGIF to IGIF and/or to the production of IFN-7 [Id.]. Both IL-_ lp and IFN-y contribute to the pathology associated with =
inflammatory, infectious, and autoimmune diseases (see, e.g., 5; J. Invest. Dermatology, 120(1), pp. 164-167 (2003); Br. J. Dermatology, 141, pp. 739-746 (1999); Science, =
282, pp. 490-493 (1998); Schweiz. Med. Wochenschr, 130, pp.
1656-1661 (2000)1.
[0005] Caspases are also key mediators in the signaling pathways for apoptosis and cell disassembly [N.A. Thornberry, Chem. Biol., 5, pp. R97-R103 (19981]. These signaling pathways vary depending on cell type and stimulus, but all apoptosis pathways appear to converge at a common effector pathway leading to proteolysis of key proteins. Caspases are involved in both the effector phase of the signaling pathway and further upstream at its initiation. The upstream caspases involved in initiation events become activated and in turn activate other caspases that are involved in the later phases of apoptosis.
Background of the Invention [0004] Caspases are a family of cysteine protease enzymes that are key mediators in inflammation. Caapase-1 (ICE) processes pre-IL-113 to produce the active form of IL-113 [WO
99/47545]. ICE has also been linked to the conversion of pro-TGIF to IGIF and/or to the production of IFN-7 [Id.]. Both IL-_ lp and IFN-y contribute to the pathology associated with =
inflammatory, infectious, and autoimmune diseases (see, e.g., 5; J. Invest. Dermatology, 120(1), pp. 164-167 (2003); Br. J. Dermatology, 141, pp. 739-746 (1999); Science, =
282, pp. 490-493 (1998); Schweiz. Med. Wochenschr, 130, pp.
1656-1661 (2000)1.
[0005] Caspases are also key mediators in the signaling pathways for apoptosis and cell disassembly [N.A. Thornberry, Chem. Biol., 5, pp. R97-R103 (19981]. These signaling pathways vary depending on cell type and stimulus, but all apoptosis pathways appear to converge at a common effector pathway leading to proteolysis of key proteins. Caspases are involved in both the effector phase of the signaling pathway and further upstream at its initiation. The upstream caspases involved in initiation events become activated and in turn activate other caspases that are involved in the later phases of apoptosis.
[0006] The utility of caspase inhibitors to treat a variety of mammalian disease states associated with an increase in cellular apoptosis has been demonstrated using peptidic caspase inhibitors. For example, in rodent models, caspase inhibitors have been shown to reduce infarct size and inhibit cardiomyocyte apoptosis after myocardial infarction, to reduce lesion volume and neurological deficit resulting from stroke, to reduce post-traumatic apoptosis and neurological deficit in traumatic brain injury, to be effective in treating fulminant liver destruction, and to improve survival after endotoxic shock [H. Yaoita et al., Circulation, 97, pp. 276-281 (1998);
M. Endres et al., J. Cerebral Blood Flow and Metabolism, 18, pp. 238-247, (1998); Y. Cheng et al., J. din. Invest., 101, pp. 1992-1999 (1998); A.G. Yakovlev et al., J. Neurosci., 17, pp. 7415-7424 (1997); I. Rodriquez et al., J. Exp. Med., 184, pp. 2067-2072 (1996); Grobmyer et al., Mol. Med., 5, p. 585 (1999)].
M. Endres et al., J. Cerebral Blood Flow and Metabolism, 18, pp. 238-247, (1998); Y. Cheng et al., J. din. Invest., 101, pp. 1992-1999 (1998); A.G. Yakovlev et al., J. Neurosci., 17, pp. 7415-7424 (1997); I. Rodriquez et al., J. Exp. Med., 184, pp. 2067-2072 (1996); Grobmyer et al., Mol. Med., 5, p. 585 (1999)].
[0007] However, due to their peptidic nature, such inhibitors are typically characterized by undesirable pharmacological properties, such as poor cellular penetration and cellular activity, poor oral absorption, poor stability and rapid metabolism [J.J. Plattner and D.W. Norbeck, in Drug Discovery Technologies, C.R. Clark and W.H. Moos, Eds. (Ellis Horwood, Chichester, England, 1990), pp. 92-126]. This has hampered their development into effective drugs. These and other studies with peptidic caspase inhibitors have demonstrated that an aspartic acid residue is involved in a key interaction with the caspase enzyme [K.P. Wilson et al., Nature, 370, pp. 270-275 (1994); Lazebnik et al., Nature, 371, p. 346 (1994)].
[0008] Accordingly, peptidyl and non-peptidyl aspartic acid compounds are useful as caspase inhibitors.
(0009] A need nevertheless exists for compounds that have the ability to act as caspase inhibitors, particularly with selective activity against certain caspases.
Summary of the Invention [0010] The present invention provides a compound of formula R, wherein the variables are as defined herein.
Summary of the Invention [0010] The present invention provides a compound of formula R, wherein the variables are as defined herein.
[0011] The present invention also provides processes for preparing these compounds, compositions, pharmaceutical compositions, and methods of using such compounds and compositions for inhibiting caspases. These compounds are particularly useful as selective caspase-1/capase-8 inhibitors.
=
Detailed Description of the Invention [0012] The present invention provides a compound of foimula RN
N
wherein:
OH
Y is 0 or R ' R is R3C (0) HC (0) , R3S02-, R30C (0) , (R3) 2NC (0) ( R3 ) (H)NC(0), R3C(0)C(0)-, R3-, (R3)2NC(0)C(0), (R3) (H)NC(0)C(0), or R30C(0)C(0)-;
R1 is H, aliphatic, cycloaliphatic, aryl, heterocyclyl, heteroaryl, cycloalkyl-aliphatic-, cycloalkenyl-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-, wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
Ring A is:
or uvw wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R3 is aliphatic, cycloaliphatic, aryl, heterocyclyl, heteroaryl, cycloaliphatic-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-; or two R3 groups bound to the same atom form together with that atom a 3-10 membered aromatic or nonaromatic ring; wherein any ring is optionally fused to an aryl, heteroaryl, cycloalkyl, or heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, S. SO, and SO2, wherein R3 is substituted with up to 6 substituents independently selected from 119;
R4 is halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylen.edioxy, -N(R9)2, -SR9, -SOR9, -S02R9, -SO2N(R9) 2, -S03R9, -C(0)R9, -C (0)C (0)R9, -C (0)C (0)0R9.
-C (0) C (0)N(R9) 2, -C (0) CH2C (0)R9, -C(S)R9, (S)0R9, (0)0R9, - (0)R9, -C (0)N(R9) 2, -OC (0)N(R9)2, (S)N(R9) ""' (CH2)0-2NHC (0)R9, -N(R9)N (R9) COR9, -N(R9)N(R9)C(0)0R9, -N(R9)N(R9) CON (R9) 2, -N (R9) SO2R9, -N (R9) SO2N (R9) 2, -N(R9)C (0) OR9, -N (R9) C (0)R9, -N (R9) C (S)R9, -N (R9) C (0)N (R9) 2, -N (R9) C (S)N (R9)2, -N(COR9)COR9, -N(0R9)R9, -C (=NH)N(R9)2, (0)N(0R9)R9, -C (=NOR9) R9, -OP (0) (OR9) 2, -13 (0) (R9)2, -P(0) (OR9) 2, or -P(0) (H) (OR9) ;
R2 is -C(R5)(R6)(R7), aryl, heteroaryl, or C3-7 cycloalkyl;
R5 is H or a C1_6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R7 is -CF3, -C3_7cycloalkyl, aryl, heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R10;
Or R5 and R7 takentogether with the carbon atom to which they are attached foLia a 3-10 membered cycloaliphatic;
R8 and RY are each independently halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methylenedioxy, 1,2-ethylenedioxy, = - 6 -N (R9) 2, -SR9, -SOR9, -S02R9, -SO2N (R9) 2, -S03R9 -C (0) R9, --c (0) C (0) R9, -C (0) C (0) OR9, -C (0) C (0)N (R9) 2, -C (0) CH2C (0) R9, -C (S) R9, -C (S) OR9, -C (0) OR9, -OC (0) R9, -C (0)N (R9) 21 -OC (0)N (R9) 2r --c (S) N (R9)2, - (Cl-I2) 0-2NHC (0) R9, -N (R9) N (R9) COR9, -N (R9)N (R9)C(0) 0R9, -N(R9)N(R9)CON(R9)2, -N(R9)S02R9, -N(R9)s02N (R9)2, -N(R9)c(0)0R9, -N(R9)C(0)R9, -N(R9)c(s)R9, -N(R9)C(0)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N (OR9) R9, -C (=NH)N (R9)2, -C (0)N (OR9)R9, -C (=NOR9) R9, -OP(0) (00)2, -P (0) (R9)2, -P (0) (OR9)2, and -P (0) (H) (0R9) ;
R is hydrogen, aliphatic, cycloaliphatic, aryl, heterocyclyl, heteroaryl, cycloaliphatic-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-;
wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the . same atom is optionally and independently replaced by carbonyl;
RI is halogen, -ORn, -NO2, -CN, -CF3, -0CF3, -Rn, or -SRn; wherein Ril is C1-4-aliphatic-.
[0012a] In a particular embodiment, the present invention relates to a compound of formula I:
A
NN/./
=
wherein:
= CA 02820541 2013-06-21 , 79580-110D
6a is L2-4((1431-1H
or ,te240 0 0¨R1 Y
R is H, C112aliphatic, C3_10cycloaliphatic, C6_10ary1, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3_10cycloa1ky1)-(C1-12aliphatic)-, cycloalkenyl-(C1_12aliphatic)-, (C6-10arY1)-(Ci-12aliphatic)-, (5-10 membered heterocycly1)-(C1-12a1iphatic)-, or (5-10 membered heteroary1)-(C1_12aliphatic)-, wherein any hydrogen atom is optionally and independently replaced by R9 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by.carbonyl;
Ring A is:
Or =AArv ;
wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
= R4 is halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methylenedioxy,.1,2-ethylenedioxy, -N(R9)2, -SR9, -SOR9, -S02R9, -SO2N (R9) 2/ -S03R9f -C (0) R9, -C (0) C (0) R9, -C (0) C (0) OR9, -C (0) C (0) N (R9) 2, -C (0) CH2C (0) R9r (S) R9, -C (S) OR9, -C (0) OR9, -OC (0) R9, -C (0)N (R9) 2, -0C (0)N (R9) 2, -C (S) N (R9) 2, = 6h - (CH2) 0-2NHC (0) R9, -N (R9) N (R9) COR9, -N (R9) N (R9) C (0) OR9, -N (R9) N (R9) CON (R9) 2, -N (R9) S02R9, -N (R9) SO2N (R9) 2, -N (R9) C (0) OR9, -N (R9) C (0) R9, -N (R9) C (S) R9, -N (R9) C (0) N (R9)2, -N (R9) C (S) N
(R9)2, -N (00R9) COR9, -N (OR9) R9, -C (=NH) N (R9)2, -C (0) N (OR9) R9, -C(=NOR9)R9, -OP(0) (OR9) 2, -P(0) (R9)2, -P(0) (OR9)2, or -P(0) (H) (OR9) ; =
R2 is -C (R6) (R6) (R7) , C6_10aryl, 5-10 membered heteroaryl, or C3-7 Cycloalkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
= R7 is -CF3, -C3_7cycloalkyl, C6_19ary1, 5-10 membered heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R1-0;
or R5 and R7 taken together with the carbon atom to which they are attached form a 3-10 membered cycloaliphatic;
and R8'. are each independently halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylenedioxy, -N (R9) 2, -SR9, -SOR9, -S02R9, -SO2N (R9) 2, -S03R9, -C (0) R9, -C (0 ) C (0) R9, -C (0) C (0) OR9, -C (0)C (0)N (R9)2, -C (0)CH2C (0) R9, =
-C (S) R9, -C (S) OR9, -C (0) OR9, -OC (0) R9, -C (0)N (R9)2, -0C (0)N (R9)2, -C (S) N (R9) 2, - (CH2) 0_2NHC (0) R9, -N (R9) N (R9) COR9, -N (R9)N (R9) C (0) OR9, ;-1\1 (R9)N (R9)CON (R9)2, -N (R9) SO2R9, -N(R9) SO2N (R9)2, -N (R9) C (0) OR9, -N (R9)C (0)R9, -N (R9) C (S)R9, -N (R9) C (0)N (R9)2, -N (R9) C (S)N (R9)2, -N(COR9)COR9, -N (OR9) R9, -C (=NH) N (R9)2, -C (0 ) N (OR9) R9, -C (=NOR9) R9, -OP(0) (OR9)2, -P (0) (R9.)2, -P (0) (OR9) 2, or -P (0) (H) (OR9) ;
6c R9 is hydrogen, C1-12aliphatic, C3_10cycloaliphatic, C6,10aryl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3,10cycloaliphatic)-(Ci_12aliphatic)-, (C6_10ary1)-(C1,12aliphatic)-, (5-10 membered heterocycly1)-(Ci_i2aliphatic)-, or heteroary1-(C1.42aliphatic)-; wherein any hydrogen atom is optionally and independently replaced by R9 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R1 is halogen, -0R11, -NO2, -CN, -CF3, -0CF3, -R11, or -SR11; and Ril is C1-1-aliphatic-.
=
Detailed Description of the Invention [0012] The present invention provides a compound of foimula RN
N
wherein:
OH
Y is 0 or R ' R is R3C (0) HC (0) , R3S02-, R30C (0) , (R3) 2NC (0) ( R3 ) (H)NC(0), R3C(0)C(0)-, R3-, (R3)2NC(0)C(0), (R3) (H)NC(0)C(0), or R30C(0)C(0)-;
R1 is H, aliphatic, cycloaliphatic, aryl, heterocyclyl, heteroaryl, cycloalkyl-aliphatic-, cycloalkenyl-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-, wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
Ring A is:
or uvw wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R3 is aliphatic, cycloaliphatic, aryl, heterocyclyl, heteroaryl, cycloaliphatic-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-; or two R3 groups bound to the same atom form together with that atom a 3-10 membered aromatic or nonaromatic ring; wherein any ring is optionally fused to an aryl, heteroaryl, cycloalkyl, or heterocyclyl; wherein up to 3 aliphatic carbon atoms may be replaced by a group selected from 0, N, S. SO, and SO2, wherein R3 is substituted with up to 6 substituents independently selected from 119;
R4 is halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylen.edioxy, -N(R9)2, -SR9, -SOR9, -S02R9, -SO2N(R9) 2, -S03R9, -C(0)R9, -C (0)C (0)R9, -C (0)C (0)0R9.
-C (0) C (0)N(R9) 2, -C (0) CH2C (0)R9, -C(S)R9, (S)0R9, (0)0R9, - (0)R9, -C (0)N(R9) 2, -OC (0)N(R9)2, (S)N(R9) ""' (CH2)0-2NHC (0)R9, -N(R9)N (R9) COR9, -N(R9)N(R9)C(0)0R9, -N(R9)N(R9) CON (R9) 2, -N (R9) SO2R9, -N (R9) SO2N (R9) 2, -N(R9)C (0) OR9, -N (R9) C (0)R9, -N (R9) C (S)R9, -N (R9) C (0)N (R9) 2, -N (R9) C (S)N (R9)2, -N(COR9)COR9, -N(0R9)R9, -C (=NH)N(R9)2, (0)N(0R9)R9, -C (=NOR9) R9, -OP (0) (OR9) 2, -13 (0) (R9)2, -P(0) (OR9) 2, or -P(0) (H) (OR9) ;
R2 is -C(R5)(R6)(R7), aryl, heteroaryl, or C3-7 cycloalkyl;
R5 is H or a C1_6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R7 is -CF3, -C3_7cycloalkyl, aryl, heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R10;
Or R5 and R7 takentogether with the carbon atom to which they are attached foLia a 3-10 membered cycloaliphatic;
R8 and RY are each independently halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methylenedioxy, 1,2-ethylenedioxy, = - 6 -N (R9) 2, -SR9, -SOR9, -S02R9, -SO2N (R9) 2, -S03R9 -C (0) R9, --c (0) C (0) R9, -C (0) C (0) OR9, -C (0) C (0)N (R9) 2, -C (0) CH2C (0) R9, -C (S) R9, -C (S) OR9, -C (0) OR9, -OC (0) R9, -C (0)N (R9) 21 -OC (0)N (R9) 2r --c (S) N (R9)2, - (Cl-I2) 0-2NHC (0) R9, -N (R9) N (R9) COR9, -N (R9)N (R9)C(0) 0R9, -N(R9)N(R9)CON(R9)2, -N(R9)S02R9, -N(R9)s02N (R9)2, -N(R9)c(0)0R9, -N(R9)C(0)R9, -N(R9)c(s)R9, -N(R9)C(0)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N (OR9) R9, -C (=NH)N (R9)2, -C (0)N (OR9)R9, -C (=NOR9) R9, -OP(0) (00)2, -P (0) (R9)2, -P (0) (OR9)2, and -P (0) (H) (0R9) ;
R is hydrogen, aliphatic, cycloaliphatic, aryl, heterocyclyl, heteroaryl, cycloaliphatic-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-;
wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the . same atom is optionally and independently replaced by carbonyl;
RI is halogen, -ORn, -NO2, -CN, -CF3, -0CF3, -Rn, or -SRn; wherein Ril is C1-4-aliphatic-.
[0012a] In a particular embodiment, the present invention relates to a compound of formula I:
A
NN/./
=
wherein:
= CA 02820541 2013-06-21 , 79580-110D
6a is L2-4((1431-1H
or ,te240 0 0¨R1 Y
R is H, C112aliphatic, C3_10cycloaliphatic, C6_10ary1, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3_10cycloa1ky1)-(C1-12aliphatic)-, cycloalkenyl-(C1_12aliphatic)-, (C6-10arY1)-(Ci-12aliphatic)-, (5-10 membered heterocycly1)-(C1-12a1iphatic)-, or (5-10 membered heteroary1)-(C1_12aliphatic)-, wherein any hydrogen atom is optionally and independently replaced by R9 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by.carbonyl;
Ring A is:
Or =AArv ;
wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
= R4 is halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methylenedioxy,.1,2-ethylenedioxy, -N(R9)2, -SR9, -SOR9, -S02R9, -SO2N (R9) 2/ -S03R9f -C (0) R9, -C (0) C (0) R9, -C (0) C (0) OR9, -C (0) C (0) N (R9) 2, -C (0) CH2C (0) R9r (S) R9, -C (S) OR9, -C (0) OR9, -OC (0) R9, -C (0)N (R9) 2, -0C (0)N (R9) 2, -C (S) N (R9) 2, = 6h - (CH2) 0-2NHC (0) R9, -N (R9) N (R9) COR9, -N (R9) N (R9) C (0) OR9, -N (R9) N (R9) CON (R9) 2, -N (R9) S02R9, -N (R9) SO2N (R9) 2, -N (R9) C (0) OR9, -N (R9) C (0) R9, -N (R9) C (S) R9, -N (R9) C (0) N (R9)2, -N (R9) C (S) N
(R9)2, -N (00R9) COR9, -N (OR9) R9, -C (=NH) N (R9)2, -C (0) N (OR9) R9, -C(=NOR9)R9, -OP(0) (OR9) 2, -P(0) (R9)2, -P(0) (OR9)2, or -P(0) (H) (OR9) ; =
R2 is -C (R6) (R6) (R7) , C6_10aryl, 5-10 membered heteroaryl, or C3-7 Cycloalkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
= R7 is -CF3, -C3_7cycloalkyl, C6_19ary1, 5-10 membered heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R1-0;
or R5 and R7 taken together with the carbon atom to which they are attached form a 3-10 membered cycloaliphatic;
and R8'. are each independently halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylenedioxy, -N (R9) 2, -SR9, -SOR9, -S02R9, -SO2N (R9) 2, -S03R9, -C (0) R9, -C (0 ) C (0) R9, -C (0) C (0) OR9, -C (0)C (0)N (R9)2, -C (0)CH2C (0) R9, =
-C (S) R9, -C (S) OR9, -C (0) OR9, -OC (0) R9, -C (0)N (R9)2, -0C (0)N (R9)2, -C (S) N (R9) 2, - (CH2) 0_2NHC (0) R9, -N (R9) N (R9) COR9, -N (R9)N (R9) C (0) OR9, ;-1\1 (R9)N (R9)CON (R9)2, -N (R9) SO2R9, -N(R9) SO2N (R9)2, -N (R9) C (0) OR9, -N (R9)C (0)R9, -N (R9) C (S)R9, -N (R9) C (0)N (R9)2, -N (R9) C (S)N (R9)2, -N(COR9)COR9, -N (OR9) R9, -C (=NH) N (R9)2, -C (0 ) N (OR9) R9, -C (=NOR9) R9, -OP(0) (OR9)2, -P (0) (R9.)2, -P (0) (OR9) 2, or -P (0) (H) (OR9) ;
6c R9 is hydrogen, C1-12aliphatic, C3_10cycloaliphatic, C6,10aryl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3,10cycloaliphatic)-(Ci_12aliphatic)-, (C6_10ary1)-(C1,12aliphatic)-, (5-10 membered heterocycly1)-(Ci_i2aliphatic)-, or heteroary1-(C1.42aliphatic)-; wherein any hydrogen atom is optionally and independently replaced by R9 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R1 is halogen, -0R11, -NO2, -CN, -CF3, -0CF3, -R11, or -SR11; and Ril is C1-1-aliphatic-.
[0013] The present invention also provides a compound of formula II:
A
R3x N(-3 , 0 ,2=NY
II
wherein:
(-1.2(4f6 Y is 0 or 0-W ;
R1 is H, aliphatic, cycloalkyl (e.g., cyclopentyl), cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-aliphatic- cycloalkenyl-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-, wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
Ring A is:
Nr?N7 VN`2( or ww ;
wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl (or in an alternative embodiment, carbonyl or (C3-C6) spirocycle; ) R4 is halogen, -00, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methyl enedioxy, 1, 2 -ethyl enedioxy, -N(R9) 2, -SR9, -SOR9, -SA4R9, -SO2N(R9)2, -S03R9, -C(0)R9, -C (0)C (0)R9, -C(0)C(0)0R9, -C(0)C(0)N(R9)2, -C(0)CH2C(0)R9, -C(S)R9, -C(S)0R9, -C(0)0R9, (0)R9, -C(0)N(R9)2, -0C(0)N(R9)2, -C(S)N(R9)2, (CH2)0-2NHC(0)R9, -N(R9)N(R9)COR9, -N(R9)N(R9)C(0)0R9, -N(R9)N(R9)CON(R9)2, -N(R9) S02R9, -N(R9) SO2N(R9) 2, -N(R9)C(0)0R9, -N(R9)C(0)R9, -N(R9)C(S)R9, -N(R9)C(0)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(0R9)R9, -C(=Nii)N(R9)2, -C(0)N(0R9)R9, -C (=NOR9) R9 , -OP (0) (OR9)2, -P(0) (R9)2, -P(0) (OR9)2, or -P(0) (H) (OR9);
R2 is -C(R5) (R6) (R7) , aryl, heteroaryl, or -C3_7 cycloalkyl;
R5 is H or a C1-6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R7 is -CF3, -C3_7 cycloalkyl, aryl, heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R10;
(or in an alternative embodiment, R5 and R7 taken together with the carbon atom to which they are attached form a 3-10 membered cycloaliphatic);
R3 is phenyl, thiophene, or pyridine, wherein each ring is optionally substituted with up to 5 groups independently selected from R8', and wherein at least one position on the phenyl, thiophen.e, or pyridine adjacent to bond x is substituted by R12, wherein R12 has no more than 5 straight-chained atoms;
R8 and R8' are each independently halogen, -0R9, -NO2, -CN, -CF3 -0CF3, -R9, 1, 2 -methylenedioxy, 1, 2-ethylenedioxy, -N(R9)2,- SR9 - SOR9 -S02R9 -SO2N (R9 ) 2 , -S03R9 , -C (0 ) R9 , -C (0 ) C(0)R9, -C (0)C (0)0R9, -C (0)C (0)N(R9) 2, -C (0)CH2C (0) R9F
- (S ) R9, -C(S)0R9, -C (0) OR9, -0C (0)R9, -C (0)N (R9)2, -0C (0)N (R9)2, -C(S)N (R9) 2, - (CH2) 0-2NHC (0) R9, -N(R9)N(R9)COR9, -N (R9)N (R9) C (0) OR9, -N(R9)N(R9)CON(R9)2, -N (R9) SO2R9, -N (R9) SO2N(R9) 2, -N(R9)C(0)0R9, -N (R9) C (0)R9, -N(R9)C(S)R9, -N(R9)C(0)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(0R9)R9, -C (=NH)N (R9) 2, -C (0)N (OR9) R9, -C (=NOR9)R9, -OP(0) (OR9) -P(0) (R9)2? -P(0) (OR9) 2, and -P(0) (H) (OR9);
R9 is hydrogen, aliphatic, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloaliphatic-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic--;
(in certain embodiments, any hydrogen atom of R9 is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl; provided that if R9 is substituted with a =
R8, wherein the R8 comprises a R9 substituent, then that R9 substituent is not substituted with R8);
R113 is halogen, -01111, -NO2, -CN, -CF3, -0CF3, or -SR11;
is C1..4-aliphatic-; and Ru is halogen, -0R11, -NO2, -CN, -CF3, -0CF3, -R11, -SR9.
A
R3x N(-3 , 0 ,2=NY
II
wherein:
(-1.2(4f6 Y is 0 or 0-W ;
R1 is H, aliphatic, cycloalkyl (e.g., cyclopentyl), cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloalkyl-aliphatic- cycloalkenyl-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic-, wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
Ring A is:
Nr?N7 VN`2( or ww ;
wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl (or in an alternative embodiment, carbonyl or (C3-C6) spirocycle; ) R4 is halogen, -00, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methyl enedioxy, 1, 2 -ethyl enedioxy, -N(R9) 2, -SR9, -SOR9, -SA4R9, -SO2N(R9)2, -S03R9, -C(0)R9, -C (0)C (0)R9, -C(0)C(0)0R9, -C(0)C(0)N(R9)2, -C(0)CH2C(0)R9, -C(S)R9, -C(S)0R9, -C(0)0R9, (0)R9, -C(0)N(R9)2, -0C(0)N(R9)2, -C(S)N(R9)2, (CH2)0-2NHC(0)R9, -N(R9)N(R9)COR9, -N(R9)N(R9)C(0)0R9, -N(R9)N(R9)CON(R9)2, -N(R9) S02R9, -N(R9) SO2N(R9) 2, -N(R9)C(0)0R9, -N(R9)C(0)R9, -N(R9)C(S)R9, -N(R9)C(0)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(0R9)R9, -C(=Nii)N(R9)2, -C(0)N(0R9)R9, -C (=NOR9) R9 , -OP (0) (OR9)2, -P(0) (R9)2, -P(0) (OR9)2, or -P(0) (H) (OR9);
R2 is -C(R5) (R6) (R7) , aryl, heteroaryl, or -C3_7 cycloalkyl;
R5 is H or a C1-6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R7 is -CF3, -C3_7 cycloalkyl, aryl, heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R10;
(or in an alternative embodiment, R5 and R7 taken together with the carbon atom to which they are attached form a 3-10 membered cycloaliphatic);
R3 is phenyl, thiophene, or pyridine, wherein each ring is optionally substituted with up to 5 groups independently selected from R8', and wherein at least one position on the phenyl, thiophen.e, or pyridine adjacent to bond x is substituted by R12, wherein R12 has no more than 5 straight-chained atoms;
R8 and R8' are each independently halogen, -0R9, -NO2, -CN, -CF3 -0CF3, -R9, 1, 2 -methylenedioxy, 1, 2-ethylenedioxy, -N(R9)2,- SR9 - SOR9 -S02R9 -SO2N (R9 ) 2 , -S03R9 , -C (0 ) R9 , -C (0 ) C(0)R9, -C (0)C (0)0R9, -C (0)C (0)N(R9) 2, -C (0)CH2C (0) R9F
- (S ) R9, -C(S)0R9, -C (0) OR9, -0C (0)R9, -C (0)N (R9)2, -0C (0)N (R9)2, -C(S)N (R9) 2, - (CH2) 0-2NHC (0) R9, -N(R9)N(R9)COR9, -N (R9)N (R9) C (0) OR9, -N(R9)N(R9)CON(R9)2, -N (R9) SO2R9, -N (R9) SO2N(R9) 2, -N(R9)C(0)0R9, -N (R9) C (0)R9, -N(R9)C(S)R9, -N(R9)C(0)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(0R9)R9, -C (=NH)N (R9) 2, -C (0)N (OR9) R9, -C (=NOR9)R9, -OP(0) (OR9) -P(0) (R9)2? -P(0) (OR9) 2, and -P(0) (H) (OR9);
R9 is hydrogen, aliphatic, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, heteroaryl, cycloaliphatic-aliphatic-, aryl-aliphatic-, heterocyclyl-aliphatic-, or heteroaryl-aliphatic--;
(in certain embodiments, any hydrogen atom of R9 is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl; provided that if R9 is substituted with a =
R8, wherein the R8 comprises a R9 substituent, then that R9 substituent is not substituted with R8);
R113 is halogen, -01111, -NO2, -CN, -CF3, -0CF3, or -SR11;
is C1..4-aliphatic-; and Ru is halogen, -0R11, -NO2, -CN, -CF3, -0CF3, -R11, -SR9.
[0014] As used in the definition of R12, IT
atoms" refers to atoms that are linearly bound, regardless of whether those atoms also have atoms bound in a branched fashion. According to this definition, an ethyl group and a trifluoromethoxy group each have three straight-chained atoms, and a methyl group has two straight-chained atoms. In the above embodiment, R12 has no more than 5 straight-chained atoms. In two other embodiments, R12 has no more than 4 straight-chained atoms and no more than 3 straight-chained atoms. In yet other embodiments, R12 has 2 straight-chained atoms or 1 atom.
atoms" refers to atoms that are linearly bound, regardless of whether those atoms also have atoms bound in a branched fashion. According to this definition, an ethyl group and a trifluoromethoxy group each have three straight-chained atoms, and a methyl group has two straight-chained atoms. In the above embodiment, R12 has no more than 5 straight-chained atoms. In two other embodiments, R12 has no more than 4 straight-chained atoms and no more than 3 straight-chained atoms. In yet other embodiments, R12 has 2 straight-chained atoms or 1 atom.
0015] As used herein, a position adjacent to the bond x refers to a position which is located next to the position at which x is bound. In an aryl ring, this position is often called "the ortho position" or, in the case of a phenyl ring, it may be called "the 2-position". By way of example, in the structures immediately below, R12 is bound to the phenyl, thiophene, and pyridine rings at "the position adjacent to bond x".
R12, R1 2....r/s R12r.) --Jw Ru R12 Ru R12 [0016] In one embodiment of this invention, R is R3C(0)-.
R12, R1 2....r/s R12r.) --Jw Ru R12 Ru R12 [0016] In one embodiment of this invention, R is R3C(0)-.
[0017] In some embodiments, R3 is optionally substituted C6_10ary1 or heteroaryl. In other embodiments R3 is optionally substituted phenyl. In yet other embodiments, R3 is a 8-10 membered optionally substituted heteroaryl (i.e. quinoline, isoquinoline, or quinazoline) In yet other embodiments, R3 is an optionally substituted 5-6 membered heteroaryl (i.e., pyridyl, pyrimidyl, pyrazinyl, thiophenyl, furanyl, thiazoly1) [0018] In some embodiments, R3 is optionally and independently substituted by 0-5 REv groups.
[0019] In one embodiment, the compound of this invention is represented by formula II:
R3 x N
II
wherein:
a) R:3 is phenyl, thiophene, or pyridine;
b) each ring is optionally substituted with up to 5 groups independently selected from Rv; and c) at least one position on the phenyl, thiophene, or pyridine adjacent to bond x is substituted by R12, wherein R12 has no more than 5 straight-chained atoms.
R3 x N
II
wherein:
a) R:3 is phenyl, thiophene, or pyridine;
b) each ring is optionally substituted with up to 5 groups independently selected from Rv; and c) at least one position on the phenyl, thiophene, or pyridine adjacent to bond x is substituted by R12, wherein R12 has no more than 5 straight-chained atoms.
[0020] Another embodiment of this invention provides a compound wherein Y is:
=
\40 [0021] In one embodiment of this invention, RI is substituted with up to 3 groups selected independently from carbonyl and R8.
=
\40 [0021] In one embodiment of this invention, RI is substituted with up to 3 groups selected independently from carbonyl and R8.
(0022] In another embodiment, RI is C1-12aliphatic or C3_10cycloalkyl, wherein each RI is optionally substituted with 1-3 groups selected independently from R8. In yet another embodiment, RI is a straight-chain or branched C1-4 alkyl that is optionally substituted with 1-3 groups selected independently from R8.
[0023] In one embodiment, RI is an unsubstituted, straight-chain or branched C1-4 alkyl (e.g., ethyl, isopropyl, n-propyl, or n-butyl) . In another embodiment, RI is ethyl.
[0024] In any of these embodiments, R8 is halogen, -ORB, -CN, -CF3, -0CF3, or -R9. In another embodiment wherein RB is -R9, that R9 is benzyl.
[0025] In another embodiment, Y is [0026] In another embodiment, Ring A is substituted with up to 3 groups (preferably, 1 group) selected independently from carbonyl and R4.
(0027] In one embodiment, Ring A is:
Ncõ..N7 VN
or optionally substituted with R4.
Ncõ..N7 VN
or optionally substituted with R4.
[0028] In yet another embodiment, Ring A is:
t242.
õ,NIR
VIAAI
optionally substituted with R4.
t242.
õ,NIR
VIAAI
optionally substituted with R4.
[0029] In another form of this embodiment, Ring A is unsubstituted proline (i.e., R4 is hydrogen).
[0030] In yet another embodiment, Ring A is:
VNN
or -- optionally substituted with R4.
. [0031] In one embodiment, Ring A is optionally substituted with R4.
[0032] In any of these embodiments, R4 is halogen, -0R9, -CF3, -0CF3, -R9, or -SR9. In certain embodiments R4 is H.
[0033] In one embodiment, R2 is a C3-4 branched alkyl group.
[0034] In another embodiment, R5 is H or -CH3, R6 is -CH3, and R7 is -CH3.
[0035] In another embodiment, R12 is -0CF3, -OCH3, -CF3, -CH3, -CH2CH3, -Cl, or -F.
[0036] In yet another embodiment, R12 is -CF3, -CH3, -Cl, or -F.
[0037] In yet another embodiment, R12 is -CH3, -Cl, or -F.
[0038] In another embodiment, each Riv, if present, is independently halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methylenedioxy, 1,2-ethylenedioxy, -N(R9)2, -SR9, -SOR9, -S02R9, -SO2N(R9)2, -C(0)R9, -c(0)C(0)N(R9)2, -C(0)N(R9)2, -0C(0)N(R9)2, -(CH2)0_2NHC(0)R9, -N(R9)S02R9, -N(R9)S02N(R9) 2i -N(R9)C(0)0R9, -N(R9)C(0)R9, Or -N(R9)C(0)N(R9)2.
[0039] In another embodiment, R8' is -NH2, -N(R9) 2, -N(R9)C(0)R9, -0CF3, -0R9, -CF3, -R9, -SR9, or halo. In this embodiment, halo is, preferably, Cl or F and R9 is, preferably, straight or branched C1-4 alkyl.
[00403 According to one embodiment, this invention provides compounds of foi.mula III:
R,NõLir 0 NT =
0,R1 III;
wherein the variables are as defined in any of the embodiments herein.
(00413 In one form of this embodiment, the compound has the stereochemistry indicated below:
R,NATN(;) 0 cd-,N40 0,R1 wherein the variables are as defined in any of the embodiments herein.
[0042] In other forms of this embodiment, the compound has the stereochemistry indicated below:
Wk R,N,Kr.NOA R, H
tJ 0 N o ,do o N
or H
0,R 0,R1 wherein the variables are as defined in any of the embodiments herein.
(0043] According to another embodiment, this invention provides compound of formula IV:
RJ
OH
IV;
wherein the variables are as defined in any of the embodiments herein.
[0044] In one form of this embodiment, the compound has the stereochemistry indicated below:
R A
wherein the variables are as defined in any of the embodiments herein.
[0045] The embodiments herein may be combined to provide a compound according to this invention.
[0046] According to one embodiment, the present invention provides a compound selected from Table 1 below:
Table 1 F.st \o * iirko *
* EX.N'i, .<0 . X- Nii 1.1.(0 =
I)c= Nii H
ON 0 N".. ON
C C C
(Xl(N Nii &LA. Nii 0 (11'%.7-....%
S H
C C C
ct ci 0 0 -0 l \---144.N.- Ni ri A.-11-N. N kli CI
,. ....
0 ,<0 0 0 1q0 i 1 o o , 1 o o o o o 0 * NI H..Nl O. . (.,..)NT
O N' . XII? N
0 1q0 0 N H 0) = if c r NI i jeo * 0 X. Ni ir.k * X N? 0 O A 00 0 4 .0 0 N 0 N'',. ON
4s, (`= 4"s.
* X.N? 0 * N Nli =
H
0 N N?
H
0 .<0 o rl H 0 H 0 ---C C
i . . -16-= vi)(9 eci'lo = hiNI?<0 .)- . * Nr-Nii H 1q0 0' N 0 N 0 N
C__/
,, CI o' CI
F3C-`-' . N..rµfi o = N.Nli 0 H ,10 0 4 ON q ON
=C
= villµlii = V.X Ni 0 0 .6 0 N = 0 N =
Ht;i1 H
L .c ' CI
0 = vi .1\11i =
INXIµI 0 * hl i 0 10) lq.0 0iN 0 N = 0 0 N H".'._ o N
H 0 a c_._/ __J ---c O
* hi Nii V-o =
0 .,0 H
ON = 0 H ''''..._ o N
oH 0 ---C C
=
CI 0 4,, CI 0 ,0 GI
o * o Ni 0 ill\lii 4$ * IIX=i,<0 * IX Nii C CC) H CC) CI o CI 0 ro o ci 0 HO ..,,,, o µ0 * 11- NT o A * NAc Nji X
H tilli 0 o o 40 o N-4. 0 N
HO H
CC) \ C
C)/
CI 0 0 c)./
HN
o 0 HN o HN * NNT
* igi Nii 0 0 N 0 .<0 HC o HC 0 \
CI 0 *F 0 F 0 v.
HN
* NN .ii ..<
00 1-N * NN? o $C) o C C \
Cl 0 CI 0 >-0 0 CI
* N NT 0 H .0 HO * N=liii.
H ,0 (121 . 0 0 0 N4 o N 0 NI? 4 ON
H o H o C C H e =
, 0 4., CI 0 µ CI 0 t\I ll [IirNiii eC(3,0 0 i * Hi?
4 I-1 N Ilk X.1\1?
0 N-1. 0 N 0 N
C
CI
jc o 1 p 0 et ti.
HN *
4 N--zt 0 o N
.kk,S H 0 C C
S,) S
CI 0 ._ri H2N o cl 0 0 1 0 /Ili t [X N? jqo to H
NA*110 Nri fito Ali CI N Alf Nri ..0 illel'Ill 0 N 0 ,Nii -I; 0 N
C C C
I Cl 0 o o 0 to N;sterii 4.0 H 0 y 4,3 o N
C C
=,,, is XI 0 ci 0 0 N0 110 PI/1\1)c 0 H 0 --- \ 0 \
Cl 0 jcrelf 0 Cl 0 0 fi *
H 40 JL * Nor N7N4 ""1/4N 0 N 0 N 0 H o-\
'-\ --A
v K A 1101 oril 4 )c, 17 .4:
,,.0 io 4-.)(4.7 N....d00 0.1 0 H zt ..--\
110 XII ,,e:
N .
O H
.5....% ../loi * Iltrorq 4:
0-, 0l 0 .
jt, * Ntra 40 filo,. 0 N
1.r.N-4140 1, 0 11 0 .
Il 0 H
== N H 0 CI 0I .)'.14 H 0-.1 1-69 .
* IX.ril 4 f-f M
IP 11..)C
.40 CI 0_, . .2,4 CI 0 il 0...., 10 0 nO
I -N Xqt\i-C
15,-.1 X
_ ..
[0047] According to another embodiment, the present invention provides a compound of formula II selected from Table 2 below:
Table 2 0 CI 0 v.,.
* I\X NT j(rOH I. N -Y)r N OH 0 H
F E
= FX0 0 40 NorNiii 4 OH N
* i_IN:: T .0H OH
4.
o r\li Lr()H
11o o N
o H2 FF a N o o a o o F o * NI NT KoHli N3, Nii ,01iii IiiOH
I* to NN
H
o o * NrNii4 OH a 400 1XKOH 4)0 f)c. N?
H
0 H 0 H 0 o N. OH
,<r H
0 N 0 N Cl H 0 H 0 H o CI o o o 0 o i o * dc-N? ,OH 419 NN? ,OH NI OH
IW 11 -r TH
CI 0 H o H 0 H o H0 H0 _ JIG' 0 N H0 N H 0 i K H H
cI 0 0 0 irCF3 Ni 11 )cr N? 0 OH Ni . IX N? i _.OH
0 N Me0 0 N
..s 0 0 N Cl 0 CF, . Nri, * OH N N? = vi-c- N 0 i ._.
OH
H 0 õ)H
H H H
, 0 0 N Me0 0 N 0 NI
H 0 H 0 H o S,>
Ci 0 I NI CF3 0 * \
[il 0 NT ,..kcOH 40 0 I.
r\ii 0 1\ ...kiOH =
ri N ., H
H
0 N TN H 0? 0 N
=
CI 0 cF3o CI o Me0 N 1OH
* Nr Ni ilk i .<kr OH hl = N?
N.. HF4 . i \X .
0? H
Me0 0 h1)(0r N F3C. i kr()OH = hi) NII OH
H
-22- =
tp.-0 ,C1 c) # CI o 4- i CI
o o 0 , o iNii_i\iTkrOH * [,iii\fi OH * 6-NT
0 N o N
H 0 rl 0 H o CI 0 )p. CI 0 y 'Cc 0 CI o * NO1:Lt0H P * rYli :Ii0H
0 H 0 H *
P1).0NTNY(A)H"
g 0 N
Oy CI 0 0 )1õ,.
HN
o HO o o .()H HN 40) 1-11µ114 i(rOH * 0 ilhi ,10H
H 0 Ei 0 N H 04\ 0 0 N 0 N
or CI o HN o o 0 F 0 *
--)1-*HN * N )(roil N
Ficc: fi ,. 1-1 HN = M 0 Isli .Dill 0 H %,.. . H ,,,.
F 0 _. CI 0 )1=õ.. CI 0 O o HN 40 tnri krol-i ---(0 =11.: NN
?OH
= 0 H LiC)1.1 HO * X
i 0X.nN 0 =-=,, 0 o N H 0 v H 0 . .,OHli CI 0 ie. CI 0 te.. CI 0 * itnrf J0 11 * Ni-Nii ,0f HN N * .
H 0 .oLr!).H
HN H OH
0 N 04)¨ 0 N 0 0 N m ' , ill CI 0 4... 0 (0:1 =
CI o CI 0 A.N?
HN 46 t.,1-N'i j(OH 0H
==== 0 H 411 I-410 N? õ NH9 0 0 0 N 0 N - o N
* X OH NX a ,, .,OH
H , N H
oy N H
CI 0 CI 0 v7kIrl * XI 40H OH
H
)1 * N
H
CI 0 ),,ir 0 CI 0 N
OH
=-A0 * Ntfor N4OH H 0 * N 0 NI H
0 F 0 -kir i)I
l irx.0 1 ..,(OH ,,0 to 11 OH
0 * IX
0 0 N n NLIr - H
" 0 0 0 0 jcrl OH
tirNtlil ,,(OH
li) 1101 N
H
H
CI CI
W., 0 Njcrl ,40HH
0 N?
OH
0 0 m a " 0 [0048] In certain embodiments of this invention, the variable definitions are selected from those depicted in the compounds of Table 1 and/or Table 2.
[0049] As used herein, a specified number atoms includes any integer therein. For example, a group having from 1-4 atoms, could have 1, 2, 3, or 4 atoms.
[0050] As used herein, an aliphatic group includes straight-chained and branched groups having the specified number of atoms. If the number of atoms is unspecified, the aliphatic group has from 1 to 12 carbon atoms. As would be understood, alkenyl and/or alkynyl aliphatic groups have a minimum of 2 carbon atoms. Preferred aliphatic groups are alkyl groups (preferably having from 1 to 6 atoms).
[0051] Cycloalkyl and cycloalkenyl groups have between 3 and 10 carbon atoms and are monocyclic or bicyclic, including linearly fused, bridged, or spirocyclic.
[0052] As used herein, "aromatic group" or "aryl" refers to a 6-10-membered ring system that contains at least one aromatic ring. Examples of aromatic rings include phenyl and naphthyl.
[0053] As used herein a "heteroaryl" refers to ring system having 5-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R9), 0, S, SO, and 502., wherein at least one ring is heteroaromatic (e.g., pyri_dyl, thiophene, or thiazole).
[0054] As used herein a "heterocycLen refers to ring system having 3-10 members and 1, 2, or 3 heberoatoms independently selected from N, N(R9) , 0, S, SO, and .S02, wherein no ring is aromatic (e.g., piperidine and morphoLine).
[0055] Further examples of heteroar-y1 rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-t_hiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetra_zoly1) , triazolyl (e.g., 2-triazoly1 and 5-triazoly1), 2-thieny-1, 3-thienyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indoly1), pyrazolyl (e.g., 2-pyrazoly1), isothia_zolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyL, 1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quin_olinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolin_ya, 3-isoquinolinyl, or 4-isoquinoliny1).
[0056] Further examples of heterocy-clic rings include 3-1H-benzimidazol-2-one, 3- (1-alkyl) -benziwiidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyL, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-py-rrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrah_ydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and 1,3-dihydro-imidazol-2-one.
[00571 Each of the above aliphatic, aryl, cycloaliphatic, heteroaryl, and heterocyclyl may contain appropriate substituents (preferably up to 5) independently selected from, for example, carbonyl and R8. Preferred substituents are halogen, -0R9, -NO2, -CF3, -0CF3, -R9, oxo, -0R9, -0-benzyl, -0-phenyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, -N(R9)2, -C(0)R9, -COOR9 or -CON(R9)2, wherein R9 is defined herein (and is preferably H, (C1-C6)-alkyl, or (C2-C6)-alkenyl and alkynyl), with (C1-C6)-alkyl being most preferred). It should be understood that this definition would include a perfluorinated alkyl group.
[0058] It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms or hydrated forms, all such forms of the compounds being within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S
configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
[0059] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen hpy a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention.
(0060] The compounds of this invention may be obtained by any method, including general, synthetic methods known to those skilled in the art for analogous compounds (see e.g., WO
99/47545). For the purposes oE illustration, the following Schemes for the synthesis of ttie compounds of the present invention are provided.
[00613 The following abbreviations are used:
EDC is 1- (3-dimethylaminopropyL ) -3-ethylcarbodiimide HOBt is 1-hydroxybenzotriazole THF is tetrahydrofuran TFA is trifluoroacetic acid DCM is dichloromethane DMAP is 4-dimethylaminopyridin DIPEA is diisopropylethylamine DMF is dimethylfo/mamide TFA is trifluoroacetic acid Z is benzyloxycarbonyl IH NMR is nuclear magnetic resonance TLC is thin layer chromatography Scheme I. General scheme for the preparation of E and F
poi OPG1 A
PG2 fiA.-2 OH "-COOH ^ 0-R1 A
R.
R2 (72 0 'TN COOH
o 0 n 0 H 0-81 [0062] Scheme I depicts a general route to prepare the compounds E and F disclosed in this invention. The amino group of species A, readily obtained from reduction of the a-carboxylic group of aspartic acid (protected with PG1 as an ester), is coupled to the carboxylic acid moiety of species B
(N-protected with PG2) to give species C. PG2 and PG2 are orthogonal protecting groups (i.e., protecting groups where a protecting group may be selectively removed in the presence of another protecting group. Ideally, PG1 should be able to be removed without removing PG2 and-vice versa). Here, the aspartate part of the molecule is then manipulated in an oxidation/ketalisation/ deprotection/cyclisation sequence to give species D. The Ring A portion of D is then functionalized further to give species E which is part of the disclosed invention. Deprotection of the ketal gives species F which represent the other part of the disclosed invention.
[0063] In various embodiments of this invention, PG2 is a suitable amine protecting group, including but not limited to, the amine protecting groups described in T.W. Greene & P.G.M
Wutz, "Protective Groups in Organic Synthesis", 3rd Edition, John Wiley & Sons, Inc. (1999 and other editions) ("Greene").
A "Z" protecting group (benzyloxycarbonyl) is a particularly useful N-protecting group for use in connection with this invention. In compounds wherein PG2is protecting the nitrogen of a proline, PG2is preferably Z. It should be understood that modified Z groups ("Z-type protecting groups") employed in connection with the compounds and processes of this invention would also fall within the scope of this invention.
For example, Z could be substituted at the CH2 group or the phenyl group with R8 (preferably halo or C1-6 straight-chained or branched alkyl) to provide a Z-type protecting group.
[0064] In various embodiments of this invention, PGi is a suitable carboxylic acid protecting group, including but not limited to the acid protecting groups described in Greene. In certain embodiments, PGI is C1-6 straight-chained or branched alkyl group. A t-butyl group is a particularly useful acid protecting group for use in connection with this invention.
[0065] In Scheme I, compound A is a modified aspartic acid residue. In addition to compound A, other modified aspartic acid residues, including the following, have been reported:
N ,R, 1\1 wherein, PG3 and PG4 are appropriate protecting groups. These modified aspartic acids may be prepared by methods known to skilled practitioners. See, for example, United States Patent Application Publication US 2002/0042376 (especially page 9, paragraph [0121] and pages 21-22, paragraph [0250] and the documents cited at paragraph [0123]) and United States Patent 6,235,899. See also, C. Gros et al. "Stereochemical control in the preparation of a-amino N-methylthiazolidine Masked Aldehydes used for Peptide Aldehyde Syn.thesi" Tetrahedron, 58, pp. 2673-2680 (2002); K.T. Chapman, "Synthesis of a Potent Reversible Inhibitor of Interleukin-Z Converting Enzyme"
Bioorg. Med. Chem. Letts., 2, pp. 613-618 (1982); M.D.
Mullican et al. "The Synthesis and Evaluatiora of Peptidyl Aspartyl Aldehydes as Inhibitors of ICE'" 4, pp. 2359-2364 (1994); M.H. Chen, et al. "An Efficient Steroselective Synthesis of [3S (1S, 9S) ] -3- [ [ [9- (Benzoylamino) octahydro-6,10-Dioxo-6H-pyridazino- (1,2-a) (1,2) -Diaz epin-1-y11-carbonyl amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) Inhibitor" 9, pp. 1587-1592 (1999). Accordingly, Scheme (and also Scheme III below) could be modified to use these other aspartic acid residues.
Scheme II. Preparation of Compounds of Formulae I and II
H2N-kstrNii H ORI
0 R2 i? R2 1 R3.1( N N? (c) R3-11 N
OH
IL
0 N o N
H oR1 H 0 HN?
o N
H ORI
Reagent and conditions: (a) R3COOH, HOBt, DMA.P, EDC, THF; (b) R3CONHCH(R2)COOH, HOBt, DMAP, EDC, THF; (c) 2M HC1, MeCN.
VNN
or -- optionally substituted with R4.
. [0031] In one embodiment, Ring A is optionally substituted with R4.
[0032] In any of these embodiments, R4 is halogen, -0R9, -CF3, -0CF3, -R9, or -SR9. In certain embodiments R4 is H.
[0033] In one embodiment, R2 is a C3-4 branched alkyl group.
[0034] In another embodiment, R5 is H or -CH3, R6 is -CH3, and R7 is -CH3.
[0035] In another embodiment, R12 is -0CF3, -OCH3, -CF3, -CH3, -CH2CH3, -Cl, or -F.
[0036] In yet another embodiment, R12 is -CF3, -CH3, -Cl, or -F.
[0037] In yet another embodiment, R12 is -CH3, -Cl, or -F.
[0038] In another embodiment, each Riv, if present, is independently halogen, -0R9, -NO2, -CN, -CF3, -0CF3, -R9, 1,2-methylenedioxy, 1,2-ethylenedioxy, -N(R9)2, -SR9, -SOR9, -S02R9, -SO2N(R9)2, -C(0)R9, -c(0)C(0)N(R9)2, -C(0)N(R9)2, -0C(0)N(R9)2, -(CH2)0_2NHC(0)R9, -N(R9)S02R9, -N(R9)S02N(R9) 2i -N(R9)C(0)0R9, -N(R9)C(0)R9, Or -N(R9)C(0)N(R9)2.
[0039] In another embodiment, R8' is -NH2, -N(R9) 2, -N(R9)C(0)R9, -0CF3, -0R9, -CF3, -R9, -SR9, or halo. In this embodiment, halo is, preferably, Cl or F and R9 is, preferably, straight or branched C1-4 alkyl.
[00403 According to one embodiment, this invention provides compounds of foi.mula III:
R,NõLir 0 NT =
0,R1 III;
wherein the variables are as defined in any of the embodiments herein.
(00413 In one form of this embodiment, the compound has the stereochemistry indicated below:
R,NATN(;) 0 cd-,N40 0,R1 wherein the variables are as defined in any of the embodiments herein.
[0042] In other forms of this embodiment, the compound has the stereochemistry indicated below:
Wk R,N,Kr.NOA R, H
tJ 0 N o ,do o N
or H
0,R 0,R1 wherein the variables are as defined in any of the embodiments herein.
(0043] According to another embodiment, this invention provides compound of formula IV:
RJ
OH
IV;
wherein the variables are as defined in any of the embodiments herein.
[0044] In one form of this embodiment, the compound has the stereochemistry indicated below:
R A
wherein the variables are as defined in any of the embodiments herein.
[0045] The embodiments herein may be combined to provide a compound according to this invention.
[0046] According to one embodiment, the present invention provides a compound selected from Table 1 below:
Table 1 F.st \o * iirko *
* EX.N'i, .<0 . X- Nii 1.1.(0 =
I)c= Nii H
ON 0 N".. ON
C C C
(Xl(N Nii &LA. Nii 0 (11'%.7-....%
S H
C C C
ct ci 0 0 -0 l \---144.N.- Ni ri A.-11-N. N kli CI
,. ....
0 ,<0 0 0 1q0 i 1 o o , 1 o o o o o 0 * NI H..Nl O. . (.,..)NT
O N' . XII? N
0 1q0 0 N H 0) = if c r NI i jeo * 0 X. Ni ir.k * X N? 0 O A 00 0 4 .0 0 N 0 N'',. ON
4s, (`= 4"s.
* X.N? 0 * N Nli =
H
0 N N?
H
0 .<0 o rl H 0 H 0 ---C C
i . . -16-= vi)(9 eci'lo = hiNI?<0 .)- . * Nr-Nii H 1q0 0' N 0 N 0 N
C__/
,, CI o' CI
F3C-`-' . N..rµfi o = N.Nli 0 H ,10 0 4 ON q ON
=C
= villµlii = V.X Ni 0 0 .6 0 N = 0 N =
Ht;i1 H
L .c ' CI
0 = vi .1\11i =
INXIµI 0 * hl i 0 10) lq.0 0iN 0 N = 0 0 N H".'._ o N
H 0 a c_._/ __J ---c O
* hi Nii V-o =
0 .,0 H
ON = 0 H ''''..._ o N
oH 0 ---C C
=
CI 0 4,, CI 0 ,0 GI
o * o Ni 0 ill\lii 4$ * IIX=i,<0 * IX Nii C CC) H CC) CI o CI 0 ro o ci 0 HO ..,,,, o µ0 * 11- NT o A * NAc Nji X
H tilli 0 o o 40 o N-4. 0 N
HO H
CC) \ C
C)/
CI 0 0 c)./
HN
o 0 HN o HN * NNT
* igi Nii 0 0 N 0 .<0 HC o HC 0 \
CI 0 *F 0 F 0 v.
HN
* NN .ii ..<
00 1-N * NN? o $C) o C C \
Cl 0 CI 0 >-0 0 CI
* N NT 0 H .0 HO * N=liii.
H ,0 (121 . 0 0 0 N4 o N 0 NI? 4 ON
H o H o C C H e =
, 0 4., CI 0 µ CI 0 t\I ll [IirNiii eC(3,0 0 i * Hi?
4 I-1 N Ilk X.1\1?
0 N-1. 0 N 0 N
C
CI
jc o 1 p 0 et ti.
HN *
4 N--zt 0 o N
.kk,S H 0 C C
S,) S
CI 0 ._ri H2N o cl 0 0 1 0 /Ili t [X N? jqo to H
NA*110 Nri fito Ali CI N Alf Nri ..0 illel'Ill 0 N 0 ,Nii -I; 0 N
C C C
I Cl 0 o o 0 to N;sterii 4.0 H 0 y 4,3 o N
C C
=,,, is XI 0 ci 0 0 N0 110 PI/1\1)c 0 H 0 --- \ 0 \
Cl 0 jcrelf 0 Cl 0 0 fi *
H 40 JL * Nor N7N4 ""1/4N 0 N 0 N 0 H o-\
'-\ --A
v K A 1101 oril 4 )c, 17 .4:
,,.0 io 4-.)(4.7 N....d00 0.1 0 H zt ..--\
110 XII ,,e:
N .
O H
.5....% ../loi * Iltrorq 4:
0-, 0l 0 .
jt, * Ntra 40 filo,. 0 N
1.r.N-4140 1, 0 11 0 .
Il 0 H
== N H 0 CI 0I .)'.14 H 0-.1 1-69 .
* IX.ril 4 f-f M
IP 11..)C
.40 CI 0_, . .2,4 CI 0 il 0...., 10 0 nO
I -N Xqt\i-C
15,-.1 X
_ ..
[0047] According to another embodiment, the present invention provides a compound of formula II selected from Table 2 below:
Table 2 0 CI 0 v.,.
* I\X NT j(rOH I. N -Y)r N OH 0 H
F E
= FX0 0 40 NorNiii 4 OH N
* i_IN:: T .0H OH
4.
o r\li Lr()H
11o o N
o H2 FF a N o o a o o F o * NI NT KoHli N3, Nii ,01iii IiiOH
I* to NN
H
o o * NrNii4 OH a 400 1XKOH 4)0 f)c. N?
H
0 H 0 H 0 o N. OH
,<r H
0 N 0 N Cl H 0 H 0 H o CI o o o 0 o i o * dc-N? ,OH 419 NN? ,OH NI OH
IW 11 -r TH
CI 0 H o H 0 H o H0 H0 _ JIG' 0 N H0 N H 0 i K H H
cI 0 0 0 irCF3 Ni 11 )cr N? 0 OH Ni . IX N? i _.OH
0 N Me0 0 N
..s 0 0 N Cl 0 CF, . Nri, * OH N N? = vi-c- N 0 i ._.
OH
H 0 õ)H
H H H
, 0 0 N Me0 0 N 0 NI
H 0 H 0 H o S,>
Ci 0 I NI CF3 0 * \
[il 0 NT ,..kcOH 40 0 I.
r\ii 0 1\ ...kiOH =
ri N ., H
H
0 N TN H 0? 0 N
=
CI 0 cF3o CI o Me0 N 1OH
* Nr Ni ilk i .<kr OH hl = N?
N.. HF4 . i \X .
0? H
Me0 0 h1)(0r N F3C. i kr()OH = hi) NII OH
H
-22- =
tp.-0 ,C1 c) # CI o 4- i CI
o o 0 , o iNii_i\iTkrOH * [,iii\fi OH * 6-NT
0 N o N
H 0 rl 0 H o CI 0 )p. CI 0 y 'Cc 0 CI o * NO1:Lt0H P * rYli :Ii0H
0 H 0 H *
P1).0NTNY(A)H"
g 0 N
Oy CI 0 0 )1õ,.
HN
o HO o o .()H HN 40) 1-11µ114 i(rOH * 0 ilhi ,10H
H 0 Ei 0 N H 04\ 0 0 N 0 N
or CI o HN o o 0 F 0 *
--)1-*HN * N )(roil N
Ficc: fi ,. 1-1 HN = M 0 Isli .Dill 0 H %,.. . H ,,,.
F 0 _. CI 0 )1=õ.. CI 0 O o HN 40 tnri krol-i ---(0 =11.: NN
?OH
= 0 H LiC)1.1 HO * X
i 0X.nN 0 =-=,, 0 o N H 0 v H 0 . .,OHli CI 0 ie. CI 0 te.. CI 0 * itnrf J0 11 * Ni-Nii ,0f HN N * .
H 0 .oLr!).H
HN H OH
0 N 04)¨ 0 N 0 0 N m ' , ill CI 0 4... 0 (0:1 =
CI o CI 0 A.N?
HN 46 t.,1-N'i j(OH 0H
==== 0 H 411 I-410 N? õ NH9 0 0 0 N 0 N - o N
* X OH NX a ,, .,OH
H , N H
oy N H
CI 0 CI 0 v7kIrl * XI 40H OH
H
)1 * N
H
CI 0 ),,ir 0 CI 0 N
OH
=-A0 * Ntfor N4OH H 0 * N 0 NI H
0 F 0 -kir i)I
l irx.0 1 ..,(OH ,,0 to 11 OH
0 * IX
0 0 N n NLIr - H
" 0 0 0 0 jcrl OH
tirNtlil ,,(OH
li) 1101 N
H
H
CI CI
W., 0 Njcrl ,40HH
0 N?
OH
0 0 m a " 0 [0048] In certain embodiments of this invention, the variable definitions are selected from those depicted in the compounds of Table 1 and/or Table 2.
[0049] As used herein, a specified number atoms includes any integer therein. For example, a group having from 1-4 atoms, could have 1, 2, 3, or 4 atoms.
[0050] As used herein, an aliphatic group includes straight-chained and branched groups having the specified number of atoms. If the number of atoms is unspecified, the aliphatic group has from 1 to 12 carbon atoms. As would be understood, alkenyl and/or alkynyl aliphatic groups have a minimum of 2 carbon atoms. Preferred aliphatic groups are alkyl groups (preferably having from 1 to 6 atoms).
[0051] Cycloalkyl and cycloalkenyl groups have between 3 and 10 carbon atoms and are monocyclic or bicyclic, including linearly fused, bridged, or spirocyclic.
[0052] As used herein, "aromatic group" or "aryl" refers to a 6-10-membered ring system that contains at least one aromatic ring. Examples of aromatic rings include phenyl and naphthyl.
[0053] As used herein a "heteroaryl" refers to ring system having 5-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R9), 0, S, SO, and 502., wherein at least one ring is heteroaromatic (e.g., pyri_dyl, thiophene, or thiazole).
[0054] As used herein a "heterocycLen refers to ring system having 3-10 members and 1, 2, or 3 heberoatoms independently selected from N, N(R9) , 0, S, SO, and .S02, wherein no ring is aromatic (e.g., piperidine and morphoLine).
[0055] Further examples of heteroar-y1 rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-t_hiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetra_zoly1) , triazolyl (e.g., 2-triazoly1 and 5-triazoly1), 2-thieny-1, 3-thienyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indoly1), pyrazolyl (e.g., 2-pyrazoly1), isothia_zolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyL, 1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quin_olinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolin_ya, 3-isoquinolinyl, or 4-isoquinoliny1).
[0056] Further examples of heterocy-clic rings include 3-1H-benzimidazol-2-one, 3- (1-alkyl) -benziwiidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyL, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-py-rrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrah_ydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and 1,3-dihydro-imidazol-2-one.
[00571 Each of the above aliphatic, aryl, cycloaliphatic, heteroaryl, and heterocyclyl may contain appropriate substituents (preferably up to 5) independently selected from, for example, carbonyl and R8. Preferred substituents are halogen, -0R9, -NO2, -CF3, -0CF3, -R9, oxo, -0R9, -0-benzyl, -0-phenyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, -N(R9)2, -C(0)R9, -COOR9 or -CON(R9)2, wherein R9 is defined herein (and is preferably H, (C1-C6)-alkyl, or (C2-C6)-alkenyl and alkynyl), with (C1-C6)-alkyl being most preferred). It should be understood that this definition would include a perfluorinated alkyl group.
[0058] It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms or hydrated forms, all such forms of the compounds being within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S
configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
[0059] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen hpy a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention.
(0060] The compounds of this invention may be obtained by any method, including general, synthetic methods known to those skilled in the art for analogous compounds (see e.g., WO
99/47545). For the purposes oE illustration, the following Schemes for the synthesis of ttie compounds of the present invention are provided.
[00613 The following abbreviations are used:
EDC is 1- (3-dimethylaminopropyL ) -3-ethylcarbodiimide HOBt is 1-hydroxybenzotriazole THF is tetrahydrofuran TFA is trifluoroacetic acid DCM is dichloromethane DMAP is 4-dimethylaminopyridin DIPEA is diisopropylethylamine DMF is dimethylfo/mamide TFA is trifluoroacetic acid Z is benzyloxycarbonyl IH NMR is nuclear magnetic resonance TLC is thin layer chromatography Scheme I. General scheme for the preparation of E and F
poi OPG1 A
PG2 fiA.-2 OH "-COOH ^ 0-R1 A
R.
R2 (72 0 'TN COOH
o 0 n 0 H 0-81 [0062] Scheme I depicts a general route to prepare the compounds E and F disclosed in this invention. The amino group of species A, readily obtained from reduction of the a-carboxylic group of aspartic acid (protected with PG1 as an ester), is coupled to the carboxylic acid moiety of species B
(N-protected with PG2) to give species C. PG2 and PG2 are orthogonal protecting groups (i.e., protecting groups where a protecting group may be selectively removed in the presence of another protecting group. Ideally, PG1 should be able to be removed without removing PG2 and-vice versa). Here, the aspartate part of the molecule is then manipulated in an oxidation/ketalisation/ deprotection/cyclisation sequence to give species D. The Ring A portion of D is then functionalized further to give species E which is part of the disclosed invention. Deprotection of the ketal gives species F which represent the other part of the disclosed invention.
[0063] In various embodiments of this invention, PG2 is a suitable amine protecting group, including but not limited to, the amine protecting groups described in T.W. Greene & P.G.M
Wutz, "Protective Groups in Organic Synthesis", 3rd Edition, John Wiley & Sons, Inc. (1999 and other editions) ("Greene").
A "Z" protecting group (benzyloxycarbonyl) is a particularly useful N-protecting group for use in connection with this invention. In compounds wherein PG2is protecting the nitrogen of a proline, PG2is preferably Z. It should be understood that modified Z groups ("Z-type protecting groups") employed in connection with the compounds and processes of this invention would also fall within the scope of this invention.
For example, Z could be substituted at the CH2 group or the phenyl group with R8 (preferably halo or C1-6 straight-chained or branched alkyl) to provide a Z-type protecting group.
[0064] In various embodiments of this invention, PGi is a suitable carboxylic acid protecting group, including but not limited to the acid protecting groups described in Greene. In certain embodiments, PGI is C1-6 straight-chained or branched alkyl group. A t-butyl group is a particularly useful acid protecting group for use in connection with this invention.
[0065] In Scheme I, compound A is a modified aspartic acid residue. In addition to compound A, other modified aspartic acid residues, including the following, have been reported:
N ,R, 1\1 wherein, PG3 and PG4 are appropriate protecting groups. These modified aspartic acids may be prepared by methods known to skilled practitioners. See, for example, United States Patent Application Publication US 2002/0042376 (especially page 9, paragraph [0121] and pages 21-22, paragraph [0250] and the documents cited at paragraph [0123]) and United States Patent 6,235,899. See also, C. Gros et al. "Stereochemical control in the preparation of a-amino N-methylthiazolidine Masked Aldehydes used for Peptide Aldehyde Syn.thesi" Tetrahedron, 58, pp. 2673-2680 (2002); K.T. Chapman, "Synthesis of a Potent Reversible Inhibitor of Interleukin-Z Converting Enzyme"
Bioorg. Med. Chem. Letts., 2, pp. 613-618 (1982); M.D.
Mullican et al. "The Synthesis and Evaluatiora of Peptidyl Aspartyl Aldehydes as Inhibitors of ICE'" 4, pp. 2359-2364 (1994); M.H. Chen, et al. "An Efficient Steroselective Synthesis of [3S (1S, 9S) ] -3- [ [ [9- (Benzoylamino) octahydro-6,10-Dioxo-6H-pyridazino- (1,2-a) (1,2) -Diaz epin-1-y11-carbonyl amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) Inhibitor" 9, pp. 1587-1592 (1999). Accordingly, Scheme (and also Scheme III below) could be modified to use these other aspartic acid residues.
Scheme II. Preparation of Compounds of Formulae I and II
H2N-kstrNii H ORI
0 R2 i? R2 1 R3.1( N N? (c) R3-11 N
OH
IL
0 N o N
H oR1 H 0 HN?
o N
H ORI
Reagent and conditions: (a) R3COOH, HOBt, DMA.P, EDC, THF; (b) R3CONHCH(R2)COOH, HOBt, DMAP, EDC, THF; (c) 2M HC1, MeCN.
[0066] Scheme II depicts formation of compounds of formula I and 11, wherein Ring A is unsubstituted proline. Here the cyclic acetal form of a compound of this invention is depicted as formula I and the aldehyde form is depicted as formula TI.
Compounds having a Ring A other than unsubstituted proline could .be substituted in the methods depicted in Scheme I.
[00673 Scheme II depicts the routes utilized to prepare compounds of formulae I and II. Compounds I can be prepared from compounds 1 by condensation of the amino group in 1 with the suitably functionalized carboxylic acid (or derivative).
In this step, standard coupling reagents to form amide bonds have been depicted; other conditions known in the art to form amide bonds can also be used.
[0068] As known to skilled practitioners, a carboxylic acid (-C(0)0H) can be coupled to the amine under appropriate conditions for coupling amines and carboxylic acids.
Alternatively, in such couplings, a carboxylic acid derivative (-C(0)X) may be employed instead of the carboxylic acid. It should be understood that in the context of coupling an amine and a carboxylic acid derivative, the derivative would activate the acid to facilitate coupling to an amine.
Appropriate X groups are essentially leaving groups and are known to skilled practitioners. "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001.
[0069] Typical conditions for coupling an amine and an acid include combining a suitable solvent, a carboxylic acid, a base, and a peptide-coupling reagent. Examples of suitable conditions are described in US2002/0042376 and WO 01/81330.
In certain embodiments, the conditions are as described in the Schemes and Examples herein.
Compounds having a Ring A other than unsubstituted proline could .be substituted in the methods depicted in Scheme I.
[00673 Scheme II depicts the routes utilized to prepare compounds of formulae I and II. Compounds I can be prepared from compounds 1 by condensation of the amino group in 1 with the suitably functionalized carboxylic acid (or derivative).
In this step, standard coupling reagents to form amide bonds have been depicted; other conditions known in the art to form amide bonds can also be used.
[0068] As known to skilled practitioners, a carboxylic acid (-C(0)0H) can be coupled to the amine under appropriate conditions for coupling amines and carboxylic acids.
Alternatively, in such couplings, a carboxylic acid derivative (-C(0)X) may be employed instead of the carboxylic acid. It should be understood that in the context of coupling an amine and a carboxylic acid derivative, the derivative would activate the acid to facilitate coupling to an amine.
Appropriate X groups are essentially leaving groups and are known to skilled practitioners. "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001.
[0069] Typical conditions for coupling an amine and an acid include combining a suitable solvent, a carboxylic acid, a base, and a peptide-coupling reagent. Examples of suitable conditions are described in US2002/0042376 and WO 01/81330.
In certain embodiments, the conditions are as described in the Schemes and Examples herein.
(0070] Examples of appropriate derivatives include, but are not limited to, compounds of the formula RX wherein X is Cl, F, OC(=0)R" (R" is aliphatic or aryl), SH, SR, SAr, or SeAr.
In some embodiments R is C(=0). Suitable conditions fox:- using these appropriate derivatives are known in the art.
Scheme III. Preparation of Compound 1 .eco2tsu (a) zni? co21su (b) (c) CO2iBu d (d) tic) (e) HN? R2 (f) ZHN CD
.* ZHN.X.y0H
H OW H OR1 H cDR1 (g) H2N 141 irko o /4"Iµ
H oW
Reagent and conditions: (a) Cbz-Pro-OH, EDC, HOBt, DMAP, DIPEA, THF; (b) Swern; (c) R1OH, 3A sieves, DCM, Ts0H; (d) TFA, DCM; (e) H2, Pd(OH)2, Et0Ac, DMF, EtiN; (f) EDC, HOBt, Et3N, Et0Ac, DMF; (g) H2, Pd/C, Citrate Acid.
[0071] Scheme III
depicts a possible route to prepare compounds 7 and compounds 1 described in scheme I. Comound 2, readily obtained from reduction of the a-carboxylic group of aspartic acid, is coupled to N-protected proline (or other ring, wherein Ring A is other than unsubstituted prolin) to form 3. Here, the proline is N-protected with a Z
(benzyloxycarbonyl) group. Compounds 3 are then oxidizei into the aldehydes 4 which are acetalized in situ to give the acetals 5. Acetals can be formed in the presence of R1-0H (or a suitable acetal forming reagent), a protic acid (for example, Ts0H), or a Lewis acid, and a suitable solvent.
Examples of suitable acetal forming reagents that form compounds wherein R1 is to become ethyl can be considered ethanol equivalents and include, but are not limited to, triethylorthoformate or a diethylacetal, such as a (CH3)2C(OCH2CH3)2. Preferably, the solvent is CH2C12, toluene, or chlorobenzene. Appropriate protic acids include, but are not limited to, TFA, p-T50H. Appropriate Lewis acids include, but are not limited to TiC14, MgEr2, and ZnC12.
[0072] In Scheme III, the oxidation of compounds 3 to compounds 4 is depicted as being done under Swern conditions.
Other oxidation conditions may also be employed to prepare compounds of this invention. Preferred oxidation conditions are those that a mild and relatively quick to minimize epimerization at the acid side chain of the modified aspartic acid residue. In one embodiment, the oxidation step is a TEMPO oxidation (see Example I-1, Method C, below). Other oxidation conditions include a Dess-Martin oxidation and a tetrapropylammonium perruthenate (TPAP) oxidation.
[0073] Aldehydes 4 may be isolated but are preferably carried through directly to 5 without isolation. Deprotection of the tert-butyl ester (in 5) is accompanied by spontaneous ring cyclization to give a mixture of diastereoisomers which were separated by column chromatography to give the enantiomerically pure syn ketals 6 and anti ketals (not represented in this scheme). The deprotection may be done under protic acid or Lewis acid conditions in an appropriate solvent. Appropriate solvents include, but are not limited to, toluene, chlorobenzene, and DCM. Appropriate protic acids include, but are not limited to, TFA, p-T50H. Appropriate Lewis acids include, but are not limited to TiC14, MgBr2, and ZnC12. For clarity of the scheme, only syn ketals are represented in the next steps to form compounds 7 and 1 but the same sequence may be used to form anti ketals. Compounds 6 are submitted to hydrogenolysis and the resulting compounds 7 are reacted with Z-protected aminoacids, using conditions known in the art to prepare amide bonds, to yield compounds 9.
Compounds 7 may be generated and used in situ. If isolated, it is preferable to use compounds 7 relatively soon after generation. Compounds 9 are finally submitted to hydrogenolysis to give compounds 1, which can be used directly to prepare compounds I, as depicted in Scheme II.
[0074] Alternatively, compounds 7 can be used to prepare compounds I, as depicted in Scheme II. In this preparation, an amino acid residue and the desired N -terminal group is =
prepared in one step (see, Scheme II, reaction (b)).
[0075] As described in connection with Scheme I, aspartic acid derivatives other than compounds 2 can be employed to obtain compounds of this invention.
Scheme IV. Preparation of Compounds of Foriuulae III and IV
Fe 11 R11)SrT4) -(-c2o-o N o OR1 " 0 44:) na TV
o N
H oW
Reagent and conditions: (a) ROH / HOBt / DMAP / EDC/ THF or Rd 1 / Et3N / DCM; (b) RNHCH(R2)COOH, HOBt, DMAP, EDC, THF;(c) 2M HC1, MeCN.
In some embodiments R is C(=0). Suitable conditions fox:- using these appropriate derivatives are known in the art.
Scheme III. Preparation of Compound 1 .eco2tsu (a) zni? co21su (b) (c) CO2iBu d (d) tic) (e) HN? R2 (f) ZHN CD
.* ZHN.X.y0H
H OW H OR1 H cDR1 (g) H2N 141 irko o /4"Iµ
H oW
Reagent and conditions: (a) Cbz-Pro-OH, EDC, HOBt, DMAP, DIPEA, THF; (b) Swern; (c) R1OH, 3A sieves, DCM, Ts0H; (d) TFA, DCM; (e) H2, Pd(OH)2, Et0Ac, DMF, EtiN; (f) EDC, HOBt, Et3N, Et0Ac, DMF; (g) H2, Pd/C, Citrate Acid.
[0071] Scheme III
depicts a possible route to prepare compounds 7 and compounds 1 described in scheme I. Comound 2, readily obtained from reduction of the a-carboxylic group of aspartic acid, is coupled to N-protected proline (or other ring, wherein Ring A is other than unsubstituted prolin) to form 3. Here, the proline is N-protected with a Z
(benzyloxycarbonyl) group. Compounds 3 are then oxidizei into the aldehydes 4 which are acetalized in situ to give the acetals 5. Acetals can be formed in the presence of R1-0H (or a suitable acetal forming reagent), a protic acid (for example, Ts0H), or a Lewis acid, and a suitable solvent.
Examples of suitable acetal forming reagents that form compounds wherein R1 is to become ethyl can be considered ethanol equivalents and include, but are not limited to, triethylorthoformate or a diethylacetal, such as a (CH3)2C(OCH2CH3)2. Preferably, the solvent is CH2C12, toluene, or chlorobenzene. Appropriate protic acids include, but are not limited to, TFA, p-T50H. Appropriate Lewis acids include, but are not limited to TiC14, MgEr2, and ZnC12.
[0072] In Scheme III, the oxidation of compounds 3 to compounds 4 is depicted as being done under Swern conditions.
Other oxidation conditions may also be employed to prepare compounds of this invention. Preferred oxidation conditions are those that a mild and relatively quick to minimize epimerization at the acid side chain of the modified aspartic acid residue. In one embodiment, the oxidation step is a TEMPO oxidation (see Example I-1, Method C, below). Other oxidation conditions include a Dess-Martin oxidation and a tetrapropylammonium perruthenate (TPAP) oxidation.
[0073] Aldehydes 4 may be isolated but are preferably carried through directly to 5 without isolation. Deprotection of the tert-butyl ester (in 5) is accompanied by spontaneous ring cyclization to give a mixture of diastereoisomers which were separated by column chromatography to give the enantiomerically pure syn ketals 6 and anti ketals (not represented in this scheme). The deprotection may be done under protic acid or Lewis acid conditions in an appropriate solvent. Appropriate solvents include, but are not limited to, toluene, chlorobenzene, and DCM. Appropriate protic acids include, but are not limited to, TFA, p-T50H. Appropriate Lewis acids include, but are not limited to TiC14, MgBr2, and ZnC12. For clarity of the scheme, only syn ketals are represented in the next steps to form compounds 7 and 1 but the same sequence may be used to form anti ketals. Compounds 6 are submitted to hydrogenolysis and the resulting compounds 7 are reacted with Z-protected aminoacids, using conditions known in the art to prepare amide bonds, to yield compounds 9.
Compounds 7 may be generated and used in situ. If isolated, it is preferable to use compounds 7 relatively soon after generation. Compounds 9 are finally submitted to hydrogenolysis to give compounds 1, which can be used directly to prepare compounds I, as depicted in Scheme II.
[0074] Alternatively, compounds 7 can be used to prepare compounds I, as depicted in Scheme II. In this preparation, an amino acid residue and the desired N -terminal group is =
prepared in one step (see, Scheme II, reaction (b)).
[0075] As described in connection with Scheme I, aspartic acid derivatives other than compounds 2 can be employed to obtain compounds of this invention.
Scheme IV. Preparation of Compounds of Foriuulae III and IV
Fe 11 R11)SrT4) -(-c2o-o N o OR1 " 0 44:) na TV
o N
H oW
Reagent and conditions: (a) ROH / HOBt / DMAP / EDC/ THF or Rd 1 / Et3N / DCM; (b) RNHCH(R2)COOH, HOBt, DMAP, EDC, THF;(c) 2M HC1, MeCN.
[0076] Scheme rv depicts formation of compounds of formula III and IV, wherein Ring A is 2-Aza-bicyclo[2.2.1]-heptane-3-carboxylic acid. Here the cyclic acetal form of a compound of this invention is depicted as formula III and the aldehyde form is depicted as formula IV. Scheme IV depicts the routes utilized to prepare compounds of formulae III and IV.
Compounds III can be prepared from compounds 11 by condensation of the amino group in 11 under conditions to provide the desired R group, such as suitably functionalized carboxylic acid (or derivative), sulfonic acid (or derivative), chloroformate or carbamoyl chloride (or isocyanate), for example, under appropriate reaction condition. In this step, standard coupling reagents to form CO-NH bonds have been depicted; other conditions known in the art to form CO-NH or alkyl-N, or S02-N) bonds can also be used to provide the desired compound comprising R-N.
Alternatively, compounds I can be prepared from compounds 17 by condensation of the amino group in 17 with the suitably functionalized carboxylic acid (or derivative), sulfonic acid (or derivative), chlorofolmate or carbamoyl chloride (or isocyanate). In this step, standard coupling reagents to form CO-NH bonds have been depicted; other conditions known in the art to form CO-NH bonds can also be used.
Compounds III can be prepared from compounds 11 by condensation of the amino group in 11 under conditions to provide the desired R group, such as suitably functionalized carboxylic acid (or derivative), sulfonic acid (or derivative), chloroformate or carbamoyl chloride (or isocyanate), for example, under appropriate reaction condition. In this step, standard coupling reagents to form CO-NH bonds have been depicted; other conditions known in the art to form CO-NH or alkyl-N, or S02-N) bonds can also be used to provide the desired compound comprising R-N.
Alternatively, compounds I can be prepared from compounds 17 by condensation of the amino group in 17 with the suitably functionalized carboxylic acid (or derivative), sulfonic acid (or derivative), chlorofolmate or carbamoyl chloride (or isocyanate). In this step, standard coupling reagents to form CO-NH bonds have been depicted; other conditions known in the art to form CO-NH bonds can also be used.
Scheme V. Preparation of Compound 11 = 62.i =
eco2tOH u (a) ZNt? LeCO21Bu (b) ZI(14 021Bu (c) ZN? CO21Bu eL ..OH ,c() fy0R1 re ow (d) zi,C? (e)R2 0 N
40 + ZHN ZHNAy0H (f)), (g) 0 = 40 H
Reagent and conditions: (a) EDC, HOBt, DMAP, DIPEA, THF; (b) Swern; (c) R1OH, 3A sieves, DCM, Ts0H; (d) TFA, DCM; (e) H2, Pd(OH)2, EtOAC, DMF, Et3N; (f) EDC, HOBt, Et3N, Et0Ac, DMF; (g) 11[2, Pd/C, Citrate Acid.
[0077] Scheme V depicts a possible route to prepare compounds 17 and compounds 11 described in scheme III.
Compound 2, readily obtained from reduction of the a-carboxylic group of aspartic acid, is coupled to N-protected 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid 10 (prepared as in Tetrahedron: Asymmetry, 13, 2002, 25-28) to form 13.
Compound 13 is then oxidized into the aldehyde 14 which is acetalized in situ to give the acetals 15. Deprotection of the tert-butyl ester is accompanied by spontaneous ring cyclization to give a mixture of diastereoisomers which were separated by column chromatography to give the enantiomerically pure syn ketals 16 and anti ketals (not represented in this scheme). Alternative Ring A groups are either commercially available, reported in the literature, or may be prepared according to methods known in the literature.
[0078] For clarity of the scheme, only syn ketals are represented in the next steps to form compounds 17 and 11 but the same sequence may be used to form anti ketals. Compounds 16 are submitted to hydrogenolysis and the resulting compounds 17 are reacted with Z-protected aminoacids, using conditions known in the art to prepare amide bonds, to yield compounds 19.
[0079] Alternatively, compounds 17 can be used to prepare compounds III, as depicted in Scheme IV. Compounds 19 are finally submitted to hydrogenolysis to give compounds 11, which can be used directly to prepare compounds III, as depicted in Scheme IV.
[0080] The R3COOH used in Scheme II are either commercially available, reported in the literature, or prepared according to methods known in the literature. For compound 11-30, 2-chloro-3-methoxybentoic acid was prepared as in J.Org.Chem, 59, 1994, 2939-2944.
[0081] For compound 11-32, 2-chloro-3-trifluoromethoxybenzoic acid was prepared from 2-amino-3-trifluoromethoxybenzoic acid (prepared as in J.Org.Chem, 68, 2003, 4693-4699) using a Sandmeyer replacement of the amino group by a chloro, according to a method substantially similar to the one reported in J.Org.Chem, 59, 1994, 2939-2944.
[0082] Accordingly, this invention also provides a process for preparing a compound of this invention.
[ 00831 In one embodiment is provided a process for preparing a compound of formula I:
o wherein Y is:
0, = R
and the other variables are as defined in any of the embodiments herein;
comprising reacting a compound of formula 1:
R
wherein the variables are as defined in any of the embodiments herein; and a compound of formula RX, wherein X is OH or an appropriate derivative (i.e., leaving group), in the presence of conditions for coupling an amine and an acid (when X is OH) or an amine and an appropriate acid derivative (when X is not OH (i.e., a leaving group; for example, Cl) to provide the compound of formula I.
[0084] Another embodiment provides a process for preparing a compound of formula I:
RNLr H
wherein Y is:
'22.246 and the other variables are as defined in any of the embodiments herein;
comprising reacting a compound of formula 7:
1(3 0 Rl wherein the variables are as defined in any of the embodiments herein, and a compound of formula RNHCH(R2)C(0)X, wherein X is OH or an appropriate derivative, in the presence of conditions for coupling an amine and an acid (when X is OH) or an appropriate acid derivative (when x is not OH; for example, X
is Cl) to provide the compound of formula I.
[0085] Yet another embodiment of this invention provides a process for preparing a compound of formula IV:
OH
= 0 IV
wherein the variables are as defined in any of the embodiments herein, comprising reacting a compound of formula I:
R, 0 ,Y
wherein Y is:
\40 wherein R and R1 are each independently as defined in any of the embodiments herein, under hydrolysis conditions, to provide the compound of formula II. In certain embodiments, R
is R3C(=0) . In yet other embodiments, when A is proline, R is R3C(=0) . Hydrolysis conditions for converting I to II are well known to skilled practitioners (see e.g., Greene). Such conditions include an appropriate solvent (e.g., acetonitrile) and aqueous acid (e.g., 2M HC1).
[0086] Another embodiment provides a process for preparing a compound of formula 6-A:
PG2 ¨N 0 wherein PG2 is a suitable nitrogen protecting group and R' is as defined in any of the embodiments herein, comprising reacting a compound of formula 5-A:
PG2¨N"1'PG1 Ges'14 ORI
under suitable ring cyclization conditions, to provide the compound of formula 6-A. Suitable ring cyclization conditions include an acid and a suitable solvent; for example, TFA in DCM.
[0087] Another embodiment provides a process for preparing a compound of formula 5-A:
PG2¨N(,) ,PG1 comprising reacting a compound of formula 4-A:
PG2 ¨N 0'PGI
ONThrH
in the presence of R.3.-OH (or a suitable acetal forming reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 5-A.
[0088] Another embodiment provides a process for preparing a compound of formula 4-A:
..
=
PG2 ¨T0 .... ,PG1 H
comprising reacting a compound of formula 3-A:
PG2---N A AoõPG' (:1?
0 N"¨') H OH
under suitable oxidation conditions (for example, a Swern oxidation: Mancuso, A.J.; Swern, D. Synthesis, 1981, 165-185) to provide the compound of formula 4-A. Preferred oxidation conditions include a TEMPO oxidation (see Example I-1, Method C, below).
[00893 Another embodiment provides a process for preparing a compound of formula 3-A:
PG2 ¨Nli2t,õ1õ ,PG1 H
OH
comprising:
reacting a compound of formula 2:
..õ.11,o,PG1 H2N----) OH
with a compound of foLmula 20-A:
_ =
under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 3-A.
[0090] Another embodiment provides a process for preparing a compound of foLmula 6:
pG2_Ny 0 N'14 OR"
wherein PG2 is a suitable nitrogen protecting group and R1 is as defined in any of the embodiments herein, comprising reacting a compound of formula 5:
PG2 ¨NO ...,PG1 OR"
under suitable cyclization conditions, to provide the compound of formula 6.
[0091] Another embodiment provides a process for preparing a compound of formula 5:
PG2 -N õ.PG1 comprising reacting a compound of formula 4:
pG2_1,1,) ,.PG1 OteyH
in the presence of 1R.3--OH (or a suitable acetal forming reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 5.
Preferably, the solvent is CH2C12, toluene, or chlorobenzene.
[0092] Another embodiment provides a process for preparing a compound of formula 4:
O Nr--yH
comprising reacting a compound of foLmula 3:
PG2-N õ..PG1 ON
OH
under suitable oxidation conditions (for example a Swern oxidation) to provide the compound of formula 4. Preferred oxidation conditions include a TEMPO oxidation (see Example I-1, Method C, below).
[0093] Another embodiment provides a process for preparing a compound of formula 3:
pG2¨d\ pG, OH
comprising:
reacting a compound of formula 2:
,PG1 OH
with a compound of formula 20:
PG2 ¨NO
under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 3.
[0094] Another embodiment provides a process for preparing a compound of formula 16:
ON
wherein PG2 is a suitable nitrogen protecting group and R1 is as defined in any of the embodiments herein, comprising reacting a compound of formula 15:
.
PG2¨N
= OR1 under suitable cycli.zation conditions, to provide the compound of formula 16.
[0095] Another embodiment provides a process for preparing a. compound of formula 15:
PG2-1V,,,. PG
0' I
= OR1 comprising reacting a compound of formula 14:
PG2 ,PG1 = 0 in the presence of R'-OH (or a suitable acetal forming reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 15.
[0096] Another embodiment provides a process for preparing a compound of formula 14:
PG2 ¨IT A .13G, N---e = 0 comprising reacting a compound of formula 13:
,PG1 OH
under suitable oxidation conditions (example, a Swern oxidation) to provide the compound of formula 14.
[0097] Another embodiment provides a process for preparing a compound of formula 13:
PG2-1\140 , ,pGi OH
comprising reacting a compound of formula 2 with a compound of formula 21:
pG2-N
under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 13.
[0098] Another embodiment provides a process for preparing a compound of formula 22:
0õ.
,PG1 comprising reacting a compound of formula 23:
=
/1:A; .,PG1 in the presence of R.1-0H (or a suitable acetal fotwing reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 22.
Acetal forming equivalents include, but are not limited to, triethylorthoformate, a diethylacetal, such as a (CH3)2C(OCH2CH3)2. Preferably, the solvent is CH2C12, toluene, or chlorobenzene.
[0099]
Another embodiment provides a process for preparing a compound of formula 23 comprising reacting a compound of =
formula 2:
0'13G1 OH
under suitable oxidation conditions (example Swern) to provide the compound of formula 23.
[0100]
Another embodiment provides a process for preparing a compound of formula 5-A
PG2¨N Poi 0' oNyOR1 wherein PG1 is a suitable carboxylic acid protecting group, PG2 is a suitable nitrogen-protecting group, and R1 is as defined in any one of claims 1 or 5-9, comprising:
=
reacting a compound of formula 20-A:
PG2¨NA
with a compound of formula 22 = õ.PG1 OR"
1-121q under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is an appropriate leaving group), to provide the compound of formula 5-.A.
[0101]
Another embodiment provides a process for preparing a compound of formula 5:
PG2¨NO PG1 comprising reacting a compound of formula 20:
with a compound of formula 22 .., .
A
' =
. W02005/085236 , H2N,..,-..i...0R1 under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid .
(when X is not OH), to provide the compound of formula 5.
.
(0102]
Another embodiment provides a process for preparing a compound of formula 5-A:
PG2 --1,.... -1:3(11 , 5-A , comprising reacting a compound of formula 21:
PG2.--N
with a compound of formula 22 PG.I
=
OW
HOs1 under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 5-A.
, _ =
[0103] In accordance with this invention, the processes may be used alone or in combination to provide a compound of this invention.
[0104] Certain specific embodiments of this invention provide processes for preparing compounds 4 from 3 (in embodiments where compounds 4 are isolated); 5 from 3 (in embodiments where compounds 4 is not isolated but carried on directly, e.g., generated in situ); 5 from 4; and 6 from 5 according to the methods disclosed herein. In a preferred embodiment, compounds 6 are prepared from. compounds 5;
compounds 5 are prepared from compounds 4 (Whether isolated or not); and compounds 4 are prepared from 3. Preferably, compounds 6 are used in the preparation of proline containing caspase inhibitors. Such proline containing caspase inhibitors include, but are not limited to, those disclosed in WO 95/35308, WO 99/47545, W0.01/81330, and WO 01/90063.
For example, compound IA (and stereoisomers thereof) of WO 01/90063 could be prepared as disclosed herein (see, e.g., page 13). For the avoidance of doubt, it should be understood that such proline containing compounds could be depicted by- formula I except that Ring A is pyrrolidine -- (i.e. is derived from proline).
0105] The processes for converting compounds 6 to proline containing caspase inhibitors are preferably as disclosed herein. The processes for preparing compounds 3 are also preferably as disclosed herein. However other processes known to skilled practitioners could be used to convert compounds 6 to proline containing caspase inhibitors and/or to prepare compounds 3.
&
, WO 2005/085236 (0106] Other embodiments of this invention provide the compounds of formula 3 to 6, 3-A to 6-A, and 13-16.
(0107] One embodiment of this invention provides the compounds of formula 4A:
PG2.--i\CD oõPG1 4A.
(0108] Another embodiment of this invention provides the compounds of formula 4:
PG2-0 o./.PG1 H
, 0 4.
[0109] Another embodiment of this invention provides the compounds of formula 14:
PGr-N ,,11,=0,PG1 14' =
O N---)(H
14.
[0110] One embodiment of this invention provides the compounds of formula 5-A:
PG2¨NO. )1.,o'Pal ONrOR1 H
5-A.
0111] Another embodiment of this invention provides the compounds of formula 5:
-PG2-N2 cr,PG1 5.
[0112] Another embodiment of this invention provides the compounds of formula 15:
PG2-1\11 o.,PG1 = OR1 15.
[0113] One embodiment of this invention provides the compounds of formula 3-A:
PG2¨N
= OH
3-A.
[0114] Another embodiment of this invention provides the compounds of formula 3:
PG2¨Ny OH
[0115] Another embodiment of this invention provides the compounds of formula 13:
PG2¨N71,A. .PG1 = OH
13.
[0116] In all the above embodiments, the variables are as defined in any of the embodiments herein. In a preferred form of 3, PG2 is Z and PG1 is C1-6 straight-chained or bran.ched alkyl group (preferably a t-butyl group), either alone or in combination.
[0117] As would be realized by skilled practitioners certain process steps may be accomplished in discrete steps or in situ. For example, deprotection and subsequent reaction of an amine may be accomplished by step-wise (by isolating the amine) or in a one step procedure (without isolating the amine).
[0118] In certain embodiments, the above processes are conducted as described herein (e.g., in the schemes, examples, and accompanying description).
[0119] Compounds such as 3 could be used in processes for preparing proline containing compounds, such as caspase inhibitors. Proline containing caspase inhibitors include, but are not limited to, those disclosed in WO 95/35308, WO
99/47545, WO 01/81330, and WO 01/90063 (which are all incorporated herein by reference). For example, compound IA
(and stereoisomers thereof) of WO 01/90063 (which are specifically incoLporated herein by reference) could be prepared as disclosed herein (see, e.g., page 13).
[0120] The compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art arid include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase =
solubility to allow administration by injection, alter metabolism and alter rate of excretion.
[0121] For example, a carboxylic acid group in a compound of this invention may be derivatized as, for example, an ester. Preferred esters would be those derived from:
a C1-6 straight-chained or branched alkyl, alkenyl, or alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with C6_10ary1, CF3, Cl, F, OMe, OFt, OCF3, CN, or NMe2:
a C1-6 cycloalkyl, wherein 1-2 carbon atoms in the cycloalkyl is optionally replaced with -0- or -NR9-.
[0122] Compounds of this invention having a carbonyl group may be similarly derivatized as, e.g., an acetal, ketal, oxime (=NOR9), hydrazine (=NN(R9)2), thioacetal, or thioketal.
[0123] Appropriate derivatives of amines are known in the art and are also included within the scope of this invention.
[0124] Certain of the above derivatives would include the protective groups known to skilled practitioners (see, e.g., Greene). As would be recognized by a skilled practitioner, these protective groups may also be employed in the processes of this invention.
[0123] The compounds of this invention may be assayed for their ability to inhibit apoptosis, the release of IL-41or caspase activity directly. Assays for each of the activities are known in the art. However, as would be recognized by a skilled practitioner, a prodrug compound of this invention should be active only in assays where the prodrug moiety would be cleaved, typically in in vivo assays.
[0126] Assays for caspase activity are described in WO
99/47545.
[0127] According to another embodiment, the present invention provides a pharmaceutical composition comprising:
=
a) a compound of the in-vention., as defined herein, or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable carrier, adjuvant or vehicle.
[0128] It should be understood that compounds and pharmaceutically acceptable salts thereof are included within this invention are. If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, diglucon.ate, dodecylsulfate, ethanesulfonate, fumarate, glucohptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoat, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-n.aphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth rrItal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl--D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
[01293 Also, the basic nitrogera-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others.
Water or oil-soluble or dispersible products are thereby obtained.
[0130] Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[0131] According to a preferred embodiment, the compositions of this invention are formulated for phaLmaceutical administration to a mammal, preferably a human being.
[0132] Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally or intravenously.
[01333 Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent c>r solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally empLoyed as a solvent or suspending medium. For this purpose, an_y bland fixed oil may be employed including synthetic mono- or di-glycerides.
Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectabls, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil =
solutions or suspensions may also contain a_ long-chain alcohol diluent or dispersant, such as carboxymethy-1 cellulose or, similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commOnly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[0134] The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used inclu_de lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch.
When aqueous suspensions are required or oral use, the active ingredient is combined with emulsifying and suspending agents.
If desired, certain sweetening, flavoring or coloring agents may also be added.
[0135] Alternatively, the pharmaceutical compositions of this invention may be administered in the foLm of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug., Such materials include cocoa butter, beeswax and polyethylene glycols.
[0136] The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the slan, or the lower intestinal tract. SuitabLe topical formulations are readily prepared for each of these areas or organs.
[0137] Topical application for the Lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.
Topically-transdermal patches may also be used.
[0138] For topical applications, the pharmaceutical compositions may be formulated in a sui_table ointment containing the active component suspenaed or dissolved in one or more carriers. Carriers for topical_ administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylenJe compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, ,cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[01393 For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH
adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum. In one embodiment, the compositions are as formulated in, e.g., U.S. Patent 6,645,994 and/or U.S. Patent =
6,630,473.
[01403 The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
[0141] The above-described compounds and compositions are particularly useful in therapeutic applications relating to an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease (e.g., bacterial infections, preferably, eye infections), a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, retinal disorders, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs. host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, hemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heat failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, JaPanese encephalitis, various forms of liver disease, renal disease, polycystic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, toxic epidermal necrolysis, pemphigus, and autoinflammatory diseases (sometimes referred to as autoinflammatory fever syndromes) and related syndromes such as Muckle-Wells Syndrome (MWS), Familial Cold Urticaria (FCU>, Familial Mediterranean Fever (FMF), Chronic Infantile Neurological Cutaneous and Articular Syndrome (CINCAS), a.k.a.
= Neonatal Onset Multisystem Inflammatory Disease (NOMID), TNFR1-Associated Periodic Syndrome (TRAPS), and Hyper-IgD
periodic fever Syndrome (HIDS). The compounds and compositions are also useful in treating complications associated with coronary artery bypass grafts. The compounds , and compositions are also useful for decreasing IGIF (also known as IL-18) or IFN-y production and for inhibiting a caspase-mediated function' in a patient. The compounds and compositions are also useful in immunotherapy as a cancer treatment.
[0142] The compounds and compositions may also be used in methods for preserving cells. These methods would be useful for preserving organs, particularly those intended for transplant, or blood products.
[0143] . The compounds of this invention are useful as dual caspase-1 and capase-8 inhibitors. Without being bound by theory, the R.2 and R3 groups of the compounds of this invention appear to be related to this surprising activity. Bridged A
groups of the compounds of this invention, such as \1-9 or , also appear to be related to this surprising activity. As such, the compounds and compositions of this invention are particularly useful in treating or preventing inflammatory conditions.
[0144] According to another embodiment, the compositions of this invention may further comprise another therapeutic agent (i.e., one or more additional agents). Such agents include, but are not limited to, thrombolytic agents such as tissue plasminogen activator and streptokinase. When an additional agent is used, the additional agent may be administered either as a separate dosage form or as part of a single dosage form with the compounds or compositions of this invention.
[0145] The amount of compound present in the compositions of this invention should be sufficient to cause a detectable decrease in the severity of the disease or in caspase activity and/or cell apoptosis, as measured by any of the assays known in the art.
[0146] Dosage levels of between about 0.01 and about 50 or about 100 mg/kg body weight per day, preferably between 0.5 and about 75 mg/kg body weight per day and most preferably between about 1 and about 25 or about 50 mg/kg body weight per day of the active ingredient compound are useful in a mono therapy.
[0147] Typically, a compound or composition of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary' depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.
[0148] When the compositions of this invention comprise a combination of a compound of this invention and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 10% to about 100%, and more preferably between about 10% to about 80% of the dosage normally administered in a monotherapy regime.
[0149] Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
[0150] As the skilled practitioner will appreciate, lower or higher doses than those recited above may be required. It should be understood that a specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound . employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the particular disease, the patient's disposition to the disease being treated, and the judgment of the treating physician. The amount of active ingredients will also depend upon the particular compound and other therapeutic agent, if present, in the composition.
L0151] In a preferred embodiment, the invention provides a method of treating a patient, preferably a mammal, having one of the aforementioned diseases, comprising the step of administering to said patient a compound or a pharmaceutically acceptable composition described above. In this embodiment, if the patient is also administered another therapeutic agent or caspase inhibitor, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage fault. When administered as a separate dosage form, the other caspase inhibitor or agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a compound of this invention.
[0152] The compounds of this invention may also be incorporated into compositions for coating implantable medical devices, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention and a carrier suitable for coating said implantable device. In still another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention and a carrier suitable for coating said implantable device.
[0153] Another aspect of the invention relates to , inhibiting caspase activity in a biological sample, which method comprises contacting said biological sample with a compound of this invention or a composition comprising said compound. The term thiological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[0154] Inhibition of caspase activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage, and biological assays.
[0155] The compounds of this invention are useful in methods for preserving cells, such as may be needed for an organ transplant or for preserving blood products. Similar -662.
uses for caspase inhibitors have been reported [Schierle et al., Nature Medicine, 5, 97 (1999)]. The method involves treating the cells or tissue to be preserved with a solution comprising the caspase inhibitor. The amount of caspase inhibitor needed will depend on the effectiveness of the inhibitor for the given cell type and the length of time required to preserve the cells from apoptotic cell death.
[01563 Without being bound by theory, applicants' cyclic acetal compounds are believed to be prodrugs. That is, the acetal portion is cleaved in vivo to provide a corresponding acid-aldehyde compound. As would be recognized by a skilled practitioner, chemical compounds may be metabolized in vivo, e.g., at a site other than the prodrug cleavage site. Any such metabolites are included within the scope of this invention.
(0157] In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
Example I-1 (S,S,S,R)-1-[(2,9)-(3-Methoxy-2-methyl-benzoylamino)-3-methyl-butyry1}-pyrrolidine-(25)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yll-amide ,o =
ilk r.1(0 H
.9580-110 Method A
(S) -3 -Amino -4-hydroxy -butyric acid tert-butyl ester oH
[0158] A solution of (S)-benzyloxycarbonylamino -4-hydroxy-butyric acid tart -butyl ester (prepared as described in Michel etal, Helvetica Chimica Acta 1999, 1960)(0.94g) in ethyl acetate (15 ml) was hydrogenated over palladium hydroxide/carbon (20% w/w, 160mg). The catalyst was removed = TM
via filtration through Celite. Concentration of the filtrate in vacuo afforded the subtitle compound as a colorless oil (486mg, 91%); IH NKR (400MHz,CDC13) 8 1.48 (9H, s), 1.95 (3H, brs), 2.28 (1H, dd), 2.46 (1H, dd), 3.29 (1H, brm), 3.42 (111, m), 3.60 (IH, m).
Method B
(1S) -2 -((S) -2-tert -Butoxycarbonyl-1 -hydroxymethyl -ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester oirNy.,a, [0159] To a stirred solution of (S)-3 -Amino -4 -hydroxy-butyric acid tert-butyl ester (800mg, 4.57mmol) and Z-Pro-OH
(1.14g, 4.57mmol) in THF (30m1) was added 2-hydroxybenzotriazole hydrate (741mg, 1.2eq,), DMAP (698mg, 1.25eq.), diisopropylethylamine (1.03m1, 1.3eq.) and 1-(3-dimethylaminopropyl) -3 -ethylcarbodiimide hydrochloride (EDC, 1.05g, 1.2eq.). The resulting mixture was stirred at ambient temperature for 18 hours then diluted with ethyl acetate. The mixture was then washed with water, saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (60% ethyl acetate/petrol) to afford the sub-title compound as a colorless solid (1.483g, 90%); MS ES (+) 407.3.
Method C
(1S)-2-((S)-2-tert-Butoxycarbony1-1-formyl-ethylcarbamoy1)-pyrrolidine-l-carboxylic acid benzyl ester y 0 1.1 .õ(J1Lro,k [01601 A solution of (1S)-2-((S)-2-tert-Butoxycarbony1-1-hydroxymethya-ethylcarbamoy1)-pyrrolidine-l-carboxylic acid benzyl ester (10 g) in DCM (100 ml) was cooled to 0 C under nitrogen. 2,2,6,6-tetramethylpiperidinyloxy (TEMPO, 38 mg) was then added followed by trichloroisocyanuric acid (6 g)1 portionwise over 30 minutes. The mixture was stirred at ambient temperature for 2 hours, then filtered through celite.
The filtrate was washed with water, 1M sodium thiosulfate solution and water. Drying over magnesium sulfate and concentration under reduced pressure gave the sub-title compound as a pale yellow oil (9.92 g, 99%); IH NMR (400MHz,d-6 DMSO) .5 1.38 (9H, d), 1.79-1,86 (3H, m), 2.08-2.23 (1H, m), 2.36-2.51 (1H, 2 x dd), 2.61-2.86 (1H, 2 x dd), 3.88-3.46 (2H, m), 4.24-4.30 (2H, m), 5.05 (2H, quin), 7.28-7.37 (5H. m), 8.59-8.64 (IH, 2 x d), 9.21 (0.57H, s), 9.37 (0.43H, s).
Method D
(1S)-2-((S)-1-tert-Butoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester y 0 :),J
41111 OyN j i15 [0161] To a solution of (1S)-2-((S)-2-tert-Butoxycarbonyl-1-formyl-ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester (4.98 g) in dichloromethane (70 ml) was added triethyl orthofoLmate (6.2 mL) and p-toluenesulfonic acid monohydrate (47 mg). The resulting mixture was stirred at ambient temperature until no aldehyde remained by TLC. The mixture was concentrated in vacuo, the re-dissolved in dichloromethane (35 mL). Saturated aqueous sodium bicarbonate solution (35 mL) was then added and the organic phase removed. This was washed with water and brine, dried (magnesium sulfate), filtered and concentrated under reduced pressure. This gave the sub-title compound as a pale yellow oil (4.85 g, 82%); 11-1 NMR (400MHz,d-6 DMSO) 5 1.04-1.11 (6H, m), 1.35-1.37 (9H, m), 1.73-1.89 (3H, m), 2.01-2.49 (3H, m), 3.43-3.52 (6H, m), 4.05-4.29 (3H, m), 4.96-5.06 (2H, m), 7.27-7.38 (5H, m), 7.80 (0.5H, d), 7.88 (0.5H, d).
Method E
(1S)-2-((2R, 3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-l-carboxylic acid benzyl ester 6.1 (1S)-2-((2S, 3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.2 Sti 0 0 0= 0õN
8y 0 N , H H
6.1 6.2 (0162] A solution of (1S)-2-((S)-1-tert-Butoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester (4.85 g) in dichloromethane (25 ml) was cooled to 0 C under nitrogen. Trifluoroacetic acid (6 ml) was then added and the mixture stirred at 0 C for 15 minutes, then warmed to ambient temperature and stirred until the reaction was complete by TLC. The mixture was then diluted with dichloromethane (90 ml) and saturated aqueous sodium bicarbonate solution (130 ml) and stirred for 15 minutes. The organic phase was then removed and washed with 1:1 saturated aqueous sodium bicarbonate/brine (100 ml), the combined aqueous washings was re-extracted with DCM (100 ml) and the combined organic layers dried (magnesium sulfate), filtered and concentrated under reduced pressure. This afforded the sub-title compound as a mixture of epimers at the ketal centre (C2). The epimers were separated on silica gel, eluting with 30% acetone/petrol. Syn-isomer 6.1 (white solid); 111 MIR
(400MHz,d-6 DMSO) 8 1.08-1.17 (311, m), 1.78-2.01 (3H, m), 2.08-2.12 (1H, m), 2.37-2.57 (1H, 2 x dd), 2.61-2.79 (111, 2 x dd), 3.35-3.51 (211, m), 3.55-3.68 (111, m), 3.71-3.82 (1H, d), 4.20-4.32 (1H, m), 4.52-4.61 (111, m), 4.98-5.11 (2H, m), 5.53-5.58 (1H, m), 7.24-7.42 (5h, m), 8.25-8.31 (111, m); MS ES +
377.3 (100%), ES - 375.3 (10%); Anti-isomer 6.2 (colorless oil); 114 NMR (400MEz,d-6 DMSO) 8 1.08-1.19 (311, m), 1.78-1.89 (3H, m), 2.10-2.34 (1H, m), 2.92-3.07 (1H, 2 x dd), 3.36-3.51 (3H, m), 3.62-3.78 (211, m), 4.12-4.21 (2H, m), 4.97-5.12 (311, m), 7.28-7.40 (5H, m), 8.51-8.58 (111, m); MS ES 377.4 (100%), ES - 375.3 (10%).
(1S)-2-((2R,3S)-2-Methoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.3 (1S)-2-((2S,3S)-2-Methoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.4 lel 0 H H
6.3 6.4 [0163] Prepared in a similar manner to that described in methods A-E, using trimethylorthoformate in step D, to afford the sub-title compounds as a mixture of epimers 6.3 and 6.4.
The epimers were separated on silica gel eluting with 30% to 40% 2-Eutanone/Petrol to 70% Acetone/Petrol. Syn-isomer 6.3 (viscous colorless oil); 1-11 NMR (400MHz,d-6 DMSO) 6 1.77-1.89 (3H, m), 2.07-2.12 (1H, m), 2.32-2.43 (1H, 2 x d), 2.55-2.61 (1H, 2 x d), 2.71-2.81 (1H, 2 x d), 3.39-3.62 (4H, m), 4.21-4.30 (1H, m), 4.57-4.64 (1H, m), 5.01-5.09. (2H, m), 5.42-5.47 (1H, m), 7.27-7.42 (5H, m), 8.24-8.31 (1H, m); Anti-isomer 6.4 (white solid); 1H NMR (400MHz,d-6 DMSO) 8 1.79-1.90 (3H, m), 2.09-2.21 (1H, m.), 2.23-41 (1H, 2 x d), 2.91-3.05 (1H, 2 x dd), 3.35-3.71 (5H, m), 4.09-4.21 (2H, m), 4.98-5.19 (3H, m), 7.28-7.41 (5H, m), 8.51-8.58 (111, m).
(1S)-2-((2R,3S)-2-Isopropoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.5 (1S)-2-((2S,3S)-2-Isopropoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.6 1.1 0 H H
6.5 6.6 =
[0164] Prepared in a similar manner to that described in Methods A-E, using triisopropylorthoformate in step D, to afford the sub-title compound as a mixture of epimers 6.5 and 6.6. The epimers were separated on silica gel eluting with 30%
to 40% 2-Butanone/Petrol. $yn-isomer 6.5 (colorless gum);
NMR (400MHz,d-6 DMSO) 8 1.07-1.16 (6H, m), 1.81-1.86 (2H, m), 2.37-2.71 (2H, m), 3.35-3.53 (2H, m), 3.86-3.90 (1H, m), 4.18-4.24 (1H, m), 4.46-4.55 (1H, m), 4.95-5.10 (2H, m), 5.63 (IH, d), 7.27-7.38 (5H, m), 8.22-8.30 (1H, m); MS ES + 391.3 (100%); Anti-isomer 6.6 (white solid); 1H NMR (400MHz,d-6 DMSO) 8 1.07-1.15 (6H, m), 1.78-1.82 (3H, m), 2.07-2.41 (2H, m), 2.87-3.01 (1H, m), 3.35-3.50 (2H, m), 3.74-3.96 (1H, m), 4.07-4.18 (2H, m), 4.95-5.11 (2H, m), 5.22 (1H, 2 x s), 7.24-7.39 (5H, m), 8.48-8.53 (1H, m); MS ES + 391.4 (100%).
(1S)-2-((2R,3S)-2-Propoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.7 (1S)-2-((2S,3S)-2-Propoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.8 410 OyNy 0 41:1 0y10 0 :(:50 0 N 0 N =
H H
6.7 6.8 [0165] Prepared in a similar manner to that described in methods A-E, using tripropylorthoformate in step D, to afford the sub-title compounds as a mixture of epimers 6.7 and 6.8.
The epimers were separated on silica gel eluting with 30% to 40% 2-Butanone/Petrol. $yn-isomer 6.7 (colorless gum); NMR
(400MHz,d-6 DMSO) 8 0.84-0.93 (3H, m), 1.55 (2H, m), 1.81-1.89 (3H, m), 2.08-2.22 (1H, m), 2.37-2.61 (1H, 2 x dd), 2.71-2.80 (1H, 2 x dd), 3.31-3.53 (2H, m), 3.60-3.69 (1H, m), 4.20-4.29 (IH, m), 4.52-4.61 (IH, m), 4.95-5.11 (2H, m), 5.50 (1H, m), =
=
7.27-7.36 (5H, m), 8.27 (1H, m); Anti-isomer 6.8 (colorless oil); 11.1 NMR (400MHz,d-6 DMSO) 8 0.82-0.90 (3H, m), 1.46-1.57 (2H, m), 1.77-1.89 (3H, m), 2.06-2.41 (1H, m), 2.90-3.05 (1H, 2 x dd), 3.33-3.66 (5H, m), 4.11-4.20 (211, m), 4.94-5.10 (3H, m), 7.28-7.37 (5H, m), 8.51(1H, m).
(1S)-2-((2R,3S)-2-Butoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.9 (15)-2-((2S,3S)-2-Butoxy-5-oxo-tetrahydro-furan-3-ylcarbamoya)-pyrrolidine-1-carboxylic acid benzyl ester 6.10 OyNy 0 0,,Nj:5y 0 ) 6.9 6.10 [0166] Prepared in a similar manner to that described in methods A-E, using tributylorthoformate in step D, to afford the sub-title compounds as a mixture of epimers 6.9 and 6.10.
The epimers were separated on silica gel eluting with 30% to 40% 2-Butanone/Petrol. Syn-isomer 6.9 (colorless gum); IH NMR
(400MHz,d-6 DMSO) 8 0.86-0.92 (3H, m), 1.28-1.37 (2H, m), 1.45-1.54 (211, m), 1.79-1.88 (3H, m), 2.07-2.21 (111, m), 2.35-2,78 (2H, m), 3.31-3.54 (2H, m), 3.63-3.70 (1H, m), 4.21-4.29 (1H, m), 4.51-4.61 (111, m), 4.95-5.09 (2H, m), 5.50 (1H, m), 7.27-7.37 (5H, m), 8.25 (IH, m); Anti-isomer 6.10 (colorless oil); 1H NMR (400MHz,d-6 DMSO) 8 0.85-0.93 (3H, m), 1.26-1.36 (2H, m), 1.44-1.56 (2H, m), 1.77-1.90 (3H, m), 2.08-2.40 (1H, m), 2.89-3.05 (111, 2 x dd), 3.34-3.70 (5H, m), 4.08-4.19 (2H, m), 4.95-5.10 (3H, m), 7.28-7.39 (5H, m), 8.53(1H, m).
=
Method F
{(S)-1-[(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-pyrrolidine-2-carbonyl]-2,2-dimethyl-propy1)-carbamic acid benzyl ester =
ANtri\3-[0167] To a solution of (1S)-2-((2R, 3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.1 (4.68g) in ethyl acetate (160m1) and DMF
(25m1) was added triethylamine (2.5g) followed by palladium hydroxide/carbon (20% w/w, lg). The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite. To the filtrate was added (S)-2-benzyloxycarbonylamino-3,3-dimethyl-butyric acid (4.93g), hydroxybenzotriazole hydrate (2.01g) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 2.85g). The resulting mixture was stirred at ambient temperature overnight. Saturated aqueous sodium bicarbonate solution (180m1) was then added and the organic phase removed.
This was washed with saturated aqueous ammonium chloride (180 ml), then brine (180m1), dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with 40-75% ethyl acetate/petrol. The sub-title compound was obtained as a white foam (4.02g, 66%); IH NMR (400MHz, CDC13) 8 0.97 (9H, s), 1.14 (3H, t), 1.79-1.94 (3H, m), 2.02-2.10 (1H, m), 2.44 (1H, dd), 2.75 (1H, dd), 3.52-3.66 (2H, m), 3.70-3.79 (2H, m), 4.22 (IH, d), 4.38-4.41 (1H, m), 4.48-4.58 (IH, m), 5.03 (2H, q), 5.56 =
(1H, d), 7.26 (1H, d), 7.29-7.40 (5H, m), 8.24 (1H, d); MS ES
+ 490.6 (100%), ES - 488.8 (10%).
Method G
(S, 3,S,R) -1- [ (23) - (3-Methoxy-2-methyl-benzoylamino) -3-methyl-butyryl] -pyrrolidine- (2,5) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide ,o o rr)r.NT
H o, (0168] To a solution of {(S)-1-[(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-pyrrolidine-2-carbonyl] -2 , 2-dimethyl-propyll-carbamic acid benzyl ester (344mg) in ethyl acetate (20m1)was added palladium hydroxide/carbon (20% w/w, 74mg). The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite and the filtrate concentrated under reduced pressure to give the amine as a brown foam (260mg). A portion of this material (153mg) was dissolved in THF and 3-methoxy-2-methyl benzoic acid (146mg), diisopropylamine (191111), hydroxybenzotriazole hydrate (77mg) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 109mg) were added. The resulting mixture was stirred at ambient temperature for 24 hours then diluted with saturated aqueous sodium bicarbonate. The organic phase was removed and washed with saturated aqueous ammonium chloride, then brine, dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with ethyl acetate. This gave the sub-title compound as a white solid (138mg, 62%); analytical data summarized in Table 3.
[01693 Compounds of .formula 1-2 to 1-58 have been prepared by methods substantially similar to those described in Example I-1.
Example I-2 (S, S, S, R) -1--[ (2S) - (2 -Methoxy-benzoylamino ) -3 -methyl-butyryl ] -pyrrolidine-(2S)-carboxylic acid [ (2R)-ethoxy-5-oxo-tetrahydro-furan- (3S) -y1]-amide \o o =
o N
H o Example 1-3 (S,S, S, R) -1- [3-Methyl- (2S) - (2-trifluoromethoxy-benzoylamino) -butyry1]-pyrrolidine- (2S) -carboxylic acid [ (2R)-ethoxy-5-oxo-tetra.hydro-furan- (3S) -y1]-amide F.sf [`nriT
o N
H o Example 1-4 (S, S, S, R) -1- [ (2S) - (3-Hydroxy-2-methyl-benzoylamino)-3-methyl-butyry1]-pyrrolidine- (2S) -carboxylic acid [ (2R)-ethoxy-5-oxo-tetrahydro-furan- (3 S) -y1]--amide =
=
=
Example I-5 (S, S, S, R) -1-- [ (2S) - ( 3 -Amino-2 -methyl-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-_ tetrahydro-furan- (35) -yl] -amide *0 0 H o Example I-6 (S, S, S, R) -1- [ (2S)- (2, 6-Dichloro-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI
\
a o o N
H
Example 1-7 (S. S, S, R) -N- { (1S) - [ (2S)- ( (2R) -Ethoxy-5-oxo-tetrahydro- furan-( 3 S) -ylcarbamoyl ) -pyrrolidine-l-carbonyl ] -2 -methyl-propyl } -2 -methyl -nico-t inamide (1-Xl(NNT
H 0 4.0 Example I - 8 (S. 5, S, R)-N- (1S) - [ (2S)- ( (2R) -Ethoxy-5 -oxo- tetrahydro- furan-( 3S) -ylcarba.moyl ) -pyrrolidine-l-carbonyl ] -2 -methyl-propy11-4-methyl -nicot.inamide o Ni? JC?
A
H
Example I-9 (S, S, S, R) -1- {3-Methyl-- (2S) -[ (3 -methyl - thiophene-2 -carbonyl ) -amino] -butyryl) -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy--oxo- tetrahydro- furan- (3S) -yl] -amide i no H CO
Example I-10 (S, S, SIR) -2, 3-Dichloro-N-{ (1S) - [ (2S) - ( (2R) -ethoxy-5-oxo-tetrahydro- furan- ( 3 S) -ylcarbamoyl ) -pyrrolidine-1- carbonyl ] -2 -methyl-propyl } -isonicotinamide Cl a o Example I-11 (S, S, S, R) -3 , 5-Dichloro-N-{ (1S) [ (2S) - ( (2R) -ethoxy-5-oxo-tetrahydro-furan- (35) -ylcarbamoyl ) -pyrrolidine-l-carbonyl] -2 -methyl -propyl } -ison.icotinamide a o N H N
=
Exampl e I-12 ( S, S, S, R) -1- [ (2S) - ( 3 -Methoxy-2-methyl-benzoylamino ) -3, 3 -dimethyl-butyryl ] -pyrrol i dine- (25) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetra]aydro-furan- (3S) -yl] -amide -o = riX.Nli Example I-13 ( S, S, S, R) -1-- [ (2S) - ( 3 -Methoxy-2 -methyl-ben.z oylamino ) -3-methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -methoxy--5-oxo-tetrahydro-furan- ( 3S) -yl ] -amide 410 Xr"i 0 H -Example 1-14 (S, S. S, R) -1- [ (2S) - ( 3 -Methoxy-2-methyl-benz oyl amino) -3-methyl -butyry1]-pyrrolidine- (2S) -carboxylic acid [ (2R) - isopropoxy-5-oxo - t etrahydro- f uran- (3S) -yl] -amide 400 NC;IT 0 4.0 H Os( Example 1-15 ( S, S, S, R) -1- [ (2S) - ( 3 -Methoxy-2 -methyl-benz oylamino ) -3-methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid (5-oxo- (2R) -propoxy-5- tetrahydro- furan- (3S) -yl] -amide 400 tIC-rji 0 HO) Example I-16 (S, S, S, R) -1- [ (2S) - (2-Ch1oro-benzoylamino) -3 -methyl -butyryl] -pyrrolidine- (25) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -y1 ] -amide 4ji f?Cr"i 0 Example I-17 (S, S, S, R) -1- [3 , 3 -Dimethyl- (2S) - (2 -methyl-benzoylamin.o ) -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -y' :J -amide 400 NYC;44i 4.0 o Example I-18 (S, S. S, R) -1- [3-Methyl-2 (S)- (2-tri fluoromethyl-benzoylamino) -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan-3 CS) -y1] -amide .<0 o N
Example I-19 (S, S. S, R) -1-- [2 (S) - (2-Ch1oro-benzoylamino) -3,3-dimethyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [ (2R) -methoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide * N? 0 )q0 H o =
Exampl e 1-20 (S, S, S, R) -1- [3 , 3-Dimethyl- (2S) - ( 2- tri fluoromethyl-benzoylamin.o ) -butyryl I -pyrrolidine- (2S) -carboxylic acid [ (2R) -isopropoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide 41* [NiT
o N
Example I-21 (S, S, S, R) -1- [ (2S) - ( 2 -Chloro-benzoylamino ) -3 , 3 -dimethyl-butyryl] -pyrrolidin.e- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide Ct o 4## Vd(ji 0 Example 1-22 (S, S, S, R) -1- [3 , 3 -Dimethyl - (2S) - (2-trifluoromethyl-benzoylamino) -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide N(r4i õ<o Example 1-23 (S, S, S,R) -1- [ (2S) - (2-Chloro-benzoylamino) -3, 3 -dimethyl-butyryl ] -pyrrolidin.e- (2S) -carboxylic acid [5-oxo- ( 2R) -prOPoxY-tetrahydro-furan- (3S) -yl] -amide ijk 11(r"i 0 H o Example 1-24 (S, S, S, R) - 1- [ (2S) ( 2 -Chloro-benz oylamino) -3, 3 -dimethyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -butoxy-5-oxo-tetrahydro-furan.- (3S) -ylj -amide 4.0 =
o N
H o Example I-25 (S, S, S, R) -1- [ (2S) - (2-Chloro-3-tri f luoromethoxy-benzoylamino) -3 , 3-dimethyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -ylj -amide ,.., CI 0 F3C-u* Nri/ 0 N
Example I-26 (S, S, SIR) -1- [ (2S) - ( 2 -Chloro-ben.zoylamino ) -3 -methyl -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ 5-oxo- (2R) -propoxy-tetrahydro- furan- (3S) -yl] -amide Cl 0 * rci\IT.<0 o N
Example I-27 (S, S. S, S) -1- [ (2S) - (2-Chloro-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [5-oxo- (2S) -propoxy-tetrahydro-furan- (3S) -yll -amide =
ININT
o N =
H
=
=
Example 1-28 (S, S, S, S) -1- [ (2S ) - ( 2 -Chloro-benzoylamino ) -3 -methyl-butyryl] -pyrrolidine- (2S) -carboxylic acid ( (2S ) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI
400 dC-ri o N =
H
S.
Example 1-29 (S, S, S, R) -1- [ (2S) - ( 2 -Chloro-benzoylamino ) -3 -methyl-butyryl ] -PYrrolidine- (2S) -carboxylic acid (2R) -butoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI o o Example 1-30 (S, S, S. S) -1- [ (2S) - ( 2 -Chloro-benzoylaraino ) -3-methyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [(2S) -butoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI ,D
o N
Example I-31 ( S, S, S, R) -1- [ (2S) - (2-Chloro-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid (2R) -is opropoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI o 400 dc-ri 0 H o Example I-32 (S, S. S, S) -I- [ (2S) - (2-Chloro-benzoylamin.o ) -3 -methyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [ (2S) -isopropoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI o 400 VA-r"i 0 H
Example I-33 (S, S, S, R) -1- [ (2S ) - ( 2 -Chloro-3-cyclopropyloxy-benzoylamino ) -3 , 3-dimethyl-butyryl] -pyrrolidine- (2S) --carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan.- (3S) -yl] -amide 7- 400 NJCriT
H
Example I-34 (S, S, S, R) -1- [ (2S) - ( 2 -Chloro-3 -methyl -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrol i dine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI
*
4.o Example I-35 (S, S, S, R) -1-- [ (2S) - ( 2 -chl oro-3 -methoxy-benzoylamino ) -3 -methyl-butyryl ] -pyrrol i dine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (35) -yl] -amide ,0 * [\XN? 0 jqo o N
=
Example 1-36 (S, S, S,R) -1- [ (2S) - (2-Chloro-3-ethyl -benzoyl amino) -3 , 3 -dimethyl -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide * NT
0 õ<cs H o Example I-37 (S, S, S, R) -1- [ (2S)- (2-chloro-4-methoxy-benzoylamino) -3-methyl-butyryl ] -pyrrolidin.e- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI 0 )r..
\O 0 H o Example 1-38 (S, S, S,R) -1- [ (2S) - (2-Chloro-3-cyclopropylmethyl -benzoylamin.o) -3 , 3 -dimethyl -butyryl ] -pyrroli dine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide r iµN N/ jeo 0 14)!
H o Example I-39 (S, S, S, R) -1- [ (2S ) (2-Chloro-3-hydroxy -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy- 5 - oxo- tetrahydro- furan- (3S) -yl] -amide HO CI
if. N? 0 Example 1-40 (S, S, S, R) -1- [ (2S) - (2-Chloro-4-acetamido-benzoylamino) -3 -methyl -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide HN
Example 1-41 (S, S, S,R) -1- [ (2S) - (2-Chloro-3-acetamido -benzoyl amino) -3 , 3 -dimethyl-butyry13 -pyrrolidine-, (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -y11 -amide HN
= AcN? 0 4.0 Example I-42 (S, S, S, R) -1- [ (2S ) - (2-methyl -3 -acetamido -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- ( 2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide * [gi irko 0 N*.=
ExampL e I-43 (S, S, S, R) -1- [ (2S) - (2-Chloro-4-acetamido -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- ( 2S) -carboxylic acid [ (2R) -ethoxy- 5 -oxo- t etrahydro- f uran- ( 3S) -yl] -amide HN 411 1)C N?
ExampL e I-44 ( S, S, S, R) -1- [ (2S) - ( 2 - fluor -4- acetamido -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- ( 2S) -carboxylic acid [ (2R) -ethoxy- 5 -oxo- te trahydro- furan- ( 3S) -yl] -amide F
HN *
= 0 0 H
ExampL e 1-45 (S, S, S, R) -1- [ (2S) - (2-fluoro -4- acetamido-benzoylamino) -3 -methyl-butyryl] -pyrrolidine- (2S ) -carboxylic acid [ (2R) -ethoxy--oxo- tetrahydro- furan- (3S) -yl] -amide HN N?
ExampL e - 4 6 (S, S, SIR) -1- [ (2S)- (2-chloro -4- isopropyloxy -benzoylamino) -3 -methyl-butyryl -pyrrolidine- (2S ) -carboxylic acid [ (2R) -eth.oxy-5 -oxo - tetrahydro- furan- (3S) -yl] -amide C'0 >'0 111 N=NT
Example 1-47 (S75,S,R)-1-[(2S)-(2-chloro -4-hydroxy -benzoylamino)-3,3-.
dimethyl-butyry1]-pyrrondine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide CI
HO
O N
Example 1-48 (S,S,S,R)-1-[(2S)-(2-chloro -4-methoxymethyl -benzoylamino)-3,3-dimethyl-butyrylj-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Cl 0 P 11# 11)N13.
o 0 O N
Example 1-49 (S,S,S,R)-1-[(2S)-(2-Chloro-4-isobutyrylamido -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Ct 0 4, ()HN
O N
Example I-50 (5,S,S,R)-1-[(2S)-(2-Chloro-4-acetamido --benzoylamino)-3-cyclohexyl]-pyrrolidine-(2S)-carboxylic aacid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide FIN=
lqo ( Example 1-51 (S, S, S, R) -1- [ (2S) - (2-Chloro-4-methoxycarloonylamino -ben.zoylamino) -3 ,3-dimethyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [(2R)-ethoxy-5-oxo-tetrahlydro-furan-(3S)-y1]-amide NNT
HN H
H o Example I-52 (S, S, S, R) -1-[ (2S ) (2-Chloro-3-phenoxy -b9nzoylarnino) -3,3-dimethyl-butyry1]-pyrrolidine- (2S)-carboxylic acid [ (2R)-ethoxy--5-oxo-tetrahydro-furan- (3S)-y1]-armide # 0 *
H o Example 1-53 (S,S,S,R)-1-[(2S)-(2-Chloro-4-thiazolylanaino -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-ceurboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yal-amaide =
C'0 FIN* rIN? jqo Example 1-54 (S,S,S,R)-1-[(2S)-(3-Amino-2-chloro-benzoylamino)-3-methyl-butyryll-pyrrolidine-(2S)-carboxylic acid [(,2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Cl 0 NT ti,(0 0 1\1-=
Example 1-55 (S,S,S,R)- 1-[(2S)-(2-Chloro-benzoylamino)-3-thiazol-4-yl-propiony1]-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide NAIN
101 H 0 ri Example 1-56 (S,S,S,R)- 1-[(2S)-(3-Methoxy-2-methyl-benzoylamino)-3-thiazol-4-yl-propiony1]-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide (1 0 =
Example 1-57 (S, S, S,R)- 1-( (2S) - (2-Chloro-3-methoxy-benzoylamino) -3,3-dimethyl-butyryl ] -pyrrolidine- (2 S ) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3 S ) -y1] -amide 0 110 )(1 N N?
Example 1-58 (S,S,S,R)- 1-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-piperidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Example 1-59 2-[(2S)-(3-Methoxy-2-methyl-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide 0i-i3 0 Aj 0 METHOD H
(1R,3S,4S)-3((S)-2-tert-Butoxycarbony1-1-hydroxymethyl-ethylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester =
=
01111 ONJOk OH =
(0170] To a stirred solution of (S)-3-Amino-4-hyc-Mcoxy-butyric acid tert-butyl ester (486mg) and (1R,3S,4S)-2-Aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2 benzya ester (prepared as described in Tararov eta/, Tett. Asymm. 2002, 13, 25-28) (767mg) in THF (18m1) was added 2-hydroxybenotriazole hydrate, (452mg), DMAP (426mg), diisopropylethylamine (63101) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 641mg). The resulting mixture waz stirred at ambient temperature for 18 hours then diluted with ethyl acetate. The mixture was then washed with water, sa-turated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, filtered and concentrated under 3reduced pressure. The residue was purified by flash-chromatc:Dgraphy (60% ethyl acetate/petrol) to afford the sub-title compound as a colorless oil (1.1g, 91%); 111 NMR (400MHz,d-6 DMSO) 8 1.13-1.25 (1H, m), 1.30-1.48 (9H, m), 1.49-1.88,(6H, m), 2.20-2.52 (2H, m), 3.09-3.34 (2H, m), 3.64 (IH, d), 4.00-4.16 (2H, brm), 4.80 (1H, m), 4.90-5.15 (2H, m), 7.21-7.41 (5H, m), 7.50-7.75 (1H, m); MS ES (+) 433.37. .
Method I
(1R,3S,4S)-3-((S)-2-tert-Butoxycarbony1-1-formyl-ethylcarbamoyl) -2-aza-bicyclo[2 .2 .1]heptane-2-carboylic acid benzyl ester a WO 2005/085236 #
[0171] A solution of (1R,3S,4S)-3((S)-2-tert-Butoxycarbony1-1-hydroxymethyl-ethylcarbamoya)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (1.1g) in DCM (10m1) was cooled to 0 C under nitrogen. 2,2,6,6-tetramethylpiperidinyloxy (TEMPO, 4mg) was then added followed by trichloroisocyanuric acid (621mg) portionwise over 30 minutes. The mixture was stirred at ambient temperature for 1 hour, then filtered through celite. The filtrate was washed with water, 1M sodium thiosulfate solution and brine. Drying over magnesium sulfate and concentration under reduced pressure gave the sub-title compound as a colorless oil (698mg, 64%); 111 NMR (400MHz,d-6 DMSO) 8 1.16-1.89 (16H, m), 2.30-2.80 (211, m), 3.68-3.81 (1H, m), 4.19 (1H, brm), 4.39, (111, m), 4.91-5.16 (2H, m), 7.21-7.43 (5H, m), 8.45 (0.4H, d), 8.60 (0.6, d), 9.19 (0.6H, s), 9.37 (0.4H, s).
Method (1R,3S,4S)-3-((S)-1-tert-Butoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester ay.74.ok [0172] To a solution of (1R,3S,4S)-3-((S)-2-tert-Butoxycarbony1-1-formyl-ethylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (698mg) in dichloromethane (10m1) was added triethyl orthoformate (720mg) and p-toluenesulfonic acid monohydrate (6mg). The resulting mixture was stirred at ambient temperature -until no aldehyde remained by TLC. Saturated aqueous sodium bicarbonate solution was then added and the organic phase removed. This was washed with water and brine, dried (magnesium sulfate), filtered and concentrated under seduced pressure. This gave the sub-title compound as a pale yellow oil (635mg, 78%); 1HNMR (400MHz,d-6 DMSO) 8 0.96-1.15 (6H, m), 1.26-1.84 (16H, m), 2.20-2.50 (2H, m), 3.40-3.81 (5H, m), 4.10-4.28 (2H, m), 4.37 (1H, m), 4.88-5.14 (2H, m), 7.20-7.40 (5H, m), 7.65 (0.5H, d), 7.80 (0.5H, d).
Method K
(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester 1.1 IrN7 [0173] A solution of (1R,35,4S)-3-((S)-1-tert-Hutoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-2-aza-bicyclo[2.2.11heptane-2-carboxylic acid benzyl ester (635mg) in dichloromethane (3m1) was cooled to 0 C under nitrc,gen.
Trifluoroacetic acid (0.7m1) was then added and the mixture stirred at 0 C for 15 minutes, then warmed to ambient temperature and stirred until the reaction was complete by TLC. The mixture was then diluted with dichloromethane (10m1) and saturated aqueous sodium bicarbonate solution (14=1.1). The organic phase was then removed and washed with 1:1 saturated aqueous sodium bicarbonate/brine (8m1), dried (magnesium sulfate), filtered and concentrated under reduced pressure.
This afforded the sub-title compound as a mixture of epimers at the ketal centre. The epimers were separated on silica gel, eluting with 30% 2-butanone/petrol. Syn-isomer (oil) (115mg, 23%); 111 NMR (400MHz,d-6 DMSO) 8 0.80-1.91 (10H, m), 2.35-2.79 (2H, m), 3.56 (1H, m), 3.66-3.80 (2H, m), 4.18 (1H, m), 4.59 (1H, m), 4.94-5.11 (2H, m), 5.53 (1H, d), 7.20-7.40 (5H, m), 8.18 (0.5H, d), 8.27 (0.5H, d); MS ES + 403.31 (100%), ES -401.37 (15%); Anti-isomer (oil)(103mg, 20%); 111 NMR (400MHz,d-6 DMSO) 8 0.80-1.85 (10H, m), 2.25-2.60 (1H, m), 2.95 (1H, m), 3.42 (1H, m), 3.5-3.75 (2H, m), 4.88-5.15 (3H, m), 7.21-7.40 (5H, m), 8.50 (0.4H, d), 8.59 (0.6H, d).
Method L
{(S)-1-[(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carbonyl]-2,2-dimethyl-propy1}-carbamic acid benzyl ester iX\T
0 H 0¨A
[0174] To a solution of (1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (5g) in ethyl acetate (160m1) and DMF (25m1) was added triethylamine (2.5g) followed by palladium hydroxide/carbon (20% w/w, 1g).
The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite. To the filtrate was added (5)-2-benzyloxycarbonylamino-3,3-dimethyl-butyric acid (4.93g), hydroxybenzotriazole hydrate (2.01g) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 2.85g). The resulting mixture was stirred at ambient temperature overnight. Saturated aqueous sodium bicarbonate solution (180m1) was then added and the organic phase removed.
This was washed with saturated aqueous ammonium chloride (180 ml), then brine (180m1), dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with 40-75% ethyl acetate/petrol. The sub-title compound was obtained as a white foam (5.25g, 81%); 1H NMR (400MHz,d-6 DMSO) 8 0.85-1.03 (10H, m), 1.07-1.20 (311, t), 1.30 (111, m), 1.40 (111, m), 1.50-1.80 (3H, m), 1.93 (IH, m), 2.40-2.50 (111, m), 2.78 (1H, m), 3.60 (1H, m), 3.78 (111, m), 3.89 (1H, s), 4.26 (111, d), 4.52 (2H, m), 4.96-5.12 (211, m), 5.56 (1H, d), 7.10 (IH, d), 7.24-7.40 (5H, m), 8.27 (IH, d); MS ES 516.93 (100%), ES - 515.05 (100%).
Method M
(1R,3S,4S)-2-[(S)-2-(3-methoxy-2-methylbenzoylamino)-3,3-dimethyl-butyry1]-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-y1)-amide =
=
(110 NIX(1\7NO
[0175] To a solution of C(S)-1-[(1R,3S,45)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-aza-bicyclo[2.2.11heptane-2-carbony1]-2,2-dimethyl-propyll-carbamic acid benzyl ester (370mg) in ethyl acetate (20m1)was added palladium hydroxide/carbon (20% w/w, 74mg). The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite and the filtrate concentrated under reduced pressure to give the amine as a brown foam (272mg). A
portion of this material (167mg) was dissolved in THF and 3-methoxy-2-methyl benzoic acid (146mg), diisopropylamirie (19101), hydroxybenzotriazole hydrate (77mg) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, =
109mg) were added. The resulting mixture was stirred at ambient temperature for 24 hours then diluted with saturated aqueous sodium bicarbonate. The organic phase was removed and washed with saturated aqueous ammonium chloride, then brine, dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with ethyl acetate. This gave the sub-title compound as a white solid (121mg, 52%); 111 NMR (400MHz,CDC13) 8 1.10 (9H, s), 1.28 (3H, t), 1.43-1.56 (IH, m), 1.79-1.86 (3H, m), 1.99 (1H, brd), 2.29 (3H, s), 2.30-2.37 (1H, m), 2.83 (1H, dd), 3.02 (1H, brs), 3.66-3.74 (1H, m), 3.87 (3H, s), 3.88-3.94 (111, m), 4.16 (111, brs), 4.54 (1H, brs), 4.66-4.74 (IH, m), 4.97 (1H, d), 5.46 (1H, d), 6.44 (1H, brd), 6.93 (1H, d), 7.00 (1H, d), 7.22 (IH, t), 7.78 (IH, brd); IR (solid) cm-1 2960, 1791, 1624, 1505, 1438, 1261, 1115, 975;, MS ES + 530; ES
- 528.
[0176]
Compounds of formula 1-60 to 1-73 have been prepared by methods substantially similar to those described in Example 1-59.
Example 1-60 2-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y13-amide oi 0 *I )(I
X
Example 1-61 2-[(2S)-(4-Acetylamino-2-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.11heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide CI 0 Icrl *0 N 0 Example 1-62 2-1(2S)-(2-Chloro-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.11heptane-(35)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(35)-y1]-amide = ci 0 0 JLN *
Example 1-63 2-[(2S)-(2-Chloro-3-isobutyrylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(38)-y1]-amide ))1-H a 0 N PI
H
Example 1-64 2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-3,3-dimethyl-butyry1]-2-(18,4R)-aza-bicyclo[2.2.11heptane-(35)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide ,0 410 1,,X474 Hoomo Example 1-65 2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-3-methyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide xi.14 Example 1-66 2-[(2S)-(3-methoxy-2-methyl-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2S)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yll-amide CH3 :irrq *H 0 0 Example 1-67 2-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2S)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide * jo ,\
Example 1-70 2-[(2S)-(4-Acetylamino-3-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.11heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Example 1-69 2-[(2S)-(3-Chloro-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide =
0 1,:ittri7 1-1 a O.
Example 1-70 2-[(2S)-(isoquinolin-1-ylcarbonylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide 11101.,.
H
Example 1-71 2-[(2S)-(4-Amino-3-ch1oro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid , =
[(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yl]amide rill l H 0 N'Y
Example 1-72 2-[(2S)-(4-Amino-3-chloro-benzoylamino)-3-methyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(35)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide ?Corl H2N 0 H 0-.1 Example 1-73 2-[(2S)-(isoquinolin-l-ylcarbonylamino)-3,3-dimethyl-butyryll-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2S)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide so 0 isti7 0 Table 3. Characterization Data for Selected Compounds of Formula I (by Compound Number) Nb. 144-1 1H-NMR
(obs) (DMSO-d6) 0.94-0.95 (311, m), 0.98-0.99 (311, m), 1.13-1.16 (3H, m), 1.80-2.0 (4H, m), 2.10 (311, s), 2.47-2.51 (211, m), 2.73 (111, m), 3.34-3.61 (2H, m), I-1 490.1 3.73-3.77 (2H, m), 3.79 (3H, s), 3.90 (1H, m), 4.39 (111, m), 4.55 (111, m), 5.55 (1H, d), 6.83 (111, d), 6.99 (111, d), 7.19 (1H, m), 8.27 (111, d), 8.34 (1H, d) (CDC13) 1.01-1.15 (6H, m), 1.26 (311, t), 1.90-2.29 (5H, m), 2.55-2.59 (1H, m), 2.75-2.83 (1H, m), 3.65-3.98 (311, m), 1-2 476.0 4.04 (3H, s), 4.44-4.49 (1H, m), 4.62-4.69 (111, m), 4.75-4.80 (111, m), 5.60 (111, d), 7.09 (1H, t), 7.19 (111, d), 7.52 (111, t), 7.97 (111, d) (CDC13) 1.02-1.10 (611, m), 1.23-1.34 (3H, m), 1.88-2.19 (511, m), 2.32-2.44 (2H, m), 2.81-2.89 (1H, m), 3.66-3.72 1-3 530.0 (2H, m), 3.83-3.98 (211, m), 4.56-4.73 (2H, m), 4.84-4.90 (111, m), 5.46 (111, d), 7.15 (111, d), 7.35-7.60 (411, m), 7.99 (111, d) (CDC13) 1.02 (311, d), 1.09 (311, d), 1.29 (3H, t), 1.93-2.19 (411, m), 2.29 (311, s), 2.39 (2H, dd), 2.84 (111, dd), 3.66-1-4 476.1 3.71 (2H, m), 3.88-3.95 (2H, m), 4.63 (1H, dd), 4.68-4.74 (111, m), 4.85 (1H, dd), 5.32 (1H, s), 5.47 (111, d), 6.44 (1H, d), 6.87 (111, d), 6.98-7.00 (111, m), 7.07-7.12 (111, m), 7.36 (111, d) ' No. m+1 1114am (obs) (CDC13) 0.95-1.10 (6H, m), 1.31 (311, t), 1.93-2.21 (4H, m), 2.25 (311, s), 2.34-2.41 (211, m), 2.80-2.88 (1H, m), 3.63-1-5 475.0 3.75 (411, m), 3.87-3.93 (211, m), 4.65-4.75 (211, m), 4.82-4.88 (1H, m), 5.47 (111, d), 6.43 (IH, d), 6.74 (111, d), 6.81 (1H, d), 7.04 (111, t), 7.40 (1H, d) (CDC13) 1.03-1.05 (311, m), 1.09-1.13 (311, m), 1.22-1.30 (311, m), 1.95 (111, m), 2.14-2.17 (2H, m), 2.44-2.51 (2H, 1-6 514.4 m), 2.79 (111, m), 3.65-3.68 (211, m), 3.86-3.90 (211, m), 4.12 (IH, m), 4.60-4.61 (211, m), 4.86 (1H, m), 5.47 (111, m), 6.4 (1H, 2 x d), 7.29-7.37 (3H, m), 7.54 (111, m) (DMS0--(16) 0.95-1.01 (6H, m), 1.13-1.16 (311, m), 1.80-2.10 (4H, m), 2.45-2.51 (511, m), 2.74 (IH, ra), 3.33-3.59 (2H, 1-7 461.1 m), 3.68 (111, m), 3.95 (111, m), 4.38-4.44 (211, m), 4.55 (1H, m), 5.55 (111, m), 7.25 (1H, m), 7.62 (111, m), 8.27 (IH, m), 8.48 (IH, m), 8.63 (111, m) (CDC13) 1.02 (3H, d), 1.08 (3H, d), 1.28 (311, t), 1.95-2.2 (411, m), 2.4-2.5 (211, m), 2.55 (3H, s), 2.8-2.9 (1H, m), 3.7-1-8 461.1 3.8 (211, m), 3.85-3.95 (211, m), 4.7-4.85 (211, m), 4.9-4.95 (1H, m), 5.55 (IH, d), 6.6-6.65 (111, m), 7.2-7.25 (1H, m), 7.35-7.4 (IH, m), 8.6 (111, d), - 8.7 (IH, s) (DmSo-d0 0.93-0.95 (3H, m), 0.99-1.00 (3H, m), 1.13-1.16 (3H, m), 1.80-2.10 (411, m), 2.40 (311, s), 2.40-2.47 (211, 1-9 465.6 m), 2.73 (1H, m), 3.59-3.61 (211, m), 3.73-3.75 (211, m), 4.37-4.43 (2H, m), 4.55 (111, m), 5.53 (111, d), 6.97 (IH, m), 7.59 (111, m), 7.81 (IH, d), 8.28 (1H, d) _ =
No. N+1 1H-NMR
(obs) (CDC13) 1.01 (3H, d), 1.25 (3H, d), 1.27 (3H, t), 1.97-2.10 (2H, m), 2.14-2.26 (1H, m) 2.38 (2H, dd), 2.84 (1H, dd), 2-10 515.0 3.67-3.71 (2H, m), 3.81-3.87 (1H, m), 3.90-3.98 (1H, m), 4.58-4.61 (1H, m), 4.65-4.73 (1H, m), 4.86-4.90 (1H, dd), 5.47 (1H, d), 6.78 (1H, d), 7.23 (1H, d), 7.42 (1H, d), 8.40 (1H, d) (CDC13) 1.01 (3H, d), 1.14 (3H, d), 1.28 (3H, t), 1.96-2.12 (211, m), 2.17-2.23 (2H, m), 2.38 (2H, dd), 2.83 (1H, dd), T-11 515.0 3.66-3.71 (211, m), 3.82-3.95 (211, m), 4.59-4.62 (111, m), 4.65-4.71 (111, m), 4.91 (1H, dd), 5.47 (111, d), 6.54 (111, br dd), 7.21 (111, br dd), 8.57 (2H, s) (DMSO-d6) 0.9-1.08 (9H, s), 1.12 (3H, t), 1.75-2.00 (3H, m), 2.00-2.15 (4H, m), 2.34-2.50 (1H, m), 2.80 (1H, m), 1-12 504.4 3.48-3.91 (7H, m), 4.40 (1H, m), 4.46-4,70 (211, m), 5.58 (111, d), 7.81 (111, d), 7.00 (1H, d), 7.19 (111, dd), 8.07 (111, d), 8.27 (1H, d) (CDC13) 0.98-1.09 (6H, m), 1.90-2.05 (4H, m), 2.35-2.56 (2H, m), 2.70-2.85 (111, m), 3.49+3.55 (3H, 2xs), 3-55-3.67 1-13 476.0 (1H, m), 3.86 (3H, s), 4.00-4.09 (1H, m), 4.58-4.90 (3H, m), 5.34-5.37 (111, m), 6.25+6.40 (1H, 2xd), 6.90-7.01 (2H, m), 7.18-7.25 (111, m), 7.37+7.54 (111, 2xd) (CDC13) 0.99-1.11 (6H, m), 1.18-1.30 (6H, m), 1.86-2.15 (411, m), 1.28+1.30 (311, 2xs), 2.36-2.86 (311, m), 3.56-3.68 1-14 504.0 (111, m), 3.86 (311, s), 3.87-4.05 (2H, m), 4.50-4.84 (311, m), 5.55+5.59 (111, 2xd), 6.86-7.01 (2H, m), 7.16-7.23 (111, m), 7.37+7.54 (1H, 2xd) (CDC13) 0.85-1.11 (9H, m), 1.55-1.73 (211, m), 1.89-2.20 (4H, m), 2.28+2.29 (3H, 2xs), 2.35-2.55 (211, m), 2.71-2.87 1-15 504.0 (111, m), 3.48-3.76 (311, m), 3.86 (311, s), 3.98-4.06 (1H, m), 4.52-4.86 (311, m), 5.44-5.49 (1H, m), 6.24+6.35 (111, 2xd), 6.88-6.99 (2H, m), 7.14-7.21 (1H, m), 7.41+7.55 (1H, 2xd) No. 14+1 (obs) (CDC13) 1.0-1.15 (6H, m), 1.3-1.4 (3H, m), 1.9-2.2 (4H, m), 2.4-2.5 (2H, m), 2.8-2.9 (1H, m), 3.7-3.8 (2H, m), 3.9-1-16 480.5 4.0 (2H, m), 4.65-4.75 (2H, m), 4.88-4.92 (1H, m), 5.5-5.52 (1H, m), 6.85-6.9 (1H, m), 7.4-7.55 (1H, m), 7.7-7.75 (1H, m) (DMSO-d6) 1.05 (9H, s), 1.15 (3H, t), 1.8-2.1 (4H, m), 2.3 (3H, s), 2.4-2.5 1-17 474.6 (1H, m), 2.7-2.8 (1H, m), 3.6-3.9 (4H, m), 4.4-4.45 (1H, m), 4.5-4.7 (2H, m), 5.55-5.6 (1H, m), 7.2-7.4 (4H, m), 8.1 (1H, d), 8.25 (1H, d) (DMSO-d6) 0.9-1.0 (6H, m), 1.15 (3H, t), 1.8-2.1 (4H, m), 2.4-2.5 (111, m), 2.7-1-18 514.5 2.8 (1H, m), 3.6-3.85 (3H, m), 3.9-3.95 (1H4, m), 4.4-4.6 (3H, m), 5.55-5.6 (1H, m), 7.4-7.45 (1H, m), 7.6-7.8 (3H, m), 8:22 (1H, d), 8.75 (1H, d) (CDC13) 1.13 (9H, s), 1.90-2.20 (3H, m), 2.35-2.44 (211, m), 2.86 (111, dd), 3.56 (3H, s), 3.72-3.74 (1H, m), 3.90-3.99 1-19 480.5 (111, m), 4.62-4.65 (1H, m), 4.69-4.70 (111, in), 4.90 (111, d), 5.36 (1H, d), 6.94 (111, d), 7.28-7.46 (411, m), 7.71 (1H, dd) (CDC13) 1.09 (9H, s), 1.27 (6H, m), 1.93-2.14 (3H, m), 2.34-2.42 (2H, m), 2.79-2.83 (111, m), 3.71 (1H, m), 3.90-1-20 542.5 3.94 (1H, m), 4.01-4.04 (1H, m), 4.62-4.67 (211, m), 4.88-4.91 (111, m), 5.56 (111, m), 6.46 (111, m), 7.40 (111, m), 7.54-7.62 (3H, m), 7.74 (111, m) (CDC13) 1.12 (9H, s), 1.29 (311, t), 1.90-2.20 (3H, m), 2.36-2.43 (2H, m), 1-21 494.5 2.85 (1H, dd), 3.67-3.72 (2H, m), 3.90-3.96 (211, m), 4.62-4.65 (2H, m) 4.91 (1H, d), 5.46 (1H, d), 6.95 (111, d), 7.34-7.46 (411, m), 7.71 (1H, dd) (CDC13) 1.10 (911, s), 1.29 (3H, t), 1.90-2.20(3H, m), 2.35-2.42 (211, m), 2.84 (1H, dd), 3.68-3.72 (211, m), 3.90-1-22 528.4 3.95 (2H, m), 4.62-4.80 (2H, m), 4.89 (111, d), 5.47 (111, d), 6.45 (1H, d), 7.43 (111, d), 7.54-7.61 (3H, m), 7.73 (1H, dd) No. M+1 LH-NMR
(obs) (CDC13) 0.95 (3H, t), 1.12 (9H, s), 1.60-1.70 (2H, m), 1.88-2.20 (3H, m), 2.35-2.45 (2H, m), 2.77-2.85 (1H, m), 1-23 508.5 3.53-3.61 (1H, m), 3.65-3.75 (1H, m), 3.76-3.84 (1H, m), 3.88-3.96 (1H, m), 4.60-4.73 (2H, m), 4.91 (11, d), 5.44 (1H, d), 6.96 (1H, d), 7.30-7.50 (4H, m), 7.73 (1H, d) (CDC13) 0.86 (3H, t), 1.18 (911, s), 1.21-1.65 (4H, m), 1.85-2.17 (3H, m), 2.36-2.59 (2H, m), 2.68-2.78 (IH, m), 1-24 522.5 3.44-3.54 (1H, m), 3.56-3.72 (211, m), 3.98-4.10 (IH, m), 4.56-4.85 (3H, m), 5.44 (111, d), 6.95-7.02 (1H, m), 7.32-7,74 (5H, m) (DMSO-d6) 0.99-1.21 (1211, m), 1.70-2.00 = (3H, m), 2.01-2.17 (111, m), 2.40-2.51 (111, m), 2.70-2.80 (1H, m), 3.50-3.88 1-25 578.3 (411, m), 4.40 (IH, m), 4.55 (1H, m), 4.65 (1H, m), 5.58 (1H, d), 7.36 (111, m), 7.50 (1H, m), 7.61 (111, m), 8.21 (111, d), 8.70 (111, d) (CDC13) 0.95 (3H, t), 1.05-1.15 (611, m), 1.55-1.8 (3H, m), 2.0-2.25 (411, m), 2.4-2.5 (IH, m), 2.6-2.9 (2H, m), 3.55-1-26 494.5 3.8 (3H, m), 3.85-3.95 (1H, m), 4.05-4,1 (111, m), 4.7-4.85 (211, m), 5.5-5.55 (111, m), 6.85-6.9 (1H, m), 7.4-7.6 (311, m), 7.7-7.8 (IH, m) (CDC13) 0.95 (311, t), 1.05-1.15 (6H, m), 1.5-1.7 (311, m), 2.0-2.2 (4H, m), 2.4-2,6 (211, m), 2.9-3.1 (111, m), 3.4-3.5 1-27 494.5 (111, m), 3.55-3.7 (211, m), 4.0-4.1 (111, m), 4.35-4.5 (211, m), 4.6-4.75 (111, m), 4.8-4.9 (0.5H, m), 5.35-5.38 (1H, m), 6.85-6.95 (111, m), 7.4-7.55 (3H, m), 7.64-7.8 (1.511, m) (CDC13) 1.02-1.19 (7H, m), 1.22-1.28 (2H, m), 1.90-2.21 (311, m), 2.32-2.53 (2H, m), 2.95 (111, 2 x dd), 3.44-3.50 1-28 480.3 (1H, m), 3.59-78 (2H, m), 3.83-3.92 (1H, m), 4.02-4.09 (1H, m), 4.29-4.41 (1H, m), 5.34 (IH, 2 x s), 6.88 (IH, 2 x brd d), 7.31-7.42 (411, m), 7.57 (1H, 2 x brd d), 7.70 (IH, 2 x dd) =
No. M+1 111-11MR.
(obs) (CDC13) 0.83-0.97 (3H, m), 1.02-1.14 (6H, m), 1.26-1.53 (3H, m), 1.55-1.66 (111, m), 1.91-2.20 (411, m), 2.35-2.61 (211, m), 2.73-2.90 (111, m), 3.54-3.74 1-29 508 (311, m), 3.84-3.90 (0.511, m), 3.99-4.06 (0.5H, m), 4.61-4.75 (2H, m), 4.77-4.93 (0.511, m), 5.45-5.51 (1H, m), 6.87 (1H, brd), 7.34-7.45 (4H, m), 7.55 (0.5H, brd), 7.70-7.22 (1H, m) (400 MHz, CDC13) 0.87-0.97 (3H, m), 0.99-1.16 (6H, m), 1.27-1.40 (211, m), 1.48-1.59 (111, m), 1.91-2.19 (4H, m), 2.30-2.52 (2H, m), 2.90-3.07 (1H, m), 3.39-3.45 (0,511, m), 3.54-3.71 (211, m), 1-30 508 3.78-3.82 (0.5H, m), 3.86-3.92 (0.511, m), 4.04-4.09 (0.5H, m), 4.31-4.35 (111, m), 4.39-4.43 (111, m), 4.56-4.59 (0.5H, m), 4.66-4.68 (1H, m), 4.80-4.86 (0.511, m), 5.32-5.41 (1H, m), 6.87-6.91 (1H, m), 7.31-7.45 (4H, m), 7.55-7.76 (2H, m) (CDC13) 1.04-1.19 (8H, m), 1.25-1.28 (311, m), 1.92-2.18 (411, m), 2.32-2.43 (1H, m), 2.62-2.87 (211, m), 3.59-3.71 1-31 494.4 (111, m), 3.85-3.95 (1H, m), 4.00-4.05 (1H, m), 4.60-4.67 (311, m), 5.60 (111, 2 x d), 6.88 (1H, brd d), 7.36-7.50 (411, m), 7.52-7.56 (1H, m), 7.76 (111, 2 x dd) (CDC13) 0.87-1.24 (1011, m), 1.88-2.07 (3H, m), 2.13-2.21 (111, m), 2.32-2.54 (2H, m), 2.94 (1H, 2 x dd), 3.57-3.68 (111, m), 3.83-3.87 (1H, m), 4.02-4.09 1-32 494.3 (111, m), 4.27-4.30 (111, m), 4.41 (111, dd), 4.51-4.69 (1H, m), 5.43 (111, 2 x s), 6.89 (1h, 2 x brd d), 7.30-7.45 (4H, m), 7.52 (111, 2 x brd d), 7.70 (1H, 2 x dd) No. M 1 111-1114R
(obs) (DMSO) 0.70 (211, in, 0112), 0.89 (211, in, CH2), 0.95-1.20 (1211, In, CH3, tbutyl), 1.71-2.13 (411, in, 0H2), 2.45 (111, in, asp CH2), 2.75 (1H, m, asp CH2), 3.35-1-33 550.5 3.89 (4H, in, 0112, CH), 3.99 (111, m, CH), 4.37 (1H, in, CH), 4.51 (111, m, CH), 4.65 (111, in, CH), 5.58 (111, d, CHO), 6.90 (1H, in, aryl H), 7.35 (111, in, aryl H), 7.45 (1H, in, aryl H), 8.25 (1H, d, NH), 8.35 (111, d, NH) DMSO) 0.99-1.21 (1211, m, 0113, tBu), 1.75-2.14 (4H, m, CH2), 2.38 (3H, S.
0113), 2.40-2.51 (111, m, asp CH2), 2.70-2.82 (111, in, asp CH2), 3.37-3.90 (411, 1-34 508.5 m, 0112, CH), 4.39 (1H, m, CH), 4.55 (1H, in, CH), 4.67 (111, in, CH), 5.58 (1H, d, CH), 7.15 (1H, m, aryl H), 7.28 (1H, in, aryl H), 7.38 (1H, in, aryl H), 8.25 (111, in, NH), 8.38 (111, in, NH) CDC13 1.00 (3H, d), 1.10 (311, d)', 1.27 (3H, t), 1.90-2.19 (411, m), 2.34-2.45 (2H, m), 2.79-2.87 (1H, M), 3.65-3.71 1-35 510 (211, m), 3.84-4.93 (211, m), 3.92 (3H, s), 4.56-4.70 (211, m), 4.82-4.88 (111, m), 4.45 (1H, d), 6.69 (111, d), 6.99 (111, d), 7.16 (111, d), 7.27 (1H, t), 7.37 (1H, d) (DMSO) 0.95-1.25 (15H, in, tBu, 0113), 1.78-2.13 (411, in, CH2), 2.43 (1H, in, CH2), 2.65-2.80 (311, m, 0112), 3.50-3.88 1-36 522.5 (411, in, 0112, CH), 4.42 (111, m, CH), 4.58 (1H, in, CH), 4.70 (111, d, CH), 5.58 (1H, d, CH), 7.15 (111, in, aryl H), 7.27 (1H, in, aryl H), 7.38 (111, in, aryl H), 8.27 (111, d, NH), 8.39 (1H, d, NH) 0D013 1.05-1.12 (6H, m), 1.25-1.3 (311, m), 1.9-2.2 (2H, m), 2.4-2.5 (2H, m), 2.8-2.9 (111, m), 3.65-3.75 (2H, m), 1-37 510.5 3.85 (3H, s), 3.9-4.0 (1H, m), 4.65-4.75 (211, m), 4.85-4.9 (1H, m), 6.9-6.93 (111, m), 6.98 (111, s), 7.05-7.1 (1H, m), 7.4-7.45 (111, m), 7.75-7.8 (1H, d) No. 14+1 H-NMR
(ohs) CDC13 0.38-0.42 (2H, m), 0.63-0.71 (2H, m), 1.11 (911, s), 1.23-1.35 (4H, m), 1.88-2.20 (3H, m), 2.34-2.45 (2H, 1-38 564 m), 2.76-2.87 (1H, m), 3.66-3.75 (2H, m), 3.87-3.96 (4H, m), 4.62-4.73 (2H, m), 4.89 (1H, d), 5.47 (1H, d), 6.80 (1H, d), 7.00 (1H, d), 7.19-7,29 (2H, m), 7.48 (1H, d) (DMSO) 1.11 (9H, s), 1.28 (311, t), 1.83-2.22 (3H, m), 2.36-2.43 (2H, m), 2.82-2.87 (111, m), 3.66-3.76 (2H, m), 1-39 510 3.86-3.97 (2H, m), 4.62-4.71 (2H, m), 4.88 (1H, d), 5.45 (1H, d), 6.31 (1H, s), 6.73 (111, d), 7.05-7.20 (3H, m), 7.38 (1H, d) (CDC13) 1.06 (611, dd), 1.28-1.31 (4H, m), 1.91-2.20 (4H, m), 2.23 (3H, s), 2.39 (1H, dd), 2.84 (1H, dd), 3,65-3.72 1-40 537.4 (211, m), 3.86-3.94 (2H, m), 4.61-4.73 (211, m), 4.87 (111, dd), 5.46 (111, dd), 7.00-7.04 (1H, m), 7.22 (111, brd s), 7.38-7.45 (211, m), 7.73 (111, d), 7.80 (1H, brd s) (DMSO) 0.95-1.20 (1211, in, tBu, CH3), 2.75-2.15 (7H, in, CH2, COCH3), 2.42 (111, m, CH2), 2.77 (111, m, CH2), 3.50-3.88 (411, in, CH2, CH), 4.37 (1H, In, 1-41 551.5 CH), 4.55 (111, in, CH), 4.67 (1H, d, CH), 5.58 (1H, d, CH), 7.09 (111, in, aryl H), 7.32 (1H, in, aryl H), 7.71 (1H, m, aryl H), 8.26 (1H, in, NH), 8.49 (111, m, NH), 9.58 (1H, in, NH) (DMSO) 0.95-1.20 (12H, m, tBu, CH3), 1.75-2.17 (1011, in, CH3, COCH3, CH2), 2.45 (1H, m, CH2), 2.77 (1H, m, CH2), 1-42 531.6 3.48-3.91 (4H, m, CH2, CH), 4.31-4.70 (3H, m, CH), 5.55 (1H, d, CH), 7.04 (1H, m, aryl H), 7.18 (111, in, aryl H), 7.41 (111, in, aryl H), 8.20 (1H, d, NH), 8.27 (111, d, NH), 9.39 (1H, brs, NH) No. 144.1 1H-NR
(obs) DMSO) 1.04 (9H, s), 1.12-1.17 (311, m), 1.78-1.95 (4H, m), 2.06 (3H, s), 2.45 (111, dd), 2.72 (1H, dd), 3.52-3.81 (411, 1-43 551.4 m), 4.36-4.39 (111, m), 4.47-4.54 (IH, m), 4.64 (111, d), 5.54 (111, dd), 7.33-7.35 (111, m), 7.43-7.46 (1H, m), 7.81 (IH, brd s), 8.21-8.25 (211, m), 10.23 (111, brd s) (DMSO) 1.02 (9H, s), 1.14 (3H, t), 1.78-1.98 (411, m), 2.08 (3H, s), 2.48 (1H, dd), 2.79 (1H, dd), 3.51-3.82 (411, 1-44 535.4 m), 4.36-4.39 (1H, m), 4.49-4.58 (111, m), 4.71 (1H, d), 5.54 (111, d), 7.31-7.34 (111, m), 7.65-7.72 (311, m), 8.49 (1H, d), 10.38 (IH, s) (DMSO) 0.95 (6H, dd), 1.12-1.16 (4H, m), 1.72-1.97 (4H, m), 2.07 (311, s), 2.48 (111, dd), 2.73 (1H, dd), 3.51-3.62 1-45 521.4 (211, m), 3.71-3.83 (211, m), 4.35-4.38 (111, m), 4.48-4.59 (211, m), 5.53 (1H, d), 7.29-7.31 (111, m), 7.59-7.67 (211, m), 8.01-8.05 (111, m), 8.28 (IH, d), 10.35 (111, s) (CDC13 1.1-1.12 (611, m), 1.3 (3H, m), 1.4 (6H, d), 2.0-2.2 (211, m), 2.4-2.5 (2H, m), 2.8-2.9 (1H, m), 3.7-3.75 (211, 1-46 538.5 m), 3.9-4.0 (IH, m), 4.6-4.75 (3H, m), 4.85-4.95 (IH, m), 6.85-6.9 (111, m), 6.95 (111, s), 7.05-7.1 (IH, m), 7.4-7.45 (111, m), 7.8 (111, d) (CDC13) 1.15 (911, m), 1.25 (311, t), 2.0-2.2 (41-1, m), 2.4-2.5 (2H, m), 2.8-2.9 (111, m), 3.7-3.85 (211, m), 3.9-4.0 1-47 510.5 (111, m), 4.05-4.1 (111, m), 4.7-4.8 (IH, m), 4.85 (1H, d), 5.5 (IH, m), 6.5 (111, d), 6.8 (111, s), 7.2 (111, d), 7.4 (1H, d), 7.55 (111, d) (CDC13) 1.12 (9H, s), 1.29 (311, t), 1.90-2.20 (3H, m), 2.36-2.43 (211, m), 2.85 (111, m), 3.42 (311, s), 3.68-3.74 1-48 538.5 (2H, m), 3.91-3.95 (211, m), 4.48 (2H, s), 4.62-4.75 (211, m), 4.90 (111, m), 5.47 (111, m), 7.00 (111, m), 7.31 (111, m), 7.43-7.54 (2H, m), 7.72 (IH, m) No. M+1 la4ata (obs) (CDC13) 1.12 (9H, s), 1.28-1.31 (9H, m), 1.90-2.20 (3H, m), 2.36-2.43 (2H, m), 2.54 (1H, m), 2.85 (1H, m), 3.68-1-49 579.5 3.72 (2H, m), 3.91-3.95 (2H, m), 4.62-4.69 (2H, m), 4.88 (1H, d), 5.47 (1H, m), 7.14 (1H, d), 7.27 (1H, m), 7.41 (1H, m), 7.50 (1H, d), 7.78 (1H, d), 7.87 (1H, m) (DMSO) 1.12-1.16 (7H, m), 1.58-1.81 (5H, m), 1.83-1.92 (5H, m), 2.04-2.08 (4H, m), 2.50 (111, ad), 2.75 (1H, dd), 3.57-3.66 (2H, m), 3.72-3.78 (1H, m), 1-50 577-3 3.82-3.91 (1H, m), 4.33-4.36 (1H, m), 4.46 (1H, t), 4.52-4.61 (1H, m), 5.54 (1H, d), 7.32 (1H, d), 7.43 (1H, dd), 7.81 (1H, d), 8.25 (1H, d), 8.47 (1H, d), 10.22 (1H, s) (DMSO) 0.98-1.25 (12H, in, tBu, CH3), 1.78-2.14 (4H, in, CH2), 2.44 (1H, m, CH2), 2.78 (1H, in, CH2), 3.50-3.88 (7H, 1-51 567.4 in, CH3, CH2, CH), 4.38 (1H, in, CH), 4.55 (1H, in, CH), 4.67 (IH, d, CH), 5.58 (1H, d, CH), 7.30-7.42 (2H, in, aryl H), 7.60 (1H, brs, NH), 8.21 (211, in, aryl H, NH), 9.99 (1H, brs, NH).
(DMSO) 0.95-1.24 (1211, in, tBu, CH3), 1.70-2.13 (4H, in, C112), 2.44 (111, in, CH2), 2.75 (111, in, CH2), 3.45-3.90 (4H, in, CH2, CH), 4.37 (111, m, CH), 4.55 1-52 586.4 (1H, m, CH), 4.70 (1H, d, CH), 5.57 (1H, d, CH), 6.91 (2H, d, aryl H), 7.06-7.19 (3H, in, aryl H), 7.30-7.45 m, aryl H), 8.20 (1H, d, NH), 8.55 (1H, d, NH) (DMSO) 0.9-1.0 (6H, m), 1.18 (3H, t), 1.8-2.15 (411, m), 2.4-2.5 (1H, m), 2.7-1-53 578.5 2.8 (1H, m), 3.6-3.85 (411, m), 4.4-4.6 (3H, m), 5.55 (111, d), 7.05 (IH, d), 7.3-7.35 (2H, m), 7.98 (1H, s), 8.3 (1H, d), 8.45 (1H, d), 10.7 (111, S) No. 14+1 1H-NMR
(obs) (DMSO) 0.94-0.98 (6H, in) , 1.13-1.18 (3H, in), 1.80-2.10 (5H, in) , 2.50 (1H, m) , 2.73 (1H, m), 3.58-3.61 (2H, m), 1-54 495.0 3.74 (1H, m), 3.9 (1H, m) , 4.38-4.41 (2H, in) , 4.60 (1H, rah 5.46 (2H, s), 5.54 (1H, in), 6.48 (111, in), 6.80 (1H, m), 7.04 (1H, in), 8.27 (1H, d) , 8.40 (1H, d) (CDC13) 1.25 (3H, t), 1.99-2.01 (3H, s), 2.30-2.39 (1H, m), 2.68 (1H, dd), 2.79 (1H, dd), 3.21-3.27 (1H, m) , 3.39 1-55 535.0 (1H, dd), 3.47-3.51 (2H, in), 3.65-3.75 (1H, rn) , 3.88-3.94 (111, in) , 4.64-4.68 (1H, in), 4.70-4.78 (1H, in) , 5.56 (1H, d) , 7.31-7.35 (511, in) , 7.63-7.65 (1H, in), 8.00 (1H, d), 8.76 (1H, d) (CDC13 ) 1.25 (311, t) , 2.01-2.03 (3H, m), 2.25 (311, s), 2.30-2.37 (11i, in) , 2.65 (111, dd), 2.80 (1H, dd), 3.27-3.41 (2H, in), 3.47 (1H, dd), 3.65-3.79 (211, 1-56 545.0 in), 3.85 (3H, s), 3.86-3.90 (1H, in), 4.64-4.67 (1H, m), 4.71-4.80 (1H, in), 5.18-5.22 (111, In), 5.54 (111, d) , 6.83 (111, d) , 6.90-6.97 (2H, m), 7.19 (1H, t), 7.24-7.28 (1H, m), 7.90 (1H, d), 8.77 (1H, d) (CDC13 ) 1.12 (911, s) , 1.31 (3H, t), 1.93-2.20 (311, in), 2.35-2.46 (211, m), 2.79-2 .86 (1H, in), 3.65-3.74 (211, In), 1-57 524.0 3.87-3 .96 (211, in), 3.95 (3H, s) , 4.65-4.74 (211, m), 4.89 (111, d), 5.47 (1H, d), 6.76 (1H, d), 7.03 (11-1, d), 7.30 (1H,t) , 7.48 (1H, d) (CDC13 ) 1.10 (911, s), 1.28 (311, t), 1.43-1.56 (111, in), 1.79-1.86 (311, in), 1.99 (111, brd), 2.29 (3H, s) , 2.30-2.37 (111, in), 2.83 (111, dd), 3.02 (111, brs), 1-58 530.4 3.66-3 .74 (111, in), 3.87 (3H, s) , 3.88-3.94 (111, in), 4.16 (111, brs), 4.54 (1H, brs), 4.66-4.74 (1H, in), 4.97 (111, d), 5.46 (111, d), 6.44 (111, brd), 6.93 (111, d), 7.00 (1H, d), 7.22 (111, t), 7.78 (111, brd) No. M+1 1H-1\1111R
(obs) (CDC13) 1.13 (9H, s), 1.29 (3H, t), 1.76-1.90 (3H, in), 2.00 (1H, brd), 2.35 (111, dd), 2.83 (1H, dd) , 3.66-3.74 (111, 1-59 520.5 m), 3,87-3.94 (1H, in), 4.15 (111, s), 4.54 (1H, brs), 4.62-4.78 (111, m), 4.99 (111, d), 5.46 (111, d) , 6.92 (1H, brd) 7.33-7.46 (3H, in), 7.69 (1H, brdd), 7.77 (1H, brd) (CDC13) 1.12 (9H, s) , 1.26-1.31 (3H, m), 1.43-1.45 (111, in), 1.83 (311, brs) 1.99 (1H, brd), 2.06 (1H, m), 2.23 (3H, s) , 2.34 (111, brdd) , 2.83 (1H, brdd) 1-60 577.5 3.01 (1H, brs), 3.66-3.74 (111, m), 3.87-3.95 (111, m), 4.12-4.19 (111, m), 4.53 (1H, brs) , 4.65-4.76 (1H, rah 4.98 (1H, d), 5.45-5.47 (111, in), 7.08 (1H, brd) , 7.30 (111, m) , 7.37 (1H, brd) , 7.73-7.75 (111, in), 7.80-7.82 (211, m) (CDC13) 1.14 (911, s), 1.22-1.30 (6H, m), 1.54-1.57 (111, in), 1.77-1.85 (3H, m), 1.97 (1H, d), 2.30-2.45 (3H, m), 2.75-2.84 (1H, m), 3.00 (1H, s), 3.63-1-61 591.5 3.72 (1H, in), 3.84-3.93 (1H, in), 4.10-4.16 (111, in), 4.51 (111, s), 4.64-4.71 (111, in), 4.96 (111, d), 5.45 (1H, d), 7.05 (111, d), 7.26 (1H, s), 7.36 (111, d), 7.73 (111, d), 7.80 (111, d), 7.82 (1H, s) (CDC13) .1.15 (911, s), 1.3 (3H, t), 1.35 (611, d) , 1.4-1.55 (3H, in), 1.8-1.95 (3H, in), 2.0-2.1 (1H, m), 2.3-2.4 (111, in), 2.65-2.75 (111, m), 2.8-2.9 1-62 605.6 (111, in), 3.05 (111, s), 3 .7-3 .8 (1H, m), 3.9-4.0 (1H, in), 4.2 (111, s), 4.55 (111, s), 4.7-4.8 (1H, m), 5.0 (1H, d), 5.5 (111, d) , 6.6 (111, d) , 7.3-7.45 (211, m), 7.75 (1H, d), 7.85 (111, s), 8.55 (1H, d) No.. 111+1 311-MMR
(obs) (CDC13) 1.13 (9H, s), 1.31 (3H, t), 1.42-1.48 (1H, m), 1.56 (1H, brs), 1.77-1.83 (3H, m), 1.99 (1H, brd), 2.35 (1H, dd), 2.83 (1E, dd), 3.01 (1H, 1-63 534.4 brs), 3.67-3.76 (111, m), 3.88-3.99 (4H, m), 4.14 (1H, brs) , 4.52 (IH, brs), 4.65-4.73 (1H, m), 5.00 (1H, dd), 5.47 (1H, d), 7.10-7.21 (2H, m), 7.34-7.39 (1H, m), 7.56-7.61 (1H, m), 7.89 (1H, d) (CDC13) 1.03 (3H, d), 1.10 (3H, d), 1.32 (3H, t), 1.50 (1H, m), 1.59 (1H, m), 1.812-1.84 (31-I, m), 2.0 (1H, m), 2.15 (1H, m), 2.36 (1H, m), 2.83 (1H, 1-64 520.5 m), 3.02 (1H, br s), 3.69 (1H, m), 3.90-3.95 (4H, m), 4.13 (111, br s), 4.40 (111, br s), 4.67 (1H, m), 4.97 (1H, m), 5.47 (1H, d), 7.12-7.21 (2H, m), 7.28 (1H, m), 7.59 (IH, m), 7.80 (1H, m) (DMSO) 0.91-2.40 (23H, m), 2.95-3.40 (2H, m), 3.51-3.81 (5H, m), 4.00-4.71 1-65 530-9 (3H, m), 5.29 (IH, m), 6.80 (IH, d), 7.00 (IH, d), 7.19 (1H, t), 7.94 (1H, d), 8.48 (1H, d) (DMS ) 0.95-1.20 (12H, m), 1.24-1.40 (2H, m), 1.41-2.40 (6H, m), 3.05 (1H, 1-66 522.8 m), 3.50-3.80 (3H, m), 4.15 (IH, m), 4.60 (IH, m), 4.70 (IH, d), 5.30 (1H, s), 7.28-7.50 (4H, m), 8.35 (1H, d), 8.48 (1H, d) (CDC13) 5 1.10 (9H, s), 1.26-1.33 (3H, m), 1.43-1.45 (1H, m), 1.74-1.83 (2H, m), 2.01 (1H, brd) , 2.06 (1H, m), 2.30 (3H, s), 2.37 (11-3, brdd), 2.85 (1H, 1_67 577.5 brdd), 2.99 (1H, brs), 3.69-3.76 (1H, m), 3.89-3.97 (1H, m), 4.11-4.31 (2H, m), 4.53 (IH, brs) , 4.65-4.76 (1H, m), 4.95 (1H, d), 5.45-5.47 (1H, m), 6.75 (1H, brd), 7.67-7.69 (2H, m), 7.78 (1H, brs), 7.92 (1H, m) , 8.55 (1H, brd) o. M+1 111¨NISR
(obs) (CDC13) 1.10 (9H, s), 1.26-1.33 (3H, m), 1.43-1.45 (1H, in), 1.74-1.83 (2H, m), 2.01 (1H, brd), 2.06 (1H, m), 2.30 (3H, s), 2.37 (1H, lordd), 2.85 (1H, 1_68 577.5 brdd), 2.99 (1H, brs) , 3.69-3.76 (IH, m), 3.89-3.97 (1H, in), 4.11-4.31 (211, m), 4.53 (111, brs), 4.65-4.76 (1H, m), 4.95 (111, d), 5.45-5.47 (1H, m), 6.75 (111, brd), 7.67-7.69 (2H, m), 7.78 (1H, brs), 7.92 (111, m), 8.55 (1H, brd) (CDC13) 1.10 (9H, s), 1.26-1.33 (6H, m), 1.42-1.16 (111, in), 1.55-1.83 (411, m), 2.01 (111, brd), 2.36 (111, dd), 2.53 (2H, q), 2.83 (1H, cad), 2.99 (111, brs), 1-69 591.5 3.69-3.76 (111, m), 3.89-3.96 (1H, m), 4.11 (111, s), 4.53 (IH, brs), 4.66-4.77 (1H, m), 4.95 (IH, (a), 5.48 (1H, d), 6.76 (111, d), 7.67-7.74 (2H, m), 8.80 (1H, s), 7.90 (111, (a), 8.58 (IH, d) (CDC13) 1.12 (911, s), 1.23-1.30 (3H, m), 1.36-1.41 (111, in), 1.73-1.84 (3H, m), 1.98-2.03 (111, In), 2.33-2.41 (111, m), 2.75-2.83 (IH, in), 2.96 (1H, brs), 1-70 537.4 3.65-3.73 (1H, m), 3.84-3.93 (111, m), 4.11 (1H, brs), 4.56 (111, s), 4.63-4.71 (111, m), 4.96-4.99 (111, m), 5.43-5.46 (111, m). 7.64-7.72 (2H, m), 7.79-7.87 (3H, m), 8.48-8.52 (111, m), 8.90 (111, brd), 9.51 (111, d) (CDC13) 1.09 (911, s), 1.32 (311, t), 1.41-1.71 (5H, m), 1.76-1.87 (3H, m), 2.00 (111, brd), 2.37 (1H, dd), 2.83 (111, dd), 2.98 (IH, brs), 3.68-3.77 1-71 535.6 (111, m), 3.89-3.97 (111, m), 4.11 (111, s), 4.54 (111, brs), 4.67-4.74 (111, 111), 4.95 (1H, d), 5.48 (111, d), 6.64 (111, brd), 6.78 (IH, d), 7.54 (111, dd), 7.71 (1H, brd), 7.78 (1H, d) =
No. 14+1 111-111v1R
(obs) _ (CDC13) 1.05 (3H, d), 1.15 (3H, d), 1.35 (3H, t), 1.5-1.6 (1H, m), 1.6-1.7 (1H, m), 1.8-1.9 (2H, s), 2.0-2.05 (1H, m), 2.15-2.25 (1H, m), 2.35-2.45 (1H, 1-72 521.5 m), 2.8-2.9 (1H, m), 2.95 (1H, s), 3.7-3.8 (1H, m), 3.9-4.0 (1H, m), 4.1 (1H, s) , 4.45 (3H, s), 4.7-4.8 (1H, in), 4.9-4.95 (1H, m), 5.55 (1H, d), 6.7 (111, d), 6.85 (1H, d), 7.65 (1H, d), 7.75 (1H, d), 7.82 ( 1H, s) (CDC13 ) 1.14 (9H, s), 1.25 (3H, t), 1.40-1.46 (1H, m), 1.77-1.89 (3H, m), 1.98-2.02 (1H, m), 2.34 (1H, dd), 2.99-3.05 (1H, m), 3.62-3.69 (1H, m), 3.83-1-73 537.4 3.91 (1H, m), 4.12 (1H, s), 4.29-4.34 (1H, ra), 4.59 (1H, s), 4.99 (1H, d), 5.38 (1H, s), 7.67-7.76 (2H, m), 7.86 (2H, dd), 8.13 (1H, d), 8.56 (1H, d), 8.96 (1H, d), 9.56 (1H, d) Example 1I-1 (S, S, S) - (3S)- ( {1- (2S)- ( 3 -Methoxy-2-methyl-benzoylamino) -3-methyl-butyryll-pyrrolidine- (2S) -c arbonyl )-amino)-4-oxo-butyric acid .-o o * OH
[01771 Method I
(S, S. 5, R) -1- ( 2 S) -(3-methoxy-2-methyl-benzoylamino)-3-methyl-butyry11-pyrrolidine-(2S)-carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S)-yli-amide (97.6mg, 0.20mmol) was dissolved in a mixture of 2M HC1 (2m1) and MeCN (2m1). The reaction mixture was stirred at room temperature for 2.5 hours. The resulting crude mixture was diluted with Et0Ac and washed with water. The aqueous layer was extracted twice with Et0Ac. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated in =
vacuo . The residue was co-evaporated with DCM/Petrol to afford the title compound as a white solid (81.3mg, 88%
yield) .
[01783 Compounds of formula 11-2 to 11-61 have been prepared by methods substantially similar to those described in Example 11-1.
Example II-2 (S, S, S) - (3S) - ( {1- [ (2S) - (2-Chloro-benzoylamino) -3-methyl-butyry1]-pyrrolidine- (25)-carbony1)-amino)-4-oxo-butyric acid a 0 Example II-3 (S, S, S) - (3S) - ( (1- [3-Methyl- (25) - (2-methyl-benzoylamino ) -butyry1]-pyrrolidine-(25)-carbonyll-amino)-4-oxo-butyric acid * rcl NT 4 or 0H
Example II-4 (S, S, S) - (35) - ( (1- [ (2S)- ( 2 -methoxy-benzoylamino ) -3 -methyl-butyryl ] -pyrrolidine- (28) -carbonyl} -amino) -4- oxo-butyri c acid \o 0 4f el# N? 4 OH
=
Exampl e II-5 (5,3, S) - (3S) - ( {1- [3-Methyl- (2S) - (2 - trifl-uoromethoxy-benzoylamino ) -butyryl] -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyri c acid F F
F)I=0 0 * X NT OH
Example II-6 (S, S, S) - (33)- ( {1- [ (2S) - ( 3 -Hydroxy-2-methyl-benzoylamino ) -3-methyl-butyryl ] -pyrrol i dine- (23) -carbonyl} -amino) -4-oxo-butyric acid *O J.
OH
Example II- 7 (3, 3, S) - ( 3 S) - ({l- [ (2S) - (3 -Amino-2-methyl -benzoylamino) -3-methyl-butyryl ] -pyrrolidine- (2S) -carbonyl} -amino) - 4- oxo-butyric acid H2N o =111 OH
O
Example 11-8 (S,S,S)-(32)-({1-[(2S)-(2,3-Dichloro-benzoylamino)-3-methyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid u 0 ço hi? KOH
Example 11-9 (S, S, S) - (3S) - ( {1- [ (2S) - (2-Chloro-3-trifluoromethyl-benzoylamino) -3 -methyl -butyryl ] -pyrrolidine- (2S) - c arbonyll amino ) -4- oxo-butyri c acid fl* N
.(rOH
Example II-10 (S, S, S) - (3S) - (U.- [ ( 2 S) (3-Chloro-2-methyl-benzoylamino) -3 -methyl -butyryl ] -pyrrolidine- (2S) -carbonyl } -amino) -4-oxo-butyric acid ci o 0 = NyoH
o o Example II-11 (S, S, S) (3S) - ( {1- [ (2S) - (2, 4-Dichloro-benzoylam no) -3-methyl-butyryl ] -pyrrol dine- (2S) -carbonyl} -amino) -4-oxo-butyric acid NIT.N?OH
CI
Example 11-12 (s, s, s) - (3s) ( {1- [ (2S) - (2, 5 -Dichloro-benzoylamino ) -3 -methyl-butyryl ] -pyrrol i dine- ( 2 S) - carbonyl } -amino) -4-oxo-butyric acid ci r.N0 H
Example 11-13 (S, S, S) (3S) - ( {1- [ (2S) - (2,6-Dichloro-benzoylamin.o) -3-methyl-butyryl ] -pyrrolidin.e- (2S) -carbonyl}-amino ) -4-oxo -butyric acid lit a N:).141 .40H
Example 11-14 (S, S, S) - (3S) - ( {1- [ (2S) - (2,6-Methyl-benzoylamino) -3-methyl-butyryl ] -pyrrolidine- (2S) -carbonyl ) -amino) -4-oxo-butyric acid NA)or ,Li(;)OH
Example 11-15 (S, S, S) - (3S) - [ (1- {3-Methyl- (2S) [ (2-methyl-pyridine-3-carbonyl ) -amino] -butyryll-pyrrolidine- (2S) -carbonyl ) -amino] -4 -oxo-butyric acid =
0 4, OH
Example I1-16 (S, S, 5)- (3S) - [ (1- {3-Methyl- (25)- [ ( 4-methyl-pyridine-3-carbonyl ) -amino] -butyryl) -pyrrolidine- (28) -carbonyl) -amino] -4-oxo-butyric acid 61(0 )r 1161(0F1 Example I1-17 (3,3, S) - (33) - [ (1- {3-Methyl- (2S) - [ (3 -methyl-thiophene-2 -carbonyl) -amino] -butyryll-pyrrolidine- (2S) -carbonyl) -amino] -4-oxo-butyric acid 6-1)&iµ)criNT
S H KOH
Example 11-18 (S, S, S) (3S) - [ (1- ( (2.9) - [ (2,3-Dichloro-pyridine-4-carbonyl) -amino] -3 -methyl-butyryl )-pyrrolidin.e- (23) -carbonyl) -amino] -4-oxo-butyric acid a a NI1 HN)cNi Example 11-19.
(S, S, S) - (3S) - [ (1-{ (2.5`) - [ (3,5-Dichloro-pyridine-4-carbonyl ) -amino] -3 -methyl-butyryll -pyrrol id.ine- (2S) -carbonyl) -amino] -4-oxo-butyric acid a Example 11-20 (S, S, S) - (3S) - ( {1- [ (2.5') - (3-Methoxy-2-methyl-benzoylamirio) -3,3-dimethyl-butyryl ] -pyrrolidine- (2S) - carbonyl} -amino) -4- oxo-butyric acid _ *OH
Example 11-21 (S,S,S)-4-0xo- (3S) - ( {1- [4,4,4-trifluoro- (2S)- (2-methy1-3 -methww-benzoylamino ) -butyryl] -pyrrolidine- (2S) -carbonyl }-amino) -butyric acid -0 o CF
Example 11-22 (S, S, S) - (3S) - ( {1- [ (2S) - (5-Methoxy-2-methyl-benzoylamino) -3 methyl -butyryl ] -pyrrolidine- (2S) - carbonyl} -amino) -4 - oxo-butyri c acid =OH
" o Example 11-23 (S, S, S) - (3S) - ({l- [ (2S) - ( 3 -Methoxy-2-methyl-ben.zoylamino) -3 -thiazol-4-yl-propionyl ] -pyrrolidine- (2S) -carbonyl} -amino ) -4-oxo-butyri c acid Me0 0 Example 11-24 (S,S, S)- (3S)- ( {1- [ (2S) - (2-Chloro-benzoylamino) -4,4,4-tri f luoro-butyryl ] -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyric acid CI o CF3 =
N_cor o OH
Example II-25 (S, S, S) - (3S) - (Cl- (2S) - (2-Ch1oro-benzoylamino) -3 -thiazo1-4-y1¨
propionyl ] -pyrrolidine- (2S) -carbonyl) -amino) -4-oxo-butyric acid CI o Example I1- 2 6 (S. S, S) ( 3 S ) (C1- [3, 3 -Dimethyl- (2S) - (2-methyl-benzoylamino) -butyryl] -pyrrolidine- (2S) -carbonyl ) -amino) -4 -oxo-butyric acid NIc"? jOH
Example II-27 (S, S, S) - (3S) ({l- [3-Methyl- (2S) - (2-trifluoromethyl-benzoylamino) -butyryl ] -pyrrolidine- (2S) -carbonyl -amino) -4-oxo-butyric acid OH
Example 11-28 ( 5, S, S) - ( 3 S) ( (1- [ ( 2S ) ( 2 -chaoro-benzoylamino ) -3, 3 -dimethyl-butyryl ] -pyrrolidine- (2S) -carbonyl) -amino) - 4 -oxo-butyric acid Cl o = N? 0H
Example 11-29 (S, S, S) - (3S) - ( {1- [3,3-Dimethyl- (2S) - (2-trifluoromethyl-benzoylamino) -butyryl I -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyric acid OH
o Example 11-30 (S, S, S) - (3S) - ( {1- [ (2S ) - (2-Chloro-3-methoxy-benzoylamino) -3,3-dimethyl -butyryl -p-yrrolidine- (2S) -carbonyl} -amino) -4- oxo-butyri c acid Me0 [1-r-Nii.OH
0 Nfl = 0 Example II-31 (S, S, S) - (3S) - ({l- [ (2S) - (2-Fluoro-3-metho3cy-benzoylamino) -3,3 -dimethyl-butyryl -pyrrolidine- (2S) -carbonyl) -amino) -4-oxo-butyric acid Me0 NNAOil 0 Nfl = 0 Example 11-32 (S, S, S) - (3S) - ( {1- [ (2S) - (2-Chloro-3-trifliaoromethoxy-benzoylamino) -3,3 -dimethyl-butyryl ) -pyrrolidine- (2S) -carbonyl} -amino) -4 -oxo-butyri c acid F3C' 410 N N
H CJH
o N
=
Example 11-33 ($,S,S)-(3S)-((1-[(2S)-(2-Chloro-3-cyclopropyloxy-benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid VD.H H
Example 11-34 (S,S,S)-(3S)-({1-[(2S)-(2-Chloro-3-methyl -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid CI 0.4, * =
OH
= 0 Example 11-35 (S,S,S)-(3S)-({1-[(2S)-(2-chloro-3-methoxy -benzoylamino)-3-methyl-butyry11-pyrrolidine-(2S)-carbonyll-amino)-4-oxo-butyric acid 1 0: 4" 0 OH
Example 11-36 (S,S,S)-(3S)-({1-[(2S)-(2-Chloro-3-ethyl -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1)7amino)-4-oxo-butyric acid * [siNNIT kr OH
= 0 =
Example 11-37 (S, S, S) ( 3 S) - ( {1- [ (2S) - ( 2 -chloro-4-methoxy -benz oylamino) -3-methyl-butyryll-pyrrolidine- (2S) -carbonyl} -amino ) -4-oxo-butyric acid C'0 '0* NI? drOH
JH
Example 11-38 (S, S, S) - ( 3 3) (C1- [ (2S) - ( 2 -Chl oro- 3 -cyclopropylmathoxy -benzoylamino ) -3, 3 -dimethyl -butyryl -pyrrolidine- (2S) -carbonyl} -amino) -4 - oxo -butyric acid * I OH
= 0 Example 11-39 (S, S, S) - (3S) - ( (1- [ (2S ) - (2-Chloro-3-hydroxy -ben.oylamino) -3,3 -dimethyl-butyryl] -pyrrolidine- (25) -carbonyl} -amino) -4- oxo-butyri c acid OH
= 0 Example 11-40 (S, S,S)- (3S) - ( {I- [ (2S) - (2-chloro-4-acetamido -bnzoylamino) -3-methyl-butyryl -pyrro 1 i dine- ( 2S) -carbonyl ) -aminc)) -4-oxo-butyric acid HN 400 11-110.1\11i.,OH
= 0 =
, Example II-41 (S, S, S) - (35) - ( {1- [ (2S) - (2-Chloro-3-acetamido -benzoylamino) 3,3 -dimethyl-butyryl ] -pyrrolidin.e- (2S) -carbonyl) -amino) -4-oxo-butyric acid OH
Example 11-42 (S, S, S) - (3S) - ( {1- [ (2S) - (2-methyl -3 -acetamido -benzoylamino) -3,3 -dimethyl -butyryl ] -pyrrolidine- (2S) - carbonyl} -amino ) -4-oxo-butyric acid (21 VNriii Example 11-43 (S, S, S)- (3S) - ( {1- [ (2S) - (2-chloro -4-acetamido -benzoylamino) 3,3 -dimethyl -butyryl ] -pyrrolidine- (2S) -carbonyl) -amino) -4 - oxo-butyric acid HN 11*
ONff Example 11-44 S, S, S) - (3S) - ( {1- [ (2S) - (2- fluor -4-acetamido -benzoylamino) -3,3 -dimethyl -butyryl -pyrrolidine- (2S) -carbonyl}--amino) -4-oxo-butyric acid =
H N HN
= 0 Example II-45 (S, S, S) (3S) - ( {1- [ (2S) - (2-fluoro -4-acetamido -ben.zoylamino) 3 -methyl-butyryl ] -pyrrolidine- (2S) -carbonyl} ¨amino) -4- oxo-butyric acid HN IXN?
= 0 Example 11-46 (S,S,S)- (3S) - ( {1- [ (2S) - (2-chloro -4-isopropyloxy -benzoylamino ) -3 -methyl-butyryl ] -pyrrolidine- (2S) - carbony11-amino ) -4-oxo-butyric acid CI \Ir.. .
. =
* LrOH =
Example 11-47 (S, S, S) - (3S) ( {1- [ (2S) - (2-chloro -4-hydroxy -benzoylamino) -3,3-dimethyl-butyryl] -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyric acid CI
HO* N.N?
= 0 Example 11-48 (S, S, S) - (3S) - ( {1- [ (2S) - (2- chloro -4-methoxymethyl -benzoylamino ) -3, 3 -dimethyl-butyryl] -pyrrolid.ine- (2S) -carbonyl} -amino) -4- oxo -butyric acid = -128-CI
41*OHH
Example 11-49 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -4-isobutyrylamido -benzoylamino)-3,3-dimethyl-butyryll-pyrrolidine-(2S)-carbonyll-amino)-4-oxo-butyric acid Cl 0 HN 410 11\-11,..0H
Example 11-50 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -4-acetamido -benzoylamino)-3-cyclohexyll-pyrrolidine-(2S)-carbonyll-amino)-4-oxo-butyric acid HN
Example 11-51 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -4-methoxycarbonylamino -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid Cl 0 4, HN410 OrifoH
00 ON( Example 11-52 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -3-phenoxy -benzoylamino)-3,3-dimethyl-butyryll-pyrrolidine-(2S)-carbony1)-amino)-4-oxo-butyric acid o 0 jH
Example 11-53 (S,S,S)-(3S)-((1-[(2S)-(2-chloro -6-amino -benzoylamino)-3-methyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid OH
Example 11-54 (S,S,S)-(3S)-({1-[(2S)-(2-chloro-benzoylamino)-3,3-dimethyl-butyryli-piperidine-(2S)-carbonyl)-amino)-4-oxo-butyric acid C'0 OH
Example 1-55 (3S)-(f2-[(2S)-(3-Methoxy-2-methyl-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyll-amino)-4-oxo-butyric acid cH3 0 iojCirl 40H
Example 11-56 (3S)-((2-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyl}-amino)-4-oxo-butyric acid =
a 0)Cirl.., OH
0 0 m "
Example 11-57 (3S)-({2-[(2S)-(4-Acetylamino-2-chloro-benzoylamino)-3,3-dimethyl-butyry1)-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyl}-amino)-4-oxo-butyric acid o %Criµ7 4 F4H
Example 11-58 (3S)-({2-[(2S)-(2-Chloro-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry11-2-(18,4R)-aza-bicyclo[2.2.1]heptane-(38)-carbonyl}-amino)-4-oxo-butyric acid a o ,,it 100 l....OH
" 0 Example 11-59 (3S)-({2-[(2S)-(2-Chloro-3-isobutyrylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyl)-amino)-4-oxo-butyric acid H CI 0 jcril " o Example 11-60 (3S)-((2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-313-dimethyl-butyry11-2-(13,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1)-amino)-4-oxo-butyric acid =
0 0 N. j(OH
Example 11-61 (3S)-({2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-3-methyl-butyrya]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1)-amino)-4-oxo-butyric acid X.Tr47 õ(OH
Example 11-62 (3S)-([2-[(2S)-(4-Acetylamino-3-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid " o a Example 11-63 (3S)-((2-[(2S)-(3-Chlor0-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid jt. X17 40H
" o a =
Example 11-64 (3S)-((2-[(2S)-(Isoquinolin-l-ylcarbonylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyll-amino)-4-oxo-butyric acid OH
H
Example 11-65 (3S)-(f2-[(2S)-(4-Amino-3-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid OH
Example 11-66 (3S)-({2-[(2S)-(4-Amino-3-chloro-benzoylamino)-3-methyl-butyry1)-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid H2N o 0 N
a N o [01791 The characterization data for compounds 11-1 to 11-66 is summarized in Table 4 below and includes HPLC, LC/MS
(observed) and IH NMR data. IH NMR data was obtained at 400 MHz, and was found to be consistent with structure.
=
Table 4. Characterization Data for Selected Compounds of Formula II (According to Compound Number) 114.1 No. 1H-NMR
(obs) (DMSO-d6) 0.82-0.98 (611, m), 1.89-2.07 (511, m), 2.10 (3H, s), 3.0 (1H, m), 3.63 (111, m), 3.79 (3H, s), 3.88 (1H, II-1 462.1 m), 4.00 (1H, m), 4.25 (111, m), 4.40-4.44 (211, m), 5.45 (1H, br s), 6.83 (1H, d), 7.00 (1H, d), 7.19 (111, t), 7.77 (1H, br s), 8.32-8.50 (211, m) (DMSO-d6) 0.95-0.99 (6H, m), 1.87-2.09 (5H, m), 3.00 (111, m), 3.64 (111, m), 11-2 452.0 3.85 (111, m), 4.04 (1H, m), 4.25 (111, m), 4.40 (1H, m), 4.47 (1H, m), 5.45 (1H, m), 7.34-7.49 (4H, m), 7.78 (1H, m), 8.40 (1H, m), 8.64 (111, m) (DMSO-d6) 0.94-0.99 (GH, m), 1.87-2.09 (5H, m), 2.30 (3H, s), 2.90 (1H, m), 11-3 432.1 3.64 (1H, m), 3.88 (111, m), 4.03 (1H, m), 4.30 J111, m), 4.44 (1H, m), 5.45 (111, m), 7.19-7.33 (411, m), 7.77 (1H, br s), 8.35-8.40 (2H, m) (CD30D) 1.05-1.18 (611, m), 2.00-2.30 (5H, m), 2.52-2.75 (2H, m), 3.66-3.83 (1H, m), 3.92-4.03 (111, m), 4.26-4.35 11-4 448.0 (1H, m), 4.45-4.55 (111, m), 4.61-4.70 (111, m), 4.78-4.85 (1H, m), 7.13 (1H, t), 7.21 (111, d), 7.57 (111, t), 8.00 (1H, d), 8.69 (1H, d) (CD30D) 0.98-1.15 (611, m), 1.95-2.26 (5H, m), 2.54-2.76 (211, m), 3.73-3.84 11-5 502.0 (1H, m), 3.99-4.06 (111, m), 4.21-4.32 (1H, m), 4.45-4.53 (111, m), 4.60-4.70 (2H, m), 7.30-4.47 (2H, m), 7.54-7.64 (2H, m) (DMSO-d6) 0.92-0.98 (611, m), 1.85-2.04 (5H, m), 2.07 (3H, s), 3.00 (1H, m), 3.63 (111, m), 3.87 (111, m), 4.03 (111, 11-6 448.1 ml 4.25 (111, m), 4.41 (111, m), 5.45 (1H, m), 6.68 (111, m), 6.82 (111, m), 7.01 (1H, m), 7.81 (111, m), 8.25 (111, d), 8.40 (1H, m), 9.5 (1H, m) =
M+1 No. 111-NMR.
(obs) (CD30D) 1.02-1.18 (6H, m), 1.88-2.28 (5H, m), 2.39 (3H, s), 2.50-2.78 (2H, 11-7 447.0 m), 3.75-3.83 (1H, m), 4.00-4.10 (1H, m), 4.21-4.32 (1H, m), 4.45-4.52 (111, m), 4.60-4.65 (2H, m), 7.39-7.54 (3H, m) (DMSO-d6) 0.94-0.99 (6H, m), 1.71-2.12 (4H, m), 2.33 (1H, br s), 2.67 (1H, br s), 2.94-3.07 (IH, m), 3.61-3.69 (1H, 11-8 446.0 m), 3.82-3.87 (111, m), 4.03-4.10 (IH, m), 4.19-4.28 (1H, m), 4.30-4.43 (2H, m), 5.42-5.47 (1H, m), 7.28-7.30 (1H, m), 7.37-7.40 (1H, m), 7.68-7.82 (2H, m), 8.77 (1H, d) (DMSO-d6) 0.94-0.99 (6H, m), 1.86-2.09 (5H, m), 3.00 (1H, m), 3.65 (Iii, m), 3.84 (1H, m), 4.05 (1H, m), 4.24 (IH, 11-9 519.9 m), 4.40 (IH, m), 4.51 (111, m), 5.45 (1H, m), 7.57-7.62 (2H, m), 7.77 (1H, d), 7.90 (1H, m), 8.40 (1H, d), 8.87 (1H, d) (DMSO-d6) 0.93-0.99 (6H, 2 x d), 1.77-2.19 (5H, m), 2.29 (3H, s), 2.97 (IH, br s), 3.62-3.65 (1H, m), 3.85-3.88 II-10 466.0 (IH, m), 4.00-4.32 (2H, br m), 4.41-4.53 (2H, m), 5.45 (1h, br s), 7.18-7.27 (2H, m), 7.45-7.50 (1H, m), 7,85 (1h, br d), 8.41 (1H, br d), 8.57 (1H, d) (DMSO-d5) 0.82-0.86 (3H, m), 0.93-0.98 (3H, m), 1.87-2.08 (5H, m), 3.00 (1H, m), 3.64 (111, m), 3.82 (1H, m), 4.10 II-11 485.9 (1H, m), 4.30 (1H, m), 4.45 (1H, m), 4.47 (1H, m), 5.44 (1H, d), 7.37 (IH, m), 7.47 (1H, m), 7.65 (1H, m), 7.77 (1H, m), 8.40 (1H, m), 8.72 (IF!, m) (DMSO-d6) 0.94-0.99 (61!, m), 1.91-2.09 (51!, m), 3.00 (1H, m), 3.64 (1H, m), 3.83 (11!, m), 4.03 (11!, m), 4.20 (11!, 11-12 485.9 m), 4.40 (11!, m), 4.47 (IH, m), 5.45 (11!, m), 7.37 (1H, s), 7.50-7.52 (21!, m), 7.78 (1H, m), 8.44 (11!, m), 8.79 (1H, m) . -=
14+1 No. 111-10R
(obs) (DMSO-d0 0.82-0.86 (3H, m), 0.92-0.99 (3H, m), 1.80-1.87 (2H, m), 1.99-2.02 (4H, m), 2.48 (0.5 H, m), 2.95 (0.5 H, 11-13 486.3 m), 3.51 (1H, m), 3.80-4.56 (4H, m), 5.00 and 5.47 (1H, 2 x m), 7.37-7.48 (3H, m), 7.76-8.32 (1H, m), 8.95-9.39 (1H, 3 x dd) (DMSO-d0 0.93-0.99 (6H, m), 1.80-2.09 (5H, m), 2.17 (6H, d), 2.95 (1H, br s), 3.63-3.65 (1H, m), 3.96-3.99 (1H, m), 11-14 446.0 4.10 (1H, br s), 4.30 (1H, br s), 4.44 (1H, t), 5.48 (1H, br s), 7.00 (2H, d), 7.14 (1H, t), 7.78 (IH, br s), 8.50 (1H, br s), 8.55 (1H, d) (DMSO-d0 0.91-1.02 (6H, m), 1.80-2.20 (5H, m), 2.66-2.68 (3H, s), 3.00 (1H, m), 3.62-3.85 (3H, m), 4.10 (1H, m), 11-15 433.1 4.24 (1H, m), 4.51 (1H, m), 5.72 (IH, m), 7.73-7.76 (2H, m), 8.19 (IH, m), 8.52 (1H, m), 8.75 (1H, d), 8.90 (1H, m) (DMSO-d0 0.9-1.05 (6H, m), 1.8-2.2 (6H, m), 2.3-2.4 (111, m), 2.7-2.75 (1H, m), 2.9-3.0 (1H, m), 3.65-3.75 (1H, m), ' 11-16 433.1 3.8_3.9 (111, ) 4.1-4.15 (1H, m), 4.3-4.4 (1H, m), 4.45-4.65 (111, m), 7.8-7.9 (1H, m), 8.7-8.8 (2H, d), 8.9.8.95 (1H, (DmS0-d6) 0.83-0.99 (6H, m), 1.80-2.20 (5H, m), 2.40 (3H, s), 3.00 (1H, m), 3.61 (1H, m), 3.81 (IH, m), 4.10 (1H, 11-17 438.0 m), 4.25 (1H, m), 4.42-4.46 (2H, m), 5,44 (1H, br s), 6.97 (1H, m), ,7.34 (1H, m), 7.59 (1H, m), 7.81 (1H, m), 8.49 (1H, m) (DMSO-d6) 0.92-1.00 (6H, m), 1.75-2.08 (5H, m), 2.30-2.34 (1H, m), 2.99 (IH, dd), 3.62-3.67 (1H, m), 3.78-3.82 (1H, 11-18 487.0 m), 3.78-3.82 (1H, m), 4.05-4.26 (1H, m), 4.38-4.54 (2H, m), 5.44-5.72 (1H, m), 7.37-7.41 (1H, m), 8.41-8.43 (2H, m), 8.97-9.00 (1H, d) _ .
=
No. 111-4ata (obs) (DMSO-dd 0.94-1.00 (611, m), 1.77-2.15 (5H, m), 3.02 (111, dd), 3.61-3.70 (111, 11-19 487.0 m), 3.80-3.90 (111, m), 4.03-4.08 (111, m), 4.52-4.56 (1H, m), 4.95 (2H, br s), 5.45 (111, s), 8.42 (111, d), 8.67 (211, s), 9.17 (111, d) (DMSO-dd 0.91-1.11 (9H, m), 1.70-2.14 (7H, m), 2.31 (111, m), 3.01 (1H, m), 11-20 476.4 3.50-3.97 (5H, m), 4.00-4.62 (311, m), ,5.50 (111, m), 6.77 (111, d), 7.00 (111, d), 7.18 (1H, dd), 7.50-8.50 (311, m) (DMSO-dd 1.80-2.00 (311, m), 2.11 (411, overlapping s and m), 2.60-2.80 (2H, m), 3.64-3.69 (1H, m), 3.80 (3H, s), 11-21 502.1 4.10 (1H, vbrs), 4.30 (1H, vbrs), 5.00 (111, m), 6.86 (1H, d), 7.03 (1H, d), 7.22 (111, t), 8.45 (1H, vbrs), 8.81 (1H, d) (DMSO-dd 0.93-1.00 (611, m), 1.70-2.15 (511, m), 2.22 (311, s), 2.33 (111, d), 2.99 (111, dd), 3.60-3.65 (211, m), 3.74 11-22 462.4 (3H, s), 4.04-4.08 (1H, m), 4.21-4.27 (1H, m), 4.40-4.58 (2H, m), 5.46 (1H, , brd d), 6.78-6.81 (111, m), 6.85-6.91 (1H, m), 7.09-7.14 (111, m), 8.37 (211, 2 x brd d) (DMSO-dd 1.77-2.19 (511, m), 2.95-3.28 (311, m), 3.60 (1H, brd d), 3.71-3.78 (411, m), 4.10-4.42 (6H, m), 4.97 (1H, 11-23 517.0 brd s), 5.45-72 (1H, m), 6.74 (111, d), 6.97 (111, d), 7.10-7.22 (111, m), 7.44 (111, m), 8.37-8.68 (2H, m), 9.05 (111, brd s) (DMSO-dd 1.75-1.98 (311, m), 2.08-2.13 (111, m), 2.64-2.77 (2H, m), 2.99 (0.511, dd), 3.63-3.73 (2H, m), 4.08 (0.511, 11-24 492.0 brt), 4.20 (0.5H, dd), 4.23-4.49 (3 multiplets, 1H total), 5.00-5.10 (1H, m), 5.42 (0.5H, s), 7.36-7.52 (411, m), 7.77 (111, m), 8.30 (0.511, d), 9.09 (1H, d) =
=
M+1 No. 11-1-4vima (ohs) (DMSO-d6) 1.79-1.96 (5H, m), 2.94-3.28 -(3H, m), 3.58 (1H, brd d), 3.73 (1H, 11-25 507.0 brd d), 4.04-4.59 (2H, m), 4.98-5.02 -(1h, m), 5.54-5.74 (2H, m), 7.26-7.46 (511, m), 8.43 (1H, d), 8.82 (1H, d), 9.39 (1H, brd s) (DMSO-d6) 1.05 (9H, s), 1.15 (3H, t), 1.8-2.1 (4H, m), 2.3 (3H, s), 2.4-2.5 (1H, m), 2.9-3.0 (1H, m), 3.7-3.75 (1H, 11-26 446.6 m), 3.8-3.85 (1H, m), 4.1-4.15 (0.5H, m), 4.25-4.3 (1H, m), 4.4-4.5 (0.5H, m), 4.7-4.75 (1H, m), 5.55-5.6 (1H, m), 7.2-7.4 (4H, m), 7.7-7.75 (1H, m), 8.1-8,15 (1H, m), 8.35-8.4 (1H, m) (DMSO-d0 0.95-1.05 (6H, m), 1.8-2.1 (4H, m), 2.4-2.5 (1H, m), 3.0-3.1 (1H, m), 3.7-3.75 (1H, m), 3.8-3.85 (1H, m), 11-27 486.5 4.1-4.15 (0.5H, m), 4.25-4.3 (1H, m), 4.4-4.5 (0.5H, m), 5.55-5.6 (1H, m), 7.4-7.45 (1H, m), 7.6-7.8 (3H, m), 8.4-8,45 (1H, m), 8.75-8.8 (1H, m) (CDC13) 1.11-1.16 (9H, m), 1.94-2.22 (4H, m), 2.38-2.50 (2H, m), 2.77-2.87 11-28 466.1 (1H, m), 3.71-3.79 (1H, m), 3.96-4.06 (1H, m), 4.56-4.67 (2H, m), 4.85-4.91 (1H, m), 6.99-7.02 (1H, .m), 7.28-7.45 (3H, m), 7.60-7.84 (2H, m) (CDC13) 1.07 (9H, s), 1.85-2.19 (2H, m), 2.37-2.40 (2H, m), 2.81-3.07 (1H, 11-29 500.2 m), 3.37 (1H, brs), 4.01 (1H, brs), 4.46-4.67 (2H, m), 4.87 (1H, d), 5.73 (1H, brs), 6.68 (1H, brs), 7.38-7.74 (5H, m) (CD30D) 1.15 (9H, s), 1.85-2.20 (4H, m), 2.46-2.72 (2H, m), 3.74-3.81 (1H, 11-30 496.2 m), 3.92 (3H, s), 3.93-4.03 (1H, m), 4.20-4.31 (1H, m), 4.45-4.52 (1H, m), 4.60-4.75 (1H, m), 4.83 (1H, s), 7.00 (1H, d), 7.15 (1H, d), 7.33 (1H, t) (DMSO-d5) 1.05 (9H, s), 1.8-2.1 (4H, m), 2.4-2.5 (1H, m), 3.75-3.8 (1H, m), 11-31 480.5 3.8-3.85 (1H, m), 3.9 (3H, s), 4.1-4.3 (1H, m), 4.7 (1H, d), 5.3-5.5 (0.5H, hr s), 7.1-7.3 (3H, m), 7.7-7.8 (1H, m), 8.0-8.1 (1H, m), 8.35-8.45 (1H, m) =
No. 111-NNR
(obs) (DMSO-d0 0.91-1.10 (9H, m), 1.70-2.15 (5H, m), 2.60-3.08 (1H, m), 3.60-3.90 11-32 550.3 (2H, m), 3.98-4.71 (3H, m), 5.40-5.80 (1H, m), 7.30-7.91 (3H, m), 8.30-8.80 (3H, m) (DMSO) 0.60-0.90 (4H, in, cyclopropyl CH2), 0.92-1.10 (9H, in, tBu), 1.71-2.21 (5H, in, CH2), 2.65-3.10 (1H, brm, CH2), 11-33 523.3 3.36-3.50 (1H, in, CH), 3.60-4.75 (6H, in, CH), 6.92 (1H, d, aryl H), 7.36 (1H, m, aryl H), 7.45 (1H, m, aryl H), 7.65-8,60 (3H, in, NH, OH) (DMSO) 0.99-1.10 (9H, in, tBu), 1.70-2,12 (5H, in, CH2), 2.35 (3H, s, CH3), 2.60-3.08 (1H, in, CH2), 3.58-3.87 (2H, 11-34 480-3 in, CH), 4.00-4.70 (3H, in, CH), 5.38-5,79 (111, in, CH), 7.12 (1H, d, aryl H), 7.24 (1H, in, aryl H), 7.38 (1H, m, aryl H), 7.69-8.55 (3H, in, NH, OH) CD3OD 1.01-1.15 (6H, m), 1.95-2.22 (5H, m), 2.48-2.69 (2H, m), 3.73-3.80 11-35 482 (1H, m), 4.92 (3H, s), 3.99-4.19 (1H, m), 4.20-4.30 (1H, m), 4.58-4.67 (2H, m), 7.00 (1H, d), 7.14 (1H, d), 7.31 (1H, t) (DMSO) 0.94-1.08 (9H,s, tBu), 1.19 (3H, t, CH3), 1.70-2.40 (5H, in, CH2), 2.60-3,08 (3H, in, CH2), 3.69 (1H, in, CH), 11-36 494.4 3.81 (1H, In, CH), 4.04-4.71 (3H, in, CH), 5.40-5.80 (1H, in, CH), 7.14 (1H, in, aryl H), 7.31 (IH, in, aryl H), 7.39 (1H, m, aryl H), 7.70-8.50 (3H, in, NH, OH) (DMSO) 0.9-1.0 (6H, m), 1.85-2.3 (4H, m), 3.0-3.1 (1H, m), 3.65-3.7 (1H, m), 3.78 (3H, s), 3.8-3.85 (1H, m), 4.1-11-37 482.5 4.15 (0.5H, m), 4.25-4.3 (0.5H, m), 4.5-4.55 (1H, m), 5.5-5.55 (1H, m), 6.93 (1H, d), 6.98 (1H, s), 7.35 (111, d), 7.75-7.8 (1H, m), 8.45 (1H, d) M+1 No.
(obs) (CD3OD ) 0.34-0.40 (2H, m), 0.60-0.67 (2H, m), 1.16 (911, s), 1.25-1.32 (1H, m), 1.93-2.22 (411, m), 2.50-2.66 (211, 21-38 536 m), 3.74-3.84 (1H, m), 3.91-4.03 (3H, m), 4.22-4.32 (1H, m), 4.45-4.54 (IH, m), 4.61-4,69 (111, m), 4.82 (111, d), 6.99 (111, d), 7.12 (111, d), 7.32 (111, t), 8.40 (1H, d) (CD3OD ) 1.12 (9H, s), 1.90-2.22 (411, in), 2.512.70 (211, in), 3.75-3.83 (1H, 1I-39 482 =m), 3.97-4.05 (1H, m), 4.23-4.30 (111, m), 4.46-4.54 (1H, m), 4.63-4.70 (111, m), 4.83 (111, d), 6.91 (111, d), 6.99 (111, d), 7.17 (1H,t), 8.36 (1H, d) (DMSO) 0.93-0.98 (611, m) 1.71-2.09 (1011, m), 2.35-2.45 (211, m), 3.61-3.64 (1H, m), 4.02-4.04 (1H, m), 4.06-4.35 "
11-40 509.3 (211, m), 4.43-4.46 (111, m), 7.33 (111, d), 7.43-7.46 (1H, m), 7.80 (111, brd s), 8.28-8.49 (2H, m), 10.25 (111, brd s) (DMSO) 0.95-1.08 (911, s, tBu), 1.70-2,38 (811, in, COCH3, CH2), 2.58-3.08 =
=
(1H, in, CH2), 3.65 (1H, in, CH), 3.82 11-41 523.3 (111, In, CHO), 3.95-4.69 (3H, in, CH), 5.40-5.60 (111, in, CH), 7.09 (1H, in, aryl H), 7.31 (1H, in, aryl H), 7.64-8,60 (411, in, aryl H, NH), 9.55 (1H, in, CH) (DMSO) 0.91-1.08 (911, s, tBu), 1.70-2,40 (11H, in, CH3, COCH3, CH2), 2.60-3,08 (111, m, C112), 3.66 (111, in, CH), 11-42 503.4 3.87 (111, in, CH), 4.00-4.65 (311, in, CH), 5.40-5.78 (1H, in, CH), 7.04 (111, in, aryl H), 7.18 (IH, in, aryl H), 7.38 (1H, in, aryl H)--, 7.65-7.88 (111, m, NH), 8.07-8.70 (211, in, NH), 9.34 (111, in, CH) (DMSO) 1.03 (9H, s), 1.71-2.00 (3H, m), 2.07 (311, s), 2.55-2.73 (111, m), 2.97 (111, dd), 3.60-3.67 (111, m), 3.75-3.82 (1H, m), 3.98-4.04 (1H, m), 4.19-4.24 21-43 523.3 (1H, m), 4.37-4.45 (111, m), 4.63 (111, d), 5.45 (111, d), 7.33-7.35 (111, m), 7.43-7.45 (111, d), 7.76-7.83 (211, m), 8.25-8.28 (111, m), 8.41-8.58 (1H, m), 10.27 (1H, s) 1441.
No. 1H-NMR
(obs) (DMSO) 1.01 (9H, 2 x s), 1.72-1.99 (4H, m), 2.05-2.09 (4H, m), 2.35-2.57 (2H, m), 2.71-3.00 (1H, brd m), 3.60-3.65 11-44 507.4 (111, m), 3.71-3.80 (1H, m), 4.08-4.37 (211, brd m), 4.70 (111, d), 7.32 (111, dd), 7.65-7.80 (311, m), 8.33-8.52 (IH, brd m), 10.37 (111, s) (DMSO) 0.94 (6H, dd), 1.72-1.99 (10H, m), 2.36-2.52 (2H, m), 3.57-3.68 (111, 11-45 493.4 m), 3.76-3.88 (111, m), 4.20-4.43 (2H, m), 4.51-4.55 (111, m), 7.30 (IH, dd), 7.58-7.77 (311, m), 8.00-8.04 (111, m), 10.34 (111, s) (DMSO) 0.95-1.0 (6H, m), 1.25 (6H, d), 1.85-2.2 (4H, m), 3.0-3.1 (IH, m), 3.9-11-46 510.5 4.0 (3H, m), 4.2-4.3 (0.511, m), 4.4-4.5 (0.5H, m), 4.7-4.8 (1H, m), 6.9-6.95 (111, d), 6.99 (111, s), 7.3 (1H, d), 8.3-8.4 (1H, m) (DMSO) 1.05 (9H, m), 1.8-2.1 (411, m), 2.6-2.7 (111, m), 2.9-3.0 (2H, m), 3.6-3.7 (211, m), 3.8-3.9 (111, m), 4.0-4.1 11-47 482.5 (111, m), 4.2-4.3 (111, m), 4.6-4.65 (1H, m), 5.5-5.55 (111, m), 6.75-6.85 (2H, m), 7.35 (1H, d), 7.75 (111, d), 8.0-8.1 (1H, m), 8.35 (1H, m), 10.25 (111, s) (DMSO) 1.03 (9H, s), 1.80-2.10 (411, m), 3.00 (1H, br s), 3.30 (311, s), 3.66 11-48 510.5 (111, m), 3.81 (111, m), 4.06 (1H, m), 4.25 (1H, m), 4.44 (211, s), 4.65 (1H, d), 5.46 111, br s), 7.29-7.39 (311, m), 7.77 (IH, br s), 8.43 (111, m) (DMSO) 1.03 (911, s), 1.09 (3H, m), 1.11 (311, m), 1.79-2.15 (411, m), 2.32 (1H, m), 2.98 (1H, m), 3.51 (1H, m), 3.79 11-49 551.5 (1H, m), 4.10 (1H, m), 4.23 (111, m), 4.40-4.65 (2H, m), 5.45-5.73 (111, m), 7.35 (111, m), 7.49 (1H, m), 7.76-7.84 (211, m), 8.23-8.60 (2H, m), 10.11 (111, s) M+1 No. 1H-NMR
(obs) (DMSO) 0.92-1.19 (4H, m), 1.49-1.90 (911, m), 1.91-1.99 (211, m), 2.06 (411, brd s), 2.49-2.52 (2H, m), 3.57-3.68' 11-50 493.3 (111, m), 3.80-3.90 (111, m), 4.01-4.28 (2H, m), 4.46 (111, t), 7.32 (1H, d), 7.43 (1H, dd), 7.81 (211, brd s), 8.31-8.78 (111, m), 8.46 (1H, d), 10.22 (1H, s) (DMSO) 0.90-1.07 (9H, s, tBu), 1.70-2.40 (411, brm, CH2), 2.54-3.07 (1H, in, CH2), 3.52-3.88 (511, in, CH3, CH), 4.00-=-51 539.3 4.65 (311, in, CH), 5.40-5.80 (111, in, CH), 7.30-7.44 (211, m, aryl H), 7.60 (1H, in, aryl H), 7.67 (111, br, NH), 8.10-8.70 (2H, m, NH), 10.00 (111, in, CH) (DMSO) 0.91-1.11 (911, s, tBu), 1.70-2.41 (4H, in, CH2), 2.56-3.09 (111, in, CH2), 3.60-3.90 (211, in, CH), 4.14-4.72 11-52 558.3 (3H, in, CH), 5.38-5.80 (111, in, CH), 6.98 (211, in, aryl H), 7.07-7.20 (3H, m, aryl H), 7.31-7.46 (311, m, aryl H), 7.66-8.67 (3H, in, NH, OH) (DMSO) 0.83-1.04 (6H, m), 1.81-2.08 (5H, m), 3.34-3.63 (111, m), 3.84-3.90 11-53 467 (1H, m), 4.00-4.60 (3H, m), 5.29-5.75 (211, m), 6.53-6.59 (1H, m), 6.70-6.90 (1H, m), 7.20-7.35 (0.5H, m), 7.78 (0.5H. brs), 8.43-8.60 (2H, m) (DMSO) 0.96 (111, s). 1.03 (911, s), 1.30-1.39 (211, m), 1.68-1.71 (211, m), 1.79-1.82 (111, m), 1.97 (111, brd), 2.11 11-55 502.6 (311, s), 3.79 (311, s), 3.84 (1H, vbrs), 4.09 (111, vbrs), 4.56-4.58 (1H, m), 4.67 (1H, d), 6.81 (111, d), 7.00 (111, d), 7.19 (1H, t), 7.79 (0.511, vbrs), 7.93 (1H, brd), 8.42 (0.511, vbrs) (CDC13) 1.08-1.14 (9H, m), 1.85-2.05 (411, m), 2.32-2.45 (111, m), 2.79-2.85 (1H, m), 3.01-3.07 (1H, m), 4.13-4.17 11-56 492.5 (111, m), 4.53-4.70 (111, m), 4.98 (111, t), 5.70 and 5.81 (1H total , brs and brd), 6.91-7.00 (1H, m), 7.34-7.44 (311, m), 7.67-7.75 (111, m) = =
No. 1-11-NMR
(obS) (DMSO) 1.03 (9H, s), 1.31-1.38 (2H, m), 1.62-1.74 (3H, m), 1.98 (1H, brt), 2.07 (3H, s), 2.36 (1H, vbrs), 2.83 (1H, 11-57 549.5 vbrs), 3.84 (1H, brs), 4.17 (1H, vbrs), 4.54-4.57 (111, m), 4.70 (1H, d), 7.34 (1H, d), 7.42-7.45 (1H, m), 8.16 (1H, t), 8.37 (11-I, brs), 10.23 (1H, s) (CD30D) 1.17 (9H, s), 1.21 (311, t), 1.41-1.55 (211, m), 1.75-1.90 (311, m), 2.03-2.19 (111, m), 2.37-2,50 (3H, m), 11-58 563.5 2.58-2.78 (2H, m), 3.87-4.02 (111, m), 4.20-4.30 (1H, m), 4.55-4.70 (2H, m), 4.91 (1H, obscured), 7.45 (111, d), 7.51 (111, d), 7.85 (111, s), 8.29 (1H, d) (DMSO) 1.05 (9H, s), 1.15 (6H, d), 1.35-1.5 (211, m), 1.75-1.9 (311, m), 2.0-2.1 (111, m), 2.3-2.45 (1H, m), 2.7-11-59 577.5 2.9 (111, m), 4.05-4.15 (111, m), 4.65 (1H, s), 4.7-4.75 (1H, m), 7.15 (111, d), 7.35 (111, t), 7.7 (111, d), 8.4-8.55 (2H, m), 9.5 (1H, s) (DMSO)1.03 (9H, s), 1.31-1.38 (211, m), 1.68 (311, m), 2.30-2.33 (2H, m), 2.67 (0.511, brs), 2.99 (0.511, brs), 3.34 11-60 506.5 (0.511, brs), 3.76 (31-1, s), 4.04 (0.5H, m), 4.58 (111, s), 4.72 (1H, d), 7.09-7.12 (1H, m), 7.16-7.20 (111, m), 7.26-7.30 (111, m), 7.78 (0,5H, vbrs), 8.02 (111, brs), 8.42 (0.511, vbrs) (DMSO) 0.95 (3H, d), 0.10 (3H, d), 1.17 (1H, m), 1.32 (1H, m), 1.64-1.80 (311, m), 2.00 (111, m), 2.30 (111, br s), 2.67 11-61 492.8 (0.5H, br s), 2.99 (0.511, br s), 3.75 (0.511, br s), 3.85 (311, s), 4.06 (0.511, m), 4.50-4.55 (211, m), 5.42 (1H, br s), 7.07 (1H, m), 7.17 (1H, m), 7.26 (1H, m), 7.80 (1H, br s), 8.35 (1H, m) DMSO) 8 1.04 (9H, s), 1.29-1.34 (2H, m), 1.59-1.67 (3H, m), 1.91-1.97 (1H, m), 2.13 (3H, s), 2.96 (111, vbrs), 3.77 (111, vbrs), 4.10 (111, vbrs), 4.72 (111, 11-62 549.5 s), 4.76 (1H, d), 7.80-7.83 (1H, m), 7.88-7.91 (111, m), 8.00-8.02 (1H, m), 8.18-8.24 (12H, m), 8.39 (1H, vbrs), 9.62 (111, s) = WO
N+1 3.
No. H-NNIR
(obs) (DMSO) 1.05 (9H, s), 1.09 (3H, t), 1.19-1.37 (3H, m), 1.47-1.77 (3H, m), 1.91-1.99 (1H, m), 2.28 (0.5H, brdd), 2.48 (2H, q), 2.63-2.74 (1H, m), 3.01 11-63 563.5 (0.5H, dd), 3.63 (0.5H, s), 3.78-4.37 (2H, total, m), 4.42-4.59 (1H. m), 4.75 (1H, d), 5.42 (0.5H, d), 7.76 (0.5H, d), 7.80-7.83 (1H, m), 7.87 (1H, d), 8.01 (1H, m), 8.08-8.15 (1H, m), 8.36 (0.5H, d), 9.53 (IH, s) (DMSO) 1.07 (9H, s), 1.34-1.37 (2H, m), 1.64-1.72 (311, m), 1.95-2.04 (1H, m), 2.31-2.35 (111, m), 2.65-2.70 (111, m), 3.01-3.03 (111, m), 3.99 (0.511, m), 11-64 509.5 4.26-4.28 (0.511, m), 4.68 (1H, s), 4.82 (1H, d), 5.45 (0.511, s), 7.73-7.86 (311, m), 8.05-8.08 (2H, m), 8.49 (0.511, d), 8.57-8.59 (111, m), 8.69 (0.511, d), 9.15 (1H, d) (DMSO) 1.02 (9H, s), 1.28-1.34 (211, m), 1.57-1.64 (3H, m), 1.90-1.96 (1H, m), 11-65 507.5 3.72-3.80 (1H, m), 4.50 (1H, brs), 4.72-4.74 (111, m), 5.91 (IH, s), 6.76 (111, d), 7.58-7.61 (1H, m), 7.81-7.83 (1H, m) 11-66 493.5 EXAMPLE III
BIOLOGICAL METHODS
[0180] Compounds of this invention may be tested using the methods described below. Table 5 lists caspase-1 and caspase-8 enzyme inhibition data for compounds 11-1-11-25. In the Table, compounds with a Ki of <10 are assigned category A, compounds with a Ki of 10-20 are assigned category B, and compounds with a Ki of 21-30 are assigned category C.
In Vitro Assays Enzyme Inhibition [0181] Ki values for test compounds with caspase-1 and caspase-8 were obtained by the method of Margolin et al. (J.
Biol. Chem., 272 pp. 7223-7228 (1997)). Other caspases may be assayed similarly (see, e.g., WO 99/47545). Assays were performed in 10 mM Tris (Sigma Corp, St Louis MO) pH 7.5, 1 mM
Dithiothreitol (DTT, Research Organic INC, Cleveland, OH) and 0.1% CHAPS (Pierce, Rockford IL) at 37 C. For caspase-3, a solution of 8% glycerol was added to the assay buffer to improve enzyme stability. A 65 pL aliquot of the assay buffer and 5 pL aliquot of the appropriate dilutions of inhibitor in DMSO where pipetted into a 96 well plate, treated with 10 pL
of caspase, than diluted in assay buffer (0.5-40 nM active protein by active site titration). A control containing DMSO
but no compound was included for each determination. The plates were then incubated for 15 minutes at 37 C, before addition of the appropriate substrate (20 pL, final concentration 1-4 X Km, final assay volume 100 pL) to initiate the reaction. Reaction rates were measured at 37 C either by following the time dependant increase in absorbance at 405 nM
(for the pNA substrates) or in fluorescence (Ex 390, Em 460) (for the AMC substrates). The rates obtained were plotted against inhibitor concentration and the data fit to the Morrison tight-binding equation for competitive inhibitors (Morrison, J. F., Biochem. Biophys. Acta, 185 pp. 269-286 (1969)). The substrates used for the individual assays were as follows:
[0182] Caspase-1 Suc-YVAD-pNA (Sachem, King of Prussia, PA) (final concentration in the assay 80 pM);
[0183] Caspase-8 Ac-DEVD-pNA (Sachem, King of Prussia, PA) (final concentration in assay 80 pM).
Table 5: Caspase-1 (Cl) and caspase-8 (c8) inhibition data.
Ki Cl Ki C8 Compound (nM) (nM) . =
PBMC Cell Assay IL-1# Assay with a Mixed Population of Human Peripheral Blood Mononuclear Cells (PBMC) or Enriched Adherent Mononuclear Cells (0184] Processing of pre-IL-1P by ICE may be measured in cell culture using a variety of cell sources. Human PBMC
obtained from healthy donors provides a mixed population of lymphocyte subtypes and mononuclear cells that produce a spectrum of interleukins and cytokines in response to many classes of physiological stimulators. Adherent mononuclear cells from PBMC provides an enriched source of normal monocytes for selective studies of cytokine production by activated cells.
Experimental Procedure:.
[0185] An initial dilution series of test compound in DMS0 or ethanol is prepared, with a subsequent dilution into RPMI-10% FBS media (containing 2 mM L-glutamine, 10 mM HEPES, 50 U
and 50 ug/ml pen/strep) respectively to yield drugs at 4x the final test concentration containing 0.4% DMSO or 0.4% ethanol.
The final concentration of DMSO is 0.1% for all drug dilutions. A concentration titration which brackets the apparent Ki for a test compound determined in an ICE
inhibition assay is generally used for the primary compound screen.
[0186] Generally 5-6 compound dilutions are tested and the cellular component of the assay is performed in duplicate, with duplicate ELISA determinations on each cell culture supernatant.
A
PBMC Isolation and IL-1 Assay:
[01873 Buffy coat cells isolated from one pint human blood (yielding 40-45 ml final volume plasma plus cells) are diluted with media to 80 ml and LeukoPREP separation tubes (Becton Dickinson) are each overlaid with 10 ml of cell suspension.
After 15 min centrifugation at 1500-1800 xg, the plasma/media layer is aspirated and then the mononuclear cell layer is collected with a Pasteur pipette and transferred to a 15 ml conical centrifuge tube (Corning). Media is added to bring the volume to 15 ml, gently mix the cells by inversion and centrifuge at 300 xg for 15 min. The PBMC pellet is resuspended in a small volume of media, the cells are counted and adjusted to 6 x 106 cells/ml.
[0188] For the cellular assay, 1.0 ml of the cell suspension is added to each well of a 24-well flat bottom tissue culture plate (Corning), 0.5 ml test compound dilution and 0.5 ml LPS solution (Sigma #L-3012; 20 ng/ml solution prepared in complete RPMI media; final LPS concentration 5 ng/ml). The 0.5 ml additions of test compound and LPS are usually sufficient to mix the contents of the wells. Three control mixtures are run per experiment, with either LPS
alone, solvent vehicle control, and/or additional media to adjust the final culture volume to 2.0 ml. The cell cultures are incubated for 16-18 hr at 37 C in the presence of 5% CO2.
[0189] At the end of the incubation period, cells are harvested and transferred to 15 ml conical centrifuge tubes.
After centrifugation for 10 min at 200 xg, supernatants are harvested and transferred to 1.5 ml Eppendorf tubes. It may be noted that the cell pellet may be utilized for a biochemical evaluation of pre-IL-1P and/or mature IL-113 content in cytosol extracts by Western blotting or ELISA with pre-IL-specific antisera.
Isolation of Adherent Mononuclear cells:
[0190] PBMC are isolated and prepared as described above.
Media (1.0 ml) is first added to wells followed by 0.5 ml of the PBMC suspension. After a one hour incubation, plates are gently shaken and nonadherent cells aspirated from each well.
Wells are then gently washed three times with 1.0 ml of media and final resuspended in 1.0 ml media. The enrichment for adherent cells generally yields 2.5-3.0 x 105 cells per well.
The addition of test compounds, LPS, cell incubation conditions and processing of supernatants proceeds as described above.
ELISA:
[0191] Quantikine kits (R&D Systems) may be used for the measurement of mature IL-113. Assays are performed according to the manufacturer's directions. Mature IL-13 levels of about 1-3 ng/na in both PBMC and adherent mononuclear cell positive controls are observed. ELISA assays are perfoLmed on 1:5, 1:10 and 1:20 dilutions of supernatants from LPS-positive controls to select the optimal dilution for supernatants in the test panel.
[0192] The inhibitory potency of the compounds can be represented by an IC50 value, which is the concentration of inhibitor at which 50% of mature IL-1D is detected in the supernatant as compared to the positive controls.
[0193] The skilled practitioner realizes that values obtained in cell assays may depend on multiple factors. The values may not necessarily represent fine quantitative results.
[0194] Selected compounds of this invention have been tested for inhibition of IL-113 release from PBMCs with IC50 values between 300nM and 4pM.
4 =
Whole Blood Assay for IL-113 Production (0195] Whole blood assay IC50 values for compounds of this invention may be obtained using the method described below:
PuLpose:
[0196] The whole blood assay is a simple method for measuring the production of IL-if (or other cytokines) and the activity of potential inhibitors. The complexity of this assay system, with its full couiplement of lymphoid and inflammatory cell types, spectrum of plasma proteins and red blood cells is an ideal in vitro representation of human in vivo physiologic conditions.
Materials:
=
Pyrogen-free syringes (- 30 cc) Pyrogen-free sterile vacuum tubes containing lyophilized Na2EDTA (4.5 mg/10 ml tube) Human whole blood sample (- 30-50 cc) 1.5 ml Eppendorf tubes Test compound stock solutions (- 25mM in DMSO or other solvent) Endotoxin -free sodium chloride solution (0.9%) and HBSS
Lipopolysaccharide (Sigma; Cat.# L-3012) stock solution at lmg/m1 in HBSS
IL-10 ELISA Kit (R & D Systems; Cat # DLB50) TNFot ELISA Kit (R & D Systems; Cat # DTA50) Water bath or incubator Whole Blood Assay Experimental Procedure:
[0197] Set incubator or water bath at 30 C. Aliquot 0.25m1 of blood into 1.5 ml eppendorf tubes. Note: be sure to invert the whole blood sample tubes after every two aliquots. Differences in replicates may result if the cells sediment and are not uniformly suspended. Use of a positive displacement pipette will also minimize differences between replicate aliquots.
[0198] Prepare drug dilutions in sterile pyrogen-free saline by serial dilution. A dilution series which brackets the apparent Ki for a test compound determined in an ICE
inhibition assay is generally used for the primary compound screen. For extremely hydrophobic compounds, prepare compound dilutions in fresh plasma obtained from the same blood donor or in PBS-containing 5% DMSO to enhance solubility.
[0199] Add 25 pl test compound dilution or vehicle control and gently mix the sample. Then add 5.0 ul UPS solution (250 ng/ml stocked prepared fresh: 5.0 ng/ml final concentration UPS), and mix again. Incubate the tubes at 30 C in a water bath for 16-18 hr with occasional mixing. Alternatively, the ' tubes can be placed in a rotator set at 4 rpm for the same incubation period. This assay should be set up in duplicate or triplicate with the following controls: negative control -no UPS; positive control - no test inhibitor; vehicle control - the highest concentration of DM50 or compound solvent used in the experiment. Additional saline is added to all control tubes to normalize volumes for both control and experimental whole blood test samples.
[0200] After the in_cubation period, whole blood samples are centrifuged for 10 min.utes at - 2000 Lim in the microfuge, plasma is transferred to a fresh microfuge tube and centrifuged at 1000 x g to pellet residual platelets if necessary. Plasma samples may be stored frozen at -70 C
prior to assay for cytokine levels by ELISA.
ELISA:
[0201] R & D Systems (614 McKinley Place N.E. Minneapolis, MN 55413) Quantikine kits may be used for measurement of IL-1J3 and TNF-a. The assays are performed according to the , .
manufacturer's directions. IL-113 levels of - 1-5 ng/ml in positive controls among a range of individuals may be observed. A 1:200 dilution of plasma for all samples is usually sufficient for experiments for ELISA results to fall on the linear range of the ELISA standard curves. It may be necessary to optimize standard dilutions if you observe differences in the whole blood assay. Nerad, J.L. et al., J.
Leukocyte Biol., 52, pp. 687-692 (1992).
[0202] Selected compounds of this invention have been . tested for inhibition of IL-1 release from whole blood with IC50 values between 1pM and 40pM.
In Vivo Assays [0203] Compounds of this invention may tested in in vivo =
assays such as those described in WO 99/47545.
[0204]
[0205] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example above.
eco2tOH u (a) ZNt? LeCO21Bu (b) ZI(14 021Bu (c) ZN? CO21Bu eL ..OH ,c() fy0R1 re ow (d) zi,C? (e)R2 0 N
40 + ZHN ZHNAy0H (f)), (g) 0 = 40 H
Reagent and conditions: (a) EDC, HOBt, DMAP, DIPEA, THF; (b) Swern; (c) R1OH, 3A sieves, DCM, Ts0H; (d) TFA, DCM; (e) H2, Pd(OH)2, EtOAC, DMF, Et3N; (f) EDC, HOBt, Et3N, Et0Ac, DMF; (g) 11[2, Pd/C, Citrate Acid.
[0077] Scheme V depicts a possible route to prepare compounds 17 and compounds 11 described in scheme III.
Compound 2, readily obtained from reduction of the a-carboxylic group of aspartic acid, is coupled to N-protected 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid 10 (prepared as in Tetrahedron: Asymmetry, 13, 2002, 25-28) to form 13.
Compound 13 is then oxidized into the aldehyde 14 which is acetalized in situ to give the acetals 15. Deprotection of the tert-butyl ester is accompanied by spontaneous ring cyclization to give a mixture of diastereoisomers which were separated by column chromatography to give the enantiomerically pure syn ketals 16 and anti ketals (not represented in this scheme). Alternative Ring A groups are either commercially available, reported in the literature, or may be prepared according to methods known in the literature.
[0078] For clarity of the scheme, only syn ketals are represented in the next steps to form compounds 17 and 11 but the same sequence may be used to form anti ketals. Compounds 16 are submitted to hydrogenolysis and the resulting compounds 17 are reacted with Z-protected aminoacids, using conditions known in the art to prepare amide bonds, to yield compounds 19.
[0079] Alternatively, compounds 17 can be used to prepare compounds III, as depicted in Scheme IV. Compounds 19 are finally submitted to hydrogenolysis to give compounds 11, which can be used directly to prepare compounds III, as depicted in Scheme IV.
[0080] The R3COOH used in Scheme II are either commercially available, reported in the literature, or prepared according to methods known in the literature. For compound 11-30, 2-chloro-3-methoxybentoic acid was prepared as in J.Org.Chem, 59, 1994, 2939-2944.
[0081] For compound 11-32, 2-chloro-3-trifluoromethoxybenzoic acid was prepared from 2-amino-3-trifluoromethoxybenzoic acid (prepared as in J.Org.Chem, 68, 2003, 4693-4699) using a Sandmeyer replacement of the amino group by a chloro, according to a method substantially similar to the one reported in J.Org.Chem, 59, 1994, 2939-2944.
[0082] Accordingly, this invention also provides a process for preparing a compound of this invention.
[ 00831 In one embodiment is provided a process for preparing a compound of formula I:
o wherein Y is:
0, = R
and the other variables are as defined in any of the embodiments herein;
comprising reacting a compound of formula 1:
R
wherein the variables are as defined in any of the embodiments herein; and a compound of formula RX, wherein X is OH or an appropriate derivative (i.e., leaving group), in the presence of conditions for coupling an amine and an acid (when X is OH) or an amine and an appropriate acid derivative (when X is not OH (i.e., a leaving group; for example, Cl) to provide the compound of formula I.
[0084] Another embodiment provides a process for preparing a compound of formula I:
RNLr H
wherein Y is:
'22.246 and the other variables are as defined in any of the embodiments herein;
comprising reacting a compound of formula 7:
1(3 0 Rl wherein the variables are as defined in any of the embodiments herein, and a compound of formula RNHCH(R2)C(0)X, wherein X is OH or an appropriate derivative, in the presence of conditions for coupling an amine and an acid (when X is OH) or an appropriate acid derivative (when x is not OH; for example, X
is Cl) to provide the compound of formula I.
[0085] Yet another embodiment of this invention provides a process for preparing a compound of formula IV:
OH
= 0 IV
wherein the variables are as defined in any of the embodiments herein, comprising reacting a compound of formula I:
R, 0 ,Y
wherein Y is:
\40 wherein R and R1 are each independently as defined in any of the embodiments herein, under hydrolysis conditions, to provide the compound of formula II. In certain embodiments, R
is R3C(=0) . In yet other embodiments, when A is proline, R is R3C(=0) . Hydrolysis conditions for converting I to II are well known to skilled practitioners (see e.g., Greene). Such conditions include an appropriate solvent (e.g., acetonitrile) and aqueous acid (e.g., 2M HC1).
[0086] Another embodiment provides a process for preparing a compound of formula 6-A:
PG2 ¨N 0 wherein PG2 is a suitable nitrogen protecting group and R' is as defined in any of the embodiments herein, comprising reacting a compound of formula 5-A:
PG2¨N"1'PG1 Ges'14 ORI
under suitable ring cyclization conditions, to provide the compound of formula 6-A. Suitable ring cyclization conditions include an acid and a suitable solvent; for example, TFA in DCM.
[0087] Another embodiment provides a process for preparing a compound of formula 5-A:
PG2¨N(,) ,PG1 comprising reacting a compound of formula 4-A:
PG2 ¨N 0'PGI
ONThrH
in the presence of R.3.-OH (or a suitable acetal forming reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 5-A.
[0088] Another embodiment provides a process for preparing a compound of formula 4-A:
..
=
PG2 ¨T0 .... ,PG1 H
comprising reacting a compound of formula 3-A:
PG2---N A AoõPG' (:1?
0 N"¨') H OH
under suitable oxidation conditions (for example, a Swern oxidation: Mancuso, A.J.; Swern, D. Synthesis, 1981, 165-185) to provide the compound of formula 4-A. Preferred oxidation conditions include a TEMPO oxidation (see Example I-1, Method C, below).
[00893 Another embodiment provides a process for preparing a compound of formula 3-A:
PG2 ¨Nli2t,õ1õ ,PG1 H
OH
comprising:
reacting a compound of formula 2:
..õ.11,o,PG1 H2N----) OH
with a compound of foLmula 20-A:
_ =
under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 3-A.
[0090] Another embodiment provides a process for preparing a compound of foLmula 6:
pG2_Ny 0 N'14 OR"
wherein PG2 is a suitable nitrogen protecting group and R1 is as defined in any of the embodiments herein, comprising reacting a compound of formula 5:
PG2 ¨NO ...,PG1 OR"
under suitable cyclization conditions, to provide the compound of formula 6.
[0091] Another embodiment provides a process for preparing a compound of formula 5:
PG2 -N õ.PG1 comprising reacting a compound of formula 4:
pG2_1,1,) ,.PG1 OteyH
in the presence of 1R.3--OH (or a suitable acetal forming reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 5.
Preferably, the solvent is CH2C12, toluene, or chlorobenzene.
[0092] Another embodiment provides a process for preparing a compound of formula 4:
O Nr--yH
comprising reacting a compound of foLmula 3:
PG2-N õ..PG1 ON
OH
under suitable oxidation conditions (for example a Swern oxidation) to provide the compound of formula 4. Preferred oxidation conditions include a TEMPO oxidation (see Example I-1, Method C, below).
[0093] Another embodiment provides a process for preparing a compound of formula 3:
pG2¨d\ pG, OH
comprising:
reacting a compound of formula 2:
,PG1 OH
with a compound of formula 20:
PG2 ¨NO
under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 3.
[0094] Another embodiment provides a process for preparing a compound of formula 16:
ON
wherein PG2 is a suitable nitrogen protecting group and R1 is as defined in any of the embodiments herein, comprising reacting a compound of formula 15:
.
PG2¨N
= OR1 under suitable cycli.zation conditions, to provide the compound of formula 16.
[0095] Another embodiment provides a process for preparing a. compound of formula 15:
PG2-1V,,,. PG
0' I
= OR1 comprising reacting a compound of formula 14:
PG2 ,PG1 = 0 in the presence of R'-OH (or a suitable acetal forming reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 15.
[0096] Another embodiment provides a process for preparing a compound of formula 14:
PG2 ¨IT A .13G, N---e = 0 comprising reacting a compound of formula 13:
,PG1 OH
under suitable oxidation conditions (example, a Swern oxidation) to provide the compound of formula 14.
[0097] Another embodiment provides a process for preparing a compound of formula 13:
PG2-1\140 , ,pGi OH
comprising reacting a compound of formula 2 with a compound of formula 21:
pG2-N
under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 13.
[0098] Another embodiment provides a process for preparing a compound of formula 22:
0õ.
,PG1 comprising reacting a compound of formula 23:
=
/1:A; .,PG1 in the presence of R.1-0H (or a suitable acetal fotwing reagent), protic or Lewis acid (for example, Ts0H), and a suitable solvent to provide the compound of formula 22.
Acetal forming equivalents include, but are not limited to, triethylorthoformate, a diethylacetal, such as a (CH3)2C(OCH2CH3)2. Preferably, the solvent is CH2C12, toluene, or chlorobenzene.
[0099]
Another embodiment provides a process for preparing a compound of formula 23 comprising reacting a compound of =
formula 2:
0'13G1 OH
under suitable oxidation conditions (example Swern) to provide the compound of formula 23.
[0100]
Another embodiment provides a process for preparing a compound of formula 5-A
PG2¨N Poi 0' oNyOR1 wherein PG1 is a suitable carboxylic acid protecting group, PG2 is a suitable nitrogen-protecting group, and R1 is as defined in any one of claims 1 or 5-9, comprising:
=
reacting a compound of formula 20-A:
PG2¨NA
with a compound of formula 22 = õ.PG1 OR"
1-121q under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is an appropriate leaving group), to provide the compound of formula 5-.A.
[0101]
Another embodiment provides a process for preparing a compound of formula 5:
PG2¨NO PG1 comprising reacting a compound of formula 20:
with a compound of formula 22 .., .
A
' =
. W02005/085236 , H2N,..,-..i...0R1 under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid .
(when X is not OH), to provide the compound of formula 5.
.
(0102]
Another embodiment provides a process for preparing a compound of formula 5-A:
PG2 --1,.... -1:3(11 , 5-A , comprising reacting a compound of formula 21:
PG2.--N
with a compound of formula 22 PG.I
=
OW
HOs1 under conditions for coupling an amine and a carboxylic acid (when X is OH), or an amine and an appropriate carboxylic acid (when X is not OH), to provide the compound of formula 5-A.
, _ =
[0103] In accordance with this invention, the processes may be used alone or in combination to provide a compound of this invention.
[0104] Certain specific embodiments of this invention provide processes for preparing compounds 4 from 3 (in embodiments where compounds 4 are isolated); 5 from 3 (in embodiments where compounds 4 is not isolated but carried on directly, e.g., generated in situ); 5 from 4; and 6 from 5 according to the methods disclosed herein. In a preferred embodiment, compounds 6 are prepared from. compounds 5;
compounds 5 are prepared from compounds 4 (Whether isolated or not); and compounds 4 are prepared from 3. Preferably, compounds 6 are used in the preparation of proline containing caspase inhibitors. Such proline containing caspase inhibitors include, but are not limited to, those disclosed in WO 95/35308, WO 99/47545, W0.01/81330, and WO 01/90063.
For example, compound IA (and stereoisomers thereof) of WO 01/90063 could be prepared as disclosed herein (see, e.g., page 13). For the avoidance of doubt, it should be understood that such proline containing compounds could be depicted by- formula I except that Ring A is pyrrolidine -- (i.e. is derived from proline).
0105] The processes for converting compounds 6 to proline containing caspase inhibitors are preferably as disclosed herein. The processes for preparing compounds 3 are also preferably as disclosed herein. However other processes known to skilled practitioners could be used to convert compounds 6 to proline containing caspase inhibitors and/or to prepare compounds 3.
&
, WO 2005/085236 (0106] Other embodiments of this invention provide the compounds of formula 3 to 6, 3-A to 6-A, and 13-16.
(0107] One embodiment of this invention provides the compounds of formula 4A:
PG2.--i\CD oõPG1 4A.
(0108] Another embodiment of this invention provides the compounds of formula 4:
PG2-0 o./.PG1 H
, 0 4.
[0109] Another embodiment of this invention provides the compounds of formula 14:
PGr-N ,,11,=0,PG1 14' =
O N---)(H
14.
[0110] One embodiment of this invention provides the compounds of formula 5-A:
PG2¨NO. )1.,o'Pal ONrOR1 H
5-A.
0111] Another embodiment of this invention provides the compounds of formula 5:
-PG2-N2 cr,PG1 5.
[0112] Another embodiment of this invention provides the compounds of formula 15:
PG2-1\11 o.,PG1 = OR1 15.
[0113] One embodiment of this invention provides the compounds of formula 3-A:
PG2¨N
= OH
3-A.
[0114] Another embodiment of this invention provides the compounds of formula 3:
PG2¨Ny OH
[0115] Another embodiment of this invention provides the compounds of formula 13:
PG2¨N71,A. .PG1 = OH
13.
[0116] In all the above embodiments, the variables are as defined in any of the embodiments herein. In a preferred form of 3, PG2 is Z and PG1 is C1-6 straight-chained or bran.ched alkyl group (preferably a t-butyl group), either alone or in combination.
[0117] As would be realized by skilled practitioners certain process steps may be accomplished in discrete steps or in situ. For example, deprotection and subsequent reaction of an amine may be accomplished by step-wise (by isolating the amine) or in a one step procedure (without isolating the amine).
[0118] In certain embodiments, the above processes are conducted as described herein (e.g., in the schemes, examples, and accompanying description).
[0119] Compounds such as 3 could be used in processes for preparing proline containing compounds, such as caspase inhibitors. Proline containing caspase inhibitors include, but are not limited to, those disclosed in WO 95/35308, WO
99/47545, WO 01/81330, and WO 01/90063 (which are all incorporated herein by reference). For example, compound IA
(and stereoisomers thereof) of WO 01/90063 (which are specifically incoLporated herein by reference) could be prepared as disclosed herein (see, e.g., page 13).
[0120] The compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art arid include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase =
solubility to allow administration by injection, alter metabolism and alter rate of excretion.
[0121] For example, a carboxylic acid group in a compound of this invention may be derivatized as, for example, an ester. Preferred esters would be those derived from:
a C1-6 straight-chained or branched alkyl, alkenyl, or alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with C6_10ary1, CF3, Cl, F, OMe, OFt, OCF3, CN, or NMe2:
a C1-6 cycloalkyl, wherein 1-2 carbon atoms in the cycloalkyl is optionally replaced with -0- or -NR9-.
[0122] Compounds of this invention having a carbonyl group may be similarly derivatized as, e.g., an acetal, ketal, oxime (=NOR9), hydrazine (=NN(R9)2), thioacetal, or thioketal.
[0123] Appropriate derivatives of amines are known in the art and are also included within the scope of this invention.
[0124] Certain of the above derivatives would include the protective groups known to skilled practitioners (see, e.g., Greene). As would be recognized by a skilled practitioner, these protective groups may also be employed in the processes of this invention.
[0123] The compounds of this invention may be assayed for their ability to inhibit apoptosis, the release of IL-41or caspase activity directly. Assays for each of the activities are known in the art. However, as would be recognized by a skilled practitioner, a prodrug compound of this invention should be active only in assays where the prodrug moiety would be cleaved, typically in in vivo assays.
[0126] Assays for caspase activity are described in WO
99/47545.
[0127] According to another embodiment, the present invention provides a pharmaceutical composition comprising:
=
a) a compound of the in-vention., as defined herein, or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable carrier, adjuvant or vehicle.
[0128] It should be understood that compounds and pharmaceutically acceptable salts thereof are included within this invention are. If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, diglucon.ate, dodecylsulfate, ethanesulfonate, fumarate, glucohptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoat, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-n.aphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth rrItal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl--D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
[01293 Also, the basic nitrogera-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others.
Water or oil-soluble or dispersible products are thereby obtained.
[0130] Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
[0131] According to a preferred embodiment, the compositions of this invention are formulated for phaLmaceutical administration to a mammal, preferably a human being.
[0132] Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally or intravenously.
[01333 Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent c>r solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally empLoyed as a solvent or suspending medium. For this purpose, an_y bland fixed oil may be employed including synthetic mono- or di-glycerides.
Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectabls, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil =
solutions or suspensions may also contain a_ long-chain alcohol diluent or dispersant, such as carboxymethy-1 cellulose or, similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commOnly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[0134] The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used inclu_de lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch.
When aqueous suspensions are required or oral use, the active ingredient is combined with emulsifying and suspending agents.
If desired, certain sweetening, flavoring or coloring agents may also be added.
[0135] Alternatively, the pharmaceutical compositions of this invention may be administered in the foLm of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug., Such materials include cocoa butter, beeswax and polyethylene glycols.
[0136] The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the slan, or the lower intestinal tract. SuitabLe topical formulations are readily prepared for each of these areas or organs.
[0137] Topical application for the Lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.
Topically-transdermal patches may also be used.
[0138] For topical applications, the pharmaceutical compositions may be formulated in a sui_table ointment containing the active component suspenaed or dissolved in one or more carriers. Carriers for topical_ administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylenJe compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, ,cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[01393 For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH
adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum. In one embodiment, the compositions are as formulated in, e.g., U.S. Patent 6,645,994 and/or U.S. Patent =
6,630,473.
[01403 The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
[0141] The above-described compounds and compositions are particularly useful in therapeutic applications relating to an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease (e.g., bacterial infections, preferably, eye infections), a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, retinal disorders, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs. host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, hemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heat failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, JaPanese encephalitis, various forms of liver disease, renal disease, polycystic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, toxic epidermal necrolysis, pemphigus, and autoinflammatory diseases (sometimes referred to as autoinflammatory fever syndromes) and related syndromes such as Muckle-Wells Syndrome (MWS), Familial Cold Urticaria (FCU>, Familial Mediterranean Fever (FMF), Chronic Infantile Neurological Cutaneous and Articular Syndrome (CINCAS), a.k.a.
= Neonatal Onset Multisystem Inflammatory Disease (NOMID), TNFR1-Associated Periodic Syndrome (TRAPS), and Hyper-IgD
periodic fever Syndrome (HIDS). The compounds and compositions are also useful in treating complications associated with coronary artery bypass grafts. The compounds , and compositions are also useful for decreasing IGIF (also known as IL-18) or IFN-y production and for inhibiting a caspase-mediated function' in a patient. The compounds and compositions are also useful in immunotherapy as a cancer treatment.
[0142] The compounds and compositions may also be used in methods for preserving cells. These methods would be useful for preserving organs, particularly those intended for transplant, or blood products.
[0143] . The compounds of this invention are useful as dual caspase-1 and capase-8 inhibitors. Without being bound by theory, the R.2 and R3 groups of the compounds of this invention appear to be related to this surprising activity. Bridged A
groups of the compounds of this invention, such as \1-9 or , also appear to be related to this surprising activity. As such, the compounds and compositions of this invention are particularly useful in treating or preventing inflammatory conditions.
[0144] According to another embodiment, the compositions of this invention may further comprise another therapeutic agent (i.e., one or more additional agents). Such agents include, but are not limited to, thrombolytic agents such as tissue plasminogen activator and streptokinase. When an additional agent is used, the additional agent may be administered either as a separate dosage form or as part of a single dosage form with the compounds or compositions of this invention.
[0145] The amount of compound present in the compositions of this invention should be sufficient to cause a detectable decrease in the severity of the disease or in caspase activity and/or cell apoptosis, as measured by any of the assays known in the art.
[0146] Dosage levels of between about 0.01 and about 50 or about 100 mg/kg body weight per day, preferably between 0.5 and about 75 mg/kg body weight per day and most preferably between about 1 and about 25 or about 50 mg/kg body weight per day of the active ingredient compound are useful in a mono therapy.
[0147] Typically, a compound or composition of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary' depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.
[0148] When the compositions of this invention comprise a combination of a compound of this invention and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 10% to about 100%, and more preferably between about 10% to about 80% of the dosage normally administered in a monotherapy regime.
[0149] Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary.
Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
[0150] As the skilled practitioner will appreciate, lower or higher doses than those recited above may be required. It should be understood that a specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound . employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the particular disease, the patient's disposition to the disease being treated, and the judgment of the treating physician. The amount of active ingredients will also depend upon the particular compound and other therapeutic agent, if present, in the composition.
L0151] In a preferred embodiment, the invention provides a method of treating a patient, preferably a mammal, having one of the aforementioned diseases, comprising the step of administering to said patient a compound or a pharmaceutically acceptable composition described above. In this embodiment, if the patient is also administered another therapeutic agent or caspase inhibitor, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage fault. When administered as a separate dosage form, the other caspase inhibitor or agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a compound of this invention.
[0152] The compounds of this invention may also be incorporated into compositions for coating implantable medical devices, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention and a carrier suitable for coating said implantable device. In still another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention and a carrier suitable for coating said implantable device.
[0153] Another aspect of the invention relates to , inhibiting caspase activity in a biological sample, which method comprises contacting said biological sample with a compound of this invention or a composition comprising said compound. The term thiological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[0154] Inhibition of caspase activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, biological specimen storage, and biological assays.
[0155] The compounds of this invention are useful in methods for preserving cells, such as may be needed for an organ transplant or for preserving blood products. Similar -662.
uses for caspase inhibitors have been reported [Schierle et al., Nature Medicine, 5, 97 (1999)]. The method involves treating the cells or tissue to be preserved with a solution comprising the caspase inhibitor. The amount of caspase inhibitor needed will depend on the effectiveness of the inhibitor for the given cell type and the length of time required to preserve the cells from apoptotic cell death.
[01563 Without being bound by theory, applicants' cyclic acetal compounds are believed to be prodrugs. That is, the acetal portion is cleaved in vivo to provide a corresponding acid-aldehyde compound. As would be recognized by a skilled practitioner, chemical compounds may be metabolized in vivo, e.g., at a site other than the prodrug cleavage site. Any such metabolites are included within the scope of this invention.
(0157] In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
Example I-1 (S,S,S,R)-1-[(2,9)-(3-Methoxy-2-methyl-benzoylamino)-3-methyl-butyry1}-pyrrolidine-(25)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yll-amide ,o =
ilk r.1(0 H
.9580-110 Method A
(S) -3 -Amino -4-hydroxy -butyric acid tert-butyl ester oH
[0158] A solution of (S)-benzyloxycarbonylamino -4-hydroxy-butyric acid tart -butyl ester (prepared as described in Michel etal, Helvetica Chimica Acta 1999, 1960)(0.94g) in ethyl acetate (15 ml) was hydrogenated over palladium hydroxide/carbon (20% w/w, 160mg). The catalyst was removed = TM
via filtration through Celite. Concentration of the filtrate in vacuo afforded the subtitle compound as a colorless oil (486mg, 91%); IH NKR (400MHz,CDC13) 8 1.48 (9H, s), 1.95 (3H, brs), 2.28 (1H, dd), 2.46 (1H, dd), 3.29 (1H, brm), 3.42 (111, m), 3.60 (IH, m).
Method B
(1S) -2 -((S) -2-tert -Butoxycarbonyl-1 -hydroxymethyl -ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester oirNy.,a, [0159] To a stirred solution of (S)-3 -Amino -4 -hydroxy-butyric acid tert-butyl ester (800mg, 4.57mmol) and Z-Pro-OH
(1.14g, 4.57mmol) in THF (30m1) was added 2-hydroxybenzotriazole hydrate (741mg, 1.2eq,), DMAP (698mg, 1.25eq.), diisopropylethylamine (1.03m1, 1.3eq.) and 1-(3-dimethylaminopropyl) -3 -ethylcarbodiimide hydrochloride (EDC, 1.05g, 1.2eq.). The resulting mixture was stirred at ambient temperature for 18 hours then diluted with ethyl acetate. The mixture was then washed with water, saturated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (60% ethyl acetate/petrol) to afford the sub-title compound as a colorless solid (1.483g, 90%); MS ES (+) 407.3.
Method C
(1S)-2-((S)-2-tert-Butoxycarbony1-1-formyl-ethylcarbamoy1)-pyrrolidine-l-carboxylic acid benzyl ester y 0 1.1 .õ(J1Lro,k [01601 A solution of (1S)-2-((S)-2-tert-Butoxycarbony1-1-hydroxymethya-ethylcarbamoy1)-pyrrolidine-l-carboxylic acid benzyl ester (10 g) in DCM (100 ml) was cooled to 0 C under nitrogen. 2,2,6,6-tetramethylpiperidinyloxy (TEMPO, 38 mg) was then added followed by trichloroisocyanuric acid (6 g)1 portionwise over 30 minutes. The mixture was stirred at ambient temperature for 2 hours, then filtered through celite.
The filtrate was washed with water, 1M sodium thiosulfate solution and water. Drying over magnesium sulfate and concentration under reduced pressure gave the sub-title compound as a pale yellow oil (9.92 g, 99%); IH NMR (400MHz,d-6 DMSO) .5 1.38 (9H, d), 1.79-1,86 (3H, m), 2.08-2.23 (1H, m), 2.36-2.51 (1H, 2 x dd), 2.61-2.86 (1H, 2 x dd), 3.88-3.46 (2H, m), 4.24-4.30 (2H, m), 5.05 (2H, quin), 7.28-7.37 (5H. m), 8.59-8.64 (IH, 2 x d), 9.21 (0.57H, s), 9.37 (0.43H, s).
Method D
(1S)-2-((S)-1-tert-Butoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester y 0 :),J
41111 OyN j i15 [0161] To a solution of (1S)-2-((S)-2-tert-Butoxycarbonyl-1-formyl-ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester (4.98 g) in dichloromethane (70 ml) was added triethyl orthofoLmate (6.2 mL) and p-toluenesulfonic acid monohydrate (47 mg). The resulting mixture was stirred at ambient temperature until no aldehyde remained by TLC. The mixture was concentrated in vacuo, the re-dissolved in dichloromethane (35 mL). Saturated aqueous sodium bicarbonate solution (35 mL) was then added and the organic phase removed. This was washed with water and brine, dried (magnesium sulfate), filtered and concentrated under reduced pressure. This gave the sub-title compound as a pale yellow oil (4.85 g, 82%); 11-1 NMR (400MHz,d-6 DMSO) 5 1.04-1.11 (6H, m), 1.35-1.37 (9H, m), 1.73-1.89 (3H, m), 2.01-2.49 (3H, m), 3.43-3.52 (6H, m), 4.05-4.29 (3H, m), 4.96-5.06 (2H, m), 7.27-7.38 (5H, m), 7.80 (0.5H, d), 7.88 (0.5H, d).
Method E
(1S)-2-((2R, 3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-l-carboxylic acid benzyl ester 6.1 (1S)-2-((2S, 3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.2 Sti 0 0 0= 0õN
8y 0 N , H H
6.1 6.2 (0162] A solution of (1S)-2-((S)-1-tert-Butoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester (4.85 g) in dichloromethane (25 ml) was cooled to 0 C under nitrogen. Trifluoroacetic acid (6 ml) was then added and the mixture stirred at 0 C for 15 minutes, then warmed to ambient temperature and stirred until the reaction was complete by TLC. The mixture was then diluted with dichloromethane (90 ml) and saturated aqueous sodium bicarbonate solution (130 ml) and stirred for 15 minutes. The organic phase was then removed and washed with 1:1 saturated aqueous sodium bicarbonate/brine (100 ml), the combined aqueous washings was re-extracted with DCM (100 ml) and the combined organic layers dried (magnesium sulfate), filtered and concentrated under reduced pressure. This afforded the sub-title compound as a mixture of epimers at the ketal centre (C2). The epimers were separated on silica gel, eluting with 30% acetone/petrol. Syn-isomer 6.1 (white solid); 111 MIR
(400MHz,d-6 DMSO) 8 1.08-1.17 (311, m), 1.78-2.01 (3H, m), 2.08-2.12 (1H, m), 2.37-2.57 (1H, 2 x dd), 2.61-2.79 (111, 2 x dd), 3.35-3.51 (211, m), 3.55-3.68 (111, m), 3.71-3.82 (1H, d), 4.20-4.32 (1H, m), 4.52-4.61 (111, m), 4.98-5.11 (2H, m), 5.53-5.58 (1H, m), 7.24-7.42 (5h, m), 8.25-8.31 (111, m); MS ES +
377.3 (100%), ES - 375.3 (10%); Anti-isomer 6.2 (colorless oil); 114 NMR (400MEz,d-6 DMSO) 8 1.08-1.19 (311, m), 1.78-1.89 (3H, m), 2.10-2.34 (1H, m), 2.92-3.07 (1H, 2 x dd), 3.36-3.51 (3H, m), 3.62-3.78 (211, m), 4.12-4.21 (2H, m), 4.97-5.12 (311, m), 7.28-7.40 (5H, m), 8.51-8.58 (111, m); MS ES 377.4 (100%), ES - 375.3 (10%).
(1S)-2-((2R,3S)-2-Methoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.3 (1S)-2-((2S,3S)-2-Methoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.4 lel 0 H H
6.3 6.4 [0163] Prepared in a similar manner to that described in methods A-E, using trimethylorthoformate in step D, to afford the sub-title compounds as a mixture of epimers 6.3 and 6.4.
The epimers were separated on silica gel eluting with 30% to 40% 2-Eutanone/Petrol to 70% Acetone/Petrol. Syn-isomer 6.3 (viscous colorless oil); 1-11 NMR (400MHz,d-6 DMSO) 6 1.77-1.89 (3H, m), 2.07-2.12 (1H, m), 2.32-2.43 (1H, 2 x d), 2.55-2.61 (1H, 2 x d), 2.71-2.81 (1H, 2 x d), 3.39-3.62 (4H, m), 4.21-4.30 (1H, m), 4.57-4.64 (1H, m), 5.01-5.09. (2H, m), 5.42-5.47 (1H, m), 7.27-7.42 (5H, m), 8.24-8.31 (1H, m); Anti-isomer 6.4 (white solid); 1H NMR (400MHz,d-6 DMSO) 8 1.79-1.90 (3H, m), 2.09-2.21 (1H, m.), 2.23-41 (1H, 2 x d), 2.91-3.05 (1H, 2 x dd), 3.35-3.71 (5H, m), 4.09-4.21 (2H, m), 4.98-5.19 (3H, m), 7.28-7.41 (5H, m), 8.51-8.58 (111, m).
(1S)-2-((2R,3S)-2-Isopropoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.5 (1S)-2-((2S,3S)-2-Isopropoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.6 1.1 0 H H
6.5 6.6 =
[0164] Prepared in a similar manner to that described in Methods A-E, using triisopropylorthoformate in step D, to afford the sub-title compound as a mixture of epimers 6.5 and 6.6. The epimers were separated on silica gel eluting with 30%
to 40% 2-Butanone/Petrol. $yn-isomer 6.5 (colorless gum);
NMR (400MHz,d-6 DMSO) 8 1.07-1.16 (6H, m), 1.81-1.86 (2H, m), 2.37-2.71 (2H, m), 3.35-3.53 (2H, m), 3.86-3.90 (1H, m), 4.18-4.24 (1H, m), 4.46-4.55 (1H, m), 4.95-5.10 (2H, m), 5.63 (IH, d), 7.27-7.38 (5H, m), 8.22-8.30 (1H, m); MS ES + 391.3 (100%); Anti-isomer 6.6 (white solid); 1H NMR (400MHz,d-6 DMSO) 8 1.07-1.15 (6H, m), 1.78-1.82 (3H, m), 2.07-2.41 (2H, m), 2.87-3.01 (1H, m), 3.35-3.50 (2H, m), 3.74-3.96 (1H, m), 4.07-4.18 (2H, m), 4.95-5.11 (2H, m), 5.22 (1H, 2 x s), 7.24-7.39 (5H, m), 8.48-8.53 (1H, m); MS ES + 391.4 (100%).
(1S)-2-((2R,3S)-2-Propoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.7 (1S)-2-((2S,3S)-2-Propoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.8 410 OyNy 0 41:1 0y10 0 :(:50 0 N 0 N =
H H
6.7 6.8 [0165] Prepared in a similar manner to that described in methods A-E, using tripropylorthoformate in step D, to afford the sub-title compounds as a mixture of epimers 6.7 and 6.8.
The epimers were separated on silica gel eluting with 30% to 40% 2-Butanone/Petrol. $yn-isomer 6.7 (colorless gum); NMR
(400MHz,d-6 DMSO) 8 0.84-0.93 (3H, m), 1.55 (2H, m), 1.81-1.89 (3H, m), 2.08-2.22 (1H, m), 2.37-2.61 (1H, 2 x dd), 2.71-2.80 (1H, 2 x dd), 3.31-3.53 (2H, m), 3.60-3.69 (1H, m), 4.20-4.29 (IH, m), 4.52-4.61 (IH, m), 4.95-5.11 (2H, m), 5.50 (1H, m), =
=
7.27-7.36 (5H, m), 8.27 (1H, m); Anti-isomer 6.8 (colorless oil); 11.1 NMR (400MHz,d-6 DMSO) 8 0.82-0.90 (3H, m), 1.46-1.57 (2H, m), 1.77-1.89 (3H, m), 2.06-2.41 (1H, m), 2.90-3.05 (1H, 2 x dd), 3.33-3.66 (5H, m), 4.11-4.20 (211, m), 4.94-5.10 (3H, m), 7.28-7.37 (5H, m), 8.51(1H, m).
(1S)-2-((2R,3S)-2-Butoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.9 (15)-2-((2S,3S)-2-Butoxy-5-oxo-tetrahydro-furan-3-ylcarbamoya)-pyrrolidine-1-carboxylic acid benzyl ester 6.10 OyNy 0 0,,Nj:5y 0 ) 6.9 6.10 [0166] Prepared in a similar manner to that described in methods A-E, using tributylorthoformate in step D, to afford the sub-title compounds as a mixture of epimers 6.9 and 6.10.
The epimers were separated on silica gel eluting with 30% to 40% 2-Butanone/Petrol. Syn-isomer 6.9 (colorless gum); IH NMR
(400MHz,d-6 DMSO) 8 0.86-0.92 (3H, m), 1.28-1.37 (2H, m), 1.45-1.54 (211, m), 1.79-1.88 (3H, m), 2.07-2.21 (111, m), 2.35-2,78 (2H, m), 3.31-3.54 (2H, m), 3.63-3.70 (1H, m), 4.21-4.29 (1H, m), 4.51-4.61 (111, m), 4.95-5.09 (2H, m), 5.50 (1H, m), 7.27-7.37 (5H, m), 8.25 (IH, m); Anti-isomer 6.10 (colorless oil); 1H NMR (400MHz,d-6 DMSO) 8 0.85-0.93 (3H, m), 1.26-1.36 (2H, m), 1.44-1.56 (2H, m), 1.77-1.90 (3H, m), 2.08-2.40 (1H, m), 2.89-3.05 (111, 2 x dd), 3.34-3.70 (5H, m), 4.08-4.19 (2H, m), 4.95-5.10 (3H, m), 7.28-7.39 (5H, m), 8.53(1H, m).
=
Method F
{(S)-1-[(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-pyrrolidine-2-carbonyl]-2,2-dimethyl-propy1)-carbamic acid benzyl ester =
ANtri\3-[0167] To a solution of (1S)-2-((2R, 3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-pyrrolidine-1-carboxylic acid benzyl ester 6.1 (4.68g) in ethyl acetate (160m1) and DMF
(25m1) was added triethylamine (2.5g) followed by palladium hydroxide/carbon (20% w/w, lg). The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite. To the filtrate was added (S)-2-benzyloxycarbonylamino-3,3-dimethyl-butyric acid (4.93g), hydroxybenzotriazole hydrate (2.01g) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 2.85g). The resulting mixture was stirred at ambient temperature overnight. Saturated aqueous sodium bicarbonate solution (180m1) was then added and the organic phase removed.
This was washed with saturated aqueous ammonium chloride (180 ml), then brine (180m1), dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with 40-75% ethyl acetate/petrol. The sub-title compound was obtained as a white foam (4.02g, 66%); IH NMR (400MHz, CDC13) 8 0.97 (9H, s), 1.14 (3H, t), 1.79-1.94 (3H, m), 2.02-2.10 (1H, m), 2.44 (1H, dd), 2.75 (1H, dd), 3.52-3.66 (2H, m), 3.70-3.79 (2H, m), 4.22 (IH, d), 4.38-4.41 (1H, m), 4.48-4.58 (IH, m), 5.03 (2H, q), 5.56 =
(1H, d), 7.26 (1H, d), 7.29-7.40 (5H, m), 8.24 (1H, d); MS ES
+ 490.6 (100%), ES - 488.8 (10%).
Method G
(S, 3,S,R) -1- [ (23) - (3-Methoxy-2-methyl-benzoylamino) -3-methyl-butyryl] -pyrrolidine- (2,5) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide ,o o rr)r.NT
H o, (0168] To a solution of {(S)-1-[(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-pyrrolidine-2-carbonyl] -2 , 2-dimethyl-propyll-carbamic acid benzyl ester (344mg) in ethyl acetate (20m1)was added palladium hydroxide/carbon (20% w/w, 74mg). The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite and the filtrate concentrated under reduced pressure to give the amine as a brown foam (260mg). A portion of this material (153mg) was dissolved in THF and 3-methoxy-2-methyl benzoic acid (146mg), diisopropylamine (191111), hydroxybenzotriazole hydrate (77mg) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 109mg) were added. The resulting mixture was stirred at ambient temperature for 24 hours then diluted with saturated aqueous sodium bicarbonate. The organic phase was removed and washed with saturated aqueous ammonium chloride, then brine, dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with ethyl acetate. This gave the sub-title compound as a white solid (138mg, 62%); analytical data summarized in Table 3.
[01693 Compounds of .formula 1-2 to 1-58 have been prepared by methods substantially similar to those described in Example I-1.
Example I-2 (S, S, S, R) -1--[ (2S) - (2 -Methoxy-benzoylamino ) -3 -methyl-butyryl ] -pyrrolidine-(2S)-carboxylic acid [ (2R)-ethoxy-5-oxo-tetrahydro-furan- (3S) -y1]-amide \o o =
o N
H o Example 1-3 (S,S, S, R) -1- [3-Methyl- (2S) - (2-trifluoromethoxy-benzoylamino) -butyry1]-pyrrolidine- (2S) -carboxylic acid [ (2R)-ethoxy-5-oxo-tetra.hydro-furan- (3S) -y1]-amide F.sf [`nriT
o N
H o Example 1-4 (S, S, S, R) -1- [ (2S) - (3-Hydroxy-2-methyl-benzoylamino)-3-methyl-butyry1]-pyrrolidine- (2S) -carboxylic acid [ (2R)-ethoxy-5-oxo-tetrahydro-furan- (3 S) -y1]--amide =
=
=
Example I-5 (S, S, S, R) -1-- [ (2S) - ( 3 -Amino-2 -methyl-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-_ tetrahydro-furan- (35) -yl] -amide *0 0 H o Example I-6 (S, S, S, R) -1- [ (2S)- (2, 6-Dichloro-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI
\
a o o N
H
Example 1-7 (S. S, S, R) -N- { (1S) - [ (2S)- ( (2R) -Ethoxy-5-oxo-tetrahydro- furan-( 3 S) -ylcarbamoyl ) -pyrrolidine-l-carbonyl ] -2 -methyl-propyl } -2 -methyl -nico-t inamide (1-Xl(NNT
H 0 4.0 Example I - 8 (S. 5, S, R)-N- (1S) - [ (2S)- ( (2R) -Ethoxy-5 -oxo- tetrahydro- furan-( 3S) -ylcarba.moyl ) -pyrrolidine-l-carbonyl ] -2 -methyl-propy11-4-methyl -nicot.inamide o Ni? JC?
A
H
Example I-9 (S, S, S, R) -1- {3-Methyl-- (2S) -[ (3 -methyl - thiophene-2 -carbonyl ) -amino] -butyryl) -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy--oxo- tetrahydro- furan- (3S) -yl] -amide i no H CO
Example I-10 (S, S, SIR) -2, 3-Dichloro-N-{ (1S) - [ (2S) - ( (2R) -ethoxy-5-oxo-tetrahydro- furan- ( 3 S) -ylcarbamoyl ) -pyrrolidine-1- carbonyl ] -2 -methyl-propyl } -isonicotinamide Cl a o Example I-11 (S, S, S, R) -3 , 5-Dichloro-N-{ (1S) [ (2S) - ( (2R) -ethoxy-5-oxo-tetrahydro-furan- (35) -ylcarbamoyl ) -pyrrolidine-l-carbonyl] -2 -methyl -propyl } -ison.icotinamide a o N H N
=
Exampl e I-12 ( S, S, S, R) -1- [ (2S) - ( 3 -Methoxy-2-methyl-benzoylamino ) -3, 3 -dimethyl-butyryl ] -pyrrol i dine- (25) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetra]aydro-furan- (3S) -yl] -amide -o = riX.Nli Example I-13 ( S, S, S, R) -1-- [ (2S) - ( 3 -Methoxy-2 -methyl-ben.z oylamino ) -3-methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -methoxy--5-oxo-tetrahydro-furan- ( 3S) -yl ] -amide 410 Xr"i 0 H -Example 1-14 (S, S. S, R) -1- [ (2S) - ( 3 -Methoxy-2-methyl-benz oyl amino) -3-methyl -butyry1]-pyrrolidine- (2S) -carboxylic acid [ (2R) - isopropoxy-5-oxo - t etrahydro- f uran- (3S) -yl] -amide 400 NC;IT 0 4.0 H Os( Example 1-15 ( S, S, S, R) -1- [ (2S) - ( 3 -Methoxy-2 -methyl-benz oylamino ) -3-methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid (5-oxo- (2R) -propoxy-5- tetrahydro- furan- (3S) -yl] -amide 400 tIC-rji 0 HO) Example I-16 (S, S, S, R) -1- [ (2S) - (2-Ch1oro-benzoylamino) -3 -methyl -butyryl] -pyrrolidine- (25) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -y1 ] -amide 4ji f?Cr"i 0 Example I-17 (S, S, S, R) -1- [3 , 3 -Dimethyl- (2S) - (2 -methyl-benzoylamin.o ) -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -y' :J -amide 400 NYC;44i 4.0 o Example I-18 (S, S. S, R) -1- [3-Methyl-2 (S)- (2-tri fluoromethyl-benzoylamino) -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan-3 CS) -y1] -amide .<0 o N
Example I-19 (S, S. S, R) -1-- [2 (S) - (2-Ch1oro-benzoylamino) -3,3-dimethyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [ (2R) -methoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide * N? 0 )q0 H o =
Exampl e 1-20 (S, S, S, R) -1- [3 , 3-Dimethyl- (2S) - ( 2- tri fluoromethyl-benzoylamin.o ) -butyryl I -pyrrolidine- (2S) -carboxylic acid [ (2R) -isopropoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide 41* [NiT
o N
Example I-21 (S, S, S, R) -1- [ (2S) - ( 2 -Chloro-benzoylamino ) -3 , 3 -dimethyl-butyryl] -pyrrolidin.e- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide Ct o 4## Vd(ji 0 Example 1-22 (S, S, S, R) -1- [3 , 3 -Dimethyl - (2S) - (2-trifluoromethyl-benzoylamino) -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide N(r4i õ<o Example 1-23 (S, S, S,R) -1- [ (2S) - (2-Chloro-benzoylamino) -3, 3 -dimethyl-butyryl ] -pyrrolidin.e- (2S) -carboxylic acid [5-oxo- ( 2R) -prOPoxY-tetrahydro-furan- (3S) -yl] -amide ijk 11(r"i 0 H o Example 1-24 (S, S, S, R) - 1- [ (2S) ( 2 -Chloro-benz oylamino) -3, 3 -dimethyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -butoxy-5-oxo-tetrahydro-furan.- (3S) -ylj -amide 4.0 =
o N
H o Example I-25 (S, S, S, R) -1- [ (2S) - (2-Chloro-3-tri f luoromethoxy-benzoylamino) -3 , 3-dimethyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -ylj -amide ,.., CI 0 F3C-u* Nri/ 0 N
Example I-26 (S, S, SIR) -1- [ (2S) - ( 2 -Chloro-ben.zoylamino ) -3 -methyl -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ 5-oxo- (2R) -propoxy-tetrahydro- furan- (3S) -yl] -amide Cl 0 * rci\IT.<0 o N
Example I-27 (S, S. S, S) -1- [ (2S) - (2-Chloro-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [5-oxo- (2S) -propoxy-tetrahydro-furan- (3S) -yll -amide =
ININT
o N =
H
=
=
Example 1-28 (S, S, S, S) -1- [ (2S ) - ( 2 -Chloro-benzoylamino ) -3 -methyl-butyryl] -pyrrolidine- (2S) -carboxylic acid ( (2S ) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI
400 dC-ri o N =
H
S.
Example 1-29 (S, S, S, R) -1- [ (2S) - ( 2 -Chloro-benzoylamino ) -3 -methyl-butyryl ] -PYrrolidine- (2S) -carboxylic acid (2R) -butoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI o o Example 1-30 (S, S, S. S) -1- [ (2S) - ( 2 -Chloro-benzoylaraino ) -3-methyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [(2S) -butoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI ,D
o N
Example I-31 ( S, S, S, R) -1- [ (2S) - (2-Chloro-benzoylamino) -3 -methyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid (2R) -is opropoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI o 400 dc-ri 0 H o Example I-32 (S, S. S, S) -I- [ (2S) - (2-Chloro-benzoylamin.o ) -3 -methyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [ (2S) -isopropoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI o 400 VA-r"i 0 H
Example I-33 (S, S, S, R) -1- [ (2S ) - ( 2 -Chloro-3-cyclopropyloxy-benzoylamino ) -3 , 3-dimethyl-butyryl] -pyrrolidine- (2S) --carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan.- (3S) -yl] -amide 7- 400 NJCriT
H
Example I-34 (S, S, S, R) -1- [ (2S) - ( 2 -Chloro-3 -methyl -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrol i dine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI
*
4.o Example I-35 (S, S, S, R) -1-- [ (2S) - ( 2 -chl oro-3 -methoxy-benzoylamino ) -3 -methyl-butyryl ] -pyrrol i dine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (35) -yl] -amide ,0 * [\XN? 0 jqo o N
=
Example 1-36 (S, S, S,R) -1- [ (2S) - (2-Chloro-3-ethyl -benzoyl amino) -3 , 3 -dimethyl -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide * NT
0 õ<cs H o Example I-37 (S, S, S, R) -1- [ (2S)- (2-chloro-4-methoxy-benzoylamino) -3-methyl-butyryl ] -pyrrolidin.e- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide CI 0 )r..
\O 0 H o Example 1-38 (S, S, S,R) -1- [ (2S) - (2-Chloro-3-cyclopropylmethyl -benzoylamin.o) -3 , 3 -dimethyl -butyryl ] -pyrroli dine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide r iµN N/ jeo 0 14)!
H o Example I-39 (S, S, S, R) -1- [ (2S ) (2-Chloro-3-hydroxy -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy- 5 - oxo- tetrahydro- furan- (3S) -yl] -amide HO CI
if. N? 0 Example 1-40 (S, S, S, R) -1- [ (2S) - (2-Chloro-4-acetamido-benzoylamino) -3 -methyl -butyryl ] -pyrrolidine- (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide HN
Example 1-41 (S, S, S,R) -1- [ (2S) - (2-Chloro-3-acetamido -benzoyl amino) -3 , 3 -dimethyl-butyry13 -pyrrolidine-, (2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -y11 -amide HN
= AcN? 0 4.0 Example I-42 (S, S, S, R) -1- [ (2S ) - (2-methyl -3 -acetamido -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- ( 2S) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S) -yl] -amide * [gi irko 0 N*.=
ExampL e I-43 (S, S, S, R) -1- [ (2S) - (2-Chloro-4-acetamido -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- ( 2S) -carboxylic acid [ (2R) -ethoxy- 5 -oxo- t etrahydro- f uran- ( 3S) -yl] -amide HN 411 1)C N?
ExampL e I-44 ( S, S, S, R) -1- [ (2S) - ( 2 - fluor -4- acetamido -benzoylamino) -3 , 3 -dimethyl-butyryl ] -pyrrolidine- ( 2S) -carboxylic acid [ (2R) -ethoxy- 5 -oxo- te trahydro- furan- ( 3S) -yl] -amide F
HN *
= 0 0 H
ExampL e 1-45 (S, S, S, R) -1- [ (2S) - (2-fluoro -4- acetamido-benzoylamino) -3 -methyl-butyryl] -pyrrolidine- (2S ) -carboxylic acid [ (2R) -ethoxy--oxo- tetrahydro- furan- (3S) -yl] -amide HN N?
ExampL e - 4 6 (S, S, SIR) -1- [ (2S)- (2-chloro -4- isopropyloxy -benzoylamino) -3 -methyl-butyryl -pyrrolidine- (2S ) -carboxylic acid [ (2R) -eth.oxy-5 -oxo - tetrahydro- furan- (3S) -yl] -amide C'0 >'0 111 N=NT
Example 1-47 (S75,S,R)-1-[(2S)-(2-chloro -4-hydroxy -benzoylamino)-3,3-.
dimethyl-butyry1]-pyrrondine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide CI
HO
O N
Example 1-48 (S,S,S,R)-1-[(2S)-(2-chloro -4-methoxymethyl -benzoylamino)-3,3-dimethyl-butyrylj-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Cl 0 P 11# 11)N13.
o 0 O N
Example 1-49 (S,S,S,R)-1-[(2S)-(2-Chloro-4-isobutyrylamido -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Ct 0 4, ()HN
O N
Example I-50 (5,S,S,R)-1-[(2S)-(2-Chloro-4-acetamido --benzoylamino)-3-cyclohexyl]-pyrrolidine-(2S)-carboxylic aacid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide FIN=
lqo ( Example 1-51 (S, S, S, R) -1- [ (2S) - (2-Chloro-4-methoxycarloonylamino -ben.zoylamino) -3 ,3-dimethyl-butyryl] -pyrrolidine- (2S) -carboxylic acid [(2R)-ethoxy-5-oxo-tetrahlydro-furan-(3S)-y1]-amide NNT
HN H
H o Example I-52 (S, S, S, R) -1-[ (2S ) (2-Chloro-3-phenoxy -b9nzoylarnino) -3,3-dimethyl-butyry1]-pyrrolidine- (2S)-carboxylic acid [ (2R)-ethoxy--5-oxo-tetrahydro-furan- (3S)-y1]-armide # 0 *
H o Example 1-53 (S,S,S,R)-1-[(2S)-(2-Chloro-4-thiazolylanaino -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-ceurboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yal-amaide =
C'0 FIN* rIN? jqo Example 1-54 (S,S,S,R)-1-[(2S)-(3-Amino-2-chloro-benzoylamino)-3-methyl-butyryll-pyrrolidine-(2S)-carboxylic acid [(,2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Cl 0 NT ti,(0 0 1\1-=
Example 1-55 (S,S,S,R)- 1-[(2S)-(2-Chloro-benzoylamino)-3-thiazol-4-yl-propiony1]-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide NAIN
101 H 0 ri Example 1-56 (S,S,S,R)- 1-[(2S)-(3-Methoxy-2-methyl-benzoylamino)-3-thiazol-4-yl-propiony1]-pyrrolidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide (1 0 =
Example 1-57 (S, S, S,R)- 1-( (2S) - (2-Chloro-3-methoxy-benzoylamino) -3,3-dimethyl-butyryl ] -pyrrolidine- (2 S ) -carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3 S ) -y1] -amide 0 110 )(1 N N?
Example 1-58 (S,S,S,R)- 1-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-piperidine-(2S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Example 1-59 2-[(2S)-(3-Methoxy-2-methyl-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide 0i-i3 0 Aj 0 METHOD H
(1R,3S,4S)-3((S)-2-tert-Butoxycarbony1-1-hydroxymethyl-ethylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester =
=
01111 ONJOk OH =
(0170] To a stirred solution of (S)-3-Amino-4-hyc-Mcoxy-butyric acid tert-butyl ester (486mg) and (1R,3S,4S)-2-Aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2 benzya ester (prepared as described in Tararov eta/, Tett. Asymm. 2002, 13, 25-28) (767mg) in THF (18m1) was added 2-hydroxybenotriazole hydrate, (452mg), DMAP (426mg), diisopropylethylamine (63101) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 641mg). The resulting mixture waz stirred at ambient temperature for 18 hours then diluted with ethyl acetate. The mixture was then washed with water, sa-turated aqueous sodium bicarbonate solution and brine, dried over magnesium sulfate, filtered and concentrated under 3reduced pressure. The residue was purified by flash-chromatc:Dgraphy (60% ethyl acetate/petrol) to afford the sub-title compound as a colorless oil (1.1g, 91%); 111 NMR (400MHz,d-6 DMSO) 8 1.13-1.25 (1H, m), 1.30-1.48 (9H, m), 1.49-1.88,(6H, m), 2.20-2.52 (2H, m), 3.09-3.34 (2H, m), 3.64 (IH, d), 4.00-4.16 (2H, brm), 4.80 (1H, m), 4.90-5.15 (2H, m), 7.21-7.41 (5H, m), 7.50-7.75 (1H, m); MS ES (+) 433.37. .
Method I
(1R,3S,4S)-3-((S)-2-tert-Butoxycarbony1-1-formyl-ethylcarbamoyl) -2-aza-bicyclo[2 .2 .1]heptane-2-carboylic acid benzyl ester a WO 2005/085236 #
[0171] A solution of (1R,3S,4S)-3((S)-2-tert-Butoxycarbony1-1-hydroxymethyl-ethylcarbamoya)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (1.1g) in DCM (10m1) was cooled to 0 C under nitrogen. 2,2,6,6-tetramethylpiperidinyloxy (TEMPO, 4mg) was then added followed by trichloroisocyanuric acid (621mg) portionwise over 30 minutes. The mixture was stirred at ambient temperature for 1 hour, then filtered through celite. The filtrate was washed with water, 1M sodium thiosulfate solution and brine. Drying over magnesium sulfate and concentration under reduced pressure gave the sub-title compound as a colorless oil (698mg, 64%); 111 NMR (400MHz,d-6 DMSO) 8 1.16-1.89 (16H, m), 2.30-2.80 (211, m), 3.68-3.81 (1H, m), 4.19 (1H, brm), 4.39, (111, m), 4.91-5.16 (2H, m), 7.21-7.43 (5H, m), 8.45 (0.4H, d), 8.60 (0.6, d), 9.19 (0.6H, s), 9.37 (0.4H, s).
Method (1R,3S,4S)-3-((S)-1-tert-Butoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester ay.74.ok [0172] To a solution of (1R,3S,4S)-3-((S)-2-tert-Butoxycarbony1-1-formyl-ethylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (698mg) in dichloromethane (10m1) was added triethyl orthoformate (720mg) and p-toluenesulfonic acid monohydrate (6mg). The resulting mixture was stirred at ambient temperature -until no aldehyde remained by TLC. Saturated aqueous sodium bicarbonate solution was then added and the organic phase removed. This was washed with water and brine, dried (magnesium sulfate), filtered and concentrated under seduced pressure. This gave the sub-title compound as a pale yellow oil (635mg, 78%); 1HNMR (400MHz,d-6 DMSO) 8 0.96-1.15 (6H, m), 1.26-1.84 (16H, m), 2.20-2.50 (2H, m), 3.40-3.81 (5H, m), 4.10-4.28 (2H, m), 4.37 (1H, m), 4.88-5.14 (2H, m), 7.20-7.40 (5H, m), 7.65 (0.5H, d), 7.80 (0.5H, d).
Method K
(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester 1.1 IrN7 [0173] A solution of (1R,35,4S)-3-((S)-1-tert-Hutoxycarbonylmethy1-2,2-diethoxy-ethylcarbamoy1)-2-aza-bicyclo[2.2.11heptane-2-carboxylic acid benzyl ester (635mg) in dichloromethane (3m1) was cooled to 0 C under nitrc,gen.
Trifluoroacetic acid (0.7m1) was then added and the mixture stirred at 0 C for 15 minutes, then warmed to ambient temperature and stirred until the reaction was complete by TLC. The mixture was then diluted with dichloromethane (10m1) and saturated aqueous sodium bicarbonate solution (14=1.1). The organic phase was then removed and washed with 1:1 saturated aqueous sodium bicarbonate/brine (8m1), dried (magnesium sulfate), filtered and concentrated under reduced pressure.
This afforded the sub-title compound as a mixture of epimers at the ketal centre. The epimers were separated on silica gel, eluting with 30% 2-butanone/petrol. Syn-isomer (oil) (115mg, 23%); 111 NMR (400MHz,d-6 DMSO) 8 0.80-1.91 (10H, m), 2.35-2.79 (2H, m), 3.56 (1H, m), 3.66-3.80 (2H, m), 4.18 (1H, m), 4.59 (1H, m), 4.94-5.11 (2H, m), 5.53 (1H, d), 7.20-7.40 (5H, m), 8.18 (0.5H, d), 8.27 (0.5H, d); MS ES + 403.31 (100%), ES -401.37 (15%); Anti-isomer (oil)(103mg, 20%); 111 NMR (400MHz,d-6 DMSO) 8 0.80-1.85 (10H, m), 2.25-2.60 (1H, m), 2.95 (1H, m), 3.42 (1H, m), 3.5-3.75 (2H, m), 4.88-5.15 (3H, m), 7.21-7.40 (5H, m), 8.50 (0.4H, d), 8.59 (0.6H, d).
Method L
{(S)-1-[(1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carbonyl]-2,2-dimethyl-propy1}-carbamic acid benzyl ester iX\T
0 H 0¨A
[0174] To a solution of (1R,3S,4S)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3-ylcarbamoy1)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (5g) in ethyl acetate (160m1) and DMF (25m1) was added triethylamine (2.5g) followed by palladium hydroxide/carbon (20% w/w, 1g).
The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite. To the filtrate was added (5)-2-benzyloxycarbonylamino-3,3-dimethyl-butyric acid (4.93g), hydroxybenzotriazole hydrate (2.01g) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, 2.85g). The resulting mixture was stirred at ambient temperature overnight. Saturated aqueous sodium bicarbonate solution (180m1) was then added and the organic phase removed.
This was washed with saturated aqueous ammonium chloride (180 ml), then brine (180m1), dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with 40-75% ethyl acetate/petrol. The sub-title compound was obtained as a white foam (5.25g, 81%); 1H NMR (400MHz,d-6 DMSO) 8 0.85-1.03 (10H, m), 1.07-1.20 (311, t), 1.30 (111, m), 1.40 (111, m), 1.50-1.80 (3H, m), 1.93 (IH, m), 2.40-2.50 (111, m), 2.78 (1H, m), 3.60 (1H, m), 3.78 (111, m), 3.89 (1H, s), 4.26 (111, d), 4.52 (2H, m), 4.96-5.12 (211, m), 5.56 (1H, d), 7.10 (IH, d), 7.24-7.40 (5H, m), 8.27 (IH, d); MS ES 516.93 (100%), ES - 515.05 (100%).
Method M
(1R,3S,4S)-2-[(S)-2-(3-methoxy-2-methylbenzoylamino)-3,3-dimethyl-butyry1]-2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-y1)-amide =
=
(110 NIX(1\7NO
[0175] To a solution of C(S)-1-[(1R,3S,45)-3-((2R,3S)-2-Ethoxy-5-oxo-tetrahydro-furan-3ylcarbamoy1)-2-aza-bicyclo[2.2.11heptane-2-carbony1]-2,2-dimethyl-propyll-carbamic acid benzyl ester (370mg) in ethyl acetate (20m1)was added palladium hydroxide/carbon (20% w/w, 74mg). The mixture was stirred under an atmosphere of hydrogen until no starting material was present by TLC. The catalyst was removed by filtration through celite and the filtrate concentrated under reduced pressure to give the amine as a brown foam (272mg). A
portion of this material (167mg) was dissolved in THF and 3-methoxy-2-methyl benzoic acid (146mg), diisopropylamirie (19101), hydroxybenzotriazole hydrate (77mg) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (EDC, =
109mg) were added. The resulting mixture was stirred at ambient temperature for 24 hours then diluted with saturated aqueous sodium bicarbonate. The organic phase was removed and washed with saturated aqueous ammonium chloride, then brine, dried (magnesium sulfate), filtered and concentrated under reduced pressure. The crude product was purified on silica gel, eluting with ethyl acetate. This gave the sub-title compound as a white solid (121mg, 52%); 111 NMR (400MHz,CDC13) 8 1.10 (9H, s), 1.28 (3H, t), 1.43-1.56 (IH, m), 1.79-1.86 (3H, m), 1.99 (1H, brd), 2.29 (3H, s), 2.30-2.37 (1H, m), 2.83 (1H, dd), 3.02 (1H, brs), 3.66-3.74 (1H, m), 3.87 (3H, s), 3.88-3.94 (111, m), 4.16 (111, brs), 4.54 (1H, brs), 4.66-4.74 (IH, m), 4.97 (1H, d), 5.46 (1H, d), 6.44 (1H, brd), 6.93 (1H, d), 7.00 (1H, d), 7.22 (IH, t), 7.78 (IH, brd); IR (solid) cm-1 2960, 1791, 1624, 1505, 1438, 1261, 1115, 975;, MS ES + 530; ES
- 528.
[0176]
Compounds of formula 1-60 to 1-73 have been prepared by methods substantially similar to those described in Example 1-59.
Example 1-60 2-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y13-amide oi 0 *I )(I
X
Example 1-61 2-[(2S)-(4-Acetylamino-2-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.11heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide CI 0 Icrl *0 N 0 Example 1-62 2-1(2S)-(2-Chloro-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.11heptane-(35)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(35)-y1]-amide = ci 0 0 JLN *
Example 1-63 2-[(2S)-(2-Chloro-3-isobutyrylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(38)-y1]-amide ))1-H a 0 N PI
H
Example 1-64 2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-3,3-dimethyl-butyry1]-2-(18,4R)-aza-bicyclo[2.2.11heptane-(35)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide ,0 410 1,,X474 Hoomo Example 1-65 2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-3-methyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide xi.14 Example 1-66 2-[(2S)-(3-methoxy-2-methyl-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2S)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yll-amide CH3 :irrq *H 0 0 Example 1-67 2-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2S)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide * jo ,\
Example 1-70 2-[(2S)-(4-Acetylamino-3-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.11heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide Example 1-69 2-[(2S)-(3-Chloro-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide =
0 1,:ittri7 1-1 a O.
Example 1-70 2-[(2S)-(isoquinolin-1-ylcarbonylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide 11101.,.
H
Example 1-71 2-[(2S)-(4-Amino-3-ch1oro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid , =
[(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-yl]amide rill l H 0 N'Y
Example 1-72 2-[(2S)-(4-Amino-3-chloro-benzoylamino)-3-methyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(35)-carboxylic acid [(2R)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide ?Corl H2N 0 H 0-.1 Example 1-73 2-[(2S)-(isoquinolin-l-ylcarbonylamino)-3,3-dimethyl-butyryll-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carboxylic acid [(2S)-ethoxy-5-oxo-tetrahydro-furan-(3S)-y1]-amide so 0 isti7 0 Table 3. Characterization Data for Selected Compounds of Formula I (by Compound Number) Nb. 144-1 1H-NMR
(obs) (DMSO-d6) 0.94-0.95 (311, m), 0.98-0.99 (311, m), 1.13-1.16 (3H, m), 1.80-2.0 (4H, m), 2.10 (311, s), 2.47-2.51 (211, m), 2.73 (111, m), 3.34-3.61 (2H, m), I-1 490.1 3.73-3.77 (2H, m), 3.79 (3H, s), 3.90 (1H, m), 4.39 (111, m), 4.55 (111, m), 5.55 (1H, d), 6.83 (111, d), 6.99 (111, d), 7.19 (1H, m), 8.27 (111, d), 8.34 (1H, d) (CDC13) 1.01-1.15 (6H, m), 1.26 (311, t), 1.90-2.29 (5H, m), 2.55-2.59 (1H, m), 2.75-2.83 (1H, m), 3.65-3.98 (311, m), 1-2 476.0 4.04 (3H, s), 4.44-4.49 (1H, m), 4.62-4.69 (111, m), 4.75-4.80 (111, m), 5.60 (111, d), 7.09 (1H, t), 7.19 (111, d), 7.52 (111, t), 7.97 (111, d) (CDC13) 1.02-1.10 (611, m), 1.23-1.34 (3H, m), 1.88-2.19 (511, m), 2.32-2.44 (2H, m), 2.81-2.89 (1H, m), 3.66-3.72 1-3 530.0 (2H, m), 3.83-3.98 (211, m), 4.56-4.73 (2H, m), 4.84-4.90 (111, m), 5.46 (111, d), 7.15 (111, d), 7.35-7.60 (411, m), 7.99 (111, d) (CDC13) 1.02 (311, d), 1.09 (311, d), 1.29 (3H, t), 1.93-2.19 (411, m), 2.29 (311, s), 2.39 (2H, dd), 2.84 (111, dd), 3.66-1-4 476.1 3.71 (2H, m), 3.88-3.95 (2H, m), 4.63 (1H, dd), 4.68-4.74 (111, m), 4.85 (1H, dd), 5.32 (1H, s), 5.47 (111, d), 6.44 (1H, d), 6.87 (111, d), 6.98-7.00 (111, m), 7.07-7.12 (111, m), 7.36 (111, d) ' No. m+1 1114am (obs) (CDC13) 0.95-1.10 (6H, m), 1.31 (311, t), 1.93-2.21 (4H, m), 2.25 (311, s), 2.34-2.41 (211, m), 2.80-2.88 (1H, m), 3.63-1-5 475.0 3.75 (411, m), 3.87-3.93 (211, m), 4.65-4.75 (211, m), 4.82-4.88 (1H, m), 5.47 (111, d), 6.43 (IH, d), 6.74 (111, d), 6.81 (1H, d), 7.04 (111, t), 7.40 (1H, d) (CDC13) 1.03-1.05 (311, m), 1.09-1.13 (311, m), 1.22-1.30 (311, m), 1.95 (111, m), 2.14-2.17 (2H, m), 2.44-2.51 (2H, 1-6 514.4 m), 2.79 (111, m), 3.65-3.68 (211, m), 3.86-3.90 (211, m), 4.12 (IH, m), 4.60-4.61 (211, m), 4.86 (1H, m), 5.47 (111, m), 6.4 (1H, 2 x d), 7.29-7.37 (3H, m), 7.54 (111, m) (DMS0--(16) 0.95-1.01 (6H, m), 1.13-1.16 (311, m), 1.80-2.10 (4H, m), 2.45-2.51 (511, m), 2.74 (IH, ra), 3.33-3.59 (2H, 1-7 461.1 m), 3.68 (111, m), 3.95 (111, m), 4.38-4.44 (211, m), 4.55 (1H, m), 5.55 (111, m), 7.25 (1H, m), 7.62 (111, m), 8.27 (IH, m), 8.48 (IH, m), 8.63 (111, m) (CDC13) 1.02 (3H, d), 1.08 (3H, d), 1.28 (311, t), 1.95-2.2 (411, m), 2.4-2.5 (211, m), 2.55 (3H, s), 2.8-2.9 (1H, m), 3.7-1-8 461.1 3.8 (211, m), 3.85-3.95 (211, m), 4.7-4.85 (211, m), 4.9-4.95 (1H, m), 5.55 (IH, d), 6.6-6.65 (111, m), 7.2-7.25 (1H, m), 7.35-7.4 (IH, m), 8.6 (111, d), - 8.7 (IH, s) (DmSo-d0 0.93-0.95 (3H, m), 0.99-1.00 (3H, m), 1.13-1.16 (3H, m), 1.80-2.10 (411, m), 2.40 (311, s), 2.40-2.47 (211, 1-9 465.6 m), 2.73 (1H, m), 3.59-3.61 (211, m), 3.73-3.75 (211, m), 4.37-4.43 (2H, m), 4.55 (111, m), 5.53 (111, d), 6.97 (IH, m), 7.59 (111, m), 7.81 (IH, d), 8.28 (1H, d) _ =
No. N+1 1H-NMR
(obs) (CDC13) 1.01 (3H, d), 1.25 (3H, d), 1.27 (3H, t), 1.97-2.10 (2H, m), 2.14-2.26 (1H, m) 2.38 (2H, dd), 2.84 (1H, dd), 2-10 515.0 3.67-3.71 (2H, m), 3.81-3.87 (1H, m), 3.90-3.98 (1H, m), 4.58-4.61 (1H, m), 4.65-4.73 (1H, m), 4.86-4.90 (1H, dd), 5.47 (1H, d), 6.78 (1H, d), 7.23 (1H, d), 7.42 (1H, d), 8.40 (1H, d) (CDC13) 1.01 (3H, d), 1.14 (3H, d), 1.28 (3H, t), 1.96-2.12 (211, m), 2.17-2.23 (2H, m), 2.38 (2H, dd), 2.83 (1H, dd), T-11 515.0 3.66-3.71 (211, m), 3.82-3.95 (211, m), 4.59-4.62 (111, m), 4.65-4.71 (111, m), 4.91 (1H, dd), 5.47 (111, d), 6.54 (111, br dd), 7.21 (111, br dd), 8.57 (2H, s) (DMSO-d6) 0.9-1.08 (9H, s), 1.12 (3H, t), 1.75-2.00 (3H, m), 2.00-2.15 (4H, m), 2.34-2.50 (1H, m), 2.80 (1H, m), 1-12 504.4 3.48-3.91 (7H, m), 4.40 (1H, m), 4.46-4,70 (211, m), 5.58 (111, d), 7.81 (111, d), 7.00 (1H, d), 7.19 (111, dd), 8.07 (111, d), 8.27 (1H, d) (CDC13) 0.98-1.09 (6H, m), 1.90-2.05 (4H, m), 2.35-2.56 (2H, m), 2.70-2.85 (111, m), 3.49+3.55 (3H, 2xs), 3-55-3.67 1-13 476.0 (1H, m), 3.86 (3H, s), 4.00-4.09 (1H, m), 4.58-4.90 (3H, m), 5.34-5.37 (111, m), 6.25+6.40 (1H, 2xd), 6.90-7.01 (2H, m), 7.18-7.25 (111, m), 7.37+7.54 (111, 2xd) (CDC13) 0.99-1.11 (6H, m), 1.18-1.30 (6H, m), 1.86-2.15 (411, m), 1.28+1.30 (311, 2xs), 2.36-2.86 (311, m), 3.56-3.68 1-14 504.0 (111, m), 3.86 (311, s), 3.87-4.05 (2H, m), 4.50-4.84 (311, m), 5.55+5.59 (111, 2xd), 6.86-7.01 (2H, m), 7.16-7.23 (111, m), 7.37+7.54 (1H, 2xd) (CDC13) 0.85-1.11 (9H, m), 1.55-1.73 (211, m), 1.89-2.20 (4H, m), 2.28+2.29 (3H, 2xs), 2.35-2.55 (211, m), 2.71-2.87 1-15 504.0 (111, m), 3.48-3.76 (311, m), 3.86 (311, s), 3.98-4.06 (1H, m), 4.52-4.86 (311, m), 5.44-5.49 (1H, m), 6.24+6.35 (111, 2xd), 6.88-6.99 (2H, m), 7.14-7.21 (1H, m), 7.41+7.55 (1H, 2xd) No. 14+1 (obs) (CDC13) 1.0-1.15 (6H, m), 1.3-1.4 (3H, m), 1.9-2.2 (4H, m), 2.4-2.5 (2H, m), 2.8-2.9 (1H, m), 3.7-3.8 (2H, m), 3.9-1-16 480.5 4.0 (2H, m), 4.65-4.75 (2H, m), 4.88-4.92 (1H, m), 5.5-5.52 (1H, m), 6.85-6.9 (1H, m), 7.4-7.55 (1H, m), 7.7-7.75 (1H, m) (DMSO-d6) 1.05 (9H, s), 1.15 (3H, t), 1.8-2.1 (4H, m), 2.3 (3H, s), 2.4-2.5 1-17 474.6 (1H, m), 2.7-2.8 (1H, m), 3.6-3.9 (4H, m), 4.4-4.45 (1H, m), 4.5-4.7 (2H, m), 5.55-5.6 (1H, m), 7.2-7.4 (4H, m), 8.1 (1H, d), 8.25 (1H, d) (DMSO-d6) 0.9-1.0 (6H, m), 1.15 (3H, t), 1.8-2.1 (4H, m), 2.4-2.5 (111, m), 2.7-1-18 514.5 2.8 (1H, m), 3.6-3.85 (3H, m), 3.9-3.95 (1H4, m), 4.4-4.6 (3H, m), 5.55-5.6 (1H, m), 7.4-7.45 (1H, m), 7.6-7.8 (3H, m), 8:22 (1H, d), 8.75 (1H, d) (CDC13) 1.13 (9H, s), 1.90-2.20 (3H, m), 2.35-2.44 (211, m), 2.86 (111, dd), 3.56 (3H, s), 3.72-3.74 (1H, m), 3.90-3.99 1-19 480.5 (111, m), 4.62-4.65 (1H, m), 4.69-4.70 (111, in), 4.90 (111, d), 5.36 (1H, d), 6.94 (111, d), 7.28-7.46 (411, m), 7.71 (1H, dd) (CDC13) 1.09 (9H, s), 1.27 (6H, m), 1.93-2.14 (3H, m), 2.34-2.42 (2H, m), 2.79-2.83 (111, m), 3.71 (1H, m), 3.90-1-20 542.5 3.94 (1H, m), 4.01-4.04 (1H, m), 4.62-4.67 (211, m), 4.88-4.91 (111, m), 5.56 (111, m), 6.46 (111, m), 7.40 (111, m), 7.54-7.62 (3H, m), 7.74 (111, m) (CDC13) 1.12 (9H, s), 1.29 (311, t), 1.90-2.20 (3H, m), 2.36-2.43 (2H, m), 1-21 494.5 2.85 (1H, dd), 3.67-3.72 (2H, m), 3.90-3.96 (211, m), 4.62-4.65 (2H, m) 4.91 (1H, d), 5.46 (1H, d), 6.95 (111, d), 7.34-7.46 (411, m), 7.71 (1H, dd) (CDC13) 1.10 (911, s), 1.29 (3H, t), 1.90-2.20(3H, m), 2.35-2.42 (211, m), 2.84 (1H, dd), 3.68-3.72 (211, m), 3.90-1-22 528.4 3.95 (2H, m), 4.62-4.80 (2H, m), 4.89 (111, d), 5.47 (111, d), 6.45 (1H, d), 7.43 (111, d), 7.54-7.61 (3H, m), 7.73 (1H, dd) No. M+1 LH-NMR
(obs) (CDC13) 0.95 (3H, t), 1.12 (9H, s), 1.60-1.70 (2H, m), 1.88-2.20 (3H, m), 2.35-2.45 (2H, m), 2.77-2.85 (1H, m), 1-23 508.5 3.53-3.61 (1H, m), 3.65-3.75 (1H, m), 3.76-3.84 (1H, m), 3.88-3.96 (1H, m), 4.60-4.73 (2H, m), 4.91 (11, d), 5.44 (1H, d), 6.96 (1H, d), 7.30-7.50 (4H, m), 7.73 (1H, d) (CDC13) 0.86 (3H, t), 1.18 (911, s), 1.21-1.65 (4H, m), 1.85-2.17 (3H, m), 2.36-2.59 (2H, m), 2.68-2.78 (IH, m), 1-24 522.5 3.44-3.54 (1H, m), 3.56-3.72 (211, m), 3.98-4.10 (IH, m), 4.56-4.85 (3H, m), 5.44 (111, d), 6.95-7.02 (1H, m), 7.32-7,74 (5H, m) (DMSO-d6) 0.99-1.21 (1211, m), 1.70-2.00 = (3H, m), 2.01-2.17 (111, m), 2.40-2.51 (111, m), 2.70-2.80 (1H, m), 3.50-3.88 1-25 578.3 (411, m), 4.40 (IH, m), 4.55 (1H, m), 4.65 (1H, m), 5.58 (1H, d), 7.36 (111, m), 7.50 (1H, m), 7.61 (111, m), 8.21 (111, d), 8.70 (111, d) (CDC13) 0.95 (3H, t), 1.05-1.15 (611, m), 1.55-1.8 (3H, m), 2.0-2.25 (411, m), 2.4-2.5 (IH, m), 2.6-2.9 (2H, m), 3.55-1-26 494.5 3.8 (3H, m), 3.85-3.95 (1H, m), 4.05-4,1 (111, m), 4.7-4.85 (211, m), 5.5-5.55 (111, m), 6.85-6.9 (1H, m), 7.4-7.6 (311, m), 7.7-7.8 (IH, m) (CDC13) 0.95 (311, t), 1.05-1.15 (6H, m), 1.5-1.7 (311, m), 2.0-2.2 (4H, m), 2.4-2,6 (211, m), 2.9-3.1 (111, m), 3.4-3.5 1-27 494.5 (111, m), 3.55-3.7 (211, m), 4.0-4.1 (111, m), 4.35-4.5 (211, m), 4.6-4.75 (111, m), 4.8-4.9 (0.5H, m), 5.35-5.38 (1H, m), 6.85-6.95 (111, m), 7.4-7.55 (3H, m), 7.64-7.8 (1.511, m) (CDC13) 1.02-1.19 (7H, m), 1.22-1.28 (2H, m), 1.90-2.21 (311, m), 2.32-2.53 (2H, m), 2.95 (111, 2 x dd), 3.44-3.50 1-28 480.3 (1H, m), 3.59-78 (2H, m), 3.83-3.92 (1H, m), 4.02-4.09 (1H, m), 4.29-4.41 (1H, m), 5.34 (IH, 2 x s), 6.88 (IH, 2 x brd d), 7.31-7.42 (411, m), 7.57 (1H, 2 x brd d), 7.70 (IH, 2 x dd) =
No. M+1 111-11MR.
(obs) (CDC13) 0.83-0.97 (3H, m), 1.02-1.14 (6H, m), 1.26-1.53 (3H, m), 1.55-1.66 (111, m), 1.91-2.20 (411, m), 2.35-2.61 (211, m), 2.73-2.90 (111, m), 3.54-3.74 1-29 508 (311, m), 3.84-3.90 (0.511, m), 3.99-4.06 (0.5H, m), 4.61-4.75 (2H, m), 4.77-4.93 (0.511, m), 5.45-5.51 (1H, m), 6.87 (1H, brd), 7.34-7.45 (4H, m), 7.55 (0.5H, brd), 7.70-7.22 (1H, m) (400 MHz, CDC13) 0.87-0.97 (3H, m), 0.99-1.16 (6H, m), 1.27-1.40 (211, m), 1.48-1.59 (111, m), 1.91-2.19 (4H, m), 2.30-2.52 (2H, m), 2.90-3.07 (1H, m), 3.39-3.45 (0,511, m), 3.54-3.71 (211, m), 1-30 508 3.78-3.82 (0.5H, m), 3.86-3.92 (0.511, m), 4.04-4.09 (0.5H, m), 4.31-4.35 (111, m), 4.39-4.43 (111, m), 4.56-4.59 (0.5H, m), 4.66-4.68 (1H, m), 4.80-4.86 (0.511, m), 5.32-5.41 (1H, m), 6.87-6.91 (1H, m), 7.31-7.45 (4H, m), 7.55-7.76 (2H, m) (CDC13) 1.04-1.19 (8H, m), 1.25-1.28 (311, m), 1.92-2.18 (411, m), 2.32-2.43 (1H, m), 2.62-2.87 (211, m), 3.59-3.71 1-31 494.4 (111, m), 3.85-3.95 (1H, m), 4.00-4.05 (1H, m), 4.60-4.67 (311, m), 5.60 (111, 2 x d), 6.88 (1H, brd d), 7.36-7.50 (411, m), 7.52-7.56 (1H, m), 7.76 (111, 2 x dd) (CDC13) 0.87-1.24 (1011, m), 1.88-2.07 (3H, m), 2.13-2.21 (111, m), 2.32-2.54 (2H, m), 2.94 (1H, 2 x dd), 3.57-3.68 (111, m), 3.83-3.87 (1H, m), 4.02-4.09 1-32 494.3 (111, m), 4.27-4.30 (111, m), 4.41 (111, dd), 4.51-4.69 (1H, m), 5.43 (111, 2 x s), 6.89 (1h, 2 x brd d), 7.30-7.45 (4H, m), 7.52 (111, 2 x brd d), 7.70 (1H, 2 x dd) No. M 1 111-1114R
(obs) (DMSO) 0.70 (211, in, 0112), 0.89 (211, in, CH2), 0.95-1.20 (1211, In, CH3, tbutyl), 1.71-2.13 (411, in, 0H2), 2.45 (111, in, asp CH2), 2.75 (1H, m, asp CH2), 3.35-1-33 550.5 3.89 (4H, in, 0112, CH), 3.99 (111, m, CH), 4.37 (1H, in, CH), 4.51 (111, m, CH), 4.65 (111, in, CH), 5.58 (111, d, CHO), 6.90 (1H, in, aryl H), 7.35 (111, in, aryl H), 7.45 (1H, in, aryl H), 8.25 (1H, d, NH), 8.35 (111, d, NH) DMSO) 0.99-1.21 (1211, m, 0113, tBu), 1.75-2.14 (4H, m, CH2), 2.38 (3H, S.
0113), 2.40-2.51 (111, m, asp CH2), 2.70-2.82 (111, in, asp CH2), 3.37-3.90 (411, 1-34 508.5 m, 0112, CH), 4.39 (1H, m, CH), 4.55 (1H, in, CH), 4.67 (111, in, CH), 5.58 (1H, d, CH), 7.15 (1H, m, aryl H), 7.28 (1H, in, aryl H), 7.38 (1H, in, aryl H), 8.25 (111, in, NH), 8.38 (111, in, NH) CDC13 1.00 (3H, d), 1.10 (311, d)', 1.27 (3H, t), 1.90-2.19 (411, m), 2.34-2.45 (2H, m), 2.79-2.87 (1H, M), 3.65-3.71 1-35 510 (211, m), 3.84-4.93 (211, m), 3.92 (3H, s), 4.56-4.70 (211, m), 4.82-4.88 (111, m), 4.45 (1H, d), 6.69 (111, d), 6.99 (111, d), 7.16 (111, d), 7.27 (1H, t), 7.37 (1H, d) (DMSO) 0.95-1.25 (15H, in, tBu, 0113), 1.78-2.13 (411, in, CH2), 2.43 (1H, in, CH2), 2.65-2.80 (311, m, 0112), 3.50-3.88 1-36 522.5 (411, in, 0112, CH), 4.42 (111, m, CH), 4.58 (1H, in, CH), 4.70 (111, d, CH), 5.58 (1H, d, CH), 7.15 (111, in, aryl H), 7.27 (1H, in, aryl H), 7.38 (111, in, aryl H), 8.27 (111, d, NH), 8.39 (1H, d, NH) 0D013 1.05-1.12 (6H, m), 1.25-1.3 (311, m), 1.9-2.2 (2H, m), 2.4-2.5 (2H, m), 2.8-2.9 (111, m), 3.65-3.75 (2H, m), 1-37 510.5 3.85 (3H, s), 3.9-4.0 (1H, m), 4.65-4.75 (211, m), 4.85-4.9 (1H, m), 6.9-6.93 (111, m), 6.98 (111, s), 7.05-7.1 (1H, m), 7.4-7.45 (111, m), 7.75-7.8 (1H, d) No. 14+1 H-NMR
(ohs) CDC13 0.38-0.42 (2H, m), 0.63-0.71 (2H, m), 1.11 (911, s), 1.23-1.35 (4H, m), 1.88-2.20 (3H, m), 2.34-2.45 (2H, 1-38 564 m), 2.76-2.87 (1H, m), 3.66-3.75 (2H, m), 3.87-3.96 (4H, m), 4.62-4.73 (2H, m), 4.89 (1H, d), 5.47 (1H, d), 6.80 (1H, d), 7.00 (1H, d), 7.19-7,29 (2H, m), 7.48 (1H, d) (DMSO) 1.11 (9H, s), 1.28 (311, t), 1.83-2.22 (3H, m), 2.36-2.43 (2H, m), 2.82-2.87 (111, m), 3.66-3.76 (2H, m), 1-39 510 3.86-3.97 (2H, m), 4.62-4.71 (2H, m), 4.88 (1H, d), 5.45 (1H, d), 6.31 (1H, s), 6.73 (111, d), 7.05-7.20 (3H, m), 7.38 (1H, d) (CDC13) 1.06 (611, dd), 1.28-1.31 (4H, m), 1.91-2.20 (4H, m), 2.23 (3H, s), 2.39 (1H, dd), 2.84 (1H, dd), 3,65-3.72 1-40 537.4 (211, m), 3.86-3.94 (2H, m), 4.61-4.73 (211, m), 4.87 (111, dd), 5.46 (111, dd), 7.00-7.04 (1H, m), 7.22 (111, brd s), 7.38-7.45 (211, m), 7.73 (111, d), 7.80 (1H, brd s) (DMSO) 0.95-1.20 (1211, in, tBu, CH3), 2.75-2.15 (7H, in, CH2, COCH3), 2.42 (111, m, CH2), 2.77 (111, m, CH2), 3.50-3.88 (411, in, CH2, CH), 4.37 (1H, In, 1-41 551.5 CH), 4.55 (111, in, CH), 4.67 (1H, d, CH), 5.58 (1H, d, CH), 7.09 (111, in, aryl H), 7.32 (1H, in, aryl H), 7.71 (1H, m, aryl H), 8.26 (1H, in, NH), 8.49 (111, m, NH), 9.58 (1H, in, NH) (DMSO) 0.95-1.20 (12H, m, tBu, CH3), 1.75-2.17 (1011, in, CH3, COCH3, CH2), 2.45 (1H, m, CH2), 2.77 (1H, m, CH2), 1-42 531.6 3.48-3.91 (4H, m, CH2, CH), 4.31-4.70 (3H, m, CH), 5.55 (1H, d, CH), 7.04 (1H, m, aryl H), 7.18 (111, in, aryl H), 7.41 (111, in, aryl H), 8.20 (1H, d, NH), 8.27 (111, d, NH), 9.39 (1H, brs, NH) No. 144.1 1H-NR
(obs) DMSO) 1.04 (9H, s), 1.12-1.17 (311, m), 1.78-1.95 (4H, m), 2.06 (3H, s), 2.45 (111, dd), 2.72 (1H, dd), 3.52-3.81 (411, 1-43 551.4 m), 4.36-4.39 (111, m), 4.47-4.54 (IH, m), 4.64 (111, d), 5.54 (111, dd), 7.33-7.35 (111, m), 7.43-7.46 (1H, m), 7.81 (IH, brd s), 8.21-8.25 (211, m), 10.23 (111, brd s) (DMSO) 1.02 (9H, s), 1.14 (3H, t), 1.78-1.98 (411, m), 2.08 (3H, s), 2.48 (1H, dd), 2.79 (1H, dd), 3.51-3.82 (411, 1-44 535.4 m), 4.36-4.39 (1H, m), 4.49-4.58 (111, m), 4.71 (1H, d), 5.54 (111, d), 7.31-7.34 (111, m), 7.65-7.72 (311, m), 8.49 (1H, d), 10.38 (IH, s) (DMSO) 0.95 (6H, dd), 1.12-1.16 (4H, m), 1.72-1.97 (4H, m), 2.07 (311, s), 2.48 (111, dd), 2.73 (1H, dd), 3.51-3.62 1-45 521.4 (211, m), 3.71-3.83 (211, m), 4.35-4.38 (111, m), 4.48-4.59 (211, m), 5.53 (1H, d), 7.29-7.31 (111, m), 7.59-7.67 (211, m), 8.01-8.05 (111, m), 8.28 (IH, d), 10.35 (111, s) (CDC13 1.1-1.12 (611, m), 1.3 (3H, m), 1.4 (6H, d), 2.0-2.2 (211, m), 2.4-2.5 (2H, m), 2.8-2.9 (1H, m), 3.7-3.75 (211, 1-46 538.5 m), 3.9-4.0 (IH, m), 4.6-4.75 (3H, m), 4.85-4.95 (IH, m), 6.85-6.9 (111, m), 6.95 (111, s), 7.05-7.1 (IH, m), 7.4-7.45 (111, m), 7.8 (111, d) (CDC13) 1.15 (911, m), 1.25 (311, t), 2.0-2.2 (41-1, m), 2.4-2.5 (2H, m), 2.8-2.9 (111, m), 3.7-3.85 (211, m), 3.9-4.0 1-47 510.5 (111, m), 4.05-4.1 (111, m), 4.7-4.8 (IH, m), 4.85 (1H, d), 5.5 (IH, m), 6.5 (111, d), 6.8 (111, s), 7.2 (111, d), 7.4 (1H, d), 7.55 (111, d) (CDC13) 1.12 (9H, s), 1.29 (311, t), 1.90-2.20 (3H, m), 2.36-2.43 (211, m), 2.85 (111, m), 3.42 (311, s), 3.68-3.74 1-48 538.5 (2H, m), 3.91-3.95 (211, m), 4.48 (2H, s), 4.62-4.75 (211, m), 4.90 (111, m), 5.47 (111, m), 7.00 (111, m), 7.31 (111, m), 7.43-7.54 (2H, m), 7.72 (IH, m) No. M+1 la4ata (obs) (CDC13) 1.12 (9H, s), 1.28-1.31 (9H, m), 1.90-2.20 (3H, m), 2.36-2.43 (2H, m), 2.54 (1H, m), 2.85 (1H, m), 3.68-1-49 579.5 3.72 (2H, m), 3.91-3.95 (2H, m), 4.62-4.69 (2H, m), 4.88 (1H, d), 5.47 (1H, m), 7.14 (1H, d), 7.27 (1H, m), 7.41 (1H, m), 7.50 (1H, d), 7.78 (1H, d), 7.87 (1H, m) (DMSO) 1.12-1.16 (7H, m), 1.58-1.81 (5H, m), 1.83-1.92 (5H, m), 2.04-2.08 (4H, m), 2.50 (111, ad), 2.75 (1H, dd), 3.57-3.66 (2H, m), 3.72-3.78 (1H, m), 1-50 577-3 3.82-3.91 (1H, m), 4.33-4.36 (1H, m), 4.46 (1H, t), 4.52-4.61 (1H, m), 5.54 (1H, d), 7.32 (1H, d), 7.43 (1H, dd), 7.81 (1H, d), 8.25 (1H, d), 8.47 (1H, d), 10.22 (1H, s) (DMSO) 0.98-1.25 (12H, in, tBu, CH3), 1.78-2.14 (4H, in, CH2), 2.44 (1H, m, CH2), 2.78 (1H, in, CH2), 3.50-3.88 (7H, 1-51 567.4 in, CH3, CH2, CH), 4.38 (1H, in, CH), 4.55 (1H, in, CH), 4.67 (IH, d, CH), 5.58 (1H, d, CH), 7.30-7.42 (2H, in, aryl H), 7.60 (1H, brs, NH), 8.21 (211, in, aryl H, NH), 9.99 (1H, brs, NH).
(DMSO) 0.95-1.24 (1211, in, tBu, CH3), 1.70-2.13 (4H, in, C112), 2.44 (111, in, CH2), 2.75 (111, in, CH2), 3.45-3.90 (4H, in, CH2, CH), 4.37 (111, m, CH), 4.55 1-52 586.4 (1H, m, CH), 4.70 (1H, d, CH), 5.57 (1H, d, CH), 6.91 (2H, d, aryl H), 7.06-7.19 (3H, in, aryl H), 7.30-7.45 m, aryl H), 8.20 (1H, d, NH), 8.55 (1H, d, NH) (DMSO) 0.9-1.0 (6H, m), 1.18 (3H, t), 1.8-2.15 (411, m), 2.4-2.5 (1H, m), 2.7-1-53 578.5 2.8 (1H, m), 3.6-3.85 (411, m), 4.4-4.6 (3H, m), 5.55 (111, d), 7.05 (IH, d), 7.3-7.35 (2H, m), 7.98 (1H, s), 8.3 (1H, d), 8.45 (1H, d), 10.7 (111, S) No. 14+1 1H-NMR
(obs) (DMSO) 0.94-0.98 (6H, in) , 1.13-1.18 (3H, in), 1.80-2.10 (5H, in) , 2.50 (1H, m) , 2.73 (1H, m), 3.58-3.61 (2H, m), 1-54 495.0 3.74 (1H, m), 3.9 (1H, m) , 4.38-4.41 (2H, in) , 4.60 (1H, rah 5.46 (2H, s), 5.54 (1H, in), 6.48 (111, in), 6.80 (1H, m), 7.04 (1H, in), 8.27 (1H, d) , 8.40 (1H, d) (CDC13) 1.25 (3H, t), 1.99-2.01 (3H, s), 2.30-2.39 (1H, m), 2.68 (1H, dd), 2.79 (1H, dd), 3.21-3.27 (1H, m) , 3.39 1-55 535.0 (1H, dd), 3.47-3.51 (2H, in), 3.65-3.75 (1H, rn) , 3.88-3.94 (111, in) , 4.64-4.68 (1H, in), 4.70-4.78 (1H, in) , 5.56 (1H, d) , 7.31-7.35 (511, in) , 7.63-7.65 (1H, in), 8.00 (1H, d), 8.76 (1H, d) (CDC13 ) 1.25 (311, t) , 2.01-2.03 (3H, m), 2.25 (311, s), 2.30-2.37 (11i, in) , 2.65 (111, dd), 2.80 (1H, dd), 3.27-3.41 (2H, in), 3.47 (1H, dd), 3.65-3.79 (211, 1-56 545.0 in), 3.85 (3H, s), 3.86-3.90 (1H, in), 4.64-4.67 (1H, m), 4.71-4.80 (1H, in), 5.18-5.22 (111, In), 5.54 (111, d) , 6.83 (111, d) , 6.90-6.97 (2H, m), 7.19 (1H, t), 7.24-7.28 (1H, m), 7.90 (1H, d), 8.77 (1H, d) (CDC13 ) 1.12 (911, s) , 1.31 (3H, t), 1.93-2.20 (311, in), 2.35-2.46 (211, m), 2.79-2 .86 (1H, in), 3.65-3.74 (211, In), 1-57 524.0 3.87-3 .96 (211, in), 3.95 (3H, s) , 4.65-4.74 (211, m), 4.89 (111, d), 5.47 (1H, d), 6.76 (1H, d), 7.03 (11-1, d), 7.30 (1H,t) , 7.48 (1H, d) (CDC13 ) 1.10 (911, s), 1.28 (311, t), 1.43-1.56 (111, in), 1.79-1.86 (311, in), 1.99 (111, brd), 2.29 (3H, s) , 2.30-2.37 (111, in), 2.83 (111, dd), 3.02 (111, brs), 1-58 530.4 3.66-3 .74 (111, in), 3.87 (3H, s) , 3.88-3.94 (111, in), 4.16 (111, brs), 4.54 (1H, brs), 4.66-4.74 (1H, in), 4.97 (111, d), 5.46 (111, d), 6.44 (111, brd), 6.93 (111, d), 7.00 (1H, d), 7.22 (111, t), 7.78 (111, brd) No. M+1 1H-1\1111R
(obs) (CDC13) 1.13 (9H, s), 1.29 (3H, t), 1.76-1.90 (3H, in), 2.00 (1H, brd), 2.35 (111, dd), 2.83 (1H, dd) , 3.66-3.74 (111, 1-59 520.5 m), 3,87-3.94 (1H, in), 4.15 (111, s), 4.54 (1H, brs), 4.62-4.78 (111, m), 4.99 (111, d), 5.46 (111, d) , 6.92 (1H, brd) 7.33-7.46 (3H, in), 7.69 (1H, brdd), 7.77 (1H, brd) (CDC13) 1.12 (9H, s) , 1.26-1.31 (3H, m), 1.43-1.45 (111, in), 1.83 (311, brs) 1.99 (1H, brd), 2.06 (1H, m), 2.23 (3H, s) , 2.34 (111, brdd) , 2.83 (1H, brdd) 1-60 577.5 3.01 (1H, brs), 3.66-3.74 (111, m), 3.87-3.95 (111, m), 4.12-4.19 (111, m), 4.53 (1H, brs) , 4.65-4.76 (1H, rah 4.98 (1H, d), 5.45-5.47 (111, in), 7.08 (1H, brd) , 7.30 (111, m) , 7.37 (1H, brd) , 7.73-7.75 (111, in), 7.80-7.82 (211, m) (CDC13) 1.14 (911, s), 1.22-1.30 (6H, m), 1.54-1.57 (111, in), 1.77-1.85 (3H, m), 1.97 (1H, d), 2.30-2.45 (3H, m), 2.75-2.84 (1H, m), 3.00 (1H, s), 3.63-1-61 591.5 3.72 (1H, in), 3.84-3.93 (1H, in), 4.10-4.16 (111, in), 4.51 (111, s), 4.64-4.71 (111, in), 4.96 (111, d), 5.45 (1H, d), 7.05 (111, d), 7.26 (1H, s), 7.36 (111, d), 7.73 (111, d), 7.80 (111, d), 7.82 (1H, s) (CDC13) .1.15 (911, s), 1.3 (3H, t), 1.35 (611, d) , 1.4-1.55 (3H, in), 1.8-1.95 (3H, in), 2.0-2.1 (1H, m), 2.3-2.4 (111, in), 2.65-2.75 (111, m), 2.8-2.9 1-62 605.6 (111, in), 3.05 (111, s), 3 .7-3 .8 (1H, m), 3.9-4.0 (1H, in), 4.2 (111, s), 4.55 (111, s), 4.7-4.8 (1H, m), 5.0 (1H, d), 5.5 (111, d) , 6.6 (111, d) , 7.3-7.45 (211, m), 7.75 (1H, d), 7.85 (111, s), 8.55 (1H, d) No.. 111+1 311-MMR
(obs) (CDC13) 1.13 (9H, s), 1.31 (3H, t), 1.42-1.48 (1H, m), 1.56 (1H, brs), 1.77-1.83 (3H, m), 1.99 (1H, brd), 2.35 (1H, dd), 2.83 (1E, dd), 3.01 (1H, 1-63 534.4 brs), 3.67-3.76 (111, m), 3.88-3.99 (4H, m), 4.14 (1H, brs) , 4.52 (IH, brs), 4.65-4.73 (1H, m), 5.00 (1H, dd), 5.47 (1H, d), 7.10-7.21 (2H, m), 7.34-7.39 (1H, m), 7.56-7.61 (1H, m), 7.89 (1H, d) (CDC13) 1.03 (3H, d), 1.10 (3H, d), 1.32 (3H, t), 1.50 (1H, m), 1.59 (1H, m), 1.812-1.84 (31-I, m), 2.0 (1H, m), 2.15 (1H, m), 2.36 (1H, m), 2.83 (1H, 1-64 520.5 m), 3.02 (1H, br s), 3.69 (1H, m), 3.90-3.95 (4H, m), 4.13 (111, br s), 4.40 (111, br s), 4.67 (1H, m), 4.97 (1H, m), 5.47 (1H, d), 7.12-7.21 (2H, m), 7.28 (1H, m), 7.59 (IH, m), 7.80 (1H, m) (DMSO) 0.91-2.40 (23H, m), 2.95-3.40 (2H, m), 3.51-3.81 (5H, m), 4.00-4.71 1-65 530-9 (3H, m), 5.29 (IH, m), 6.80 (IH, d), 7.00 (IH, d), 7.19 (1H, t), 7.94 (1H, d), 8.48 (1H, d) (DMS ) 0.95-1.20 (12H, m), 1.24-1.40 (2H, m), 1.41-2.40 (6H, m), 3.05 (1H, 1-66 522.8 m), 3.50-3.80 (3H, m), 4.15 (IH, m), 4.60 (IH, m), 4.70 (IH, d), 5.30 (1H, s), 7.28-7.50 (4H, m), 8.35 (1H, d), 8.48 (1H, d) (CDC13) 5 1.10 (9H, s), 1.26-1.33 (3H, m), 1.43-1.45 (1H, m), 1.74-1.83 (2H, m), 2.01 (1H, brd) , 2.06 (1H, m), 2.30 (3H, s), 2.37 (11-3, brdd), 2.85 (1H, 1_67 577.5 brdd), 2.99 (1H, brs), 3.69-3.76 (1H, m), 3.89-3.97 (1H, m), 4.11-4.31 (2H, m), 4.53 (IH, brs) , 4.65-4.76 (1H, m), 4.95 (1H, d), 5.45-5.47 (1H, m), 6.75 (1H, brd), 7.67-7.69 (2H, m), 7.78 (1H, brs), 7.92 (1H, m) , 8.55 (1H, brd) o. M+1 111¨NISR
(obs) (CDC13) 1.10 (9H, s), 1.26-1.33 (3H, m), 1.43-1.45 (1H, in), 1.74-1.83 (2H, m), 2.01 (1H, brd), 2.06 (1H, m), 2.30 (3H, s), 2.37 (1H, lordd), 2.85 (1H, 1_68 577.5 brdd), 2.99 (1H, brs) , 3.69-3.76 (IH, m), 3.89-3.97 (1H, in), 4.11-4.31 (211, m), 4.53 (111, brs), 4.65-4.76 (1H, m), 4.95 (111, d), 5.45-5.47 (1H, m), 6.75 (111, brd), 7.67-7.69 (2H, m), 7.78 (1H, brs), 7.92 (111, m), 8.55 (1H, brd) (CDC13) 1.10 (9H, s), 1.26-1.33 (6H, m), 1.42-1.16 (111, in), 1.55-1.83 (411, m), 2.01 (111, brd), 2.36 (111, dd), 2.53 (2H, q), 2.83 (1H, cad), 2.99 (111, brs), 1-69 591.5 3.69-3.76 (111, m), 3.89-3.96 (1H, m), 4.11 (111, s), 4.53 (IH, brs), 4.66-4.77 (1H, m), 4.95 (IH, (a), 5.48 (1H, d), 6.76 (111, d), 7.67-7.74 (2H, m), 8.80 (1H, s), 7.90 (111, (a), 8.58 (IH, d) (CDC13) 1.12 (911, s), 1.23-1.30 (3H, m), 1.36-1.41 (111, in), 1.73-1.84 (3H, m), 1.98-2.03 (111, In), 2.33-2.41 (111, m), 2.75-2.83 (IH, in), 2.96 (1H, brs), 1-70 537.4 3.65-3.73 (1H, m), 3.84-3.93 (111, m), 4.11 (1H, brs), 4.56 (111, s), 4.63-4.71 (111, m), 4.96-4.99 (111, m), 5.43-5.46 (111, m). 7.64-7.72 (2H, m), 7.79-7.87 (3H, m), 8.48-8.52 (111, m), 8.90 (111, brd), 9.51 (111, d) (CDC13) 1.09 (911, s), 1.32 (311, t), 1.41-1.71 (5H, m), 1.76-1.87 (3H, m), 2.00 (111, brd), 2.37 (1H, dd), 2.83 (111, dd), 2.98 (IH, brs), 3.68-3.77 1-71 535.6 (111, m), 3.89-3.97 (111, m), 4.11 (111, s), 4.54 (111, brs), 4.67-4.74 (111, 111), 4.95 (1H, d), 5.48 (111, d), 6.64 (111, brd), 6.78 (IH, d), 7.54 (111, dd), 7.71 (1H, brd), 7.78 (1H, d) =
No. 14+1 111-111v1R
(obs) _ (CDC13) 1.05 (3H, d), 1.15 (3H, d), 1.35 (3H, t), 1.5-1.6 (1H, m), 1.6-1.7 (1H, m), 1.8-1.9 (2H, s), 2.0-2.05 (1H, m), 2.15-2.25 (1H, m), 2.35-2.45 (1H, 1-72 521.5 m), 2.8-2.9 (1H, m), 2.95 (1H, s), 3.7-3.8 (1H, m), 3.9-4.0 (1H, m), 4.1 (1H, s) , 4.45 (3H, s), 4.7-4.8 (1H, in), 4.9-4.95 (1H, m), 5.55 (1H, d), 6.7 (111, d), 6.85 (1H, d), 7.65 (1H, d), 7.75 (1H, d), 7.82 ( 1H, s) (CDC13 ) 1.14 (9H, s), 1.25 (3H, t), 1.40-1.46 (1H, m), 1.77-1.89 (3H, m), 1.98-2.02 (1H, m), 2.34 (1H, dd), 2.99-3.05 (1H, m), 3.62-3.69 (1H, m), 3.83-1-73 537.4 3.91 (1H, m), 4.12 (1H, s), 4.29-4.34 (1H, ra), 4.59 (1H, s), 4.99 (1H, d), 5.38 (1H, s), 7.67-7.76 (2H, m), 7.86 (2H, dd), 8.13 (1H, d), 8.56 (1H, d), 8.96 (1H, d), 9.56 (1H, d) Example 1I-1 (S, S, S) - (3S)- ( {1- (2S)- ( 3 -Methoxy-2-methyl-benzoylamino) -3-methyl-butyryll-pyrrolidine- (2S) -c arbonyl )-amino)-4-oxo-butyric acid .-o o * OH
[01771 Method I
(S, S. 5, R) -1- ( 2 S) -(3-methoxy-2-methyl-benzoylamino)-3-methyl-butyry11-pyrrolidine-(2S)-carboxylic acid [ (2R) -ethoxy-5-oxo-tetrahydro-furan- (3S)-yli-amide (97.6mg, 0.20mmol) was dissolved in a mixture of 2M HC1 (2m1) and MeCN (2m1). The reaction mixture was stirred at room temperature for 2.5 hours. The resulting crude mixture was diluted with Et0Ac and washed with water. The aqueous layer was extracted twice with Et0Ac. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated in =
vacuo . The residue was co-evaporated with DCM/Petrol to afford the title compound as a white solid (81.3mg, 88%
yield) .
[01783 Compounds of formula 11-2 to 11-61 have been prepared by methods substantially similar to those described in Example 11-1.
Example II-2 (S, S, S) - (3S) - ( {1- [ (2S) - (2-Chloro-benzoylamino) -3-methyl-butyry1]-pyrrolidine- (25)-carbony1)-amino)-4-oxo-butyric acid a 0 Example II-3 (S, S, S) - (3S) - ( (1- [3-Methyl- (25) - (2-methyl-benzoylamino ) -butyry1]-pyrrolidine-(25)-carbonyll-amino)-4-oxo-butyric acid * rcl NT 4 or 0H
Example II-4 (S, S, S) - (35) - ( (1- [ (2S)- ( 2 -methoxy-benzoylamino ) -3 -methyl-butyryl ] -pyrrolidine- (28) -carbonyl} -amino) -4- oxo-butyri c acid \o 0 4f el# N? 4 OH
=
Exampl e II-5 (5,3, S) - (3S) - ( {1- [3-Methyl- (2S) - (2 - trifl-uoromethoxy-benzoylamino ) -butyryl] -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyri c acid F F
F)I=0 0 * X NT OH
Example II-6 (S, S, S) - (33)- ( {1- [ (2S) - ( 3 -Hydroxy-2-methyl-benzoylamino ) -3-methyl-butyryl ] -pyrrol i dine- (23) -carbonyl} -amino) -4-oxo-butyric acid *O J.
OH
Example II- 7 (3, 3, S) - ( 3 S) - ({l- [ (2S) - (3 -Amino-2-methyl -benzoylamino) -3-methyl-butyryl ] -pyrrolidine- (2S) -carbonyl} -amino) - 4- oxo-butyric acid H2N o =111 OH
O
Example 11-8 (S,S,S)-(32)-({1-[(2S)-(2,3-Dichloro-benzoylamino)-3-methyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid u 0 ço hi? KOH
Example 11-9 (S, S, S) - (3S) - ( {1- [ (2S) - (2-Chloro-3-trifluoromethyl-benzoylamino) -3 -methyl -butyryl ] -pyrrolidine- (2S) - c arbonyll amino ) -4- oxo-butyri c acid fl* N
.(rOH
Example II-10 (S, S, S) - (3S) - (U.- [ ( 2 S) (3-Chloro-2-methyl-benzoylamino) -3 -methyl -butyryl ] -pyrrolidine- (2S) -carbonyl } -amino) -4-oxo-butyric acid ci o 0 = NyoH
o o Example II-11 (S, S, S) (3S) - ( {1- [ (2S) - (2, 4-Dichloro-benzoylam no) -3-methyl-butyryl ] -pyrrol dine- (2S) -carbonyl} -amino) -4-oxo-butyric acid NIT.N?OH
CI
Example 11-12 (s, s, s) - (3s) ( {1- [ (2S) - (2, 5 -Dichloro-benzoylamino ) -3 -methyl-butyryl ] -pyrrol i dine- ( 2 S) - carbonyl } -amino) -4-oxo-butyric acid ci r.N0 H
Example 11-13 (S, S, S) (3S) - ( {1- [ (2S) - (2,6-Dichloro-benzoylamin.o) -3-methyl-butyryl ] -pyrrolidin.e- (2S) -carbonyl}-amino ) -4-oxo -butyric acid lit a N:).141 .40H
Example 11-14 (S, S, S) - (3S) - ( {1- [ (2S) - (2,6-Methyl-benzoylamino) -3-methyl-butyryl ] -pyrrolidine- (2S) -carbonyl ) -amino) -4-oxo-butyric acid NA)or ,Li(;)OH
Example 11-15 (S, S, S) - (3S) - [ (1- {3-Methyl- (2S) [ (2-methyl-pyridine-3-carbonyl ) -amino] -butyryll-pyrrolidine- (2S) -carbonyl ) -amino] -4 -oxo-butyric acid =
0 4, OH
Example I1-16 (S, S, 5)- (3S) - [ (1- {3-Methyl- (25)- [ ( 4-methyl-pyridine-3-carbonyl ) -amino] -butyryl) -pyrrolidine- (28) -carbonyl) -amino] -4-oxo-butyric acid 61(0 )r 1161(0F1 Example I1-17 (3,3, S) - (33) - [ (1- {3-Methyl- (2S) - [ (3 -methyl-thiophene-2 -carbonyl) -amino] -butyryll-pyrrolidine- (2S) -carbonyl) -amino] -4-oxo-butyric acid 6-1)&iµ)criNT
S H KOH
Example 11-18 (S, S, S) (3S) - [ (1- ( (2.9) - [ (2,3-Dichloro-pyridine-4-carbonyl) -amino] -3 -methyl-butyryl )-pyrrolidin.e- (23) -carbonyl) -amino] -4-oxo-butyric acid a a NI1 HN)cNi Example 11-19.
(S, S, S) - (3S) - [ (1-{ (2.5`) - [ (3,5-Dichloro-pyridine-4-carbonyl ) -amino] -3 -methyl-butyryll -pyrrol id.ine- (2S) -carbonyl) -amino] -4-oxo-butyric acid a Example 11-20 (S, S, S) - (3S) - ( {1- [ (2.5') - (3-Methoxy-2-methyl-benzoylamirio) -3,3-dimethyl-butyryl ] -pyrrolidine- (2S) - carbonyl} -amino) -4- oxo-butyric acid _ *OH
Example 11-21 (S,S,S)-4-0xo- (3S) - ( {1- [4,4,4-trifluoro- (2S)- (2-methy1-3 -methww-benzoylamino ) -butyryl] -pyrrolidine- (2S) -carbonyl }-amino) -butyric acid -0 o CF
Example 11-22 (S, S, S) - (3S) - ( {1- [ (2S) - (5-Methoxy-2-methyl-benzoylamino) -3 methyl -butyryl ] -pyrrolidine- (2S) - carbonyl} -amino) -4 - oxo-butyri c acid =OH
" o Example 11-23 (S, S, S) - (3S) - ({l- [ (2S) - ( 3 -Methoxy-2-methyl-ben.zoylamino) -3 -thiazol-4-yl-propionyl ] -pyrrolidine- (2S) -carbonyl} -amino ) -4-oxo-butyri c acid Me0 0 Example 11-24 (S,S, S)- (3S)- ( {1- [ (2S) - (2-Chloro-benzoylamino) -4,4,4-tri f luoro-butyryl ] -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyric acid CI o CF3 =
N_cor o OH
Example II-25 (S, S, S) - (3S) - (Cl- (2S) - (2-Ch1oro-benzoylamino) -3 -thiazo1-4-y1¨
propionyl ] -pyrrolidine- (2S) -carbonyl) -amino) -4-oxo-butyric acid CI o Example I1- 2 6 (S. S, S) ( 3 S ) (C1- [3, 3 -Dimethyl- (2S) - (2-methyl-benzoylamino) -butyryl] -pyrrolidine- (2S) -carbonyl ) -amino) -4 -oxo-butyric acid NIc"? jOH
Example II-27 (S, S, S) - (3S) ({l- [3-Methyl- (2S) - (2-trifluoromethyl-benzoylamino) -butyryl ] -pyrrolidine- (2S) -carbonyl -amino) -4-oxo-butyric acid OH
Example 11-28 ( 5, S, S) - ( 3 S) ( (1- [ ( 2S ) ( 2 -chaoro-benzoylamino ) -3, 3 -dimethyl-butyryl ] -pyrrolidine- (2S) -carbonyl) -amino) - 4 -oxo-butyric acid Cl o = N? 0H
Example 11-29 (S, S, S) - (3S) - ( {1- [3,3-Dimethyl- (2S) - (2-trifluoromethyl-benzoylamino) -butyryl I -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyric acid OH
o Example 11-30 (S, S, S) - (3S) - ( {1- [ (2S ) - (2-Chloro-3-methoxy-benzoylamino) -3,3-dimethyl -butyryl -p-yrrolidine- (2S) -carbonyl} -amino) -4- oxo-butyri c acid Me0 [1-r-Nii.OH
0 Nfl = 0 Example II-31 (S, S, S) - (3S) - ({l- [ (2S) - (2-Fluoro-3-metho3cy-benzoylamino) -3,3 -dimethyl-butyryl -pyrrolidine- (2S) -carbonyl) -amino) -4-oxo-butyric acid Me0 NNAOil 0 Nfl = 0 Example 11-32 (S, S, S) - (3S) - ( {1- [ (2S) - (2-Chloro-3-trifliaoromethoxy-benzoylamino) -3,3 -dimethyl-butyryl ) -pyrrolidine- (2S) -carbonyl} -amino) -4 -oxo-butyri c acid F3C' 410 N N
H CJH
o N
=
Example 11-33 ($,S,S)-(3S)-((1-[(2S)-(2-Chloro-3-cyclopropyloxy-benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid VD.H H
Example 11-34 (S,S,S)-(3S)-({1-[(2S)-(2-Chloro-3-methyl -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid CI 0.4, * =
OH
= 0 Example 11-35 (S,S,S)-(3S)-({1-[(2S)-(2-chloro-3-methoxy -benzoylamino)-3-methyl-butyry11-pyrrolidine-(2S)-carbonyll-amino)-4-oxo-butyric acid 1 0: 4" 0 OH
Example 11-36 (S,S,S)-(3S)-({1-[(2S)-(2-Chloro-3-ethyl -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1)7amino)-4-oxo-butyric acid * [siNNIT kr OH
= 0 =
Example 11-37 (S, S, S) ( 3 S) - ( {1- [ (2S) - ( 2 -chloro-4-methoxy -benz oylamino) -3-methyl-butyryll-pyrrolidine- (2S) -carbonyl} -amino ) -4-oxo-butyric acid C'0 '0* NI? drOH
JH
Example 11-38 (S, S, S) - ( 3 3) (C1- [ (2S) - ( 2 -Chl oro- 3 -cyclopropylmathoxy -benzoylamino ) -3, 3 -dimethyl -butyryl -pyrrolidine- (2S) -carbonyl} -amino) -4 - oxo -butyric acid * I OH
= 0 Example 11-39 (S, S, S) - (3S) - ( (1- [ (2S ) - (2-Chloro-3-hydroxy -ben.oylamino) -3,3 -dimethyl-butyryl] -pyrrolidine- (25) -carbonyl} -amino) -4- oxo-butyri c acid OH
= 0 Example 11-40 (S, S,S)- (3S) - ( {I- [ (2S) - (2-chloro-4-acetamido -bnzoylamino) -3-methyl-butyryl -pyrro 1 i dine- ( 2S) -carbonyl ) -aminc)) -4-oxo-butyric acid HN 400 11-110.1\11i.,OH
= 0 =
, Example II-41 (S, S, S) - (35) - ( {1- [ (2S) - (2-Chloro-3-acetamido -benzoylamino) 3,3 -dimethyl-butyryl ] -pyrrolidin.e- (2S) -carbonyl) -amino) -4-oxo-butyric acid OH
Example 11-42 (S, S, S) - (3S) - ( {1- [ (2S) - (2-methyl -3 -acetamido -benzoylamino) -3,3 -dimethyl -butyryl ] -pyrrolidine- (2S) - carbonyl} -amino ) -4-oxo-butyric acid (21 VNriii Example 11-43 (S, S, S)- (3S) - ( {1- [ (2S) - (2-chloro -4-acetamido -benzoylamino) 3,3 -dimethyl -butyryl ] -pyrrolidine- (2S) -carbonyl) -amino) -4 - oxo-butyric acid HN 11*
ONff Example 11-44 S, S, S) - (3S) - ( {1- [ (2S) - (2- fluor -4-acetamido -benzoylamino) -3,3 -dimethyl -butyryl -pyrrolidine- (2S) -carbonyl}--amino) -4-oxo-butyric acid =
H N HN
= 0 Example II-45 (S, S, S) (3S) - ( {1- [ (2S) - (2-fluoro -4-acetamido -ben.zoylamino) 3 -methyl-butyryl ] -pyrrolidine- (2S) -carbonyl} ¨amino) -4- oxo-butyric acid HN IXN?
= 0 Example 11-46 (S,S,S)- (3S) - ( {1- [ (2S) - (2-chloro -4-isopropyloxy -benzoylamino ) -3 -methyl-butyryl ] -pyrrolidine- (2S) - carbony11-amino ) -4-oxo-butyric acid CI \Ir.. .
. =
* LrOH =
Example 11-47 (S, S, S) - (3S) ( {1- [ (2S) - (2-chloro -4-hydroxy -benzoylamino) -3,3-dimethyl-butyryl] -pyrrolidine- (2S) -carbonyl} -amino) -4-oxo-butyric acid CI
HO* N.N?
= 0 Example 11-48 (S, S, S) - (3S) - ( {1- [ (2S) - (2- chloro -4-methoxymethyl -benzoylamino ) -3, 3 -dimethyl-butyryl] -pyrrolid.ine- (2S) -carbonyl} -amino) -4- oxo -butyric acid = -128-CI
41*OHH
Example 11-49 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -4-isobutyrylamido -benzoylamino)-3,3-dimethyl-butyryll-pyrrolidine-(2S)-carbonyll-amino)-4-oxo-butyric acid Cl 0 HN 410 11\-11,..0H
Example 11-50 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -4-acetamido -benzoylamino)-3-cyclohexyll-pyrrolidine-(2S)-carbonyll-amino)-4-oxo-butyric acid HN
Example 11-51 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -4-methoxycarbonylamino -benzoylamino)-3,3-dimethyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid Cl 0 4, HN410 OrifoH
00 ON( Example 11-52 (S,S,S)-(3S)-({1-[(2S)-(2-chloro -3-phenoxy -benzoylamino)-3,3-dimethyl-butyryll-pyrrolidine-(2S)-carbony1)-amino)-4-oxo-butyric acid o 0 jH
Example 11-53 (S,S,S)-(3S)-((1-[(2S)-(2-chloro -6-amino -benzoylamino)-3-methyl-butyry1]-pyrrolidine-(2S)-carbony1}-amino)-4-oxo-butyric acid OH
Example 11-54 (S,S,S)-(3S)-({1-[(2S)-(2-chloro-benzoylamino)-3,3-dimethyl-butyryli-piperidine-(2S)-carbonyl)-amino)-4-oxo-butyric acid C'0 OH
Example 1-55 (3S)-(f2-[(2S)-(3-Methoxy-2-methyl-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyll-amino)-4-oxo-butyric acid cH3 0 iojCirl 40H
Example 11-56 (3S)-((2-[(2S)-(2-Chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyl}-amino)-4-oxo-butyric acid =
a 0)Cirl.., OH
0 0 m "
Example 11-57 (3S)-({2-[(2S)-(4-Acetylamino-2-chloro-benzoylamino)-3,3-dimethyl-butyry1)-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyl}-amino)-4-oxo-butyric acid o %Criµ7 4 F4H
Example 11-58 (3S)-({2-[(2S)-(2-Chloro-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry11-2-(18,4R)-aza-bicyclo[2.2.1]heptane-(38)-carbonyl}-amino)-4-oxo-butyric acid a o ,,it 100 l....OH
" 0 Example 11-59 (3S)-({2-[(2S)-(2-Chloro-3-isobutyrylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyl)-amino)-4-oxo-butyric acid H CI 0 jcril " o Example 11-60 (3S)-((2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-313-dimethyl-butyry11-2-(13,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1)-amino)-4-oxo-butyric acid =
0 0 N. j(OH
Example 11-61 (3S)-({2-[(2S)-(2-Fluoro-3-methoxy-benzoylamino)-3-methyl-butyrya]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1)-amino)-4-oxo-butyric acid X.Tr47 õ(OH
Example 11-62 (3S)-([2-[(2S)-(4-Acetylamino-3-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid " o a Example 11-63 (3S)-((2-[(2S)-(3-Chlor0-4-propionylamino-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid jt. X17 40H
" o a =
Example 11-64 (3S)-((2-[(2S)-(Isoquinolin-l-ylcarbonylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbonyll-amino)-4-oxo-butyric acid OH
H
Example 11-65 (3S)-(f2-[(2S)-(4-Amino-3-chloro-benzoylamino)-3,3-dimethyl-butyry1]-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid OH
Example 11-66 (3S)-({2-[(2S)-(4-Amino-3-chloro-benzoylamino)-3-methyl-butyry1)-2-(1S,4R)-aza-bicyclo[2.2.1]heptane-(3S)-carbony1}-amino)-4-oxo-butyric acid H2N o 0 N
a N o [01791 The characterization data for compounds 11-1 to 11-66 is summarized in Table 4 below and includes HPLC, LC/MS
(observed) and IH NMR data. IH NMR data was obtained at 400 MHz, and was found to be consistent with structure.
=
Table 4. Characterization Data for Selected Compounds of Formula II (According to Compound Number) 114.1 No. 1H-NMR
(obs) (DMSO-d6) 0.82-0.98 (611, m), 1.89-2.07 (511, m), 2.10 (3H, s), 3.0 (1H, m), 3.63 (111, m), 3.79 (3H, s), 3.88 (1H, II-1 462.1 m), 4.00 (1H, m), 4.25 (111, m), 4.40-4.44 (211, m), 5.45 (1H, br s), 6.83 (1H, d), 7.00 (1H, d), 7.19 (111, t), 7.77 (1H, br s), 8.32-8.50 (211, m) (DMSO-d6) 0.95-0.99 (6H, m), 1.87-2.09 (5H, m), 3.00 (111, m), 3.64 (111, m), 11-2 452.0 3.85 (111, m), 4.04 (1H, m), 4.25 (111, m), 4.40 (1H, m), 4.47 (1H, m), 5.45 (1H, m), 7.34-7.49 (4H, m), 7.78 (1H, m), 8.40 (1H, m), 8.64 (111, m) (DMSO-d6) 0.94-0.99 (GH, m), 1.87-2.09 (5H, m), 2.30 (3H, s), 2.90 (1H, m), 11-3 432.1 3.64 (1H, m), 3.88 (111, m), 4.03 (1H, m), 4.30 J111, m), 4.44 (1H, m), 5.45 (111, m), 7.19-7.33 (411, m), 7.77 (1H, br s), 8.35-8.40 (2H, m) (CD30D) 1.05-1.18 (611, m), 2.00-2.30 (5H, m), 2.52-2.75 (2H, m), 3.66-3.83 (1H, m), 3.92-4.03 (111, m), 4.26-4.35 11-4 448.0 (1H, m), 4.45-4.55 (111, m), 4.61-4.70 (111, m), 4.78-4.85 (1H, m), 7.13 (1H, t), 7.21 (111, d), 7.57 (111, t), 8.00 (1H, d), 8.69 (1H, d) (CD30D) 0.98-1.15 (611, m), 1.95-2.26 (5H, m), 2.54-2.76 (211, m), 3.73-3.84 11-5 502.0 (1H, m), 3.99-4.06 (111, m), 4.21-4.32 (1H, m), 4.45-4.53 (111, m), 4.60-4.70 (2H, m), 7.30-4.47 (2H, m), 7.54-7.64 (2H, m) (DMSO-d6) 0.92-0.98 (611, m), 1.85-2.04 (5H, m), 2.07 (3H, s), 3.00 (1H, m), 3.63 (111, m), 3.87 (111, m), 4.03 (111, 11-6 448.1 ml 4.25 (111, m), 4.41 (111, m), 5.45 (1H, m), 6.68 (111, m), 6.82 (111, m), 7.01 (1H, m), 7.81 (111, m), 8.25 (111, d), 8.40 (1H, m), 9.5 (1H, m) =
M+1 No. 111-NMR.
(obs) (CD30D) 1.02-1.18 (6H, m), 1.88-2.28 (5H, m), 2.39 (3H, s), 2.50-2.78 (2H, 11-7 447.0 m), 3.75-3.83 (1H, m), 4.00-4.10 (1H, m), 4.21-4.32 (1H, m), 4.45-4.52 (111, m), 4.60-4.65 (2H, m), 7.39-7.54 (3H, m) (DMSO-d6) 0.94-0.99 (6H, m), 1.71-2.12 (4H, m), 2.33 (1H, br s), 2.67 (1H, br s), 2.94-3.07 (IH, m), 3.61-3.69 (1H, 11-8 446.0 m), 3.82-3.87 (111, m), 4.03-4.10 (IH, m), 4.19-4.28 (1H, m), 4.30-4.43 (2H, m), 5.42-5.47 (1H, m), 7.28-7.30 (1H, m), 7.37-7.40 (1H, m), 7.68-7.82 (2H, m), 8.77 (1H, d) (DMSO-d6) 0.94-0.99 (6H, m), 1.86-2.09 (5H, m), 3.00 (1H, m), 3.65 (Iii, m), 3.84 (1H, m), 4.05 (1H, m), 4.24 (IH, 11-9 519.9 m), 4.40 (IH, m), 4.51 (111, m), 5.45 (1H, m), 7.57-7.62 (2H, m), 7.77 (1H, d), 7.90 (1H, m), 8.40 (1H, d), 8.87 (1H, d) (DMSO-d6) 0.93-0.99 (6H, 2 x d), 1.77-2.19 (5H, m), 2.29 (3H, s), 2.97 (IH, br s), 3.62-3.65 (1H, m), 3.85-3.88 II-10 466.0 (IH, m), 4.00-4.32 (2H, br m), 4.41-4.53 (2H, m), 5.45 (1h, br s), 7.18-7.27 (2H, m), 7.45-7.50 (1H, m), 7,85 (1h, br d), 8.41 (1H, br d), 8.57 (1H, d) (DMSO-d5) 0.82-0.86 (3H, m), 0.93-0.98 (3H, m), 1.87-2.08 (5H, m), 3.00 (1H, m), 3.64 (111, m), 3.82 (1H, m), 4.10 II-11 485.9 (1H, m), 4.30 (1H, m), 4.45 (1H, m), 4.47 (1H, m), 5.44 (1H, d), 7.37 (IH, m), 7.47 (1H, m), 7.65 (1H, m), 7.77 (1H, m), 8.40 (1H, m), 8.72 (IF!, m) (DMSO-d6) 0.94-0.99 (61!, m), 1.91-2.09 (51!, m), 3.00 (1H, m), 3.64 (1H, m), 3.83 (11!, m), 4.03 (11!, m), 4.20 (11!, 11-12 485.9 m), 4.40 (11!, m), 4.47 (IH, m), 5.45 (11!, m), 7.37 (1H, s), 7.50-7.52 (21!, m), 7.78 (1H, m), 8.44 (11!, m), 8.79 (1H, m) . -=
14+1 No. 111-10R
(obs) (DMSO-d0 0.82-0.86 (3H, m), 0.92-0.99 (3H, m), 1.80-1.87 (2H, m), 1.99-2.02 (4H, m), 2.48 (0.5 H, m), 2.95 (0.5 H, 11-13 486.3 m), 3.51 (1H, m), 3.80-4.56 (4H, m), 5.00 and 5.47 (1H, 2 x m), 7.37-7.48 (3H, m), 7.76-8.32 (1H, m), 8.95-9.39 (1H, 3 x dd) (DMSO-d0 0.93-0.99 (6H, m), 1.80-2.09 (5H, m), 2.17 (6H, d), 2.95 (1H, br s), 3.63-3.65 (1H, m), 3.96-3.99 (1H, m), 11-14 446.0 4.10 (1H, br s), 4.30 (1H, br s), 4.44 (1H, t), 5.48 (1H, br s), 7.00 (2H, d), 7.14 (1H, t), 7.78 (IH, br s), 8.50 (1H, br s), 8.55 (1H, d) (DMSO-d0 0.91-1.02 (6H, m), 1.80-2.20 (5H, m), 2.66-2.68 (3H, s), 3.00 (1H, m), 3.62-3.85 (3H, m), 4.10 (1H, m), 11-15 433.1 4.24 (1H, m), 4.51 (1H, m), 5.72 (IH, m), 7.73-7.76 (2H, m), 8.19 (IH, m), 8.52 (1H, m), 8.75 (1H, d), 8.90 (1H, m) (DMSO-d0 0.9-1.05 (6H, m), 1.8-2.2 (6H, m), 2.3-2.4 (111, m), 2.7-2.75 (1H, m), 2.9-3.0 (1H, m), 3.65-3.75 (1H, m), ' 11-16 433.1 3.8_3.9 (111, ) 4.1-4.15 (1H, m), 4.3-4.4 (1H, m), 4.45-4.65 (111, m), 7.8-7.9 (1H, m), 8.7-8.8 (2H, d), 8.9.8.95 (1H, (DmS0-d6) 0.83-0.99 (6H, m), 1.80-2.20 (5H, m), 2.40 (3H, s), 3.00 (1H, m), 3.61 (1H, m), 3.81 (IH, m), 4.10 (1H, 11-17 438.0 m), 4.25 (1H, m), 4.42-4.46 (2H, m), 5,44 (1H, br s), 6.97 (1H, m), ,7.34 (1H, m), 7.59 (1H, m), 7.81 (1H, m), 8.49 (1H, m) (DMSO-d6) 0.92-1.00 (6H, m), 1.75-2.08 (5H, m), 2.30-2.34 (1H, m), 2.99 (IH, dd), 3.62-3.67 (1H, m), 3.78-3.82 (1H, 11-18 487.0 m), 3.78-3.82 (1H, m), 4.05-4.26 (1H, m), 4.38-4.54 (2H, m), 5.44-5.72 (1H, m), 7.37-7.41 (1H, m), 8.41-8.43 (2H, m), 8.97-9.00 (1H, d) _ .
=
No. 111-4ata (obs) (DMSO-dd 0.94-1.00 (611, m), 1.77-2.15 (5H, m), 3.02 (111, dd), 3.61-3.70 (111, 11-19 487.0 m), 3.80-3.90 (111, m), 4.03-4.08 (111, m), 4.52-4.56 (1H, m), 4.95 (2H, br s), 5.45 (111, s), 8.42 (111, d), 8.67 (211, s), 9.17 (111, d) (DMSO-dd 0.91-1.11 (9H, m), 1.70-2.14 (7H, m), 2.31 (111, m), 3.01 (1H, m), 11-20 476.4 3.50-3.97 (5H, m), 4.00-4.62 (311, m), ,5.50 (111, m), 6.77 (111, d), 7.00 (111, d), 7.18 (1H, dd), 7.50-8.50 (311, m) (DMSO-dd 1.80-2.00 (311, m), 2.11 (411, overlapping s and m), 2.60-2.80 (2H, m), 3.64-3.69 (1H, m), 3.80 (3H, s), 11-21 502.1 4.10 (1H, vbrs), 4.30 (1H, vbrs), 5.00 (111, m), 6.86 (1H, d), 7.03 (1H, d), 7.22 (111, t), 8.45 (1H, vbrs), 8.81 (1H, d) (DMSO-dd 0.93-1.00 (611, m), 1.70-2.15 (511, m), 2.22 (311, s), 2.33 (111, d), 2.99 (111, dd), 3.60-3.65 (211, m), 3.74 11-22 462.4 (3H, s), 4.04-4.08 (1H, m), 4.21-4.27 (1H, m), 4.40-4.58 (2H, m), 5.46 (1H, , brd d), 6.78-6.81 (111, m), 6.85-6.91 (1H, m), 7.09-7.14 (111, m), 8.37 (211, 2 x brd d) (DMSO-dd 1.77-2.19 (511, m), 2.95-3.28 (311, m), 3.60 (1H, brd d), 3.71-3.78 (411, m), 4.10-4.42 (6H, m), 4.97 (1H, 11-23 517.0 brd s), 5.45-72 (1H, m), 6.74 (111, d), 6.97 (111, d), 7.10-7.22 (111, m), 7.44 (111, m), 8.37-8.68 (2H, m), 9.05 (111, brd s) (DMSO-dd 1.75-1.98 (311, m), 2.08-2.13 (111, m), 2.64-2.77 (2H, m), 2.99 (0.511, dd), 3.63-3.73 (2H, m), 4.08 (0.511, 11-24 492.0 brt), 4.20 (0.5H, dd), 4.23-4.49 (3 multiplets, 1H total), 5.00-5.10 (1H, m), 5.42 (0.5H, s), 7.36-7.52 (411, m), 7.77 (111, m), 8.30 (0.511, d), 9.09 (1H, d) =
=
M+1 No. 11-1-4vima (ohs) (DMSO-d6) 1.79-1.96 (5H, m), 2.94-3.28 -(3H, m), 3.58 (1H, brd d), 3.73 (1H, 11-25 507.0 brd d), 4.04-4.59 (2H, m), 4.98-5.02 -(1h, m), 5.54-5.74 (2H, m), 7.26-7.46 (511, m), 8.43 (1H, d), 8.82 (1H, d), 9.39 (1H, brd s) (DMSO-d6) 1.05 (9H, s), 1.15 (3H, t), 1.8-2.1 (4H, m), 2.3 (3H, s), 2.4-2.5 (1H, m), 2.9-3.0 (1H, m), 3.7-3.75 (1H, 11-26 446.6 m), 3.8-3.85 (1H, m), 4.1-4.15 (0.5H, m), 4.25-4.3 (1H, m), 4.4-4.5 (0.5H, m), 4.7-4.75 (1H, m), 5.55-5.6 (1H, m), 7.2-7.4 (4H, m), 7.7-7.75 (1H, m), 8.1-8,15 (1H, m), 8.35-8.4 (1H, m) (DMSO-d0 0.95-1.05 (6H, m), 1.8-2.1 (4H, m), 2.4-2.5 (1H, m), 3.0-3.1 (1H, m), 3.7-3.75 (1H, m), 3.8-3.85 (1H, m), 11-27 486.5 4.1-4.15 (0.5H, m), 4.25-4.3 (1H, m), 4.4-4.5 (0.5H, m), 5.55-5.6 (1H, m), 7.4-7.45 (1H, m), 7.6-7.8 (3H, m), 8.4-8,45 (1H, m), 8.75-8.8 (1H, m) (CDC13) 1.11-1.16 (9H, m), 1.94-2.22 (4H, m), 2.38-2.50 (2H, m), 2.77-2.87 11-28 466.1 (1H, m), 3.71-3.79 (1H, m), 3.96-4.06 (1H, m), 4.56-4.67 (2H, m), 4.85-4.91 (1H, m), 6.99-7.02 (1H, .m), 7.28-7.45 (3H, m), 7.60-7.84 (2H, m) (CDC13) 1.07 (9H, s), 1.85-2.19 (2H, m), 2.37-2.40 (2H, m), 2.81-3.07 (1H, 11-29 500.2 m), 3.37 (1H, brs), 4.01 (1H, brs), 4.46-4.67 (2H, m), 4.87 (1H, d), 5.73 (1H, brs), 6.68 (1H, brs), 7.38-7.74 (5H, m) (CD30D) 1.15 (9H, s), 1.85-2.20 (4H, m), 2.46-2.72 (2H, m), 3.74-3.81 (1H, 11-30 496.2 m), 3.92 (3H, s), 3.93-4.03 (1H, m), 4.20-4.31 (1H, m), 4.45-4.52 (1H, m), 4.60-4.75 (1H, m), 4.83 (1H, s), 7.00 (1H, d), 7.15 (1H, d), 7.33 (1H, t) (DMSO-d5) 1.05 (9H, s), 1.8-2.1 (4H, m), 2.4-2.5 (1H, m), 3.75-3.8 (1H, m), 11-31 480.5 3.8-3.85 (1H, m), 3.9 (3H, s), 4.1-4.3 (1H, m), 4.7 (1H, d), 5.3-5.5 (0.5H, hr s), 7.1-7.3 (3H, m), 7.7-7.8 (1H, m), 8.0-8.1 (1H, m), 8.35-8.45 (1H, m) =
No. 111-NNR
(obs) (DMSO-d0 0.91-1.10 (9H, m), 1.70-2.15 (5H, m), 2.60-3.08 (1H, m), 3.60-3.90 11-32 550.3 (2H, m), 3.98-4.71 (3H, m), 5.40-5.80 (1H, m), 7.30-7.91 (3H, m), 8.30-8.80 (3H, m) (DMSO) 0.60-0.90 (4H, in, cyclopropyl CH2), 0.92-1.10 (9H, in, tBu), 1.71-2.21 (5H, in, CH2), 2.65-3.10 (1H, brm, CH2), 11-33 523.3 3.36-3.50 (1H, in, CH), 3.60-4.75 (6H, in, CH), 6.92 (1H, d, aryl H), 7.36 (1H, m, aryl H), 7.45 (1H, m, aryl H), 7.65-8,60 (3H, in, NH, OH) (DMSO) 0.99-1.10 (9H, in, tBu), 1.70-2,12 (5H, in, CH2), 2.35 (3H, s, CH3), 2.60-3.08 (1H, in, CH2), 3.58-3.87 (2H, 11-34 480-3 in, CH), 4.00-4.70 (3H, in, CH), 5.38-5,79 (111, in, CH), 7.12 (1H, d, aryl H), 7.24 (1H, in, aryl H), 7.38 (1H, m, aryl H), 7.69-8.55 (3H, in, NH, OH) CD3OD 1.01-1.15 (6H, m), 1.95-2.22 (5H, m), 2.48-2.69 (2H, m), 3.73-3.80 11-35 482 (1H, m), 4.92 (3H, s), 3.99-4.19 (1H, m), 4.20-4.30 (1H, m), 4.58-4.67 (2H, m), 7.00 (1H, d), 7.14 (1H, d), 7.31 (1H, t) (DMSO) 0.94-1.08 (9H,s, tBu), 1.19 (3H, t, CH3), 1.70-2.40 (5H, in, CH2), 2.60-3,08 (3H, in, CH2), 3.69 (1H, in, CH), 11-36 494.4 3.81 (1H, In, CH), 4.04-4.71 (3H, in, CH), 5.40-5.80 (1H, in, CH), 7.14 (1H, in, aryl H), 7.31 (IH, in, aryl H), 7.39 (1H, m, aryl H), 7.70-8.50 (3H, in, NH, OH) (DMSO) 0.9-1.0 (6H, m), 1.85-2.3 (4H, m), 3.0-3.1 (1H, m), 3.65-3.7 (1H, m), 3.78 (3H, s), 3.8-3.85 (1H, m), 4.1-11-37 482.5 4.15 (0.5H, m), 4.25-4.3 (0.5H, m), 4.5-4.55 (1H, m), 5.5-5.55 (1H, m), 6.93 (1H, d), 6.98 (1H, s), 7.35 (111, d), 7.75-7.8 (1H, m), 8.45 (1H, d) M+1 No.
(obs) (CD3OD ) 0.34-0.40 (2H, m), 0.60-0.67 (2H, m), 1.16 (911, s), 1.25-1.32 (1H, m), 1.93-2.22 (411, m), 2.50-2.66 (211, 21-38 536 m), 3.74-3.84 (1H, m), 3.91-4.03 (3H, m), 4.22-4.32 (1H, m), 4.45-4.54 (IH, m), 4.61-4,69 (111, m), 4.82 (111, d), 6.99 (111, d), 7.12 (111, d), 7.32 (111, t), 8.40 (1H, d) (CD3OD ) 1.12 (9H, s), 1.90-2.22 (411, in), 2.512.70 (211, in), 3.75-3.83 (1H, 1I-39 482 =m), 3.97-4.05 (1H, m), 4.23-4.30 (111, m), 4.46-4.54 (1H, m), 4.63-4.70 (111, m), 4.83 (111, d), 6.91 (111, d), 6.99 (111, d), 7.17 (1H,t), 8.36 (1H, d) (DMSO) 0.93-0.98 (611, m) 1.71-2.09 (1011, m), 2.35-2.45 (211, m), 3.61-3.64 (1H, m), 4.02-4.04 (1H, m), 4.06-4.35 "
11-40 509.3 (211, m), 4.43-4.46 (111, m), 7.33 (111, d), 7.43-7.46 (1H, m), 7.80 (111, brd s), 8.28-8.49 (2H, m), 10.25 (111, brd s) (DMSO) 0.95-1.08 (911, s, tBu), 1.70-2,38 (811, in, COCH3, CH2), 2.58-3.08 =
=
(1H, in, CH2), 3.65 (1H, in, CH), 3.82 11-41 523.3 (111, In, CHO), 3.95-4.69 (3H, in, CH), 5.40-5.60 (111, in, CH), 7.09 (1H, in, aryl H), 7.31 (1H, in, aryl H), 7.64-8,60 (411, in, aryl H, NH), 9.55 (1H, in, CH) (DMSO) 0.91-1.08 (911, s, tBu), 1.70-2,40 (11H, in, CH3, COCH3, CH2), 2.60-3,08 (111, m, C112), 3.66 (111, in, CH), 11-42 503.4 3.87 (111, in, CH), 4.00-4.65 (311, in, CH), 5.40-5.78 (1H, in, CH), 7.04 (111, in, aryl H), 7.18 (IH, in, aryl H), 7.38 (1H, in, aryl H)--, 7.65-7.88 (111, m, NH), 8.07-8.70 (211, in, NH), 9.34 (111, in, CH) (DMSO) 1.03 (9H, s), 1.71-2.00 (3H, m), 2.07 (311, s), 2.55-2.73 (111, m), 2.97 (111, dd), 3.60-3.67 (111, m), 3.75-3.82 (1H, m), 3.98-4.04 (1H, m), 4.19-4.24 21-43 523.3 (1H, m), 4.37-4.45 (111, m), 4.63 (111, d), 5.45 (111, d), 7.33-7.35 (111, m), 7.43-7.45 (111, d), 7.76-7.83 (211, m), 8.25-8.28 (111, m), 8.41-8.58 (1H, m), 10.27 (1H, s) 1441.
No. 1H-NMR
(obs) (DMSO) 1.01 (9H, 2 x s), 1.72-1.99 (4H, m), 2.05-2.09 (4H, m), 2.35-2.57 (2H, m), 2.71-3.00 (1H, brd m), 3.60-3.65 11-44 507.4 (111, m), 3.71-3.80 (1H, m), 4.08-4.37 (211, brd m), 4.70 (111, d), 7.32 (111, dd), 7.65-7.80 (311, m), 8.33-8.52 (IH, brd m), 10.37 (111, s) (DMSO) 0.94 (6H, dd), 1.72-1.99 (10H, m), 2.36-2.52 (2H, m), 3.57-3.68 (111, 11-45 493.4 m), 3.76-3.88 (111, m), 4.20-4.43 (2H, m), 4.51-4.55 (111, m), 7.30 (IH, dd), 7.58-7.77 (311, m), 8.00-8.04 (111, m), 10.34 (111, s) (DMSO) 0.95-1.0 (6H, m), 1.25 (6H, d), 1.85-2.2 (4H, m), 3.0-3.1 (IH, m), 3.9-11-46 510.5 4.0 (3H, m), 4.2-4.3 (0.511, m), 4.4-4.5 (0.5H, m), 4.7-4.8 (1H, m), 6.9-6.95 (111, d), 6.99 (111, s), 7.3 (1H, d), 8.3-8.4 (1H, m) (DMSO) 1.05 (9H, m), 1.8-2.1 (411, m), 2.6-2.7 (111, m), 2.9-3.0 (2H, m), 3.6-3.7 (211, m), 3.8-3.9 (111, m), 4.0-4.1 11-47 482.5 (111, m), 4.2-4.3 (111, m), 4.6-4.65 (1H, m), 5.5-5.55 (111, m), 6.75-6.85 (2H, m), 7.35 (1H, d), 7.75 (111, d), 8.0-8.1 (1H, m), 8.35 (1H, m), 10.25 (111, s) (DMSO) 1.03 (9H, s), 1.80-2.10 (411, m), 3.00 (1H, br s), 3.30 (311, s), 3.66 11-48 510.5 (111, m), 3.81 (111, m), 4.06 (1H, m), 4.25 (1H, m), 4.44 (211, s), 4.65 (1H, d), 5.46 111, br s), 7.29-7.39 (311, m), 7.77 (IH, br s), 8.43 (111, m) (DMSO) 1.03 (911, s), 1.09 (3H, m), 1.11 (311, m), 1.79-2.15 (411, m), 2.32 (1H, m), 2.98 (1H, m), 3.51 (1H, m), 3.79 11-49 551.5 (1H, m), 4.10 (1H, m), 4.23 (111, m), 4.40-4.65 (2H, m), 5.45-5.73 (111, m), 7.35 (111, m), 7.49 (1H, m), 7.76-7.84 (211, m), 8.23-8.60 (2H, m), 10.11 (111, s) M+1 No. 1H-NMR
(obs) (DMSO) 0.92-1.19 (4H, m), 1.49-1.90 (911, m), 1.91-1.99 (211, m), 2.06 (411, brd s), 2.49-2.52 (2H, m), 3.57-3.68' 11-50 493.3 (111, m), 3.80-3.90 (111, m), 4.01-4.28 (2H, m), 4.46 (111, t), 7.32 (1H, d), 7.43 (1H, dd), 7.81 (211, brd s), 8.31-8.78 (111, m), 8.46 (1H, d), 10.22 (1H, s) (DMSO) 0.90-1.07 (9H, s, tBu), 1.70-2.40 (411, brm, CH2), 2.54-3.07 (1H, in, CH2), 3.52-3.88 (511, in, CH3, CH), 4.00-=-51 539.3 4.65 (311, in, CH), 5.40-5.80 (111, in, CH), 7.30-7.44 (211, m, aryl H), 7.60 (1H, in, aryl H), 7.67 (111, br, NH), 8.10-8.70 (2H, m, NH), 10.00 (111, in, CH) (DMSO) 0.91-1.11 (911, s, tBu), 1.70-2.41 (4H, in, CH2), 2.56-3.09 (111, in, CH2), 3.60-3.90 (211, in, CH), 4.14-4.72 11-52 558.3 (3H, in, CH), 5.38-5.80 (111, in, CH), 6.98 (211, in, aryl H), 7.07-7.20 (3H, m, aryl H), 7.31-7.46 (311, m, aryl H), 7.66-8.67 (3H, in, NH, OH) (DMSO) 0.83-1.04 (6H, m), 1.81-2.08 (5H, m), 3.34-3.63 (111, m), 3.84-3.90 11-53 467 (1H, m), 4.00-4.60 (3H, m), 5.29-5.75 (211, m), 6.53-6.59 (1H, m), 6.70-6.90 (1H, m), 7.20-7.35 (0.5H, m), 7.78 (0.5H. brs), 8.43-8.60 (2H, m) (DMSO) 0.96 (111, s). 1.03 (911, s), 1.30-1.39 (211, m), 1.68-1.71 (211, m), 1.79-1.82 (111, m), 1.97 (111, brd), 2.11 11-55 502.6 (311, s), 3.79 (311, s), 3.84 (1H, vbrs), 4.09 (111, vbrs), 4.56-4.58 (1H, m), 4.67 (1H, d), 6.81 (111, d), 7.00 (111, d), 7.19 (1H, t), 7.79 (0.511, vbrs), 7.93 (1H, brd), 8.42 (0.511, vbrs) (CDC13) 1.08-1.14 (9H, m), 1.85-2.05 (411, m), 2.32-2.45 (111, m), 2.79-2.85 (1H, m), 3.01-3.07 (1H, m), 4.13-4.17 11-56 492.5 (111, m), 4.53-4.70 (111, m), 4.98 (111, t), 5.70 and 5.81 (1H total , brs and brd), 6.91-7.00 (1H, m), 7.34-7.44 (311, m), 7.67-7.75 (111, m) = =
No. 1-11-NMR
(obS) (DMSO) 1.03 (9H, s), 1.31-1.38 (2H, m), 1.62-1.74 (3H, m), 1.98 (1H, brt), 2.07 (3H, s), 2.36 (1H, vbrs), 2.83 (1H, 11-57 549.5 vbrs), 3.84 (1H, brs), 4.17 (1H, vbrs), 4.54-4.57 (111, m), 4.70 (1H, d), 7.34 (1H, d), 7.42-7.45 (1H, m), 8.16 (1H, t), 8.37 (11-I, brs), 10.23 (1H, s) (CD30D) 1.17 (9H, s), 1.21 (311, t), 1.41-1.55 (211, m), 1.75-1.90 (311, m), 2.03-2.19 (111, m), 2.37-2,50 (3H, m), 11-58 563.5 2.58-2.78 (2H, m), 3.87-4.02 (111, m), 4.20-4.30 (1H, m), 4.55-4.70 (2H, m), 4.91 (1H, obscured), 7.45 (111, d), 7.51 (111, d), 7.85 (111, s), 8.29 (1H, d) (DMSO) 1.05 (9H, s), 1.15 (6H, d), 1.35-1.5 (211, m), 1.75-1.9 (311, m), 2.0-2.1 (111, m), 2.3-2.45 (1H, m), 2.7-11-59 577.5 2.9 (111, m), 4.05-4.15 (111, m), 4.65 (1H, s), 4.7-4.75 (1H, m), 7.15 (111, d), 7.35 (111, t), 7.7 (111, d), 8.4-8.55 (2H, m), 9.5 (1H, s) (DMSO)1.03 (9H, s), 1.31-1.38 (211, m), 1.68 (311, m), 2.30-2.33 (2H, m), 2.67 (0.511, brs), 2.99 (0.511, brs), 3.34 11-60 506.5 (0.511, brs), 3.76 (31-1, s), 4.04 (0.5H, m), 4.58 (111, s), 4.72 (1H, d), 7.09-7.12 (1H, m), 7.16-7.20 (111, m), 7.26-7.30 (111, m), 7.78 (0,5H, vbrs), 8.02 (111, brs), 8.42 (0.511, vbrs) (DMSO) 0.95 (3H, d), 0.10 (3H, d), 1.17 (1H, m), 1.32 (1H, m), 1.64-1.80 (311, m), 2.00 (111, m), 2.30 (111, br s), 2.67 11-61 492.8 (0.5H, br s), 2.99 (0.511, br s), 3.75 (0.511, br s), 3.85 (311, s), 4.06 (0.511, m), 4.50-4.55 (211, m), 5.42 (1H, br s), 7.07 (1H, m), 7.17 (1H, m), 7.26 (1H, m), 7.80 (1H, br s), 8.35 (1H, m) DMSO) 8 1.04 (9H, s), 1.29-1.34 (2H, m), 1.59-1.67 (3H, m), 1.91-1.97 (1H, m), 2.13 (3H, s), 2.96 (111, vbrs), 3.77 (111, vbrs), 4.10 (111, vbrs), 4.72 (111, 11-62 549.5 s), 4.76 (1H, d), 7.80-7.83 (1H, m), 7.88-7.91 (111, m), 8.00-8.02 (1H, m), 8.18-8.24 (12H, m), 8.39 (1H, vbrs), 9.62 (111, s) = WO
N+1 3.
No. H-NNIR
(obs) (DMSO) 1.05 (9H, s), 1.09 (3H, t), 1.19-1.37 (3H, m), 1.47-1.77 (3H, m), 1.91-1.99 (1H, m), 2.28 (0.5H, brdd), 2.48 (2H, q), 2.63-2.74 (1H, m), 3.01 11-63 563.5 (0.5H, dd), 3.63 (0.5H, s), 3.78-4.37 (2H, total, m), 4.42-4.59 (1H. m), 4.75 (1H, d), 5.42 (0.5H, d), 7.76 (0.5H, d), 7.80-7.83 (1H, m), 7.87 (1H, d), 8.01 (1H, m), 8.08-8.15 (1H, m), 8.36 (0.5H, d), 9.53 (IH, s) (DMSO) 1.07 (9H, s), 1.34-1.37 (2H, m), 1.64-1.72 (311, m), 1.95-2.04 (1H, m), 2.31-2.35 (111, m), 2.65-2.70 (111, m), 3.01-3.03 (111, m), 3.99 (0.511, m), 11-64 509.5 4.26-4.28 (0.511, m), 4.68 (1H, s), 4.82 (1H, d), 5.45 (0.511, s), 7.73-7.86 (311, m), 8.05-8.08 (2H, m), 8.49 (0.511, d), 8.57-8.59 (111, m), 8.69 (0.511, d), 9.15 (1H, d) (DMSO) 1.02 (9H, s), 1.28-1.34 (211, m), 1.57-1.64 (3H, m), 1.90-1.96 (1H, m), 11-65 507.5 3.72-3.80 (1H, m), 4.50 (1H, brs), 4.72-4.74 (111, m), 5.91 (IH, s), 6.76 (111, d), 7.58-7.61 (1H, m), 7.81-7.83 (1H, m) 11-66 493.5 EXAMPLE III
BIOLOGICAL METHODS
[0180] Compounds of this invention may be tested using the methods described below. Table 5 lists caspase-1 and caspase-8 enzyme inhibition data for compounds 11-1-11-25. In the Table, compounds with a Ki of <10 are assigned category A, compounds with a Ki of 10-20 are assigned category B, and compounds with a Ki of 21-30 are assigned category C.
In Vitro Assays Enzyme Inhibition [0181] Ki values for test compounds with caspase-1 and caspase-8 were obtained by the method of Margolin et al. (J.
Biol. Chem., 272 pp. 7223-7228 (1997)). Other caspases may be assayed similarly (see, e.g., WO 99/47545). Assays were performed in 10 mM Tris (Sigma Corp, St Louis MO) pH 7.5, 1 mM
Dithiothreitol (DTT, Research Organic INC, Cleveland, OH) and 0.1% CHAPS (Pierce, Rockford IL) at 37 C. For caspase-3, a solution of 8% glycerol was added to the assay buffer to improve enzyme stability. A 65 pL aliquot of the assay buffer and 5 pL aliquot of the appropriate dilutions of inhibitor in DMSO where pipetted into a 96 well plate, treated with 10 pL
of caspase, than diluted in assay buffer (0.5-40 nM active protein by active site titration). A control containing DMSO
but no compound was included for each determination. The plates were then incubated for 15 minutes at 37 C, before addition of the appropriate substrate (20 pL, final concentration 1-4 X Km, final assay volume 100 pL) to initiate the reaction. Reaction rates were measured at 37 C either by following the time dependant increase in absorbance at 405 nM
(for the pNA substrates) or in fluorescence (Ex 390, Em 460) (for the AMC substrates). The rates obtained were plotted against inhibitor concentration and the data fit to the Morrison tight-binding equation for competitive inhibitors (Morrison, J. F., Biochem. Biophys. Acta, 185 pp. 269-286 (1969)). The substrates used for the individual assays were as follows:
[0182] Caspase-1 Suc-YVAD-pNA (Sachem, King of Prussia, PA) (final concentration in the assay 80 pM);
[0183] Caspase-8 Ac-DEVD-pNA (Sachem, King of Prussia, PA) (final concentration in assay 80 pM).
Table 5: Caspase-1 (Cl) and caspase-8 (c8) inhibition data.
Ki Cl Ki C8 Compound (nM) (nM) . =
PBMC Cell Assay IL-1# Assay with a Mixed Population of Human Peripheral Blood Mononuclear Cells (PBMC) or Enriched Adherent Mononuclear Cells (0184] Processing of pre-IL-1P by ICE may be measured in cell culture using a variety of cell sources. Human PBMC
obtained from healthy donors provides a mixed population of lymphocyte subtypes and mononuclear cells that produce a spectrum of interleukins and cytokines in response to many classes of physiological stimulators. Adherent mononuclear cells from PBMC provides an enriched source of normal monocytes for selective studies of cytokine production by activated cells.
Experimental Procedure:.
[0185] An initial dilution series of test compound in DMS0 or ethanol is prepared, with a subsequent dilution into RPMI-10% FBS media (containing 2 mM L-glutamine, 10 mM HEPES, 50 U
and 50 ug/ml pen/strep) respectively to yield drugs at 4x the final test concentration containing 0.4% DMSO or 0.4% ethanol.
The final concentration of DMSO is 0.1% for all drug dilutions. A concentration titration which brackets the apparent Ki for a test compound determined in an ICE
inhibition assay is generally used for the primary compound screen.
[0186] Generally 5-6 compound dilutions are tested and the cellular component of the assay is performed in duplicate, with duplicate ELISA determinations on each cell culture supernatant.
A
PBMC Isolation and IL-1 Assay:
[01873 Buffy coat cells isolated from one pint human blood (yielding 40-45 ml final volume plasma plus cells) are diluted with media to 80 ml and LeukoPREP separation tubes (Becton Dickinson) are each overlaid with 10 ml of cell suspension.
After 15 min centrifugation at 1500-1800 xg, the plasma/media layer is aspirated and then the mononuclear cell layer is collected with a Pasteur pipette and transferred to a 15 ml conical centrifuge tube (Corning). Media is added to bring the volume to 15 ml, gently mix the cells by inversion and centrifuge at 300 xg for 15 min. The PBMC pellet is resuspended in a small volume of media, the cells are counted and adjusted to 6 x 106 cells/ml.
[0188] For the cellular assay, 1.0 ml of the cell suspension is added to each well of a 24-well flat bottom tissue culture plate (Corning), 0.5 ml test compound dilution and 0.5 ml LPS solution (Sigma #L-3012; 20 ng/ml solution prepared in complete RPMI media; final LPS concentration 5 ng/ml). The 0.5 ml additions of test compound and LPS are usually sufficient to mix the contents of the wells. Three control mixtures are run per experiment, with either LPS
alone, solvent vehicle control, and/or additional media to adjust the final culture volume to 2.0 ml. The cell cultures are incubated for 16-18 hr at 37 C in the presence of 5% CO2.
[0189] At the end of the incubation period, cells are harvested and transferred to 15 ml conical centrifuge tubes.
After centrifugation for 10 min at 200 xg, supernatants are harvested and transferred to 1.5 ml Eppendorf tubes. It may be noted that the cell pellet may be utilized for a biochemical evaluation of pre-IL-1P and/or mature IL-113 content in cytosol extracts by Western blotting or ELISA with pre-IL-specific antisera.
Isolation of Adherent Mononuclear cells:
[0190] PBMC are isolated and prepared as described above.
Media (1.0 ml) is first added to wells followed by 0.5 ml of the PBMC suspension. After a one hour incubation, plates are gently shaken and nonadherent cells aspirated from each well.
Wells are then gently washed three times with 1.0 ml of media and final resuspended in 1.0 ml media. The enrichment for adherent cells generally yields 2.5-3.0 x 105 cells per well.
The addition of test compounds, LPS, cell incubation conditions and processing of supernatants proceeds as described above.
ELISA:
[0191] Quantikine kits (R&D Systems) may be used for the measurement of mature IL-113. Assays are performed according to the manufacturer's directions. Mature IL-13 levels of about 1-3 ng/na in both PBMC and adherent mononuclear cell positive controls are observed. ELISA assays are perfoLmed on 1:5, 1:10 and 1:20 dilutions of supernatants from LPS-positive controls to select the optimal dilution for supernatants in the test panel.
[0192] The inhibitory potency of the compounds can be represented by an IC50 value, which is the concentration of inhibitor at which 50% of mature IL-1D is detected in the supernatant as compared to the positive controls.
[0193] The skilled practitioner realizes that values obtained in cell assays may depend on multiple factors. The values may not necessarily represent fine quantitative results.
[0194] Selected compounds of this invention have been tested for inhibition of IL-113 release from PBMCs with IC50 values between 300nM and 4pM.
4 =
Whole Blood Assay for IL-113 Production (0195] Whole blood assay IC50 values for compounds of this invention may be obtained using the method described below:
PuLpose:
[0196] The whole blood assay is a simple method for measuring the production of IL-if (or other cytokines) and the activity of potential inhibitors. The complexity of this assay system, with its full couiplement of lymphoid and inflammatory cell types, spectrum of plasma proteins and red blood cells is an ideal in vitro representation of human in vivo physiologic conditions.
Materials:
=
Pyrogen-free syringes (- 30 cc) Pyrogen-free sterile vacuum tubes containing lyophilized Na2EDTA (4.5 mg/10 ml tube) Human whole blood sample (- 30-50 cc) 1.5 ml Eppendorf tubes Test compound stock solutions (- 25mM in DMSO or other solvent) Endotoxin -free sodium chloride solution (0.9%) and HBSS
Lipopolysaccharide (Sigma; Cat.# L-3012) stock solution at lmg/m1 in HBSS
IL-10 ELISA Kit (R & D Systems; Cat # DLB50) TNFot ELISA Kit (R & D Systems; Cat # DTA50) Water bath or incubator Whole Blood Assay Experimental Procedure:
[0197] Set incubator or water bath at 30 C. Aliquot 0.25m1 of blood into 1.5 ml eppendorf tubes. Note: be sure to invert the whole blood sample tubes after every two aliquots. Differences in replicates may result if the cells sediment and are not uniformly suspended. Use of a positive displacement pipette will also minimize differences between replicate aliquots.
[0198] Prepare drug dilutions in sterile pyrogen-free saline by serial dilution. A dilution series which brackets the apparent Ki for a test compound determined in an ICE
inhibition assay is generally used for the primary compound screen. For extremely hydrophobic compounds, prepare compound dilutions in fresh plasma obtained from the same blood donor or in PBS-containing 5% DMSO to enhance solubility.
[0199] Add 25 pl test compound dilution or vehicle control and gently mix the sample. Then add 5.0 ul UPS solution (250 ng/ml stocked prepared fresh: 5.0 ng/ml final concentration UPS), and mix again. Incubate the tubes at 30 C in a water bath for 16-18 hr with occasional mixing. Alternatively, the ' tubes can be placed in a rotator set at 4 rpm for the same incubation period. This assay should be set up in duplicate or triplicate with the following controls: negative control -no UPS; positive control - no test inhibitor; vehicle control - the highest concentration of DM50 or compound solvent used in the experiment. Additional saline is added to all control tubes to normalize volumes for both control and experimental whole blood test samples.
[0200] After the in_cubation period, whole blood samples are centrifuged for 10 min.utes at - 2000 Lim in the microfuge, plasma is transferred to a fresh microfuge tube and centrifuged at 1000 x g to pellet residual platelets if necessary. Plasma samples may be stored frozen at -70 C
prior to assay for cytokine levels by ELISA.
ELISA:
[0201] R & D Systems (614 McKinley Place N.E. Minneapolis, MN 55413) Quantikine kits may be used for measurement of IL-1J3 and TNF-a. The assays are performed according to the , .
manufacturer's directions. IL-113 levels of - 1-5 ng/ml in positive controls among a range of individuals may be observed. A 1:200 dilution of plasma for all samples is usually sufficient for experiments for ELISA results to fall on the linear range of the ELISA standard curves. It may be necessary to optimize standard dilutions if you observe differences in the whole blood assay. Nerad, J.L. et al., J.
Leukocyte Biol., 52, pp. 687-692 (1992).
[0202] Selected compounds of this invention have been . tested for inhibition of IL-1 release from whole blood with IC50 values between 1pM and 40pM.
In Vivo Assays [0203] Compounds of this invention may tested in in vivo =
assays such as those described in WO 99/47545.
[0204]
[0205] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example above.
Claims (51)
1. A compound of formula I:
wherein:
R1 is H, C1-12aliphatic, C3-10cycloaliphatic, C6-10aryl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3-10cycloalkyl )-(C1-12aliphatic)-, cycloalkenyl-(C1-12aliphatic)-, (C6-10aryl)-(C1-12aliphatic)-, (5-10 membered heterocyclyl)-(C1-12aliphatic)-, or (5-10 membered heteroaryl)-(C1-12aliphatic)-, wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
Ring A is:
wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R4 is halogen, -OR9, -NO2, -CN, -CF3, -OCF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylenedioxy, -N (R9)2, -SR9, -SOR9, -SO2R9, -SO2N(R9)2, -SO3R9, -C(O)R9, -C(O)C(O)R9, -C(O)C(O)OR9, -C(O)C(O)N(R9)2, -C(O)CH2C(O)R9, -C(S)R9, -C(S)OR9, -C(O)OR9, -OC(O)R9, -C(O)N(R9)2, -OC(O)N(R9)2, -C(S)N(R9)2, -(CH2) 0-2NHC(O)R9, -N(R9)N(R9)COR9, -N(R9)N(R9)C(O)OR9, -N(R9)N(R9)CON(R9)2, -N(R9)SO2R9, -N(R9)SO2N(R9)2, -N(R9)C(O)OR9, -N(R9)C(O)R9, -N(R9)C(S)R9, -N(R9)C(O)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(OR9)R9, -C(=NH)N(R9)2, -C(O)N(OR9)R9, -C(=NOR9)R9, -OP(O)(OR9)2, -P(O)(R9)2, -P(O)(OR9)2, or -P(O)(H)(OR9) ;
R2 is -C(R5)(R6)(R7) , C6-10aryl, 5-10 membered heteroaryl, or C3-7 cycloalkyl;
R5 is H or a C1-6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R7 is -CF3, -C3-7cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R10;
or R5 and R7 taken together with the carbon atom to which they are attached form a 3-10 membered cycloaliphatic;
R8 and R8', are each independently halogen, -OR9, -NO2, -CN, -CF3, -OCF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylenedioxy, -N(R9)2, -SR9, -SOR9, -SO2R9, -SO2N(R9)2, -SO3R9, -C(O)R9, -C(O)C(O)R9, -C (O)C(O)OR9, -C(O)C(O)N(R9)2, -C(O)CH2C(O)R9, -C(S)R9, -C(S)OR9, -C(O)OR9, -OC(O)R9, -C(O)N(R9)2, -OC(O)N(R9)2, -C(S)N(R9)2, (CH2) 0-2NHC(O)R9, -N(R9)N(R9)COR9, -N(R9)N(R9) C(O)OR9, -N(R9)N(R9) CON(R9)2, -N(R9)SO2R9, -N(R9)SO2N(R9)2, -N(R9)C(O)OR9, -N(R9)C(O)R9, -N(R9)C(S)R9, -N(R9)C(O)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(OR9)R9, -C(=NH)N(R9)2, -C(O)N(OR9)R9, -C(=NOR9)R9, -OP(O)(OR9)2, -P(O)(R9)2, -P(O)(OR9)2, or -P(O)(H)(OR9);
R9 is hydrogen, C1-12aliphatic, C3-10cycloaliphatic, C6-10aryl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3-10cycloaliphatic)-(C1-12aliphatic)-, (C6-10aryl) -(C1-12aliphatic)-, (5-10 membered heterocyclyl)-(C1-12aliphatic)-, or heteroaryl-(C1-12aliphatic)-; wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R10 is halogen, -OR11, -NO2, -CN, -CF3, -OCF3, -R11, or -SR11; and R11 is C1-4-aliphatic-.
wherein:
R1 is H, C1-12aliphatic, C3-10cycloaliphatic, C6-10aryl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3-10cycloalkyl )-(C1-12aliphatic)-, cycloalkenyl-(C1-12aliphatic)-, (C6-10aryl)-(C1-12aliphatic)-, (5-10 membered heterocyclyl)-(C1-12aliphatic)-, or (5-10 membered heteroaryl)-(C1-12aliphatic)-, wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
Ring A is:
wherein, in each ring, any hydrogen atom is optionally and independently replaced by R4 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R4 is halogen, -OR9, -NO2, -CN, -CF3, -OCF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylenedioxy, -N (R9)2, -SR9, -SOR9, -SO2R9, -SO2N(R9)2, -SO3R9, -C(O)R9, -C(O)C(O)R9, -C(O)C(O)OR9, -C(O)C(O)N(R9)2, -C(O)CH2C(O)R9, -C(S)R9, -C(S)OR9, -C(O)OR9, -OC(O)R9, -C(O)N(R9)2, -OC(O)N(R9)2, -C(S)N(R9)2, -(CH2) 0-2NHC(O)R9, -N(R9)N(R9)COR9, -N(R9)N(R9)C(O)OR9, -N(R9)N(R9)CON(R9)2, -N(R9)SO2R9, -N(R9)SO2N(R9)2, -N(R9)C(O)OR9, -N(R9)C(O)R9, -N(R9)C(S)R9, -N(R9)C(O)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(OR9)R9, -C(=NH)N(R9)2, -C(O)N(OR9)R9, -C(=NOR9)R9, -OP(O)(OR9)2, -P(O)(R9)2, -P(O)(OR9)2, or -P(O)(H)(OR9) ;
R2 is -C(R5)(R6)(R7) , C6-10aryl, 5-10 membered heteroaryl, or C3-7 cycloalkyl;
R5 is H or a C1-6 straight-chained or branched alkyl;
R6 is H or a C1-6 straight-chained or branched alkyl;
R7 is -CF3, -C3-7cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, heterocycle, or a C1-6 straight-chained or branched alkyl, wherein each carbon atom of the alkyl is optionally and independently substituted with R10;
or R5 and R7 taken together with the carbon atom to which they are attached form a 3-10 membered cycloaliphatic;
R8 and R8', are each independently halogen, -OR9, -NO2, -CN, -CF3, -OCF3, -R9, 1, 2-methylenedioxy, 1, 2-ethylenedioxy, -N(R9)2, -SR9, -SOR9, -SO2R9, -SO2N(R9)2, -SO3R9, -C(O)R9, -C(O)C(O)R9, -C (O)C(O)OR9, -C(O)C(O)N(R9)2, -C(O)CH2C(O)R9, -C(S)R9, -C(S)OR9, -C(O)OR9, -OC(O)R9, -C(O)N(R9)2, -OC(O)N(R9)2, -C(S)N(R9)2, (CH2) 0-2NHC(O)R9, -N(R9)N(R9)COR9, -N(R9)N(R9) C(O)OR9, -N(R9)N(R9) CON(R9)2, -N(R9)SO2R9, -N(R9)SO2N(R9)2, -N(R9)C(O)OR9, -N(R9)C(O)R9, -N(R9)C(S)R9, -N(R9)C(O)N(R9)2, -N(R9)C(S)N(R9)2, -N(COR9)COR9, -N(OR9)R9, -C(=NH)N(R9)2, -C(O)N(OR9)R9, -C(=NOR9)R9, -OP(O)(OR9)2, -P(O)(R9)2, -P(O)(OR9)2, or -P(O)(H)(OR9);
R9 is hydrogen, C1-12aliphatic, C3-10cycloaliphatic, C6-10aryl, 5-10 membered heterocyclyl, 5-10 membered heteroaryl, (C3-10cycloaliphatic)-(C1-12aliphatic)-, (C6-10aryl) -(C1-12aliphatic)-, (5-10 membered heterocyclyl)-(C1-12aliphatic)-, or heteroaryl-(C1-12aliphatic)-; wherein any hydrogen atom is optionally and independently replaced by R8 and any set of two hydrogen atoms bound to the same atom is optionally and independently replaced by carbonyl;
R10 is halogen, -OR11, -NO2, -CN, -CF3, -OCF3, -R11, or -SR11; and R11 is C1-4-aliphatic-.
2. The compound according to claim 1 wherein R is R3C(O)-; and R3 is C6-10aryl or 5-10 membered heteroaryl, wherein any hydrogen atom of R3 is optionally and independently substituted by R8'.
3. The compound according to claim 1 or 2, wherein Y is
4. The compound according to claim 3, wherein R1 is C1-12aliphatic or C3-10cycloalkyl, wherein each group is optionally substituted with 1-3 groups selected independently from R8.
5. The compound according to claim 4 wherein R1 is a straight-chain or branched C1-4 alkyl that is optionally substituted with 1-3 groups selected independently from R8.
6. The compound according to claim 5 wherein R1 is an unsubstituted, straight-chain or branched C1-4 alkyl.
7. The compound according to claim 6, wherein R1 is ethyl, isopropyl, n-propyl, or n-butyl.
8. The compound according to claim 7, wherein R1 is ethyl.
9. The compound according to claim 8, wherein R8 is halogen, -OR9, -CN, -CF3, -OCF3, or -R9.
10. The compound according to claim 9, wherein R8 is benzyl.
11. The compound according to claim 1 or 2, wherein Y is
12. The compound according to any one of claims 1 to 11, wherein ring A is:
<MG> optionally substituted by R4.
<MG> optionally substituted by R4.
13. The compound according to any one of claims 1-12, wherein R4 is halogen, -OR9, -CF3, -OCF3, -R9, or -SR9.
14. The compound according to claim 13, wherein R4 is H.
15. The compound according to any one of claims 1-14, wherein R2 is a C3-4 branched alkyl group.
16. The compound according to any one of claims 1-15, wherein R5 is H or -CH3, R6 is -CH3, and R7 is -CH3.
17. The compound according to any one of claims 1-16, wherein each R8' is independently halogen, -OR9' -NO2, -CN, -CF3, -OCF3, -R9, 1,2-methylenedioxy, 1,2-ethylenedioxy, -N(R9)2, -SR9, -SOR9, -SO2R9, -SO2N (R9) 2, -C (O) R9, -C (O) C (O) N (R9) 2, -C (O)N (R9) 2, -OC (O)N (R9) 2, -(CH2 ) 0-2NHC (O) R9, -N (R9) SO2R9, -N (R9) SO2N (R9)2, -N (R9) C (O) OR9, -N (R9)C (O) R9, or -N (R9)C (O)N (R9) 2 .
18. The compound according to claim 17, wherein each R8' is independently -NH2, -N(R9)2, -N(R9)C(O)R9, -OCF3, -OR9, -CF3, -R9, -SR9, or halo.
19. A compound:
20. A pharmaceutical composition comprising:
a) a compound according to any one of claims 1-19;
and b) a pharmaceutically acceptable carrier, adjuvant or vehicle.
a) a compound according to any one of claims 1-19;
and b) a pharmaceutically acceptable carrier, adjuvant or vehicle.
21. Use of a compound according to any one of claims 1 to 19 for the preparation of a medicament for treating a disease, wherein said disease is an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, an autoinflammatory disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, retinal disorders, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs. host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, leukemias and related disorders, Myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, hemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage'due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, various forms of liver disease, renal disease, polycystic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, toxic epidermal necrolysis, pemphigus, Muckle-Wells Syndrome, Familial Cold Urticaria, Familial Mediterranean Fever, Chronic Infantile Neurological Cutaneous and Articular Syndrome, Neonatal Onset Multisystem Inflammatory Disease, TNFR1-Associated Periodic Syndrome, or Hyper-IgD periodic fever Syndrome.
22. Use of a compound according to any one of claims 1 to 19 for the preparation of a medicament for inhibiting a caspase-mediated function in a patient.
23. Use of a compound according to any one of claims 1 to 19 for the preparation of a medicament for decreasing IGIF
or IFN-.gamma. production'in a patient.
or IFN-.gamma. production'in a patient.
24. An ex vivo method of preserving cells, said method comprising the step of bathing the cells in a composition of the compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.
25. The method according to claim 24, wherein said cells are in:
a) an organ intended for transplant; or b) a blood product.
a) an organ intended for transplant; or b) a blood product.
26. Use of a compound according to any one of claims 1 to 19 for the preparation of a medicament of treating cancer using immunotherapy, wherein said immunotherapy comprises as a component thereof a compound according to any one of claims 1 to 19.
27. The use according to any one of claims 21 to 23 and 26, or the method according to claim 24 or 25, wherein said composition comprises an additional therapeutic agent.
28. Use of a compound according to any one of claims 1 to 19 for the treatment of a disease, wherein said disease is an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, an autoinflammatory disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, retinal disorders, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs. host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, hemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, various forms of liver disease, renal disease, polycystic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, toxic epidermal necrolysis, pemphigus, Muckle-Wells Syndrome, Familial Cold Urticaria, Familial Mediterranean Fever, Chronic Infantile Neurological Cutaneous and Articular Syndrome, Neonatal Onset Multisystem Inflammatory Disease, TNFR1-Associated Periodic Syndrome, or Hyper-IgD periodic fever Syndrome.
29. Use of a compound according to any one of claims 1 to 19 for inhibiting a caspase-mediated function in a patient.
30. Use of a compound according to any one of claims 1 to 19 for decreasing IGIF or IFN-.gamma. production in a patient.
31. Use of a compound according to any one of claims 1 to 19 for treating cancer using immunotherapy, wherein said immunotherapy comprises as a component thereof a compound according to any one of claims 1 to 19.
32. The compound according to any one of claims 1 to 19 for use in the treatment of a disease, wherein said disease is an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, an autoinflammatory disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, retinal disorders, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs. host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, hemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, various forms of liver disease, renal disease, polycystic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, toxic epidermal necrolysis, pemphigus, Muckle-Wells Syndrome, Familial Cold Urticaria, Familial Mediterranean Fever, Chronic Infantile Neurological Cutaneous and Articular Syndrome, Neonatal Onset Multisystem Inflammatory Disease, TNFR1-Associated Periodic Syndrome, or Hyper-IgD periodic fever Syndrome.
33. The compound according to any one of claims 1 to 19 for use in inhibiting a caspase-mediated function in a patient.
34. The compound according to any one of claims 1 to 19 for use in decreasing TGIF or IFN-.gamma. production in a patient.
35. The compound according to any one of claims 1 to 19 for use in the treatment of cancer using immunotherapy, wherein said immunotherapy comprises as a component thereof a compound according to any one of claims 1 to 19.
36. The pharmaceutical composition of claim 20 for use in the treatment of a disease, wherein said disease is an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, an autoinflammatory disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, an excess dietary alcohol intake disease, a viral mediated disease, retinal disorders, uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, scarring, graft vs. host disease, organ transplant rejection, organ apoptosis after burn injury, osteoporosis, leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, hemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, aging, alopecia, neurological damage'due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, hepatitis-C, hepatitis-G, yellow fever, dengue fever, Japanese encephalitis, various forms of liver disease, renal disease, polycystic kidney disease, H. pylori-associated gastric and duodenal ulcer disease, HIV infection, tuberculosis, meningitis, toxic epidermal necrolysis, pemphigus, Muckle-Wells Syndrome, Familial Cold Urticaria, Familial Mediterranean Fever, Chronic Infantile Neurological Cutaneous and Articular Syndrome, Neonatal Onset Multisystem Inflammatory Disease, TNFR1-Associated Periodic Syndrome, or Hyper-IgD periodic fever Syndrome.
37. The pharmaceutical composition of claim 20 for use in inhibiting a caspase-mediated function in a patient.
38. The pharmaceutical composition of claim 20 for use in decreasing IGIF or IFN-.gamma. production in a patient.
39. The pharmaceutical composition of claim 20 for use in the treatment of cancer using immunotherapy, wherein said immunotherapy comprises as a component thereof a compound according to any one of claims 1 to 19.
40. The pharmaceutical composition of any one of claims 20 and 36 to 39 which further comprises an additional therapeutic agent.
41. A process for preparing a compound of formula I:
wherein Y is:
<MC>
and R, R1, R2 and Ring A are as defined in claim 1 comprising reacting a compound of formula 1:
<vac>
wherein R1, R2 and Ring A are as defined in claim 1, and a compound of formula RX, wherein X is OH or an appropriate derivative or leaving group and R is as defined in claim 1, in the presence of conditions for coupling an amine and an acid when X is OH, or appropriate acid derivative when X is an appropriate leaving group, to provide the compound of formula I.
wherein Y is:
<MC>
and R, R1, R2 and Ring A are as defined in claim 1 comprising reacting a compound of formula 1:
<vac>
wherein R1, R2 and Ring A are as defined in claim 1, and a compound of formula RX, wherein X is OH or an appropriate derivative or leaving group and R is as defined in claim 1, in the presence of conditions for coupling an amine and an acid when X is OH, or appropriate acid derivative when X is an appropriate leaving group, to provide the compound of formula I.
42. A
process for preparing a compound of formula I:
wherein Y is:
and R, R1, R2 and Ring A are as defined in claim 1, comprising reacting a compound of formula 7-A:
wherein R, R1 and Ring A are as defined in claim 1, and a compound of formula RNHCH(R2)C(O)X, wherein X is OH or an appropriate derivative or leaving group and R and R2 are as defined in claim 1, in the presence of conditions for coupling an amine and an acid when X is OH, or appropriate acid derivative when X iS not OH, to provide the compound of formula I.
process for preparing a compound of formula I:
wherein Y is:
and R, R1, R2 and Ring A are as defined in claim 1, comprising reacting a compound of formula 7-A:
wherein R, R1 and Ring A are as defined in claim 1, and a compound of formula RNHCH(R2)C(O)X, wherein X is OH or an appropriate derivative or leaving group and R and R2 are as defined in claim 1, in the presence of conditions for coupling an amine and an acid when X is OH, or appropriate acid derivative when X iS not OH, to provide the compound of formula I.
43. A process for preparing a compound of formula IV:
IV, wherein R, R2, and Ring A are as defined in claim 1, comprising reacting a compound of formula I:
wherein R, R2, and Ring A are as defined in claim 1, and Y is:
wherein R1 is as defined in claim 1, under hydrolysis conditions, to provide the compound of formula IV.
IV, wherein R, R2, and Ring A are as defined in claim 1, comprising reacting a compound of formula I:
wherein R, R2, and Ring A are as defined in claim 1, and Y is:
wherein R1 is as defined in claim 1, under hydrolysis conditions, to provide the compound of formula IV.
44. A process for preparing a compound of formula 3-A:
wherein PG1 is a suitable carboxylic acid protecting group;
PG2 is a suitable nitrogen-protecting group; and ring A is as defined in claim 1; comprising:
reacting a compound of formula 2-A:
wherein PG1 is a suitable carboxylic acid protecting group;
and a compound of formula 20-A:
wherein E)2 is a suitable nitrogen-protecting group;
ring A is as defined in claim 1; and X is OH or an appropriate leaving group, under conditions for coupling an amine and a carboxylic acid when X is OH, or an amine and an appropriate carboxylic acid when X is an appropriate leaving group, to provide the compound of formula 3-A.
wherein PG1 is a suitable carboxylic acid protecting group;
PG2 is a suitable nitrogen-protecting group; and ring A is as defined in claim 1; comprising:
reacting a compound of formula 2-A:
wherein PG1 is a suitable carboxylic acid protecting group;
and a compound of formula 20-A:
wherein E)2 is a suitable nitrogen-protecting group;
ring A is as defined in claim 1; and X is OH or an appropriate leaving group, under conditions for coupling an amine and a carboxylic acid when X is OH, or an amine and an appropriate carboxylic acid when X is an appropriate leaving group, to provide the compound of formula 3-A.
45. A process for preparing a compound of formula 13:
wherein PG1 is a suitable carboxylic acid protecting group and PG2 is a suitable nitrogen-protecting group, comprising:
reacting a compound of formula 2:
with a compound of formula 21:
under conditions for coupling an amine and a carboxylic acid when X is OH, or an amine and an appropriate carboxylic acid when X is an appropriate leaving group, to provide the compound of formula 13.
wherein PG1 is a suitable carboxylic acid protecting group and PG2 is a suitable nitrogen-protecting group, comprising:
reacting a compound of formula 2:
with a compound of formula 21:
under conditions for coupling an amine and a carboxylic acid when X is OH, or an amine and an appropriate carboxylic acid when X is an appropriate leaving group, to provide the compound of formula 13.
46. A compound of formula 5-A:
wherein PG1 is a suitable carboxylic acid protecting group, PG2 is a suitable nitrogen-protecting group, and R1 and Ring A are as defined in claim 1.
wherein PG1 is a suitable carboxylic acid protecting group, PG2 is a suitable nitrogen-protecting group, and R1 and Ring A are as defined in claim 1.
47. A compound of formula 15:
wherein PG1 is a suitable carboxylic acid protecting group and PG2 is a suitable nitrogen-protecting group.
wherein PG1 is a suitable carboxylic acid protecting group and PG2 is a suitable nitrogen-protecting group.
48. A compound of formula 3-A:
<MG>
wherein PG1, PG2, and Ring A, are as defined in claim 46.
<MG>
wherein PG1, PG2, and Ring A, are as defined in claim 46.
49. A compound of formula 13:
wherein PG1, and PG2 are as defined in claim 46.
wherein PG1, and PG2 are as defined in claim 46.
50. A compound of formula 4A:
wherein Ring A, PG1 and PG2 are as defined in claim 46.
wherein Ring A, PG1 and PG2 are as defined in claim 46.
51. A compound of formula 14:
wherein PG1 and PG2 are as defined in claim 46.
wherein PG1 and PG2 are as defined in claim 46.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54861004P | 2004-02-27 | 2004-02-27 | |
| US60/548,610 | 2004-02-27 | ||
| US62974304P | 2004-11-19 | 2004-11-19 | |
| US62966104P | 2004-11-19 | 2004-11-19 | |
| US60/629,743 | 2004-11-19 | ||
| US60/629,661 | 2004-11-19 | ||
| CA2557645A CA2557645C (en) | 2004-02-27 | 2005-02-28 | Caspase inhibitors and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2557645A Division CA2557645C (en) | 2004-02-27 | 2005-02-28 | Caspase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2820541A1 true CA2820541A1 (en) | 2005-09-15 |
Family
ID=37959787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2820541A Abandoned CA2820541A1 (en) | 2004-02-27 | 2005-02-28 | Caspase inhibitors and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN1942466B (en) |
| CA (1) | CA2820541A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979403A (en) * | 2010-09-13 | 2011-02-23 | 沈陵陵 | Novel broad caspase inhibitor and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| EP2261232A3 (en) * | 1998-03-19 | 2011-04-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
| PE20011350A1 (en) * | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROPHARMAC OF AN INHIBITOR OF INTERLEUKIN-1ß CONVERTER ENZYME (ICE) |
-
2005
- 2005-02-28 CA CA2820541A patent/CA2820541A1/en not_active Abandoned
- 2005-02-28 CN CN2005800112311A patent/CN1942466B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1942466A (en) | 2007-04-04 |
| CN1942466B (en) | 2011-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100105914A1 (en) | Caspase inhibitors and uses thereof | |
| CN112218859B (en) | Proteolytic modulators and related methods of use | |
| DE60014345T2 (en) | MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | |
| CA3183740A1 (en) | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections | |
| CA2324226C (en) | Inhibitors of caspases | |
| AU735075B2 (en) | Inhibitors of interleukin-1beta converting enzyme | |
| CA3199074A1 (en) | Compounds and methods for the targeted degradation of androgen receptor protein | |
| JP2020528918A (en) | Compounds and methods for targeted degradation of androgen receptors | |
| KR20180029061A (en) | Alanine regulators of protein degradation and related uses | |
| JP2009046511A (en) | Inhibitors of imidazole and benzimidazole caspases and their use | |
| RU2427582C2 (en) | Caspase inhibitor prodrugs | |
| JPH058191B2 (en) | ||
| AU2009263076A1 (en) | New heterocyclic carboxamides for use as thrombin inhibitors | |
| CA2820541A1 (en) | Caspase inhibitors and uses thereof | |
| AU2011226946B2 (en) | Caspase Inhibitors and Uses Thereof | |
| MXPA06009771A (en) | Caspase inhibitors and uses thereof | |
| HK1099757B (en) | Caspase inhibitors and uses thereof | |
| HK1159614B (en) | Caspase inhibitors and uses thereof | |
| AU2006233208A1 (en) | Hepatitis C virus inhibitors | |
| AU2007200251A1 (en) | Inhibitors of Caspases | |
| JPS6054366A (en) | Acylated hydrazine compound, manufacture and medicine | |
| JP2008512365A (en) | N- (1- (2,3-dihydro-1H-inden-5yl) -2-oxo-3-pyrrolidinyl) -sulfonamide derivatives for use as factor Xa inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130621 |
|
| FZDE | Dead |
Effective date: 20160302 |